The Sixth Report of the Joint National Committee on Pr Treatment of High Blood Pressure

Archives of Internal Medicine 157, 2413

DOI: 10.1001/archinte.1997.00440420033005

Citation Report

#	Article	IF	CITATIONS
1	Treatment of Diabetic Nephropathy in its Early Stages. , 1997, 13, 51-61.		17
2	Relationship between joint national committeeâ€ v l classification of hypertension and ambulatory blood pressure in patients with hypertension diagnosed by casual blood pressure. Clinical Cardiology, 1998, 21, 801-806.	0.7	9
3	Revascularization in atherosclerotic renal artery disease. Kidney International, 1998, 53, 799-811.	2.6	87
4	Rationale and Design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial. Contemporary Clinical Trials, 1998, 19, 370-390.	2.0	88
5	Efficacy of Low-Dose Combination of Bisoprolol/Hydrochlorothiazide Compared With Amlodipine and Enalapril in Men and Women With Essential Hypertension. American Journal of Cardiology, 1998, 81, 1363-1365.	0.7	8
6	Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. American Journal of Cardiology, 1998, 82, 9-14.	0.7	154
7	The International Nifedipine GITS Study of Intervention as a Goal in Hypertension Treatment (INSIGHT) trial. American Journal of Cardiology, 1998, 82, 23-28.	0.7	28
8	Overview of angiotensin II-receptor antagonists. American Journal of Cardiology, 1998, 82, 475-495.	0.7	29
9	Overview of angiotensin II-receptor antagonists. American Journal of Cardiology, 1998, 82, S47-S49.	0.7	11
11	Nephroprotection by long-term ACE inhibition with ramipril in spontaneously hypertensive stroke prone rats. Kidney International, 1998, 54, 2037-2044.	2.6	19
12	Therapeutic implications and new perspectives for essential hypertension and renal damage. Kidney International, 1998, 54, S46-S50.	2.6	7
13	Use of indapamide in hospital and community clinics and its effect on plasma potassium in Chinese patients. Journal of Clinical Pharmacy and Therapeutics, 1998, 23, 295-302.	0.7	5
14	The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. Journal of Clinical Pharmacy and Therapeutics, 1998, 23, 433-440.	0.7	36
15	Exaggerated blood pressure response to exercise: importance of resting blood pressure. Clinical Physiology, 1998, 18, 457-462.	0.7	21
16	Effects of clonidine on power spectral analysis of heart rate variability in mild essential hypertension. Journal of the Autonomic Nervous System, 1998, 74, 152-159.	1.9	17
17	Trends in prescribing calcium-channel blockers. Lancet, The, 1998, 352, 1708.	6.3	2
18	JNC VI guidelines. Lancet, The, 1998, 351, 289-290.	6.3	2
19	Angiotensin II, VEGF, and diabetic retinopathy. Lancet, The, 1998, 351, 836-837.	6.3	8

#	Article	IF	Citations
20	Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet, The, 1998, 352, 213-219.	6.3	476
21	Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, The, 1998, 351, 1755-1762.	6.3	5,398
22	Hypertension Optimal Treatment (HOT) trial. Lancet, The, 1998, 352, 571.	6.3	3
23	Prevention of stroke. Lancet, The, 1998, 352, S15-S18.	6.3	39
24	Continuation of initial antihypertensive medication after 1 year of therapy. Clinical Therapeutics, 1998, 20, 671-681.	1.1	288
25	\hat{l}^2 -blockers were not as efficacious as diuretics when used as first-line therapy in elderly patients with uncomplicated hypertension. Evidence-based Cardiovascular Medicine, 1998, 2, 102.	0.0	0
26	The use of calcium antagonists and ACE inhibitors increased between 1992 and 1995. Evidence-based Cardiovascular Medicine, 1998, 2, 54.	0.0	0
27	Secondary prevention of coronary heart disease. Archives of Physical Medicine and Rehabilitation, 1998, 79, 1006-1017.	0.5	10
28	T-channelâ€"selective calcium channel blockade: a review of published data and therapeutic potential. Current Therapeutic Research, 1998, 59, 754-761.	0.5	5
29	The DIET Study. Journal of the American Dietetic Association, 1998, 98, 1276-1281.	1.3	22
30	Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. Journal of the American College of Cardiology, 1998, 32, 1228-1237.	1.2	144
31	Hypertension in Women: Current Understanding of Gender Differences. Mayo Clinic Proceedings, 1998, 73, 157-165.	1.4	50
32	NEPHROPATHY AND HYPERTENSION IN DIABETES. Medical Clinics of North America, 1998, 82, 877-907.	1.1	31
33	Blood Pressure Monitoring in Women with Previous Diagnosis of Preeclampsia: The Influence of the Menstrual Cycle. Hypertension in Pregnancy, 1998, 17, 251-263.	0.5	1
35	Lessons from hypertension trials. American Journal of Medicine, 1998, 104, 50S-53S.	0.6	17
36	The cardiovascular dysmetabolic syndrome. American Journal of Medicine, 1998, 105, 77S-82S.	0.6	100
37	Effects of alcohol restriction on 24-hour ambulatory blood pressure in japanese men with hypertension. American Journal of Medicine, 1998, 105, 307-311.	0.6	37
38	Comparative Tolerability Profile of Hypertensive Crisis Treatments. Drug Safety, 1998, 19, 99-122.	1.4	61

#	Article	IF	CITATIONS
39	Moexipril. Drugs, 1998, 55, 845-860.	4.9	18
40	Drug Treatment of Hypertension Complicating Diabetes Mellitus. Drugs, 1998, 56, 189-202.	4.9	26
41	Candesartan Cilexetil. Drugs, 1998, 56, 847-869.	4.9	122
42	Trandolapril. Drugs, 1998, 56, 871-893.	4.9	15
43	Efficacy and Tolerability of Valsartan in Combination with Hydrochlorothiazide in Essential Hypertension. Clinical Drug Investigation, 1998, 16, 203-210.	1.1	26
44	Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients. Clinical Drug Investigation, 1998, 16, 229-240.	1.1	8
45	Urapidil. Drugs, 1998, 56, 929-955.	4.9	52
46	Guidelines for the Prevention of Coronary Heart Disease. Disease Management and Health Outcomes, 1998, 4, 217-224.	0.3	0
47	Hypertension as a Candidate for Disease Management Initiatives. Disease Management and Health Outcomes, 1998, 3, 215-227.	0.3	2
48	Conference Report on Stroke Mortality in the Southeastern United States. Hypertension, 1998, 31, 1206-1215.	1.3	106
49	Insulin and Coronary Artery Disease: Is Syndrome X the Unifying Hypothesis?. Annals of Pharmacotherapy, 1998, 32, 233-247.	0.9	26
50	Renin System Analysis: A Rational Method for the Diagnosis and Treatment of the Individual Patient with Hypertension. American Journal of Hypertension, 1998, 11, 894-896.	1.0	64
51	Strategies for Improving Blood Pressure Control. American Journal of Hypertension, 1998, 11, 897-899.	1.0	8
52	Low-dose Diuretic and/or Dietary Sodium Restriction when Blood Pressure Is Resistant to ACE Inhibitor. Blood Pressure, 1998, 7, 299-307.	0.7	31
53	Angiotensinogen Genotype, Sodium Reduction, Weight Loss, and Prevention of Hypertension. Hypertension, 1998, 32, 393-401.	1.3	174
54	Problems on the Pathway From Risk Assessment to Risk Reduction. Circulation, 1998, 97, 1761-1762.	1.6	36
55	Is There a Racial Predisposition to Hypertension?. Hypertension, 1998, 32, 817-819.	1.3	13
56	Characteristics of 9194 Patients With Left Ventricular Hypertrophy. Hypertension, 1998, 32, 989-997.	1.3	272

#	Article	IF	Citations
57	Dietary Electrolytes and Blood Pressure. Circulation, 1998, 98, 613-617.	1.6	111
58	Angiotensin-Converting Enzyme Inhibitors. Circulation, 1998, 97, 1411-1420.	1.6	687
59	Ambulatory Pulse Pressure. Hypertension, 1998, 32, 983-988.	1.3	367
60	Reference Values for 24-Hour Ambulatory Blood Pressure Monitoring Based on a Prognostic Criterion. Hypertension, 1998, 32, 255-259.	1.3	181
61	Blood Pressure in Spain. Hypertension, 1998, 32, 998-1002.	1.3	259
62	Effects of Magnesium Supplementation in Hypertensive Patients. Hypertension, 1998, 32, 260-265.	1.3	147
63	Prospective Study of Calcium Channel Blocker Use, Cardiovascular Disease, and Total Mortality Among Hypertensive Women. Circulation, 1998, 97, 1540-1548.	1.6	37
64	Behavior and Biology: The Basic Sciences for AHA Action. Circulation, 1998, 97, 807-810.	1.6	11
65	Relationships of Abdominal Obesity and Hyperinsulinemia to Angiographically Assessed Coronary Artery Disease in Men With Known Mutations in the LDL Receptor Gene. Circulation, 1998, 97, 871-877.	1.6	91
66	Tight blood pressure control and risk of macrovascular and microvascular complications in type 2Adiabetes: UKPDS 38. BMJ: British Medical Journal, 1998, 317, 703-713.	2.4	5,635
67	A Review of the Three Types of Biomedical Literature and the Systematic Approach to Answer a Drug Information Request. Journal of Pharmacy Practice, 1998, 11, 148-162.	0.5	4
68	Evidence-Based Practice in Health Care. Journal of Pharmacy Practice, 1998, 11, 251-267.	0.5	2
69	Combination Drug Therapy in Hypertension: A Rational Approach for the Pharmacist. Journal of the American Pharmacists Association, 1998, 38, 469-479.	0.6	3
70	Sleep-related breathing as a of hypertension. Current Opinion in Nephrology and Hypertension, 1998, 7, 353-358.	1.0	78
71	Behavior and Biology: The Basic Sciences for AHA Action. Stroke, 1998, 29, 739-742.	1.0	1
72	Management of Older Persons After Myocardial Infarction. Journal of the American Geriatrics Society, 1998, 46, 1459-1468.	1.3	12
73	Coughâ€Challenge Trial with a New Angiotensinâ€Converting Enzyme Inhibitor, Imidapril. Journal of Clinical Pharmacology, 1998, 38, 442-446.	1.0	10
74	Alpha ₁ -blocker combination therapy for hypertension. Postgraduate Medicine, 1998, 104, 167-187.	0.9	3

#	ARTICLE	IF	CITATIONS
75	Use of Angiotensinâ€Converting Enzyme Inhibitors as Monotherapy and in Combination with Diuretics and Calcium Channel Blockers. Journal of Clinical Pharmacology, 1998, 38, 477-491.	1.0	9
76	Anger Expression and Incident Hypertension. Psychosomatic Medicine, 1998, 60, 730-735.	1.3	149
77	Recent advances: General medicine. BMJ: British Medical Journal, 1998, 317, 792-795.	2.4	0
79	Screening for diabetes: what are we really doing?. BMJ: British Medical Journal, 1998, 317, 1644-1646.	2.4	24
80	Diuretics, Pâ€blockers and ginâ€andâ€tonic: In reply. Medical Journal of Australia, 1998, 169, 344-344.	0.8	0
81	New Guidelines for Prevention, Detection, Evaluation, and Treatment of Hypertension. Chest, 1998, 113, 263-265.	0.4	23
82	Potential New Cardiovascular Risk Factors: Left Ventricular Hypertrophy, Homocysteine, Lipoprotein(a), Triglycerides, Oxidative Stress, and Fibrinogen. Annals of Internal Medicine, 1999, 131, 376.	2.0	128
83	New Hypertension Guidelines: Commentary. AAOHN Journal, 1999, 47, 114-116.	0.5	O
84	Abated cardiovascular responses to chronic oral lisinopril treatment in conscious elderly rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1999, 276, R1408-R1415.	0.9	3
85	Renal artery stenosis as a cause of renal impairment: implications for treatment of hypertension and congestive heart failure. Journal of the Royal Society of Medicine, 1999, 92, 505-510.	1.1	9
86	British guidelines on managing hypertension. BMJ: British Medical Journal, 1999, 319, 589-590.	2.4	15
87	Hypertension in Athletes and Active Patients. Physician and Sportsmedicine, 1999, 27, 35-44.	1.0	1
88	Increased dietary micronutrients decrease serum homocysteine concentrations in patients at high risk of cardiovascular disease. American Journal of Clinical Nutrition, 1999, 70, 881-887.	2.2	46
89	Assessing the Impact of Medication Consultations with a Medication Event Monitoring System. Hospital Pharmacy, 1999, 34, 539-550.	0.4	8
90	Management of Hypertension for Stroke Prevention in Older People. Clinics in Geriatric Medicine, 1999, 15, 663-684.	1.0	5
91	Physician Knowledge and Practice Patterns Relating to Diabetic Nephropathy. Journal of the American Pharmacists Association, 1999, 39, 785-790.	0.6	14
92	The 1999 WHO–ISH Guidelines for the Management of Hypertension. Medical Journal of Australia, 1999, 171, 458-459.	0.8	59
93	Taking an accurate blood pressure. Practice Nursing, 1999, 10, 31-32.	0.1	0

#	ARTICLE	IF	CITATIONS
94	Hormone replacement therapies in women at risk of cardiovascular disease and osteoporosis in South Australia in 1997. Medical Journal of Australia, 1999, 171, 275-275.	0.8	0
95	6. Does the blood pressure need lowering?. Medical Journal of Australia, 1999, 170, 609-615.	0.8	0
96	Hypertension in Continuous Ambulatory Peritoneal Dialysis Patients: What do we know and What can we do about It?. Peritoneal Dialysis International, 1999, 19, 138-143.	1.1	55
97	Reliability of patients measuring blood pressure at home: prospective observational study. BMJ: British Medical Journal, 1999, 319, 1172-1172.	2.4	53
98	Abnormalities of Kidney Function as a Cause and a Consequence of Cardiovascular Disease. American Journal of the Medical Sciences, 1999, 317, 176-182.	0.4	5
99	Bell's Palsy in an Older Patient with Uncontrolled Hypertension Due to Medication Nonadherence. Annals of Pharmacotherapy, 1999, 33, 1269-1273.	0.9	12
101	Risk Factors for Stroke in Blacks: A Critical Review. American Journal of Epidemiology, 1999, 150, 1266-1274.	1.6	60
102	Trends in Antihypertensive Drug Advertising, 1985–1996. Circulation, 1999, 99, 2055-2057.	1.6	65
103	Effect of Alcohol Abstinence on Blood Pressure. Hypertension, 1999, 33, 653-657.	1.3	92
104	Hypertension in Diet Versus Pharmacologically Treated Diabetics. Hypertension, 1999, 33, 1002-1007.	1.3	20
105	Effect of Hypertension on Mortality in Pima Indians. Circulation, 1999, 100, 33-40.	1.6	22
106	Blood Pressure Response During Treadmill Testing as a Risk Factor for New-Onset Hypertension. Circulation, 1999, 99, 1831-1836.	1.6	375
107	Descriptive Epidemiology of Blood Pressure Response to Change in Body Position. Hypertension, 1999, 33, 1123-1129.	1.3	103
108	Single-Unit Sympathetic Discharge. Circulation, 1999, 100, 1305-1310.	1.6	171
109	Genetic Isolation of a Chromosome 1 Region Affecting Susceptibility to Hypertension-Induced Renal Damage in the Spontaneously Hypertensive Rat. Hypertension, 1999, 34, 187-191.	1.3	47
110	Daily Aerobic Exercise Improves Reactive Hyperemia in Patients With Essential Hypertension. Hypertension, 1999, 33, 591-597.	1.3	153
111	Guide to Preventive Cardiology for Women. Circulation, 1999, 99, 2480-2484.	1.6	317
112	Rarefaction of Skin Capillaries in Borderline Essential Hypertension Suggests an Early Structural Abnormality. Hypertension, 1999, 34, 655-658.	1.3	218

#	ARTICLE	IF	CITATIONS
113	Blood Pressure and the Progression of Carotid Atherosclerosis in Middle-Aged Men. Hypertension, 1999, 34, 51-56.	1.3	120
114	Candesartan Cilexetil: An Angiotensin II Receptor Blocker. Annals of Pharmacotherapy, 1999, 33, 1287-1298.	0.9	14
115	Association of Lifestyle Parameters with the Prevention of Hypertension in Elderly Japanese Men and Women: A Four-Year Follow-up of Normotensive Subjects. Asia-Pacific Journal of Public Health, 1999, 11, 77-81.	0.4	12
116	Differential Impact of Systolic and Diastolic Blood Pressure Level on JNC-VI Staging. Hypertension, 1999, 34, 381-385.	1.3	141
117	Detection and Control of High Blood Pressure in the Community. Hypertension, 1999, 34, 466-471.	1.3	113
118	Risk Mechanisms in Hypertensive Heart Disease. Hypertension, 1999, 34, 782-789.	1.3	161
119	Impaired Renal Adaptation to Stress in the Elderly With Isolated Systolic Hypertension. Hypertension, 1999, 34, 1106-1111.	1.3	16
120	Blood pressure control, microalbuminuria and cardiovascular risk in Type 2 diabetes mellitus. Diabetic Medicine, 1999, 16, 358-372.	1.2	23
121	Reappearance of the J-Shaped Curve. Hypertension, 1999, 34, 1179-1180.	1.3	7
122	Diuretics Shift Circadian Rhythm of Blood Pressure From Nondipper to Dipper in Essential Hypertension. Circulation, 1999, 100, 1635-1638.	1.6	272
123	Medical Aspects of Pregnancy. Journal of Women's Health, 1999, 8, 335-346.	0.9	2
124	Adherent and Nonadherent Medication-Taking in Elderly Hypertensive Patients. Clinical Nursing Research, 1999, 8, 318-335.	0.7	76
125	Pharmacology of irbesartan. Expert Opinion on Investigational Drugs, 1999, 8, 655-670.	1.9	10
126	Implementation of WHO/ISH Guidelines: Role and Activities of WHO. Clinical and Experimental Hypertension, 1999, 21, 659-669.	0.5	6
127	Is Pulse Pressure Useful in Predicting Risk for Coronary Heart Disease?. Circulation, 1999, 100, 354-360.	1.6	1,602
128	A Sibling-Pair Analysis of Fasting Lipids and Anthropometric Measurements and Their Relationship to Hypertension. Clinical and Experimental Hypertension, 1999, 21, 1161-1176.	0.5	21
129	Management of essential hypertension. Expert Opinion on Pharmacotherapy, 1999, 1, 71-80.	0.9	3
130	Antihypertensive Profiles with Ascending Dose Combinations of Ramipril and Felodipine Er. Clinical and Experimental Hypertension, 1999, 21, 1447-1462.	0.5	14

#	Article	IF	CITATIONS
131	The Paradigm Has Shifted, to Systolic Blood Pressure. Hypertension, 1999, 34, 386-387.	1.3	113
132	Clinical management of diabetic nephropathy. Diabetes, Obesity and Metabolism, 1999, 1, 307-315.	2.2	5
133	Letter. Diabetic Medicine, 1999, 16, 528-529.	1.2	7
134	AMLODIPINE, A LONG-ACTING CALCIUM CHANNEL BLOCKER, ATTENUATES MORNING BLOOD PRESSURE RISE IN HYPERTENSIVE PATIENTS. Clinical and Experimental Pharmacology and Physiology, 1999, 26, 500-504.	0.9	17
135	HBV and proteinuria in relatives and contacts of children with hepatitis B virus-associated membranous nephropathy. Kidney International, 1999, 55, 2440-2449.	2.6	15
136	Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney International, 1999, 56, 2214-2219.	2.6	730
137	Efficacy of treating hypertension in women. Journal of General Internal Medicine, 1999, 14, 718-729.	1.3	30
138	Pharmacology of Antihypertensive Drugs. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 1999, 28, 649-659.	0.2	3
139	Cardiovascular Pathways: Socioeconomic Status and Stress Effects on Hypertension and Cardiovascular Function. Annals of the New York Academy of Sciences, 1999, 896, 262-277.	1.8	144
140	The importance of randomized clinical trials and evidenceâ€based medicine: A clinician's perspective. Clinical Cardiology, 1999, 22, 6-12.	0.7	21
141	Nonpharmacologic therapies that reduce blood pressure: A fresh perspective. Clinical Cardiology, 1999, 22, 1-5.	0.7	42
142	Dietary approaches to stop hypertension (DASH) in clinical practice: A primary care experience. Clinical Cardiology, 1999, 22, 16-22.	0.7	38
143	Risk factors for nephropathy in type 2 diabetes mellitus. Comprehensive Therapy, 1999, 25, 366-369.	0.2	8
144	Hypertensive cardiovascular disease in African Americans. Current Hypertension Reports, 1999, 1, 521-528.	1.5	28
145	Obesity, hypertension, and sympathetic nervous system activity. Current Hypertension Reports, 1999, 1, 119-126.	1.5	62
146	Obesity, hypertension, and vascular disease. Current Hypertension Reports, 1999, 1, 140-144.	1.5	8
147	Current Trials. Current Hypertension Reports, 1999, 1, 201-203.	1.5	0
148	Isolated systolic hypertension, pulse pressure, and arterial stiffness as risk factors for cardiovascular disease. Current Hypertension Reports, 1999, 1, 204-211.	1.5	46

#	ARTICLE	IF	CITATIONS
149	The renin-angiotensin system antagonism in the treatment of hypertension. Current Hypertension Reports, 1999, 1, 275-277.	1.5	1
150	Old antihypertensive agents-diuretics and \hat{l}^2 -Blockers: Do we know how and in whom they lower blood pressure?. Current Hypertension Reports, 1999, 1, 296-304.	1.5	10
151	Reflections on the sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Current Hypertension Reports, 1999, 1, 342-345.	1.5	10
152	Three recently published trials in hypertension. Current Hypertension Reports, 1999, 1, 377-378.	1.5	0
153	Hypertension: Goal systolic and diastolic blood pressure. Current Hypertension Reports, 1999, 1, 411-413.	1.5	0
154	Calcium-channel blockers and the progression of renal disease. Current Hypertension Reports, 1999, 1, 436-445.	1.5	16
155	Hypertensive crises. Current Treatment Options in Cardiovascular Medicine, 1999, 1, 1-9.	0.4	0
156	Renal artery stenosis. Current Treatment Options in Cardiovascular Medicine, 1999, 1, 55-62.	0.4	4
157	Summary of the dietary approaches to stop hypertension (dash) randomized clinical trial. Current Treatment Options in Cardiovascular Medicine, 1999, 1, 295-298.	0.4	5
158	Left ventricular hypertrophy. Current Treatment Options in Cardiovascular Medicine, 1999, 1, 219-230.	0.4	5
159	Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction. Progress in Cardiovascular Diseases, 1999, 41, 265-300.	1.6	33
160	Ambulatory blood pressure monitoring and echocardiographyâ€"Noninvasive techniques for evaluation of the hypertensive patient. Progress in Cardiovascular Diseases, 1999, 41, 397-440.	1.6	14
161	Pathophysiologic and prognostic implications of measuring arterial compliance in hypertensive disease. Progress in Cardiovascular Diseases, 1999, 41, 441-450.	1.6	32
162	Nonpharmacologic therapy in hypertension: From single components to overall dietary management. Progress in Cardiovascular Diseases, 1999, 41, 451-460.	1.6	6
163	Special considerations in the therapy of diabetic hypertension. Progress in Cardiovascular Diseases, 1999, 41, 461-470.	1.6	14
164	Influence of age and gender on exercise training-induced blood pressure reduction in systemic hypertension. American Journal of Cardiology, 1999, 84, 192-196.	0.7	79
165	Effects of candesartan cilexetil in patients with severe systemic hypertension. American Journal of Cardiology, 1999, 84, 289-293.	0.7	35
166	Prevalence and prognostic significance of unrecognized systemic hypertension in patients with diabetes mellitus and healed myocardial infarction and/or stable angina pectoris. American Journal of Cardiology, 1999, 84, 294-298.	0.7	19

#	Article	IF	Citations
167	Impact of hypertension and antihypertensive treatment on organ damage. American Journal of Cardiology, 1999, 84, 18-24.	0.7	107
168	Optimal dosing characteristics of the angiotensin II receptor antagonist telmisartan. American Journal of Cardiology, 1999, 84, 7-12.	0.7	13
169	Guidelines for assessing outcomes of antihypertensive treatment. American Journal of Cardiology, 1999, 84, 2-4.	0.7	9
170	Relation of maximum blood pressure during exercise and regular physical activity in normotensive men with left ventricular mass and hypertrophy. American Journal of Cardiology, 1999, 84, 890-893.	0.7	27
171	Value of a simple echocardiographic linear predictor of left ventricular mass in systemic hypertension. American Journal of Cardiology, 1999, 84, 1209-1214.	0.7	9
172	Long-term benefits of angiotensin II blockade: is the consensus changing?. American Journal of Cardiology, 1999, 84, 16-21.	0.7	54
173	Do pharmacologic differences among antihypertensive agents point to clinical benefits?. American Journal of Cardiology, 1999, 84, 22-27.	0.7	1
174	Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension. American Journal of Cardiology, 1999, 84, 28-34.	0.7	99
175	Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension. American Journal of Cardiology, 1999, 84, 35-41.	0.7	13
176	Nutritionally Complete Prepared Meal Plan to Reduce Cardiovascular Risk Factors. Journal of the American Dietetic Association, 1999, 99, 1077-1083.	1.3	34
177	Outcomes of a Cardiovascular Nutrition Counseling Program in African-Americans with Elevated Blood Pressure or Cholesterol Level. Journal of the American Dietetic Association, 1999, 99, 1380-1391.	1.3	39
178	The Effects of Dietary Patterns on Quality of Life. Journal of the American Dietetic Association, 1999, 99, S84-S89.	1.3	60
179	Translating the Dietary Approaches to Stop Hypertension Diet from Research to Practice. Journal of the American Dietetic Association, 1999, 99, S90-S95.	1.3	24
180	Current status of calcium channel blockers in patients with cardiovascular disease. Current Problems in Cardiology, 1999, 24, 229-340.	1.1	13
181	The diabetic patient as paradigm for selective antihypertensive therapy. Clinical Cornerstone, 1999, 2, 1-12.	1.0	10
182	Update on Hypertension Management. Geriatric Nursing, 1999, 20, 218-219.	0.9	5
183	Galenic Development and Pharmacokinetic Profile of Indapamide Sustained Release 1.5mg. Clinical Pharmacokinetics, 1999, 37, 13-19.	1.6	8
184	Clinical Implications of Indapamide Sustained Release 1.5mg in Hypertension. Clinical Pharmacokinetics, 1999, 37, 21-32.	1.6	9

#	Article	IF	Citations
185	Concluding Remarks. Clinical Pharmacokinetics, 1999, 37, 33-38.	1.6	4
186	THE TREATMENT OF HYPERTENSION AND DYSLIPIDEMIA IN DIABETES MELLITUS. Primary Care - Clinics in Office Practice, 1999, 26, 951-964.	0.7	5
188	Finding Consensus in the Dietary Calcium-Blood Pressure Debate. Journal of the American College of Nutrition, 1999, 18, 398S-405S.	1.1	100
189	Effect of Dietary Fiber and Protein Intake on Blood Pressure: A Review of Epidemiologic Evidence. Clinical and Experimental Hypertension, 1999, 21, 785-796.	0.5	128
190	1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Clinical and Experimental Hypertension, 1999, 21, 1009-1060.	0.5	471
191	Long-Term Safety and Antihypertensive Efficacy of Irbesartan: Pooled Results of Five Open-Label Studies. Clinical and Experimental Hypertension, 1999, 21, 1273-1295.	0.5	26
192	α-Blockers in Hypertension. Current Medical Research and Opinion, 1999, 15, 95-103.	0.9	14
193	Quantifying Risk of Death and Disability Associated with Raised Blood Pressure. Clinical and Experimental Hypertension, 1999, 21, 571-582.	0.5	5
194	Implementation of International Guidelines on Hypertension: The Indian Experience. Clinical and Experimental Hypertension, 1999, 21, 693-701.	0.5	2
195	Pharmacodynamics and Pharmacokinetics of Irbesartan in Patients With Mild to Moderate Hypertension. Journal of Cardiovascular Pharmacology and Therapeutics, 1999, 4, 67-75.	1.0	8
196	Thiazide Diuretics in Hypertension. Clinical and Experimental Hypertension, 1999, 21, 805-814.	0.5	4
197	Compliance with Antihypertensive Therapy. Clinical and Experimental Hypertension, 1999, 21, 973-985.	0.5	87
198	The Antihypertensive Efficacy of the Combination of Irbesartan and Hydrochlorotfflazide Assessed by 24-Hour Ambulatory Blood Pressure Monitoring. Clinical and Experimental Hypertension, 1999, 21, 1373-1396.	0.5	36
199	Women's health, chronic disease, and disease management: new words and old music?. Women's Health Issues, 1999, 9, 2-17.	0.9	16
200	Penn Health for Women: the evolution of a women's health program in an academic setting. Women's Health Issues, 1999, 9, 162-175.	0.9	0
201	Quality measurement issues in heart disease in women. Women's Health Issues, 1999, 9, 241-249.	0.9	0
202	JNC-VI, hypertension, and you. Home Care Provider, 1999, 4, 142-143.	0.1	0
203	Antihypertensive agents. Journal of Perianesthesia Nursing, 1999, 14, 278-283.	0.3	O

#	Article	IF	Citations
204	Population Trends in Antihypertensive Drug Use. Journal of Clinical Epidemiology, 1999, 52, 695-703.	2.4	29
205	The acute effects of sublingual estradiol on left ventricular diastolic function in normotensive and hypertensive postmenopausal women. Maturitas, 1999, 33, 145-152.	1.0	12
206	Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. American Journal of Kidney Diseases, 1999, 34, 809-817.	2.1	170
207	Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. American Journal of Kidney Diseases, 1999, 33, 225-234.	2.1	231
208	Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation. American Journal of Kidney Diseases, 1999, 33, 1004-1010.	2.1	528
209	Trandolapril and human diabetic neuropathy. Lancet, The, 1999, 353, 926.	6.3	5
210	Trandolapril and human diabetic neuropathy. Lancet, The, 1999, 353, 927.	6.3	0
211	Which drug for treatment of hypertension?. Lancet, The, 1999, 353, 604-605.	6.3	31
212	Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet, The, 1999, 353, 611-616.	6.3	1,938
213	Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet, The, 1999, 353, 2008-2013.	6.3	323
214	Lifetime risk of developing coronary heart disease. Lancet, The, 1999, 353, 89-92.	6.3	796
215	Cardiovascular and renal function in normotensive and hypertensive patients with compensated cirrhosis: effects of posture. Journal of Hepatology, 1999, 30, 632-638.	1.8	42
216	Long-term effects of lercanidipine on the lipoprotein and apolipoprotein profile of patients with mild-to-moderate essential hypertension. Current Therapeutic Research, 1999, 60, 228-236.	0.5	10
217	EVALUATION AND TREATMENT OF HYPERTENSION. Rheumatic Disease Clinics of North America, 1999, 25, 521-537.	0.8	3
222	HYPERTENSION IN THE ELDERLY. Cardiology Clinics, 1999, 17, 79-92.	0.9	13
223	Nebivolol in the Management of Essential Hypertension. Drugs, 1999, 57, 633-651.	4.9	96
224	Perindopril 2mg/Indapamide 0.625mg. Drugs, 1999, 58, 297-302.	4.9	6
225	Perindopril/Indapamide. Drugs, 1999, 58, 303-304.	4.9	1

#	Article	IF	CITATIONS
226	How to Use Calcium Antagonists in Hypertension. Drugs, 1999, 58, 579-587.	4.9	14
227	Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction. Journal of the American College of Cardiology, 1999, 33, 1948-1955. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina 11 This	1.2	1,245
228	document was approved by the American College of Cardiology Board of Trustees in March 1999, the American Heart Association Science Advisory and Coordinating Committee in March 1999, and the American College of Physicians-American Society of Internal Medicine Board of Regents in February 1999. When citing this document, please use the following citation format: Gibbons RJ, Chatterjee K,	1.2	608
229	The necessity for Fecognition Candure at mehre of patients with gae of milda the pertension is 1200 and investment was written during Dr. Frohlicha €™s tenure representing the American College of Cardiology on the Joint National Committee of the National High Blood Pressure Education Program of the National Heart. Lung, and Blood Institute lournal of the American College of Cardiology. 1999. 34. 1369-1377.	1.2	5
230	Hypertension detection, treatment and control. Journal of the American College of Cardiology, 1999, 34, 1360-1362.	1.2	13
231	Static and pulsatile blood pressure correlates of left ventricular structure and function in black and white young adults: The CARDIA study. American Heart Journal, 1999, 138, 856-864.	1.2	48
232	Elevated systolic blood pressure and risk of cardiovascular and renal disease: Overview of evidence from observational epidemiologic studies and randomized controlled trials. American Heart Journal, 1999, 138, S211-S219.	1.2	261
233	Risk reduction associated with lowering systolic blood pressure: Review of clinical trial data. American Heart Journal, 1999, 138, S225-S230.	1.2	28
234	Risk factors for heart failure in the elderly: a prospective community-based study. American Journal of Medicine, 1999, 106, 605-612.	0.6	236
235	Aerobic Exercise and Resting Blood Pressure among Women: A Meta-Analysis. Preventive Medicine, 1999, 28, 264-275.	1.6	79
236	Pharmacist Counseling on Nutrition and Physical Activity â€" Part 1 of 2: Understanding Current Guidelines. Journal of the American Pharmacists Association, 1999, 39, 479-491.	0.6	9
237	Imaging and stenting for renal artery stenosis. British Journal of Hospital Medicine, 1999, 60, 329-336.	0.3	0
238	Length of Dialysis Session Is More Important Than Large Kt/V in Hemodialysis. Home Hemodialysis International International Symposium on Daily Home Hemodialysis, 1999, 3, 16-22.	0.8	16
239	Dealing with diabetic nephropathy. Postgraduate Medicine, 1999, 105, 83-94.	0.9	10
240	Safer Alternatives to Sublingual Nifedipine for the Treatment of Hypertensive Urgencies. Journal of Pharmacy Technology, 1999, 15, 199-203.	0.5	2
241	Antihypertensive drugs. Side Effects of Drugs Annual, 1999, 22, 224-232.	0.6	0
242	Pharmacist Counseling on Nutrition and Physical Activityâ€" Part 2 of 2: Helping Patients Make Changes. Journal of the American Pharmacists Association, 1999, 39, 613-627.	0.6	8
243	Drug Treatment of Hypertension in Older Persons in an Academic Hospital-Based Geriatrics Practice. Journal of the American Geriatrics Society, 1999, 47, 597-599.	1.3	25

#	ARTICLE	IF	CITATIONS
244	1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Journal of Hypertension, 1999, 17, 151???183.	0.3	1,232
245	Strength Training Normalizes Resting Blood Pressure in 65―to 73â€Yearâ€Old Men and Women with High Normal Blood Pressure. Journal of the American Geriatrics Society, 1999, 47, 1215-1221.	1.3	67
246	Measuring Blood Pressure and Treating Hypertension in (Frail) Older People. Journal of the American Geriatrics Society, 1999, 47, 373-374.	1.3	0
247	Supplement to the Guidelines for the Management of Transient Ischemic Attacks. Stroke, 1999, 30, 2502-2511.	1.0	156
248	1999 World Health Organization $\hat{a} \in$ "International Society of Hypertension Guidelines for the Management of Hypertension. Blood Pressure, 1999, 8, 9-43.	0.7	303
249	Ambulatory Blood Pressure, Heart Rate, and Neuroendocrine Responses in Women Nurses During Work and Off Work Days. Psychosomatic Medicine, 1999, 61, 387-396.	1.3	73
250	Angiotensin-converting enzyme and cardiovascular disease risk. Current Opinion in Lipidology, 1999, 10, 407-416.	1.2	19
251	Blood pressure level and incidence of myocardial infarction among patients treated for hypertension American Journal of Public Health, 1999, 89, 1414-1417.	1.5	22
252	Age―and Genderâ€Related Use of Lowâ€Dose Drug Therapy: The Need to Manufacture Lowâ€Dose Therapy and Evaluate the Minimum Effective Dose. Journal of the American Geriatrics Society, 1999, 47, 954-959.	1.3	32
253	Torasemide Inhibits Angiotensin II–Induced Vasoconstriction and Intracellular Calcium Increase in the Aorta of Spontaneously Hypertensive Rats. Hypertension, 1999, 34, 138-143.	1.3	48
254	Impact of Hypertension Guideline Implementation on Blood Pressure Control and Drug Use in Primary Care Clinics. The Joint Commission Journal on Quality Improvement, 1999, 25, 68-77.	1.5	28
255	Adapting a National Guideline for Local Use: A Comparative Case Study in a US and an Israeli Health Maintenance Organization. Journal of Health Services Research and Policy, 2000, 5, 148-155.	0.8	9
256	Improving Hypertension Control: A Team Approach in a Primary Care Setting. The Joint Commission Journal on Quality Improvement, 2000, 26, 623-632.	1.5	20
257	Does Blood Pressure Control by Gentle Ultrafiltration Improve Survival in Hemodialysis Patients?. Hemodialysis International, 2000, 4, 62-67.	0.4	2
258	Pharmacotherapy for hypertension in women of different races. The Cochrane Library, 2000, , CD002146.	1.5	10
259	Antihypertensive Effect of Low-Dose Hydrochlorothiazide Alone or in Combination with Quinapril in Black Patients with Mild to Moderate Hypertension. Journal of Clinical Pharmacology, 2000, 40, 713-721.	1.0	11
260	Admission Serum Potassium in Patients With Acute Myocardial Infarction. Chest, 2000, 118, 904-913.	0.4	56
261	Risk Factors for Symptomatic Peripheral Arterial Disease in Older Persons in an Academic Hospital-Based Geriatrics Practice. Journal of the American Geriatrics Society, 2000, 48, 312-314.	1.3	7 5

#	Article	IF	Citations
262	Effect of Voluntary Weight Loss on Bone Mineral Density in Older Overweight Women. Journal of the American Geriatrics Society, 2000, 48, 753-759.	1.3	104
263	Risk of Stroke in Relation to Level of Blood Pressure and Other Risk Factors in Treated Hypertensive Patients. Stroke, 2000, 31, 48-52.	1.0	21
264	Control of Blood Pressure and Risk of Stroke Among Pharmacologically Treated Hypertensive Patients. Stroke, 2000, 31, 420-424.	1.0	66
265	An Overview of Antihypertensive Therapy in the 20th Century. Journal of Clinical Pharmacology, 2000, 40, 967-977.	1.0	19
266	Physician-evaluated and self-reported morbidity for predicting disability. American Journal of Public Health, 2000, 90, 103-108.	1.5	63
267	MANAGEMENT OF MILD CHRONIC HYPERTENSION DURING PREGNANCY. Obstetrics and Gynecology, 2000, 96, 849-860.	1.2	4
268	The Association of Left Ventricular Mass with Cardiovascular Risk Factors in African American Women. American Journal of the Medical Sciences, 2000, 320, 13-17.	0.4	2
269	Clinical Preventive Medicine in Primary Care: Background and Practice: 1. Rationale and Current Preventive Practices. Mayo Clinic Proceedings, 2000, 75, 165-172.	1.4	33
270	Blood Pressure Exceeding National Guidelines Among Women After Stroke. Stroke, 2000, 31, 415-419.	1.0	39
271	G-Protein \hat{I}^2 3 subunit gene (GNB3) polymorphism 825C→T in patients with hypertensive crisis. Critical Care Medicine, 2000, 28, 3203-3206.	0.4	20
272	The Future of Clinical Trials in Chronic Renal Disease: Outcome of an NIH/FDA/Physician Specialist Conference. Journal of Clinical Pharmacology, 2000, 40, 815-825.	1.0	16
273	Evolution of Drugs That Preserve Renal Function. Journal of Clinical Pharmacology, 2000, 40, 978-989.	1.0	5
274	Contributing factors in resistant hypertension. Postgraduate Medicine, 2000, 107, 57-70.	0.9	15
275	Self-Reported Cardiac Risk Factors in Emergency Department Nurses and Paramedics. Prehospital and Disaster Medicine, 2000, 15, 14-17.	0.7	17
276	Diet, blood pressure and hypertension. British Journal of Nutrition, 2000, 83, S113-S119.	1.2	152
277	Selecting antihypertensive therapy in the pregnant woman with diabetes mellitus., 2000, 9, 66-69.		3
278	Color Doppler sonographic appearance of renal perforating vessels in subjects with normal and impaired renal function. Journal of Clinical Ultrasound, 2000, 28, 267-276.	0.4	27
279	Selective use of calcium channel blockers to treat high-risk hypertensive patients. , 2000, 9, 1-9.		5

#	Article	IF	Citations
280	The calcium-channel blocker controversy: historical perspective and important lessons for future pharmacotherapies. An international society of pharmacoepidemiology ?hot topic?., 2000, 9, 25-35.		7
281	Early detection of undiagnosed diabetes mellitus: a US perspective. Diabetes/Metabolism Research and Reviews, 2000, 16, 230-236.	1.7	229
282	Blood pressure reactivity to mental stress and aerobic fitness in normotensive young adult African-American males with parental history of hypertension. Stress and Health, 2000, 16, 219-227.	0.7	1
283	Inadequate diagnosis and therapy of arterial hypertension as causes of left ventricular hypertrophy in uremic dialysis patients. Kidney International, 2000, 58, 260-268.	2.6	58
284	Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney International, 2000, 58, 353-362.	2.6	662
285	Pulse pressure and isolated systolic hypertension: Association with microalbuminuria. Kidney International, 2000, 58, 1211-1218.	2.6	82
286	Long-term survival in renal transplant recipients with graft function. Kidney International, 2000, 57, 307-313.	2.6	704
287	Women's health. Journal of General Internal Medicine, 2000, 15, 600-602.	1.3	14
289	The challenge of obesity-related chronic diseases. Journal of General Internal Medicine, 2000, 15, 828-829.	1.3	27
290	Failure of evidence-based medicine in the treatment of hypertension in older patients. Journal of General Internal Medicine, 2000, 15, 702-709.	1.3	30
291	Vascular disease prevention in patients with diabetes. Diabetes, Obesity and Metabolism, 2000, 2, 25-36.	2.2	5
292	Using dose-response characteristics of therapeutic agents for treatment decisions in type 2 diabetes. Diabetes, Obesity and Metabolism, 2000, 2, 139-147.	2.2	17
293	Implications of cardiovascular risk in patients with type 2 diabetes who have abnormal lipid profiles: is lower enough?. Diabetes, Obesity and Metabolism, 2000, 2, 263-270.	2.2	4
294	A double-blind placebo-controlled study of the effectiveness and tolerability of oral stevioside in human hypertension. British Journal of Clinical Pharmacology, 2000, 50, 215-220.	1.1	186
295	Achieving haemodynamic baseline values with Finapres in elderly subjects during supine rest. Clinical Physiology, 2000, 20, 466-473.	0.7	10
296	Microvascular angina (cardiological syndrome X) per se is not associated with hyperinsulinaemia or insulin resistance. European Journal of Clinical Investigation, 2000, 30, 481-486.	1.7	13
297	Trends in lipid levels and hypercholesterolemia in hypertensive and normotensive Finnish adults from 1982 to 1997. Journal of Internal Medicine, 2000, 247, 53-62.	2.7	21
298	Prevalence of carotid artery kinking in 590 consecutive subjects evaluated by Echocolordoppler. Is there a correlation with arterial hypertension?. Journal of Internal Medicine, 2000, 248, 7-12.	2.7	120

#	Article	IF	Citations
299	Non-linear effects of blood pressure and glycosylated haemoglobin on progression of diabetic nephropathy. Journal of Internal Medicine, 2000, 247, 131-138.	2.7	11
300	Controlled drug delivery: therapeutic and pharmacological aspects. Journal of Internal Medicine, 2000, 248, 357-376.	2.7	38
301	Microvascular complications of diabetes: the role of angiotensin converting enzyme inhibitors Proceedings of a Round Table Meeting, June 1999, San Diego, USA. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2000, 17, S1-S12.	0.2	0
302	Defining the margins for errors in patient compliance with prescribed drug regimens. Pharmacoepidemiology and Drug Safety, 2000, 9, 565-568.	0.9	15
303	Co-morbidity of ?Clinical Trial? versus ?Real-World? patients using cardiovascular drugs. Pharmacoepidemiology and Drug Safety, 2000, 9, 569-579.	0.9	23
304	Assistance programs available for medications commonly used in transplant patients. Clinical Transplantation, 2000, 14, 269-281.	0.8	5
305	Hypertension in patients presenting with epistaxis. Annals of Emergency Medicine, 2000, 35, 126-130.	0.3	71
306	The Trp64Arg polymorphism of the \hat{I}^2 3-adrenergic receptor gene and obesity in Chinese subjects with components of the metabolic syndrome. International Journal of Obesity, 2000, 24, 545-551.	1.6	7 3
307	Overweight, Obesity, and Blood Pressure: The Effects of Modest Weight Reduction. Obesity, 2000, 8, 270-278.	4.0	241
308	Diabetes mellitus and coronary heart disease ―from prevention to intervention: Part I. Australian and New Zealand Journal of Medicine, 2000, 30, 351-359.	0.5	8
309	Cardiovascular disease prevention practices by U.S. physicians for patients with diabetes. Journal of General Internal Medicine, 2000, 15, 220-228.	1.3	55
310	Pretreatment blood pressure reliably predicts progression of chronic nephropathies. Kidney International, 2000, 58, 2093-2101.	2.6	10
311	Importance of blood pressure control in hemodialysis patient survival. Kidney International, 2000, 58, 2147-2154.	2.6	148
312	Pre-operative evaluation and risk assessment of patients undergoing vascular surgery. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2000, 14, 1-16.	1.7	0
313	The effects of alpha2-adrenoceptor agonists on circulation and respiration. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2000, 14, 449-458.	1.7	2
314	Cardiovascular risk in diabetes. Journal of Diabetes and Its Complications, 2000, 14, 108-115.	1.2	86
315	Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: A critical analysis based on 100 studies. Progress in Cardiovascular Diseases, 2000, 43, 171-196.	1.6	94
316	Hypertension, hormones, and aging. Translational Research, 2000, 135, 379-386.	2.4	25

#	Article	IF	CITATIONS
317	A Hemodynamic Approach to Resistant Hypertension. Congestive Heart Failure, 2000, 6, 90-93.	2.0	4
318	The prevalence and prognostic significance of electrocardiographic abnormalities. Current Problems in Cardiology, 2000, 25, 1-72.	1.1	87
319	Serum Leptin Levels and Blood Pressure in the Overweight Elderly. Archives of Medical Research, 2000, 31, 425-428.	1.5	30
320	Response:. Journal of the American Dietetic Association, 2000, 100, 1300-1303.	1.3	1
321	Prognosis of congestive heart failure after prior myocardial infarction in older men and women with abnormal versus normal left ventricular ejection fraction. American Journal of Cardiology, 2000, 85, 1382-1384.	0.7	44
322	Increased plasma homocysteine is an independent predictor of new coronary events in older persons. American Journal of Cardiology, 2000, 86, 346-347.	0.7	23
323	Increased plasma homocysteine is an independent predictor of new atherothrombotic brain infarction in older persons. American Journal of Cardiology, 2000, 86, 585-586.	0.7	25
324	Certain cardiac risk factors predict risk factor interventions and influence communication between physicians and patients. American Journal of Cardiology, 2000, 86, 783-785.	0.7	1
325	Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. American Journal of Cardiology, 2000, 86, 1182-1187.	0.7	122
326	The role of diet in the prevention and treatment of hypertension. Current Atherosclerosis Reports, 2000, 2, 521-528.	2.0	32
327	Development and assessment of antiatherosclerotic therapies beyond low-density lipoprotein cholesterol and blood pressure. Current Atherosclerosis Reports, 2000, 2, 281-283.	2.0	0
328	Doxazosin arm of the ALLHAT study discontinued: How equal are antihypertensive drugs?. Current Hypertension Reports, 2000, 2, 241-242.	1.5	4
329	Joint national committee VI: Individualized versus indiscriminate therapy for hypertension. Current Hypertension Reports, 2000, 2, 243-246.	1.5	3
330	The influence of national guidelines on antihypertensive prescribing patterns. Current Hypertension Reports, 2000, 2, 247-252.	1.5	9
331	Is there a preferred antihypertensive therapy for isolated systolic hypertension and reduced arterial compliance?. Current Hypertension Reports, 2000, 2, 253-259.	1.5	30
332	Optimal antihypertensive therapy for prevention and treatment of left ventricular hypertrophy. Current Hypertension Reports, 2000, 2, 260-270.	1.5	0
333	Antihypertensive drug therapy in the third millennium: Are there benefits beyond blood pressure?. Current Hypertension Reports, 2000, 2, 291-294.	1.5	1
334	Treatment of hypertension in diabetes mellitus. Current Hypertension Reports, 2000, 2, 335-342.	1.5	8

#	ARTICLE	IF	CITATIONS
335	The need to lower systolic blood pressure. Current Hypertension Reports, 2000, 2, 433-440.	1.5	4
336	How aggressively should blood pressure be treated in renal transplant recipients?. Current Hypertension Reports, 2000, 2, 473-477.	1.5	2
337	The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure. Current Hypertension Reports, 2000, 2, 378-383.	1.5	12
338	Vasopeptidase inhibition: A new direction in cardiovascular treatment. Current Hypertension Reports, 2000, 2, 384-391.	1.5	9
339	Angiotensin converting enzyme inhibitors: Are they preferred first-line therapy?. Current Hypertension Reports, 2000, 2, 392-397.	1.5	0
340	Evidence-based treatment of hypertension. Current Hypertension Reports, 2000, 2, 398-398.	1.5	3
341	Treatment of white coat hypertension. Current Hypertension Reports, 2000, 2, 412-417.	1.5	24
342	Postmenopausal hypertension. Current Hypertension Reports, 2000, 2, 202-207.	1.5	34
343	Preventing renal disease progression: Is it the drug or the blood pressure reduction, or both?. Current Hypertension Reports, 2000, 2, 497-499.	1.5	3
344	Observational studies of antihypertensive medication use and compliance: Is drug choice a factor in treatment adherence?. Current Hypertension Reports, 2000, 2, 515-524.	1.5	60
345	Recent advances in the management of hypertension in the elderly. Current Hypertension Reports, 2000, 2, 543-550.	1.5	1
346	Hypertension in patients presenting with stroke. Current Hypertension Reports, 2000, 2, 551-557.	1.5	4
347	Ambulatory blood pressure monitoring. Current Hypertension Reports, 2000, 2, 558-564.	1.5	23
348	Unstable angina. Current Treatment Options in Cardiovascular Medicine, 2000, 2, 37-53.	0.4	0
349	Cardiovascular responses to anesthetic induction in patients chronically treated with angiotensin-converting enzyme inhibitors. Canadian Journal of Anaesthesia, 2000, 47, 433-440.	0.7	53
350	Antihypertensive Therapy: Beta-Blockers and Diuretics—Why Do Physicians Not Always Follow Guidelines?. Baylor University Medical Center Proceedings, 2000, 13, 128-134.	0.2	10
351	Other Views (Commentary on "Antihypertensive Therapy: Beta-Blockers and Diureticsâ€). Baylor University Medical Center Proceedings, 2000, 13, 131-136.	0.2	0
352	New therapies in diabetes – thiazolidinediones. Expert Opinion on Emerging Drugs, 2000, 5, 441-456.	1.1	7

#	ARTICLE	IF	CITATIONS
353	Ischemia and fibrosis: the risk mechanisms of hypertensive heart disease. Brazilian Journal of Medical and Biological Research, 2000, 33, 693-700.	0.7	17
354	PGH ₂ -TxA ₂ -receptor blockade restores vasoreactivity in a new rodent model of genetic hypertension. Journal of Applied Physiology, 2000, 88, 1983-1988.	1.2	16
355	Nutritionâ€Related Cardiovascular Risk Factors in Older People: Results from the Third National Health and Nutrition Examination Survey. Journal of the American Geriatrics Society, 2000, 48, 1486-1489.	1.3	12
356	Unrecognized High Blood Pressure. AAOHN Journal, 2000, 48, 338-343.	0.5	8
358	A Pharmacokinetic and Pharmacodynamic Study of the Potential Drug Interaction between Tasosartan and Atenolol in Patients with Stage 1 and 2 Essential Hypertension. Journal of Clinical Pharmacology, 2000, 40, 231-241.	1.0	3
359	Importance of Systolic Blood Pressure in Older Americans. Hypertension, 2000, 35, 1021-1024.	1.3	363
360	Serum Carboxy-Terminal Propeptide of Procollagen Type I Is a Marker of Myocardial Fibrosis in Hypertensive Heart Disease. Circulation, 2000, 101, 1729-1735.	1.6	334
361	Platelet-Derived Nitric Oxide and Coronary Risk Factors. Hypertension, 2000, 35, 904-907.	1.3	60
362	Recognition of Systolic Hypertension for Hypertension. Hypertension, 2000, 35, 1019-1020.	1.3	14
363	Modern approaches to blood pressure measurement. Occupational and Environmental Medicine, 2000, 57, 510-520.	1.3	57
364	Can Aerobic Exercise Training Be Hazardous to Human Vessels?. Circulation, 2000, 102, E168.	1.6	2
365	Hypertension Risk Status and Effect of Caffeine on Blood Pressure. Hypertension, 2000, 36, 137-141.	1.3	125
366	Review: low-dose thiazides are the most effective first-line drugs for hypertension. Evidence-Based Medicine, 2000, 5, 10-10.	0.6	0
367	Glucocorticoid-Remediable Aldosteronism and Pregnancy. Hypertension, 2000, 35, 668-672.	1.3	59
368	Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ: British Medical Journal, 2000, 321, 412-419.	2.4	1,737
369	Response to Antihypertensive Therapy in Older Patients With Sustained and Nonsustained Systolic Hypertension. Circulation, 2000, 102, 1139-1144.	1.6	271
370	Evidence for a Gene Influencing Blood Pressure on Chromosome 17. Hypertension, 2000, 36, 477-483.	1.3	534
371	Transient U Wave Inversion During Treadmill Exercise Testing in Patients with Left Anterior Descending Coronary Artery Disease. Angiology, 2000, 51, 581-589.	0.8	10

#	Article	IF	CITATIONS
372	Hypertension in the Political Arena. Hypertension, 2000, 35, 1179-1182.	1.3	17
373	Captopril prevention project—what shall we do about captopril and the risk of stroke?. Nephrology Dialysis Transplantation, 2000, 15, 2-5.	0.4	9
374	Identifying patients at risk for coronary heart disease: implications from trials of lipidâ€lowering drug therapy. QJM - Monthly Journal of the Association of Physicians, 2000, 93, 567-574.	0.2	30
375	Benefits of Dairy Product Consumption on Blood Pressure in Humans: A Summary of the Biomedical Literature. Journal of the American College of Nutrition, 2000, 19, 147S-164S.	1.1	79
376	Diuretic Complications. American Journal of the Medical Sciences, 2000, 319, 10-24.	0.4	130
377	The Diagnosis and Management of Hypertensive Crises. Chest, 2000, 118, 214-227.	0.4	246
378	Evidence-based therapy for type 2 diabetes. Postgraduate Medicine, 2000, 107, 27-47.	0.9	6
379	Gender Differences in the Prevalence of Metabolic Complications in Familial Partial Lipodystrophy (Dunnigan Variety)*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1776-1782.	1.8	139
380	Exercise Guidance in Hypertension. Physician and Sportsmedicine, 2000, 28, 81-82.	1.0	2
381	RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM GENE POLYMORPHISMS AND HYPERTENSION IN HONG KONG CHINESE. Clinical and Experimental Hypertension, 2000, 22, 87-97.	0.5	34
382	Hypokalemia Associated With Diuretic Use and Cardiovascular Events in the Systolic Hypertension in the Elderly Program. Hypertension, 2000, 35, 1025-1030.	1.3	278
383	Lipid Management and Control of Other Coronary Risk Factors in the Postmenopausal Woman. Journal of Women's Health and Gender-Based Medicine, 2000, 9, 235-243.	1.7	2
384	Hypertension Incidence Is Predicted by High Levels of Hopelessness in Finnish Men. Hypertension, 2000, 35, 561-567.	1.3	145
386	ACE inhibition and AT1 receptor blockers: efficacy and duration in hypertension. British Heart Journal, 2000, 84, 39i-41.	2.2	4
387	New Issues in the Treatment of Isolated Systolic Hypertension. Circulation, 2000, 102, 1079-1081.	1.6	30
388	Resting Metabolic Rate and Substrate Use in Obesity Hypertension. Hypertension, 2000, 36, 26-32.	1.3	66
389	Regular Aerobic Exercise Prevents and Restores Age-Related Declines in Endothelium-Dependent Vasodilation in Healthy Men. Circulation, 2000, 102, 1351-1357.	1.6	760
390	The past, present and future of hypertension management: a potential role for AT1-receptor antagonists. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2000, 1, 5-10.	1.0	14

#	Article	IF	CITATIONS
391	Chronic I ₁ -Imidazoline Agonism. Hypertension, 2000, 35, 1264-1269.	1.3	32
392	Regular Aerobic Exercise Augments Endothelium-Dependent Vascular Relaxation in Normotensive and Hypertensive Subjects: Role of Endothelium-Derived Nitric Oxide. Circulation, 2000, 102, E119-20.	1.6	4
394	Increased Arterial Intima-Media Thickness and In Vivo LDL Oxidation in Young Men With Borderline Hypertension. Hypertension, 2000, 36, 929-933.	1.3	120
395	Brachial Artery Blood Flow Velocity Pattern in Patients with Congestive Heart Failure: Duplex Doppler Ultrasonographic Assessment. Angiology, 2000, 51, 207-212.	0.8	4
396	Essential Hypertension. Circulation, 2000, 101, 329-335.	1.6	829
397	Positional Genomic Analysis Identifies the \hat{I}^2 2 -Adrenergic Receptor Gene as a Susceptibility Locus for Human Hypertension. Circulation, 2000, 101, 2877-2882.	1.6	170
398	Increased Vascular Adrenergic Vasoconstriction and Decreased Vasodilation in Blacks. Hypertension, 2000, 36, 945-951.	1.3	127
399	A Chronobiologic Approach to the Pharmacotherapy of Hypertension and Angina. Annals of Pharmacotherapy, 2000, 34, 1313-1319.	0.9	5
400	Differential Control of Systolic and Diastolic Blood Pressure. Hypertension, 2000, 36, 594-599.	1.3	378
401	Diastolic blood pressure and weight gain predicted future risk of hypertension. Evidence-based Nursing, 2000, 3, 26-26.	0.1	0
402	Invited Review: The Medical Management of Obesity and the Role of Pharmacotherapy: An Update. Nutrition in Clinical Practice, 2000, 15, 5-12.	1.1	2
403	Doxazosin was associated with more stroke and cardiovascular disease events than chlorthalidone in high risk hypertension. Evidence-Based Medicine, 2000, 5, 172-172.	0.6	0
404	Trends in Antihypertensive Drug Treatment. Circulation, 2000, 101, E209.	1.6	0
405	Ambulatory Blood Pressure Monitoring and Postprandial Hypotension in Elderly Persons With Falls or Syncopes. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2000, 55, M535-M540.	1.7	85
406	Transforming Growth Factor \hat{l}^2 in Hypertensives With Cardiorenal Damage. Hypertension, 2000, 36, 517-522.	1.3	125
407	Two-Year Changes in Blood Pressure and Subsequent Risk of Cardiovascular Disease in Men. Circulation, 2000, 102, 307-312.	1.6	38
408	A genetic model defines the importance of the atrial natriuretic peptide receptor (guanylyl cyclase-A) in the regulation of kidney function. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 4369-4373.	3.3	40
409	Trends in Antihypertensive Drug Therapy of Ambulatory Patients by US Office-Based Physicians. Hypertension, 2000, 36, 600-603.	1.3	67

#	Article	IF	CITATIONS
410	Systolic and Diastolic Blood Pressure, Pulse Pressure, and Mean Arterial Pressure as Predictors of Cardiovascular Disease Risk in Men. Hypertension, 2000, 36, 801-807.	1.3	470
411	The Use of ACE Inhibitors as Renoprotective Agents in Medicaid Patients with Diabetes. Annals of Pharmacotherapy, 2000, 34, 1002-1006.	0.9	20
412	Vascular events in hypertensive patients with systemic lupus erythematosus. Lupus, 2000, 9, 672-675.	0.8	50
413	Treatment of Hypertension in the Perioperative Patient. Annals of Pharmacotherapy, 2000, 34, 66-79.	0.9	23
414	Association of Blood Pressure With Fibrinolytic Potential in the Framingham Offspring Population. Circulation, 2000, 101, 264-269.	1.6	167
415	Independent Association of High Blood Pressure and Aortic Atherosclerosis. Circulation, 2000, 102, 2087-2093.	1.6	112
416	High- or Low-Salt Diet From Weaning to Adulthood. Hypertension, 2000, 35, 424-429.	1.3	62
417	Prevalence, Treatment, and Control of Hypertension by Sociodemographic Factors Among the Dutch Elderly. Hypertension, 2000, 35, 814-821.	1.3	87
418	Prognostic Value of Ambulatory Blood Pressure. Hypertension, 2000, 35, 844-851.	1.3	532
419	Blood Pressure–Measuring Devices. Hypertension, 2000, 35, 1037-1037.	1.3	12
420	Modulation of Blood Pressure and Obesity With the Dopamine D2 Receptor Gene Taq I Polymorphism. Hypertension, 2000, 36, 177-182.	1.3	67
421	Blockade of the Renin-Angiotensin and Endothelin Systems on Progressive Renal Injury. Hypertension, 2000, 36, 561-568.	1.3	93
422	Characteristics of Inactive Primary Care Patients: Baseline Data from the Activity Counseling Trial. Preventive Medicine, 2000, 31, 513-521.	1.6	25
423	Progressive Resistance Exercise and Resting Blood Pressure. Hypertension, 2000, 35, 838-843.	1.3	437
424	A Chronotherapeutic Approach to Effective Blood Pressure Management. Journal of Clinical Hypertension, 2000, 5, 15-19.	1.0	2
425	Interpretation of echocardiographic measurements: A call for standardization. American Heart Journal, 2000, 139, 412-422.	1.2	65
426	Diuretics and Î ² -blockers: Is there a risk for dyslipidemia?. American Heart Journal, 2000, 139, 174-184.	1.2	50
427	The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertensionâ^—â^—Access the "Journal Club―discussion of this paper at http://www.elsevier.com/locate/ajmselect/. American Journal of Medicine, 2000, 108, 359-365.	0.6	81

#	Article	IF	CITATIONS
428	Association between elevated brain natriuretic peptide levels and the development of left ventricular hypertrophy in patients with hypertension. American Journal of Medicine, 2000, 108, 627-633.	0.6	29
429	Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study. American Journal of Medicine, 2000, 109, 1-8.	0.6	141
430	Management of patients with hypertension and diabetes mellitus: advances in the evidence for intensive treatment. American Journal of Medicine, 2000, 108, 238-245.	0.6	31
431	The HOPE study and diabetes. Lancet, The, 2000, 355, 1182-1183.	6.3	6
432	What does STOP-2 tell us about management of hypertension?. Lancet, The, 2000, 355, 653.	6.3	1
433	HOPE and extension of the indications for ACE inhibitors?. Lancet, The, 2000, 355, 246-247.	6.3	18
434	Measures and meaning of blood pressure. Lancet, The, 2000, 355, 159.	6.3	9
435	Systolic blood pressure and mortality. Lancet, The, 2000, 355, 175-180.	6.3	201
436	Efficacy of valsartan in patients aged ≥65 years with systolic hypertension. Clinical Therapeutics, 2000, 22, 961-969.	1.1	32
437	Determinants of glaucoma awareness in a general eye clinic. Ophthalmology, 2000, 107, 303-308.	2.5	84
438	G protein β3 subunit variant and essential hypertension in Taiwan â€" a caseâ€"control study. International Journal of Cardiology, 2000, 73, 191-195.	0.8	21
439	Absence of preinfarction angina is associated with a risk of no-reflow phenomenon after primary coronary angioplasty for a first anterior wall acute myocardial infarction. International Journal of Cardiology, 2000, 75, 253-260.	0.8	20
440	Reasons for adherence with antihypertensive medication. International Journal of Cardiology, 2000, 76, 157-163.	0.8	176
441	Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. American Journal of Kidney Diseases, 2000, 35, 427-432.	2.1	129
442	Influence of proteinuria on long-term outcome among patients with diabetes: The evidence continues to accumulate. American Heart Journal, 2000, 139, 934-935.	1.2	4
443	Association of a uteroglobin polymorphism with rate of progression in patients with IgA nephropathy. American Journal of Kidney Diseases, 2000, 36, 468-473.	2.1	33
444	Ambulatory Blood Pressure Monitoring and Organ Damage. Hypertension, 2000, 36, 894-900.	1.3	295
445	Prevalence, Treatment, Control, and Awareness of High Blood Pressure and the Risk of Stroke in Northwest England. Preventive Medicine, 2000, 30, 288-294.	1.6	8

#	Article	IF	CITATIONS
446	Trends in hypertension prevalence and management in Southwestern France, 1985–1996. Journal of Clinical Epidemiology, 2000, 53, 1230-1235.	2.4	20
447	White coat hypertension in type 1 diabetic patients without nephropathy. American Journal of Hypertension, 2000, 13, 560-563.	1.0	15
448	Hypertension articles in primary care journals. American Journal of Hypertension, 2000, 13, 568-569.	1.0	2
449	Different association of hypertension and insulin-related metabolic syndrome between men and women in 8437 nondiabetic Chinese. American Journal of Hypertension, 2000, 13, 846-853.	1.0	63
450	Normal values of blood pressure self-measurement in view of the 1999 World Health Organization-International Society of Hypertension guidelines. American Journal of Hypertension, 2000, 13, 940-943.	1.0	36
451	An insulin receptor gene polymorphism is associated with diastolic blood pressure in Chinese subjects with components of the metabolic syndrome. American Journal of Hypertension, 2000, 13, 745-752.	1.0	26
452	Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: The LIFE study. American Journal of Hypertension, 2000, 13, 899-906.	1.0	54
453	Left ventricular mass and atrial volume determined by cine magnetic resonance imaging in essential hypertension. American Journal of Hypertension, 2000, 13, 1103-1109.	1.0	13
454	Elevated blood pressure in men accompanying patients to the obstetrician's office. American Journal of Hypertension, 2000, 13, 1042-1044.	1.0	2
455	Blood pressure self-measurement: Where do we go from here?. American Journal of Hypertension, 2000, 13, 946-947.	1.0	1
456	A clinic and community-based approach to hypertension control for an underserved minority population: design and methods. American Journal of Hypertension, 2000, 13, 177-183.	1.0	21
457	Insulin and hypertension in the NHLBI family heart study: A sibpair approach to a controversial issue. American Journal of Hypertension, 2000, 13, 240-250.	1.0	11
458	Pretreatment blood pressure as a predictor of 21-year mortality. American Journal of Hypertension, 2000, 13, 724-733.	1.0	26
459	Additive Pressor Effects of Caffeine and Stress in Male Medical Students at Risk for Hypertension. American Journal of Hypertension, 2000, 13, 475-481.	1.0	50
460	The Addition of Doxazosin to the Therapeutic Regimen of Hypertensive Patients Inadequately Controlled with Other Antihypertensive Medications: A Randomized, Placebo-Controlled Study. American Journal of Hypertension, 2000, 13, 468-474.	1.0	50
461	The use of antihypertensive therapy in Spain (1986-1994). American Journal of Hypertension, 2000, 13, 607-610.	1.0	29
462	Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. American Journal of Hypertension, 2000, 13, 504-511.	1.0	50
463	The risks of hypertension: a renewed call for high blood pressure control. American Journal of Hypertension, 2000, 13, 736-738.	1.0	1

#	ARTICLE	IF	CITATIONS
464	Clinically additive effect between doxazosin and amlodipine in the treatment of essential hypertension. American Journal of Hypertension, 2000, 13, 921-926.	1.0	19
465	The effect of dietary patterns on blood pressure control in hypertensive patients: Results from the dietary approaches to stop hypertension (DASH) trial. American Journal of Hypertension, 2000, 13, 949-955.	1.0	252
466	Can risk factor modification prevent nephropathy in type 2 diabetes mellitus?. American Journal of Kidney Diseases, 2000, 36, 1054-1056.	2.1	2
467	Progress in blood pressure control in autosomal dominant polycystic kidney disease. American Journal of Kidney Diseases, 2000, 36, 266-271.	2.1	36
468	Impact of angiotensin II on the kidney: Does an angiotensin II receptor blocker make sense?. American Journal of Kidney Diseases, 2000, 36, S18-S23.	2.1	18
469	Treating high-risk diabetic hypertensive patients with comorbid conditions. American Journal of Kidney Diseases, 2000, 36, S10-S17.	2.1	17
470	Rationale for angiotensin II receptor blockers in patients with low-renin hypertension. American Journal of Kidney Diseases, 2000, 36, S24-S30.	2.1	64
471	Nutrition in the prevention of disease. American Journal of Preventive Medicine, 2000, 18, 351-353.	1.6	2
472	Efficacy of celiprolol in the treatment of hypertension in the elderly: An open-label study. Current Therapeutic Research, 2000, 61, 49-60.	0.5	0
473	Drug surveillance study of amlodipine in patients with hypertension not controlled with drug therapy: NORCON study. Current Therapeutic Research, 2000, 61, 863-870.	0.5	4
474	Prevention of coronary heart disease. Disease-a-Month, 2000, 46, 1-123.	0.4	3
475	Implications of discontinuation of doxazosin arm of ALLHAT. Lancet, The, 2000, 355, 863-864.	6.3	61
476	Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet, The, 2000, 356, 366-372.	6.3	1,156
477	Hypertensive emergencies. Lancet, The, 2000, 356, 411-417.	6.3	479
478	Selection of initial antihypertensive drug therapy. Lancet, The, 2000, 356, 1942-1943.	6.3	35
479	Blood pressure biofeedback treatment of white-coat hypertension. Journal of Psychosomatic Research, 2000, 48, 161-169.	1.2	31
481	La insuficiencia cardÃaca congestiva en atención primaria (I) Semergen, 2000, 26, 5-13.	0.2	5
482	Epoetin Alfa Drug Use Evaluation Using A Software System. Disease Management and Health Outcomes, 2000, 8, 287-295.	0.3	1

#	Article	IF	CITATIONS
483	Achieving Patient Buy-In and Long Term Compliance with Antihypertensive Treatment. Disease Management and Health Outcomes, 2000, 7, 13-20.	0.3	3
484	Losartan. Drugs and Aging, 2000, 16, 227-250.	1.3	39
485	Clinical Positioning of Indapamide Sustained Release 1.5mg in Management Protocols for Hypertension. Drugs, 2000, 59, 27-38.	4.9	17
486	Hypertension and Its Treatment in Postmenopausal Women. Hypertension, 2000, 36, 780-789.	1.3	214
487	Hipertensi \tilde{A}^3 n arterial y capacidad intelectual. Hipertension Y Riesgo Vascular, 2000, 17, 216-224.	0.3	1
488	Valsartan: a novel angiotensin Type 1 receptor antagonist. Expert Opinion on Pharmacotherapy, 2000, 1 , 337-350.	0.9	32
489	Blood Pressure Measurement - Bringing It All Back Home. Blood Pressure, 2000, 9, 180-181.	0.7	0
490	The fixed combination of verapamil SR/trandolapril. Expert Opinion on Pharmacotherapy, 2000, 1, 515-535.	0.9	3
491	Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ: British Medical Journal, 2000, 321, 1440-1444.	2.4	908
492	Relationships between blood pressure, anthropometric characteristics and blood lipids in high- and low-altitude populations from Central Asia. Annals of Human Biology, 2000, 27, 19-28.	0.4	40
493	Psychosocial factors in the development of hypertension. Annals of Medicine, 2000, 32, 371-375.	1.5	56
494	Nebivolol: a possible novel mechanism in hypertension?. Drugs and Therapy Perspectives, 2000, 16, 1-5.	0.3	0
497	Jornada de análisis de las dislipidemias en España (estudio JADE): subanálisis de los pacientes dislipidémicos hipertensos. Hipertension Y Riesgo Vascular, 2000, 17, 47-52.	0.3	1
498	GuÃas de práctica clÃnica de la Sociedad Española de CardiologÃa en pruebas de esfuerzo. Revista Espanola De Cardiologia, 2000, 53, 1063-1094.	0.6	51
503	Equipos de monitorización ambulatoria de la presión arterial: normas e indicaciones para su utilización, análisis y valoración de los diferentes parámetros. Hipertension Y Riesgo Vascular, 2000, 17, 307-316.	0.3	2
504	Difficult-to-Control Hypertension: In Response. Mayo Clinic Proceedings, 2000, 75, 655-656.	1.4	0
505	\hat{A}_i Se utilizan adecuadamente los f \tilde{A}_i rmacos antihipertensivos?. Hipertension Y Riesgo Vascular, 2000, 17, 302-306.	0.3	1
508	DANGEROUS AND COMMON DRUG INTERACTIONS IN PATIENTS WITH DIABETES MELLITUS. Endocrinology and Metabolism Clinics of North America, 2000, 29, 789-801.	1.2	31

#	Article	IF	CITATIONS
509	HYPERTENSION. Primary Care - Clinics in Office Practice, 2000, 27, 589-614.	0.7	1
511	Hipertensi \tilde{A}^3 n arterial en pacientes mayores de 80 a $\tilde{A}\pm$ os. Hipertension Y Riesgo Vascular, 2000, 17, 208-215.	0.3	0
512	Automedidas de presi \tilde{A}^3 n arterial domiciliarias con aparatos electr \tilde{A}^3 nicos autom \tilde{A}_i ticos. Ventajas e inconvenientes en su utilizaci \tilde{A}^3 n como t \tilde{A} ©cnica de medici \tilde{A}^3 n de la presi \tilde{A}^3 n arterial. Hipertension Y Riesgo Vascular, 2000, 17, 53-61.	0.3	7
514	Recomendaciones para la elecci \tilde{A}^3 n del tratamiento farmacol \tilde{A}^3 gico en la hipertensi \tilde{A}^3 n arterial. Hipertension Y Riesgo Vascular, 2000, 17, 402-408.	0.3	1
515	Obesidad e hipertensión arterial. Hipertension Y Riesgo Vascular, 2000, 17, 414-416.	0.3	2
516	HipertensiÃ ³ n arterial refractaria. Hipertension Y Riesgo Vascular, 2000, 17, 114-123.	0.3	4
517	HipertensiÃ ³ n arterial de bata blanca inversa. Frecuencia, caracterÃsticas e implicaciones clÃnicas. Hipertension Y Riesgo Vascular, 2000, 17, 251-257.	0.3	2
518	Clinical Preventive Medicine in Primary Care: Background and Practice: 1. Rationale and Current Preventive Practices. Mayo Clinic Proceedings, 2000, 75, 165-172.	1.4	50
519	Idoneidad en el tratamiento de pacientes con hipertensi \tilde{A}^3 n arterial. Hipertension Y Riesgo Vascular, 2000, 17, 351-356.	0.3	1
522	Economic evaluation and end-stage renal disease: From basics to bedside. American Journal of Kidney Diseases, 2000, 36, 12-28.	2.1	38
531	Transesophageal Echocardiography Assessment of Left Atrial Appendage Function in Untreated Systemic Hypertensive Patients in Sinus Rhythm. Journal of the American Society of Echocardiography, 2000, 13, 271-276.	1.2	27
534	Seguridad y efectividad de amlodipino en pacientes hipertensos no controlados farmacol \tilde{A}^3 gicamente en el \tilde{A}_1 mbito de Atenci \tilde{A}^3 n Primaria. Hipertension Y Riesgo Vascular, 2000, 17, 296-301.	0.3	2
535	Grado de control de la hipertensión arterial en un cupo de Atención Primaria: importancia de una correcta toma de las cifras de presión arterial. Hipertension Y Riesgo Vascular, 2000, 17, 347-350.	0.3	1
536	El tratamiento de la insuficiencia cardÃaca. Revista Clinica Espanola, 2000, 200, 551-562.	0.2	10
537	Hipertensión arterial y astenia marcada. Semergen, 2000, 26, 414-415.	0.2	0
539	NefropatÃa diabética. Medicine, 2000, 8, 1001-1008.	0.0	0
540	Hipertensión maligna. Hipertension Y Riesgo Vascular, 2000, 17, 198-207.	0.3	0
541	Indicaciones para el empleo de la monitorizaci \tilde{A}^3 n ambulatoria de la presi \tilde{A}^3 n arterial. Revista Clinica Espanola, 2000, 200, 435-437.	0.2	0

#	Article	IF	CITATIONS
542	Hipertensi \tilde{A}^3 n arterial y menopausia reciente: estudio comparativo de dos f \tilde{A}_i rmacos hipotensores. Hipertension Y Riesgo Vascular, 2000, 17, 42-46.	0.3	0
544	Efecto del trandolapril sobre la presión arterial y la microalbuminuria en el paciente diabético: estudio GALITRAN. Hipertension Y Riesgo Vascular, 2000, 17, 238-242.	0.3	0
546	HEART DISEASE IN WOMEN. Primary Care - Clinics in Office Practice, 2000, 27, 741-766.	0.7	17
548	Prescripción de las medidas no farmacológicas en el tratamiento de la hipertensión arterial en Atención Primaria. Hipertension Y Riesgo Vascular, 2000, 17, 137-141.	0.3	1
551	La disfunción diastólica del hipertenso mal controlado. Hipertension Y Riesgo Vascular, 2000, 17, 80-86.	0.3	0
553	La hipertensi $ ilde{A}^3$ n arterial en la diabetes mellitus tipo 2. Hipertension Y Riesgo Vascular, 2000, 17 , 272-283.	0.3	2
554	Nifedipine, a calcium antagonist, was just as effective as co-amilozide, a diuretic, in preventing stroke, MI, heart failure or cardiovascular death in hypertensive patients. Evidence-based Cardiovascular Medicine, 2000, 4, 101-103.	0.0	O
555	Felodipine/Metoprolol. Drugs, 2000, 59, 141-157.	4.9	29
556	Irbesartan. Drugs, 2000, 59, 1187-1206.	4.9	39
557	Eprosartan. Drugs, 2000, 60, 177-201.	4.9	26
558	Management of Type 2 Diabetes Mellitus and Cardiovascular Risk. Drugs, 2000, 60, 975-983.	4.9	41
559	Lercanidipine. Drugs, 2000, 60, 1123-1140.	4.9	86
560	A Comparative Evaluation of Amlodipine and Hydrochlorothiazide as Monotherapy in the Treatment of Isolated Systolic Hypertension in the Elderly. Clinical Drug Investigation, 2000, 19, 317-326.	1.1	10
561	Efficacy and Safety of Quinapril 40mg Once Daily as Monotherapy for Patients with Poorly Controlled Hypertension. Clinical Drug Investigation, 2000, 20, 81-88.	1.1	3
562	Patterns and Costs for Hypertension Treatment in the United States. Clinical Drug Investigation, 2000, 20, 181-195.	1.1	15
563	Cardiovascular risk changes after lipid lowering medications: are they predictable?. Atherosclerosis, 2000, 152, 1-8.	0.4	14
564	Pulse pressure and risk for myocardial infarction and heart failure in the elderly. Journal of the American College of Cardiology, 2000, 36, 130-138.	1.2	255
565	Management of coronary artery disease: therapeutic options in patients with diabetes. Journal of the American College of Cardiology, 2000, 36, 355-365.	1.2	229

#	Article	IF	CITATIONS
566	Medical therapy versus coronary angioplasty in stable coronary artery disease: a critical review of the literature. Journal of the American College of Cardiology, 2000, 36, 668-673.	1.2	53
567	How deadly is the "deadly quartet�. Journal of the American College of Cardiology, 2000, 36, 1159-1165.	1.2	43
568	First line drugs in chronic stable effort anginaâ€"the case for newer, longer-acting calcium channel blocking agents. Journal of the American College of Cardiology, 2000, 36, 1967-1971.	1.2	19
570	Treating Hypertension in Women of Child-Bearing Age and during Pregnancy. Drug Safety, 2001, 24, 457-474.	1.4	50
571	Metabolic Profile of Indapamide Sustained-Release in Patients with Hypertension. Drug Safety, 2001, 24, 1155-1165.	1.4	52
572	Drug Interactions with Irbesartan. Clinical Pharmacokinetics, 2001, 40, 605-614.	1.6	32
573	Perindopril. Drugs, 2001, 61, 867-896.	4.9	60
574	Monotherapy versus Combination Therapy as First Line Treatment of Uncomplicated Arterial Hypertension. Drugs, 2001, 61, 943-954.	4.9	46
575	Perindopril/Indapamide 2/0.625 mg/day. Drugs, 2001, 61, 1211-1229.	4.9	13
576	Telmisartan. Drugs, 2001, 61, 1501-1529.	4.9	176
577	Manidipine. Drugs, 2001, 61, 1777-1799.	4.9	30
578	Antihypertensive Effects and Tolerability of Candesartan Cilexetil Alone and in Combination with Amlodipine. Clinical Drug Investigation, 2001, 21, 17-23.	1.1	21
579	Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?. Journal of the American College of Cardiology, 2001, 37, 1-8.	1.2	143
580	Should diastolic and systolic blood pressure be considered for cardiovascular risk evaluation: a study in middle-aged men and women. Journal of the American College of Cardiology, 2001, 37, 163-168.	1.2	78
581	Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. Journal of the American College of Cardiology, 2001, 37, 434-439.	1.2	171
582	Blood pressure reductions with exercise and sodium restriction in postmenopausal women with elevated systolic pressure: role of arterial stiffness. Journal of the American College of Cardiology, 2001, 38, 506-513.	1.2	167
584	Doxazosin and congestive heart failure. Journal of the American College of Cardiology, 2001, 38, 1295-1296.	1.2	27
585	Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. Journal of the American College of Cardiology, 2001, 38, 1711-1717.	1.2	148

#	Article	IF	CITATIONS
586	Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. Journal of the American College of Cardiology, 2001, 38, 1829-1835.	1.2	325
587	HYPERTENSION. Obstetrics and Gynecology Clinics of North America, 2001, 28, 321-332.	0.7	0
590	MANAGEMENT OF TYPE 2 DIABETES. Obstetrics and Gynecology Clinics of North America, 2001, 28, 401-420.	0.7	1
591	Variabilidad y coste de la terapia antihipertensiva. Hipertension Y Riesgo Vascular, 2001, 18, 364-373.	0.3	2
593	Diferencias de presión arterial entre dÃas laborables y festivos utilizando dispositivos automáticos de automedida en el domicilio. Hipertension Y Riesgo Vascular, 2001, 18, 357-363.	0.3	1
594	Hipertensión arterial (II). Aspectos médicos y sanitarios. ClÃnica E Investigación En Arteriosclerosis, 2001, 13, 125-129.	0.4	0
595	Algunas consideraciones sobre el Consenso de la Sociedad Española de Diabetes y de la Sociedad Española de Medicina Familiar y Comunitaria sobre los criterios y pautas de terapia combinada en la diabetes tipo 2. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2001, 48, 220-221.	0.8	0
597	Decisiones y actitudes terapéuticas en los pacientes con hipertensión clÃnica aislada. Revista Clinica Espanola, 2001, 201, 174-178.	0.2	7
598	Benefits of Treating Hypertension in the Elderly. Drugs and Aging, 2001, 18, 631-638.	1.3	5
599	Hypertension in the Very Elderly Trial (HYVET). Drugs and Aging, 2001, 18, 151-164.	1.3	141
600	Treatment Expectations in Hypertension. Disease Management and Health Outcomes, 2001, 9, 631-640.	0.3	1
601	Implementation of Guidelines for Diagnosing and Treating Hypertension. Disease Management and Health Outcomes, 2001, 9, 361-369.	0.3	4
602	EXERCISE AS HYPERTENSION THERAPY. Cardiology Clinics, 2001, 19, 507-516.	0.9	81
603	Comparative Pharmacokinetics and Pharmacodynamics of Amlodipine in Hypertensive Patients with and without Type II Diabetes Mellitus. Journal of Clinical Pharmacology, 2001, 41, 1215-1224.	1.0	13
604	Health Care Improvement and Cost Reduction Opportunities in Hypertensive Medicaid Beneficiaries. Journal of Clinical Hypertension, 2001, 3, 279-318.	1.0	2
605	Combination Calcium Channel Blocker Therapy in the Treatment of Hypertension. Journal of Clinical Hypertension, 2001, 3, 322-327.	1.0	17
606	Advances in Antihypertensive Combination Therapy: Benefits of Low-Dose Thiazide Diuretics in Conjunction With Omapatrilat, a Vasopeptidase Inhibitor. Journal of Clinical Hypertension, 2001, 3, 307-312.	1.0	4
607	Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension. Journal of Clinical Hypertension, 2001, 3, 283-318.	1.0	233

#	Article	IF	CITATIONS
608	Low-Dose Combination Therapy: Why Include a Diuretic?. Journal of Clinical Hypertension, 2001, 3, 273-275.	1.0	1
609	Up-Regulation of Endothelial Nitric Oxide Synthase through β2-Adrenergic Receptor—The Role of a β-Blocker with NO-Releasing Action. Biochemical and Biophysical Research Communications, 2001, 280, 589-594.	1.0	28
610	Current utilization trends for \hat{l}^2 -blockers in cardiovascular disease. American Journal of Medicine, 2001, 110, 2-6.	0.6	18
611	Pitfalls in assessing the quality of care for patients with cardiovascular disease. American Journal of Medicine, $2001, 111, 297-303$.	0.6	18
612	Optimizing medical management of patients with pre–end-stage renal disease. American Journal of Medicine, 2001, 111, 559-568.	0.6	13
613	The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. American Journal of Medicine, 2001, 111, 633-642.	0.6	159
614	Do conventional risk factors predict subclinical coronary artery disease? Results from the Prospective Army Coronary Calcium Project. American Heart Journal, 2001, 141, 463-468.	1.2	130
615	Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure. American Heart Journal, 2001, 141, 410-417.	1.2	33
616	Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: The LIFE Study. American Heart Journal, 2001, 141, 784-791.	1.2	68
617	Primary renal artery stenting: Characteristics and outcomes after 363 procedures. American Heart Journal, 2001, 142, 314-323.	1.2	222
618	The chiropractic profession, dietary calcium, and the diseases associated with calcium-deficient diets. Journal of Manipulative and Physiological Therapeutics, 2001, 24, 305-307.	0.4	0
619	Medically supervised water-only fasting in the treatment of hypertension. Journal of Manipulative and Physiological Therapeutics, 2001, 24, 335-339.	0.4	55
620	Reducing the personal risk of perceived disease: The chiropractic patients' self-care endeavor. Journal of Manipulative and Physiological Therapeutics, 2001, 24, 378-384.	0.4	2
621	Dahl salt-sensitive and salt-resistant rats: examination of learning and memory performance, blood pressure, and the expression of central nicotinic acetylcholine receptors. Neuroscience, 2001, 103, 351-363.	1.1	19
622	A STUDY OF HYPERINSULINAEMIA AND DYSLIPIDAEMIA IN HYPERTENSIVE PATIENTS OF ARMED FORCES. Medical Journal Armed Forces India, 2001, 57, 312-316.	0.3	0
623	Effects of an ace-inhibitory agent, katsuobushi oligopeptide, in the spontaneously hypertensive rat and in borderline and mildly hypertensive subjects. Nutrition Research, 2001, 21, 1149-1158.	1.3	133
624	A randomized, double-blind, placebo-controlled, prospective, 16 week crossover study to determine the role of Pycnogenol in modifying blood pressure in mildly hypertensive patients. Nutrition Research, 2001, 21, 1251-1260.	1.3	66
625	Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications. American Journal of Kidney Diseases, 2001, 37, 677-688.	2.1	140

#	Article	IF	CITATIONS
626	Clustering of traditional risk factors and precocity of coronary disease in women. International Journal of Cardiology, 2001, 81, 205-209.	0.8	9
627	Prevalence of type 2 diabetes mellitus in Taiwan: ethnic variation and risk factors. Diabetes Research and Clinical Practice, 2001, 51, 59-66.	1.1	24
628	Angiotensin-converting enzyme gene polymorphism and microvascular complications in Turkish type 2 diabetic patients. Diabetes Research and Clinical Practice, 2001, 54, 95-104.	1.1	34
629	Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Research and Clinical Practice, 2001, 54, 191-201.	1.1	89
630	Angiotensin-converting enzyme inhibitors. Advances in Protein Chemistry, 2001, 56, 13-75.	4.4	48
631	An evidence-based review of patient-centered behavioral interventions for hypertension 11 The full text of this review article is available via AJPM Online at www.elsevier.com/locate/ajpmonline American Journal of Preventive Medicine, 2001, 21, 221-232.	1.6	108
632	Novel approaches to the treatment of progressive renal disease. Current Opinion in Pharmacology, 2001, 1, 183-189.	1.7	11
633	Characterization of proteinuria in asymptomatic family members and household contacts of children with hepatitis B virus-associated membranous nephropathy. American Journal of Kidney Diseases, 2001, 37, 125-133.	2.1	7
634	Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. American Journal of Kidney Diseases, 2001, 37, 484-489.	2.1	184
635	Efficacy and safety of omapatrilat with hydrochlorothiazide for the treatment of hypertension in subjects nonresponsive to hydrochlorothiazide alone. American Journal of Hypertension, 2001, 14, 788-793.	1.0	18
636	Relationship between 24-H blood pressure and sleep disordered breathing in a normotensive community sample. American Journal of Hypertension, 2001, 14, 743-748.	1.0	21
637	Antihypertensive medications in pregnant women with chronic hypertension. Primary Care Update for Ob/Gyns, 2001, 8, 175-177.	0.1	0
638	Hypertension in children and adolescents: definition, pathophysiology, risk factors, and long-term sequelae. Current Therapeutic Research, 2001, 62, 283-297.	0.5	22
639	An approach to the use of antihypertensive drugs in children and adolescents. Current Therapeutic Research, 2001, 62, 329-350.	0.5	12
640	Efficacy and safety of angiotensin receptor blockers: a review of losartan in essential hypertension. Current Therapeutic Research, 2001, 62, 79-91.	0.5	14
641	Cardiovascular safety of lercanidipine in patients with angina pectoris: a review of six randomized clinical trials. Current Therapeutic Research, 2001, 62, 3-15.	0.5	8
642	A review of irbesartan in antihypertensive therapy: comparison with other antihypertensive agents. Current Therapeutic Research, 2001, 62, 505-523.	0.5	17
643	Effect of controlled-release nifedipine on left ventricular hypertrophy in Japanese patients with hypertension: An open-label, uncontrolled study. Current Therapeutic Research, 2001, 62, 773-782.	0.5	2

#	Article	IF	CITATIONS
644	Optimal medical management of patients with chronic ischemic heart disease. Disease-a-Month, 2001, 47, 150-196.	0.4	0
645	ABCs of secondary prevention of CHD: easier said than done. Lancet, The, 2001, 357, 972-973.	6.3	36
646	Blood-pressure lowering for the secondary prevention of stroke. Lancet, The, 2001, 358, 1026-1027.	6.3	49
647	Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet, The, 2001, 358, 1682-1686.	6.3	878
648	Renoprotection by angiotensin-receptor blockers and ACE inhibitors in hypertension. Lancet, The, 2001, 358, 1829-1831.	6.3	37
649	Manejo terapéutico de la urgencia hipertensiva (réplica). Hipertension Y Riesgo Vascular, 2001, 18, 250.	0.3	0
650	Riesgo cardiovascular asociado a la insuficiencia renal. Hipertension Y Riesgo Vascular, 2001, 18, 285-290.	0.3	1
651	Papel de los antagonistas de los receptores de la angiotensina II en la insuficiencia cardÃaca. Hipertension Y Riesgo Vascular, 2001, 18, 186-196.	0.3	1
652	Hipertensión y tratamiento antihipertensivo como factores de riesgo de diabetes mellitus tipo 2. ClÁnica E Investigación En Arteriosclerosis, 2001, 13, 44-45.	0.4	0
653	\hat{A}_{ℓ} C \hat{A}^{3} mo diagnosticar la hipertensi \hat{A}^{3} n secundaria?. FMC Formacion Medica Continuada En Atencion Primaria, 2001, 8, 447-457.	0.0	1
654	Riesgo cardiovascular absoluto en hipertensos y su evoluci \tilde{A}^3 n con el tratamiento antihipertensivo. Hipertension Y Riesgo Vascular, 2001, 18, 72-77.	0.3	2
655	Automedida de la presi $ ilde{A}^3$ n arterial: estado actual de la cuesti $ ilde{A}^3$ n. Semergen, 2001, 27, 70-79.	0.2	10
656	Metaan \tilde{A}_i lisis: claves para interpretar una herramienta de investigaci \tilde{A}^3 n controvertida. Hipertension Y Riesgo Vascular, 2001, 18, 232-240.	0.3	3
657	Los nuevos factores de riesgo cardiovascular. Hipertension Y Riesgo Vascular, 2001, 18, 171-185.	0.3	1
658	El documento Colesterol 2000: ¿útil para el enfermo renal?. Revista Espanola De Cardiologia, 2001, 54, 807.	0.6	1
659	Estudio de farmacovigilancia para evaluar la seguridad y efectividad de doxazosina GITS en pacientes hipertensos que recib\(^Aan\) tratamiento previo con doxazosina est\(^A_1\)ndar. Hipertension Y Riesgo Vascular, 2001, 18, 411-417.	0.3	2
660	Las interacciones medicamentosas con los antihipertensivos en la práctica clÃnica. Hipertension Y Riesgo Vascular, 2001, 18, 118-124.	0.3	1
661	Association of Atrial Fibrillation and Aortic Atherosclerosis: A Population-Based Study. Mayo Clinic Proceedings, 2001, 76, 252-259.	1.4	24

#	Article	IF	CITATIONS
662	¿Comparado con qué es seguro y efectivo el tratamiento combinado con Verapamilo y Trandolapril?. Revista Espanola De Geriatria Y Gerontologia, 2001, 36, 302-303.	0.2	0
663	Evaluación de la eficacia de la combinación de verapamilo y trandolapril en ancianos hipertensos institucionalizados, insuficientemente controlados con monoterapia. Revista Espanola De Geriatria Y Gerontologia, 2001, 36, 15-20.	0.2	3
665	¿Controlamos correctamente la presión arterial en nuestros pacientes diabéticos? (Evolución) Tj ETQq0 0 0	rgBT /Ove	erlgck 10 Tf 5
669	EXERCISE IN WEIGHT MANAGEMENT OF OBESITY. Cardiology Clinics, 2001, 19, 459-470.	0.9	201
670	HYPERTENSIVE EMERGENCIES. Critical Care Clinics, 2001, 17, 435-451.	1.0	36
672	Hipertensión arterial (I). Aspectos fisiopatológicos. ClÃnica E Investigación En Arteriosclerosis, 2001, 13, 80-84.	0.4	2
673	Hipertensión arterial (III). Aspectos diagnósticos y terapéuticos. ClÃnica E Investigación En Arteriosclerosis, 2001, 13, 167-171.	0.4	0
679	Efectos sobre la presión arterial de la restricción dietética del sodio y dieta del Dietary Approaches to Stop Hypertension (DASH) Study. ClÃnica E Investigación En Arteriosclerosis, 2001, 13, 282-283.	0.4	0
681	Detección del fenómeno de bata blanca en atención primaria. Semergen, 2001, 27, 51-53.	0.2	0
682	Impacto de la hipertensión en las cardiopatÃas en España. Estudio CARDIOTENS 1999. Revista Espanola De Cardiologia, 2001, 54, 139-149.	0.6	82
689	Step Care Therapy for Hypertension in Diabetic Patients. Mayo Clinic Proceedings, 2001, 76, 1266-1274.	1.4	9
690	Hipertensión arterial en el paciente dislipémico. ClÃnica E Investigación En Arteriosclerosis, 2001, 13, 179-194.	0.4	4
692	Simultaneous aortic replacement and renal artery revascularization: The influence of preoperative renal function on early risk and late outcome. Journal of Vascular Surgery, 2001, 34, 1041-1049.	0.6	19
693	Estudio de la hipertensión arterial en población dislipidémica. Hipertension Y Riesgo Vascular, 2001, 18, 406-410.	0.3	0
694	Caso clÃnico paciente con múltiples factores de riesgo cardiovascular y arterioesclerosis subclÃnica. Medicine, 2001, 8, 2263-2266.	0.0	0
695	Pharmacogenomics: A Clinician's Primer on Emerging Technologies for Improved Patient Care. Mayo Clinic Proceedings, 2001, 76, 299-309.	1.4	76
696	Incidencia de alteraciones electrocardiográficas en la hipertensión arterial. Estudio MINACOR. Hipertension Y Riesgo Vascular, 2001, 18, 213-217.	0.3	0
697	The current status of antihypertensive treatments: into the new millennium. Expert Opinion on Pharmacotherapy, 2001, 2, 731-737.	0.9	2

#	Article	IF	CITATIONS
698	Amlodipine/benazepril: fixed dose combination therapy for hypertension. Expert Opinion on Pharmacotherapy, 2001, 2, 165-178.	0.9	10
699	Pharmacoeconomics of Hypertension Management. Pharmacoeconomics, 2001, 19, 337-347.	1.7	32
700	What is the Optimal Blood Pressure in Patients with Diabetes Mellitus?. American Journal of Cardiovascular Drugs, 2001, 1, 173-177.	1.0	3
701	AT 1 -receptor Blocker-based Combination Therapy in Hypertension. Blood Pressure, 2001, 10, 18-25.	0.7	4
702	Characteristics of 15314 Hypertensive Patients at High Coronary Risk. The VALUE Trial. Blood Pressure, 2001, 10, 83-91.	0.7	80
703	A Common Variant of Endothelial Nitric Oxide Synthase (Glu298Asp) Is an Independent Risk Factor for Carotid Atherosclerosis. Stroke, 2001, 32, 735-740.	1.0	163
704	Oral Arginine Improves Blood Pressure in Renal Transplant and Hemodialysis Patients. Journal of Parenteral and Enteral Nutrition, 2001, 25, 194-202.	1.3	17
705	Aerobic Exercise and Resting Blood Pressure in Older Adults: A Meta-analytic Review of Randomized Controlled Trials. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2001, 56, M298-M303.	1.7	90
706	Effects of a Short-Term Vitamin D3 and Calcium Supplementation on Blood Pressure and Parathyroid Hormone Levels in Elderly Women1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1633-1637.	1.8	510
707	Insulin action and secretion in healthy Hispanic-Mexican first-degree relatives of subjects with Type 2 diabetes. Journal of Endocrinological Investigation, 2001, 24, 580-586.	1.8	16
708	Correlates of knowledge of one's blood pressure and cholesterol levels among older members of a managed care plan. Aging Clinical and Experimental Research, 2001, 13, 95-104.	1.4	7
709	Hypertensive Urgency: A Focus on Oral Therapy. Hospital Pharmacy, 2001, 36, 912-915.	0.4	1
710	Existe concordância no acometimento renal e retiniano da microangiopatia diabética?. Arquivos Brasileiros De Endocrinologia E Metabologia, 2001, 45, 452-459.	1.3	3
711	Improved Hypertension Management and Control. Hypertension, 2001, 38, 827-832.	1.3	232
712	Influence of dexamethasone and weight loss on the regulation of serum leptin levels in obese individuals. Brazilian Journal of Medical and Biological Research, 2001, 34, 479-487.	0.7	18
713	Lifestyle Modifications in the Prevention and Treatment of Hypertension. Endocrine Practice, 2001, 7, 392-399.	1.1	36
714	Differences in Mechanisms between Weight Loss-Sensitive and -Resistant Blood Pressure Reduction in Obese Subjects Hypertension Research, 2001, 24, 371-376.	1.5	28
715	Management of Diabetic Nephropathy. Journal of the Royal Society of Medicine, 2001, 94, 210-217.	1.1	21

#	ARTICLE	IF	CITATIONS
716	Muscle sympathetic nerve activity and hemodynamic alterations in middle-aged obese women. Brazilian Journal of Medical and Biological Research, 2001, 34, 475-478.	0.7	42
717	Typical and Atypical Symptoms of Myocardial Infarction Among African-Americans, Whites, and Koreans. Critical Care Nursing Clinics of North America, 2001, 13, 531-539.	0.4	13
718	PBS/RPBS cost implications of trends and guideline recommendations in the pharmacological management of hypertension in Australia, 1994–1998. Medical Journal of Australia, 2001, 174, 565-568.	0.8	18
719	Should Angiotensin-Converting Enzyme Inhibitors Be Added To The Water Supply Of Patients With Diabetes?. Endocrine Practice, 2001, 7, 59-63.	1.1	2
720	Laboratory Adaptationsâ€"Changing Expectations. Clinical Chemistry, 2001, 47, 1509-1515.	1.5	1
721	Reduced Regional and Global Cerebral Blood Flow During Fenoldopam-Induced Hypotension in Volunteers. Anesthesia and Analgesia, 2001, 93, 45-52.	1.1	21
722	ABCs of Cardiovascular Disease Risk Management. Cardiology in Review, 2001, 9, 96-105.	0.6	17
723	Arg389Gly ??1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics and Genomics, 2001, 11, 191-197.	5.7	100
724	Hypertension in black people: study of specific genotypes and phenotypes will provide a greater understanding of interindividual and interethnic variability in blood pressure regulation than studies based on race. Pharmacogenetics and Genomics, 2001, 11, 95-110.	5.7	30
725	Cyclooxygenase-2???Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients. American Journal of Therapeutics, 2001, 8, 85-95.	0.5	321
726	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2001, 8, 73-79.	1.5	12
727	DEMENTIA ATTRIBUTABLE TO SUBCORTICAL ISCHEMIC VASCULAR DISEASE. Neurologist, 2001, 7, 208-219.	0.4	3
728	Verapamil Revisited. Heart Disease (Hagerstown, Md), 2001, 3, 55-62.	1.3	36
729	Appropriate Use of Calcium Antagonists in Hypertension. Hospital Practice (1995), 2001, 36, 47-55.	0.5	0
730	Initial antihypertensive therapy. Postgraduate Medicine, 2001, 110, 39-54.	0.9	13
731	Increased circulating levels of ouabain-like factor in patients with asymptomatic left ventricular dysfunction. European Journal of Heart Failure, 2001, 3, 165-171.	2.9	39
732	Daily regimen and compliance with treatment. BMJ: British Medical Journal, 2001, 323, 647-647.	2.4	94
733	Endstage Renal Disease Owing to Diabetic Nephropathy in Mississippi. Journal of Investigative Medicine, 2001, 49, 284-291.	0.7	21

#	Article	IF	CITATIONS
734	ACUTE ABDOMINAL SYMPTOMS IN MALIGNANT HYPERTENSION: CLINICAL PRESENTATION IN FIVE CASES. Clinical and Experimental Hypertension, 2001, 23, 461-469.	0.5	7
735	Obesity, Hypertension, and the Heart. American Journal of the Medical Sciences, 2001, 321, 242-248.	0.4	85
736	Building a Gateway to Promote Cardiovascular Health Research in African-American Communities: Lessons and Findings from the Field. American Journal of the Medical Sciences, 2001, 322, 288-293.	0.4	9
737	Sexual Dysfunction in Hypertensive Patients Treated with Losartan. American Journal of the Medical Sciences, 2001, 321, 336-341.	0.4	137
738	Transforming Exercise-based Cardiac Rehabilitation Programs Into Secondary Prevention Centers: A National Imperative. Journal of Cardiopulmonary Rehabilitation and Prevention, 2001, 21, 263-272.	0.5	53
739	Lercanidipine. Heart Disease (Hagerstown, Md), 2001, 3, 398-407.	1.3	34
740	Prospective Study of Depressive Symptoms and Risk of Stroke Among Japanese. Stroke, 2001, 32, 903-908.	1.0	133
741	Changes in Cardiovascular Risk Factors During the Perimenopause and Postmenopause and Carotid Artery Atherosclerosis in Healthy Women. Stroke, 2001, 32, 1104-1111.	1.0	183
742	Vascular complications in diabetes and their prevention. Vascular Medicine, 2001, 6, 249-255.	0.8	34
743	Primary Prevention of Ischemic Stroke. Stroke, 2001, 32, 280-299.	1.0	512
744	Changes in blood pressure among students attending Glasgow University between 1948 and 1968: analyses of cross sectional surveys Commentary: Changing population blood pressure levels. BMJ: British Medical Journal, 2001, 322, 885-889.	2.4	42
745	Diabetes Mellitus in Tassin, France: Remarkable Transformation in Incidence and Outcome of ESRD in Diabetes. Advances in Chronic Kidney Disease, 2001, 8, 42-56.	2.2	20
746	Seniors and Systolic Hypertension. Chest, 2001, 119, 323-327.	0.4	1
747	Controlling high blood pressure: A simple and effective approach. Comprehensive Therapy, 2001, 27, 209-212.	0.2	1
748	Treatment of coexisting diabetes and hypertension. Current Cardiology Reports, 2001, 3, 498-503.	1.3	3
749	Drugs for cardiovascular risk reduction in the diabetic patient. Current Diabetes Reports, 2001, 1, 133-139.	1.7	5
750	Some economic consequences of noncompliance. Current Hypertension Reports, 2001, 3, 473-480.	1.5	23
751	Actual practice in hypertension: Implications for persistence with and effectiveness of therapy. Current Hypertension Reports, 2001, 3, 481-487.	1.5	11

#	ARTICLE	IF	CITATIONS
752	Problems in the control of systolic blood pressure. Current Hypertension Reports, 2001, 3, 173-174.	1.5	0
7 53	Resistant hypertension and the birmingham hypertension square. Current Hypertension Reports, 2001, 3, 203-208.	1.5	5
754	Are sleep-related breathing disorders important contributing factors to the production of essential hypertension?. Current Hypertension Reports, 2001, 3, 209-215.	1.5	82
755	Choices and goals in the treatment of the diabetic hypertensive patient. Current Hypertension Reports, 2001, 3, 387-391.	1.5	2
756	Using out of office blood pressure monitoring in the management of hypertension. Current Hypertension Reports, 2001, 3, 400-405.	1.5	13
757	Use of gene markers to guide antihypertensive therapy. Current Hypertension Reports, 2001, 3, 410-415.	1.5	6
758	The calcium channel blocker controversy in patients with diabetic nephropathy: Is there an issue?. Current Hypertension Reports, 2001, 3, 419-421.	1.5	1
759	What is the optimal strategy to intensify blood pressure control and prevent progression of renal failure?. Current Hypertension Reports, 2001, 3, 422-428.	1.5	11
760	Systolic hypertension and cardiovascular risk reduction: A clinical review. Current Hypertension Reports, 2001, 3, S11-S15.	1.5	4
761	Psychologic factors as precursors to hypertension. Current Hypertension Reports, 2001, 3, 25-32.	1.5	46
762	Statins and blood pressure regulation. Current Hypertension Reports, 2001, 3, 281-288.	1.5	49
763	Lessons learned from prematurely terminated clinical trials. Current Hypertension Reports, 2001, 3, 360-366.	1.5	2
764	The cardiovascular actions of omapatrilat in spontaneously hypertensive rats. Current Hypertension Reports, 2001, 3, S1-S5.	1.5	3
765	Intermittent claudication. Current Treatment Options in Cardiovascular Medicine, 2001, 3, 167-180.	0.4	6
766	Renal artery stenosis. Current Treatment Options in Cardiovascular Medicine, 2001, 3, 187-194.	0.4	3
767	Hypertension. Current Treatment Options in Cardiovascular Medicine, 2001, 3, 333-345.	0.4	1
768	Population-based screening with the Coronary Heart Disease Risk Factor Calculator $\hat{A}^{\text{@}}$. Advances in Therapy, 2001, 18, 21-32.	1.3	7
769	New insights into the effects on blood pressure of diets low in salt and high in fruits and vegetables and low-fat dairy products. Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 71-74.	1.5	24

#	Article	IF	Citations
770	Diuretics: again the first step in the treatment of most patients with hypertension., 2001, 2, 244.		5
771	Comments on ALLHAT and doxazosin. , 2001, 2, 254.		9
772	How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 298.	1.5	12
773	Isolated systolic hypertension: pressure on the anaesthetist?. Anaesthesia, 2001, 56, 505-510.	1.8	85
774	Relationships between the TaqI polymorphism of the dopamine D2 receptor and blood pressure in hyperglycaemic and normoglycaemic Chinese subjects. Clinical Endocrinology, 2001, 55, 605-611.	1.2	46
775	Affecting the decline of renal function in diabetes mellitus. Kidney International, 2001, 60, 378-379.	2.6	7
776	Renoprotection: One or many therapies?. Kidney International, 2001, 59, 1211-1226.	2.6	159
777	Teaching about cost-effective use of medical resources. Journal of General Internal Medicine, 2001, 16, 419-421.	1.3	4
778	A Self-Paced Step Test to Predict Aerobic Fitness in Older Adults in the Primary Care Clinic. Journal of the American Geriatrics Society, 2001, 49, 632-638.	1.3	94
779	Cost-effectiveness of using angiotensin-converting enzyme inhibitors to slow nephropathy in normotensive patients with diabetes type II and microalbuminuria. Nephrology, 2001, 6, 71-77.	0.7	7
780	Nephropathy in type 2 diabetes: current therapeutic strategies. Nephrology, 2001, 6, 266-269.	0.7	2
781	Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension. Diabetes, Obesity and Metabolism, 2001, 3, 319-325.	2.2	33
782	Treatment of high-risk diabetic patients with angiotensin II receptor blockers. Diabetes, Obesity and Metabolism, 2001, 3, 472-476.	2.2	1
783	Use of beta-blockers in obesity hypertension: potential role of weight gain. Obesity Reviews, 2001, 2, 275-280.	3.1	78
784	Primary stroke prevention. European Journal of Neurology, 2001, 8, 1-15.	1.7	36
785	Recent Developments Concerning Diet And Hypertension. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 1078-1082.	0.9	8
786	The nurse - a resource in hypertension care. Journal of Advanced Nursing, 2001, 35, 582-589.	1.5	20
787	Controlled drug delivery: therapeutic and pharmacological aspects. Journal of Internal Medicine, 2001, 249, 75-94.	2.7	5

#	Article	IF	CITATIONS
788	Multiple risk intervention trial in high risk hypertensive men: comparison of ultrasound intima-media thickness and clinical outcome during 6 years of follow-up. Journal of Internal Medicine, 2001, 249, 305-314.	2.7	58
789	Blood pressure variability and leukoaraiosis amount in cerebral small-vessel disease. Acta Neurologica Scandinavica, 2001, 104, 358-363.	1.0	9
790	Antihypertensive drug prescription trends at the primary health care centres in Bahrain. Pharmacoepidemiology and Drug Safety, 2001, 10, 219-227.	0.9	17
791	Antihypertensives and myocardial infarction risk: the modifying effect of history of drug use. Pharmacoepidemiology and Drug Safety, 2001, 10, 287-294.	0.9	3
792	Exercise Standards for Testing and Training. Circulation, 2001, 104, 1694-1740.	1.6	1,542
793	Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. Clinical Cardiology, 2001, 24, 66-72.	0.7	46
794	Angiotensin receptor blockers: Evidence for preserving target organs. Clinical Cardiology, 2001, 24, 183-190.	0.7	36
795	A prospective study of the impact of stress on quality of life: An investigation of low-income individuals with hypertension. Annals of Behavioral Medicine, 2001, 23, 112-119.	1.7	31
796	Value of Structured Meals for Weight Management: Risk Factors and Longâ€Term Weight Maintenance. Obesity, 2001, 9, 284S-289S.	4.0	91
797	Tumor necrosis factor-뱉^308 G/A polymorphism in obese Caucasians. International Journal of Obesity, 2001, 25, 581-585.	1.6	63
798	Prognostic significance of blood pressure measured on rising. Journal of Human Hypertension, 2001, 15, 413-417.	1.0	31
799	Long-term diuretic therapy in patients with coronary disease: increased colon cancer-related mortality over a 5-year follow-up. Journal of Human Hypertension, 2001, 15, 373-379.	1.0	16
800	First-line treatment of hypertension: from monotherapy to fixed low-dose combination therapy. Journal of Human Hypertension, 2001, 15, 443-446.	1.0	4
801	Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension. Journal of Human Hypertension, 2001, 15, 559-565.	1.0	13
802	Effect of the Valsalva manoeuver on diastolic filling indices in patients with essential hypertension. Journal of Human Hypertension, 2001, 15, 607-612.	1.0	4
803	Effects of long-acting ACE inhibitor (temocapril) and long-acting Ca channel blocker (amlodipine) on 24-h ambulatory BP in elderly hypertensive patients. Journal of Human Hypertension, 2001, 15, 643-648.	1.0	10
804	Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy. Journal of Human Hypertension, 2001, 15, 763-770.	1.0	56
805	What should be the goal blood pressure?. Journal of Human Hypertension, 2001, 15, 831-832.	1.0	0

#	Article	IF	CITATIONS
806	Ambulatory blood pressure in heart failure. European Journal of Clinical Investigation, 2001, 31, 18-25.	1.7	3
807	A Summary of the Science Supporting the New National Cholesterol Education Program Dietary Recommendations. Journal of the American Dietetic Association, 2001, 101, 1148-1154.	1.3	19
808	Prognosis of congestive heart failure after prior myocardial infarction in older persons with atrial fibrillation versus sinus rhythm. American Journal of Cardiology, 2001, 87, 224-225.	0.7	63
809	Inappropriate left ventricular mass in normotensive and hypertensive patients. American Journal of Cardiology, 2001, 87, 361-363.	0.7	44
810	Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. American Journal of Cardiology, 2001, 87, 727-731.	0.7	53
811	Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and diabetes mellitus. American Journal of Cardiology, 2001, 87, 780-781.	0.7	39
812	Clinical studies of CS-866, the newest angiotensin II receptor antagonist. American Journal of Cardiology, 2001, 87, 37-43.	0.7	69
813	The systolic blood pressure versus pulse pressure controversy. American Journal of Cardiology, 2001, 87, 1278-1281.	0.7	17
814	Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. American Journal of Cardiology, 2001, 87, 1284-1286.	0.7	84
815	Association of coronary risk factors with progression of valvular aortic stenosis in older persons. American Journal of Cardiology, 2001, 87, 1313-1314.	0.7	76
816	Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies. American Journal of Cardiology, 2001, 87, 3-13.	0.7	110
817	Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone. American Journal of Cardiology, 2001, 88, 556-557.	0.7	27
818	Efficacy of perindopril in the treatment of systemic hypertension. American Journal of Cardiology, 2001, 88, 3-12.	0.7	3
819	Dosage considerations with perindopril for systemic hypertension. American Journal of Cardiology, 2001, 88, 13-18.	0.7	19
820	Safety profile of perindopril. American Journal of Cardiology, 2001, 88, 36-40.	0.7	22
821	United states cholesterol guidelines 2001: expanded scope of intensive low-density lipoprotein–lowering therapy. American Journal of Cardiology, 2001, 88, 23-27.	0.7	103
822	Low Serum Magnesium Levels and Foot Ulcers in Subjects with Type 2 Diabetes. Archives of Medical Research, 2001, 32, 300-303.	1.5	38
823	Operational Aspects of Terminating the Doxazosin Arm of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Contemporary Clinical Trials, 2001, 22, 29-41.	2.0	23

#	Article	IF	Citations
825	Calcium channel blockers in treatment of hypertension. Progress in Cardiovascular Diseases, 2001, 44, 207-216.	1.6	27
826	Optimal medical management of patients with chronic ischemic heart disease. Current Problems in Cardiology, 2001, 26, 195-238.	1.1	0
827	Cultural Competence: Cardiovascular Medications. Progress in Cardiovascular Nursing, 2001, 16, 152-161.	0.5	5
828	Dietary Management of Cardiovascular Disease: A Year 2002 Perspective. Nutrition in Clinical Care: an Official Publication of Tufts University, 2001, 4, 314-331.	0.2	1
829	Antihypertensives. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2001, 15, 827-845.	1.4	49
830	How can the risk of long-term consequences of rheumatoid arthritis be reduced?. Best Practice and Research in Clinical Rheumatology, 2001, 15, 139-170.	1.4	24
831	Designer milks for the new millennium. Livestock Science, 2001, 72, 99-109.	1.2	38
832	Comparison of 24-Hour Blood Pressure Profiles in Patients with Hypertension Who Were Switched from Amlodipine to Nisoldipine. Pharmacotherapy, 2001, 21, 898-903.	1.2	3
833	Slowing the Progression of Renal Disease in Diabetic Patients. Annals of Pharmacotherapy, 2001, 35, 452-463.	0.9	15
834	Platelet-Dependent Thrombin Generation in Patients with Unstable Angina Pectoris. Angiology, 2001, 52, 811-818.	0.8	3
835	Sodium Sensitivity Related to Albuminuria Appearing Before Hypertension in Type 2 Diabetic Patients. Diabetes Care, 2001, 24, 111-116.	4.3	55
836	Recommendations for Preparticipation Screening and the Assessment of Cardiovascular Disease in Masters Athletes. Circulation, 2001, 103, 327-334.	1.6	205
837	Cardiac and Vascular Remodeling in Older Adults With Borderline Isolated Systolic Hypertension. Hypertension, 2001, 38, 1372-1376.	1.3	10
838	Physicians' Knowledge, Attitudes, and Practice of Pharmacologic Treatment of Hypertension. Annals of Pharmacotherapy, 2001, 35, 1173-1179.	0.9	32
839	Impact of hypertension on the accuracy of exercise stress myocardial perfusion imaging for the diagnosis of coronary artery disease. British Heart Journal, 2001, 85, 655-661.	2.2	41
840	Hypertension in Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2001, 56, M217-M225.	1.7	55
841	Arterial Calcification and Calcium Antagonists. Hypertension, 2001, 37, 1414-1415.	1.3	2
842	Comparison Between Isosorbide Dinitrate in Aerosol and in Tablets for the Treatment of Hypertensive Emergencies. Angiology, 2001, 52, 131-135.	0.8	5

#	Article	IF	Citations
843	Increasing daily walking lowers blood pressure in postmenopausal women. Medicine and Science in Sports and Exercise, 2001, 33, 1825-1831.	0.2	210
844	Hypertension syndrome and cardiovascular events. Postgraduate Medicine, 2001, 110, 29-36.	0.9	14
845	Past history of nephrolithiasis and incidence of hypertension in men: a reappraisal based on the results of the Olivetti Prospective Heart Study. Nephrology Dialysis Transplantation, 2001, 16, 2232-2235.	0.4	51
846	Comparing the Efficacy of Staff Versus Housestaff Instruction in an Intervention to Improve Hypertension Management. Academic Medicine, 2001, 76, 1257-1260.	0.8	27
847	The Diversity of Diagnoses of Preeclampsia. Hypertension in Pregnancy, 2001, 20, 57-67.	0.5	27
848	Blood pressure outcomes of dental patients screened chronobiologically. Journal of the American Dental Association, 2001, 132, 891-899.	0.7	18
849	GENDER DIFFERENCE IN THE RELATIONSHIPS AMONG HYPERLEPTINEMIA, HYPERINSULINEMIA, AND HYPERTENSION. Clinical and Experimental Hypertension, 2001, 23, 357-368.	0.5	40
850	A Comparison of Cognitive Ability in Normotensive and Hypertensive 68-Year-Old Men: Results from Population Study "Men Born in 1914,―in Malmö, Sweden. Experimental Aging Research, 2001, 27, 319-340	0.6	30
851	Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial. Hypertension, 2001, 37, 12-18.	1.3	177
852	Secondary prevention of coronary artery disease in patients undergoing elective surgery for peripheral arterial disease. Vascular Medicine, 2001, 6, 35-41.	0.8	40
853	<i>T+31C</i> Polymorphism of Angiotensinogen Gene and Essential Hypertension. Hypertension, 2001, 37, 281-285.	1.3	37
854	Lipid and Blood Pressure Treatment Goals for Type 1 Diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care, 2001, 24, 1053-1059.	4.3	165
855	Relation of Serum Ascorbic Acid to Mortality Among US Adults. Journal of the American College of Nutrition, 2001, 20, 255-263.	1.1	86
856	Review: Promise of prevention and reversal of target organ involvement in hypertension. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2001, 2, S4-S9.	1.0	6
857	Polymorphisms in the <i>hANP (Human Atrial Natriuretic Peptide) Gene, Albuminuria, and Hypertension</i> . Hypertension, 2001, 37, 1416-1422.	1.3	43
858	ACE Inhibitors and Appearance of Renal Events in Hypertensive Nephrosclerosis. Hypertension, 2001, 38, 645-649.	1.3	41
859	Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension, 2001, 37, 19-27.	1.3	112
860	Blood Pressure Control and Benefits of Antihypertensive Therapy. Hypertension, 2001, 38, 537-542.	1.3	36

#	Article	IF	CITATIONS
861	Reduced Cardiovascular Morbidity and Mortality in Hypertensive Diabetic Patients on First-Line Therapy With an ACE Inhibitor Compared With a Diuretic/Â-Blocker-Based Treatment Regimen: A subanalysis of the Captopril Prevention Project. Diabetes Care, 2001, 24, 2091-2096.	4.3	230
862	Orthostatic Hypertension in Patients With Type 2 Diabetes. Diabetes Care, 2001, 24, 1783-1786.	4.3	73
863	<i>Hypothesis:</i> β-Adrenergic Receptor Blockers and Weight Gain. Hypertension, 2001, 37, 250-254.	1.3	278
864	Genomic Scan for Exercise Blood Pressure in the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study. Hypertension, 2001, 38, 30-37.	1.3	51
865	Isolated Systolic Hypertension in Elderly WKY Is Reversed With I-Arginine and ACE Inhibition. Hypertension, 2001, 38, 1422-1426.	1.3	28
866	Fibrinogen and Preclinical Echocardiographic Target Organ Damage. Hypertension, 2001, 38, 1068-1074.	1.3	39
867	Sodium Sensitivity of Blood Pressure Appearing Before Hypertension and Related to Histological Damage in Immunoglobulin A Nephropathy. Hypertension, 2001, 38, 81-85.	1.3	44
868	Use of Antihypertensive and Antithrombotic Medications after Stroke in Community-Based Care. Annals of Pharmacotherapy, 2001, 35, 811-816.	0.9	10
869	Renin-Angiotensin System Gene Polymorphisms, Blood Pressure, Dyslipidemia, and Diabetes in Hong Kong Chinese: A significant association of the ACE insertion/deletion polymorphism with type 2 diabetes. Diabetes Care, 2001, 24, 356-361.	4.3	96
870	Effect of Blood Pressure Reduction on Abnormal Left Atrial Appendage Function in Untreated Systemic Hypertensive Patients with Sinus Rhythm. Angiology, 2001, 52, 621-626.	0.8	4
871	Pulse Pressure Changes With Six Classes of Antihypertensive Agents in a Randomized, Controlled Trial. Hypertension, 2001, 38, 953-957.	1.3	66
872	Primary Prevention of Ischemic Stroke. Circulation, 2001, 103, 163-182.	1.6	340
873	Effect of Estrogen Replacement Therapy on Endothelial Function in Peripheral Resistance Arteries in Normotensive and Hypertensive Postmenopausal Women. Hypertension, 2001, 37, 651-657.	1.3	87
874	Hypertensive Nephrosclerosis as a Relevant Cause of Chronic Renal Failure. Hypertension, 2001, 38, 171-176.	1.3	55
875	High serum enalaprilat in chronic renal failure. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2001, 2, 240-245.	1.0	9
876	Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus, 2001, 10, 359-363.	0.8	40
877	Blood Pressure Monitoring with Home Monitors versus Mercury Sphygmomanometer. Annals of Pharmacotherapy, 2001, 35, 817-822.	0.9	18
878	Predictors of Uncontrolled Hypertension in Ambulatory Patients. Hypertension, 2001, 38, 809-814.	1.3	174

#	Article	IF	CITATIONS
879	Effects of Alcohol Reduction on Blood Pressure. Hypertension, 2001, 38, 1112-1117.	1.3	639
880	Use of angiotensin II receptor blockers alone and in combination with other drugs: a large clinical experience trial. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2001, 2, S217-S222.	1.0	0
881	Improvement in Blood Pressure, Arterial Stiffness and Wave Reflections With a Very-Low-Dose Perindopril/Indapamide Combination in Hypertensive Patient. Hypertension, 2001, 38, 922-926.	1.3	420
882	Predominance of Isolated Systolic Hypertension Among Middle-Aged and Elderly US Hypertensives. Hypertension, 2001, 37, 869-874.	1.3	624
883	Cardiovascular Mortality in Hypertensive Men According to Presence of Associated Risk Factors. Hypertension, 2001, 37, 1256-1261.	1.3	125
884	Risk factors related to hypertension in a Spanish systemic lupus erythematosus cohort. Lupus, 2001, 10, 451-452.	0.8	12
885	One-Year Study of Felodipine or Placebo for Stage 1 Isolated Systolic Hypertension. Hypertension, 2001, 38, 1118-1123.	1.3	26
886	Local Hemodynamic Changes in Hypertension. Hypertension, 2001, 38, 1388-1394.	1.3	33
887	Prescribing Patterns and Therapeutic Implications for Diabetic Hypertension in Bahrain. Annals of Pharmacotherapy, 2001, 35, 1350-1359.	0.9	22
888	The Minnesota Regional Peripheral Arterial Disease Screening Program: toward a definition of community standards of care. Vascular Medicine, 2001, 6, 87-96.	0.8	93
889	Mercury Sphygmomanometers Should Not be Abandoned: An Advisory Statement From the Council for High Blood Pressure Research, American Heart Association. Hypertension, 2001, 37, 185-186.	1.3	66
890	Discordant responses to two classes of drugs acting on the renin-angiotensin system. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2001, 2, 25-30.	1.0	11
891	Fasting Plasma Homocysteine Levels in the Insulin Resistance Syndrome: The Framingham Offspring Study. Diabetes Care, 2001, 24, 1403-1410.	4.3	288
892	Patient Priorities and Needs for Diabetes Care Among Urban African American Adults. The Diabetes Educator, 2001, 27, 405-412.	2.6	36
893	Relation Between Soluble Adhesion Molecules and Insulin Sensitivity in Type 2 Diabetic Individuals: Role of adipose tissue. Diabetes Care, 2001, 24, 1961-1966.	4.3	49
894	Meta-analysis of Hypertension Trials in Diabetic Patients: Response to Parving and Rossing. Diabetes Care, 2001, 24, 178-180.	4.3	0
895	Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study. BMJ: British Medical Journal, 2001, 323, 142-146.	2.4	99
896	Angiotensin II receptor blockers for the treatment of hypertension. Expert Opinion on Pharmacotherapy, 2001, 2, 1795-1804.	0.9	23

#	Article	IF	CITATIONS
897	The Interaction of Age and Cognitive Representations in Predicting Blood Pressure. Western Journal of Nursing Research, 2001, 23, 476-489.	0.6	7
898	Effect of Type 2 Diabetes Mellitus on Left Ventricular Geometry and Systolic Function in Hypertensive Subjects. Circulation, 2001, 103, 102-107.	1.6	285
899	Intracellular Partition of Plasma Glucose Disposal in Hypertensive and Normotensive Subjects with Type 2 Diabetes Mellitus 1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2073-2079.	1.8	10
900	Calcium Modulation of Hypertension and Obesity: Mechanisms and Implications. Journal of the American College of Nutrition, 2001, 20, 428S-435S.	1.1	188
901	DASH (Dietary Approaches to Stop Hypertension) Diet Is Effective Treatment for Stage 1 Isolated Systolic Hypertension. Hypertension, 2001, 38, 155-158.	1.3	154
902	Risk factors and incident coronary heart disease in Chinese, Malay and Asian Indian males: the Singapore Cardiovascular Cohort Study. International Journal of Epidemiology, 2001, 30, 983-988.	0.9	138
903	The Effect Duration of Candesartan Cilexetil Once Daily, in Comparison with Enalapril Once Daily, in Patients with Mild to Moderate Hypertension. Blood Pressure, 2001, 10, 43-51.	0.7	25
904	Motivations for Exercise and Weight Loss Among African-American Women: Focus group results and their contribution towards program development. Ethnicity and Health, 2001, 6, 227-245.	1.5	85
905	Common Drug Pathways and Interactions. Diabetes Spectrum, 2002, 15, 249-255.	0.4	10
906	Electrocardiographic and Hemodynamic Effects of Panax Ginseng. Annals of Pharmacotherapy, 2002, 36, 758-763.	0.9	76
907	Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT). Hypertension, 2002, 40, 612-618.	1.3	270
908	Sociocultural Influences in Genetic Designs of Aging: Unexplored Perspectives. Experimental Aging Research, 2002, 28, 391-405.	0.6	6
909	Hypertension, Insulin, and Proinsulin in Participants With Impaired Glucose Tolerance. Hypertension, 2002, 40, 679-686.	1.3	45
910	Microalbuminuria, Cardiovascular, and Renal Risk in Primary Hypertension. Journal of the American Society of Nephrology: JASN, 2002, 13, S169-S172.	3.0	62
911	Target organ damage: use of pulse wave analysis as a manifestation of aortic degeneration in the assessment of hypertension. Vascular Medicine, 2002, 7, 83-85.	0.8	7
912	THE TOLERANCE-HYPERBARIC TEST: A CHRONOBIOLOGIC APPROACH FOR IMPROVED DIAGNOSIS OF HYPERTENSION. Chronobiology International, 2002, 19, 1183-1211.	0.9	51
913	Impairment in Cardiac Autonomic Regulation Preceding Arterial Hypertension in Humans. Circulation, 2002, 106, 2673-2679.	1.6	158
914	Efficacy and Safety of Barnidipine Compared with Felodipine in the Treatment of Hypertension in Chinese Patients. Journal of International Medical Research, 2002, 30, 330-336.	0.4	10

#	Article	IF	CITATIONS
915	Reducing Disparities in Hypertension Control: A Community-Based Hypertension Control Project (CHIP) for an Ethnically Diverse Population. Health Promotion Practice, 2002, 3, 264-275.	0.9	40
916	Methodology to Determine Duration of Action for Antihypertensive Drugs. Annals of Pharmacotherapy, 2002, 36, 874-881.	0.9	6
917	Blood Pressure as a Surrogate End Point for Hypertension. Annals of Pharmacotherapy, 2002, 36, 87-92.	0.9	6
918	Risk and Predictors of Stroke After Myocardial Infarction Among the Elderly. Circulation, 2002, 105, 1082-1087.	1.6	82
919	Reduction of New Coronary Events and New Atherothrombotic Brain Infarction in Older Persons With Diabetes Mellitus, Prior Myocardial Infarction, and Serum Low-Density Lipoprotein Cholesterol >=125 mg/dl Treated With Statins. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2002, 57, M747-M750.	1.7	49
920	The Kidney as a Sensor of Cardiovascular Risk in Essential Hypertension. Journal of the American Society of Nephrology: JASN, 2002, 13, S165-S168.	3.0	36
921	Antihypertensive Medication Compliance in a Veterans Affairs Healthcare System. Annals of Pharmacotherapy, 2002, 36, 986-991.	0.9	25
922	The Prevalence of Hypertension and Utilization of Antihypertensive Therapy in a District Diabetes Population. Diabetes Care, 2002, 25, 2107-2108.	4.3	17
923	Effects of Doxazosin and Propranolol on A2AAdenosine Receptors in Essential Hypertension. Hypertension, 2002, 40, 909-913.	1.3	14
924	Sympathetic activity and the heterogenous blood pressure response to exercise training in hypertensives. Journal of Applied Physiology, 2002, 92, 1434-1442.	1.2	35
925	Angiotensinogen Gene Promoter Region Variant Modifies Body Size–Ambulatory Blood Pressure Relations in Hypertension. Circulation, 2002, 106, 1483-1487.	1.6	61
926	Efficacy of Eplerenone Added to Renin-Angiotensin Blockade in Hypertensive Patients. Hypertension, 2002, 40, 117-123.	1.3	206
927	Development of Predictive Models for Long-Term Cardiovascular Risk Associated With Systolic and Diastolic Blood Pressure. Hypertension, 2002, 39, 105-110.	1.3	116
928	Ambulatory Blood Pressure Monitoring in Children and Adolescents. Clinical Pediatrics, 2002, 41, 549-564.	0.4	19
930	Clinical benefit of renal artery angioplasty with stenting for the control of recurrent and refractory congestive heart failure. Vascular Medicine, 2002, 7, 275-279.	0.8	158
931	Cellular Basis of Diabetic Nephropathy: 1. Study Design and Renal Structural-Functional Relationships in Patients With Long-Standing Type 1 Diabetes. Diabetes, 2002, 51, 506-513.	0.3	188
932	Review: Rationale for combination therapy in the treatment of hypertension. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2002, 3, 63-65.	1.0	4
933	Hydrochlorothiazide Effectively Reduces Urinary Calcium Excretion in Two Japanese Patients with Gain-of-Function Mutations of the Calcium-Sensing Receptor Gene. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3068-3073.	1.8	67

#	Article	IF	CITATIONS
934	Cardioselective beta-blockers for chronic obstructive pulmonary disease. , 2002, , CD003566.		33
935	Isolated Systolic Hypertension Is Associated with Adverse Outcomes from Coronary Artery Bypass Grafting Surgery. Anesthesia and Analgesia, 2002, 94, 1079-1084.	1.1	126
936	Dexmedetomidine-Induced Sedation in Volunteers Decreases Regional and Global Cerebral Blood Flow. Anesthesia and Analgesia, 2002, 95, 1052-1059.	1.1	53
937	Dexmedetomidine-Induced Sedation in Volunteers Decreases Regional and Global Cerebral Blood Flow. Anesthesia and Analgesia, 2002, 95, 1052-1059.	1.1	159
938	Care of the kidney transplant recipient. Postgraduate Medicine, 2002, 112, 93-112.	0.9	1
939	Body mass index is a good predictor of hypertension and hyperlipidemia in a rural Japanese population. International Journal of Obesity, 2002, 26, 725-729.	1.6	54
940	ACE-I and ARBs in early diabetic nephropathy. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2002, 3, 262-269.	1.0	52
941	Irbesartan Substitution for Valsartan or Losartan in Treating Hypertension. Annals of Pharmacotherapy, 2002, 36, 1840-1844.	0.9	6
942	Elevated Dehydroepiandrosterone Sulfate Levels as the Reproductive Phenotype in the Brothers of Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2134-2138.	1.8	134
943	Habitual fat intake and basal fat oxidation in obese and non-obese Caucasians. International Journal of Obesity, 2002, 26, 150-156.	1.6	10
944	Fixed dose combination therapy in the treatment of hypertension. Journal of Human Hypertension, 2002, 16, 75-78.	1.0	34
945	Exercise in Treating Hypertension. Physician and Sportsmedicine, 2002, 30, 11-50.	1.0	6
946	Salt intake, hypertension and diabetes mellitus. Journal of Human Hypertension, 2002, 16, S48-S51.	1.0	34
947	Is adiposity at normal body weight relevant for cardiovascular disease risk?. International Journal of Obesity, 2002, 26, 176-183.	1.6	44
948	Distribution of blood pressure and prevalence of hypertension in Tehran adult population: Tehran Lipid and Glucose Study (TLGS), 1999–2000. Journal of Human Hypertension, 2002, 16, 305-312.	1.0	80
949	Bruce Psaty and the risks of calcium channel blockers. Quality and Safety in Health Care, 2002, 11, 294-296.	2.5	5
950	Ambulatory blood pressure and brain atrophy in the healthy elderly. Neurology, 2002, 59, 713-719.	1.5	70
951	Risk Factors for Proteinuria in a Large, Multiracial, Southeast Asian Population. Journal of the American Society of Nephrology: JASN, 2002, 13, 1907-1917.	3.0	140

#	Article	IF	CITATIONS
952	Goal-Oriented Hypertension Management. Hypertension, 2002, 40, 464-469.	1.3	78
953	Age-Related Bias in the Management of Hypertension: A National Survey of Physicians' Opinions on Hypertension in Elderly Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2002, 57, M487-M491.	1.7	46
954	Influence of Left Ventricular Geometry on Regional Systolic and Diastolic Function in Patients with Essential Hypertension. Scandinavian Cardiovascular Journal, 2002, 36, 292-296.	0.4	11
955	The Impact of JNC-VI Guidelines on Treatment Recommendations in the US Population. Hypertension, 2002, 39, 897-902.	1.3	53
958	Prevalence and Association of Ventricular Tachycardia and Complex Ventricular Arrhythmias With New Coronary Events in Older Men and Women With and Without Cardiovascular Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2002, 57, M178-M180.	1.7	33
959	Losartan reduced cardiovascular morbidity and mortality more than atenolol in patients with diabetes and essential hypertension. Evidence-Based Medicine, 2002, 7, 173-173.	0.6	0
960	Role of Race in the Pharmacotherapy of Heart Failure. Annals of Pharmacotherapy, 2002, 36, 471-478.	0.9	7
961	Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertension. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2002, 3, 176-180.	1.0	51
963	Classification of Blood Pressure Levels by Ambulatory Blood Pressure in Hypertension. Hypertension, 2002, 40, 817-822.	1.3	27
964	Review: The frequent need for three or more drugs to treat essential hypertension. What evidence for optimal combinations?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2002, 3, 103-108.	1.0	2
965	Contemporary Medical Options for Treating Patients With Heart Failure. Circulation, 2002, 105, 2244-2246.	1.6	18
966	Associations Between Birth Weight and Antihypertensive Medication in Black and White Medicaid Recipients. Hypertension, 2002, 39, 179-183.	1.3	46
967	The Dietary Approaches to Stop Hypertension diet lowered systolic blood pressure in stage 1 isolated systolic hypertension. Evidence-Based Medicine, 2002, 7, 41-41.	0.6	0
968	Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy. Circulation, 2002, 106, 2526-2529.	1.6	259
969	Emergency Department and Hospital Preventive Care of Elderly Next of Kin of Victims of Sudden Cardiac Death and Fatal Acute Myocardial Infarction. Circulation, 2002, 105, e191.	1.6	0
970	Renal and Cardiovascular Protection in Type 2 Diabetes Mellitus: Angiotensin II Receptor Blockers. Journal of the American Society of Nephrology: JASN, 2002, 13, S224-S229.	3.0	47
971	Review: Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT1-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2002, 3, 79-89.	1.0	9
972	Cardiovascular and Renal Protection in Type 2 Diabetes Mellitus: The Role of Calcium Channel Blockers. Journal of the American Society of Nephrology: JASN, 2002, 13, S216-S223.	3.0	31

#	Article	IF	CITATIONS
973	Relation of Drinking Alcohol to Atherosclerotic Risk in Type 2 Diabetes. Diabetes Care, 2002, 25, 1223-1228.	4.3	46
974	Eight-Year Blood Pressure Change in Middle-Aged Men. Hypertension, 2002, 39, 1000-1006.	1.3	153
975	Noninvasive Study of Endothelial Function in White Coat Hypertension. Hypertension, 2002, 40, 304-309.	1.3	40
976	Antecedent Blood Pressure and Risk of Cardiovascular Disease. Circulation, 2002, 105, 48-53.	1.6	136
977	Losartan reduced strokes and new onset diabetes more than atenolol in essential hypertension. Evidence-Based Medicine, 2002, 7, 174-174.	0.6	0
978	A New Fixed-Dose Combination for Added Blood Pressure Control: Telmisartan Plus Hydrochlorothiazide. Journal of International Medical Research, 2002, 30, 366-379.	0.4	17
979	The National High Blood Pressure Education Program. Hypertension, 2002, 39, 941-942.	1.3	27
980	Treatment and Control of Hypertension in the Community. Hypertension, 2002, 40, 640-646.	1.3	103
981	Control of Cardiovascular Risk Factors in Patients With Diabetes and Hypertension at Urban Academic Medical Centers. Diabetes Care, 2002, 25, 718-723.	4.3	211
982	Incidence of New Atherothrombotic Brain Infarction in Older Persons With Prior Myocardial Infarction and Serum Low-Density Lipoprotein Cholesterol >=125 mg/dl Treated With Statins Versus No Lipid-Lowering Drug. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2002-57 M333-M335	1.7	46
983	Hypertension Staging Through Ambulatory Blood Pressure Monitoring. Hypertension, 2002, 40, 792-794.	1.3	6
984	Percutaneous Mechanical Reperfusion During Acute Myocardial Infarction. Journal of Intensive Care Medicine, 2002, 17, 162-173.	1.3	1
985	Commentary: Salt intake, hypertension and risk of cardiovascular disease: an important public health challenge. International Journal of Epidemiology, 2002, 31, 327-331.	0.9	32
986	Secondary Prevention of Coronary Heart Disease in the Elderly (With Emphasis on Patients ≥75 Years) Tj ETQ	q1 <u>1</u> 0.78	4314 rgBT /(
987	Prevalence and Incidence of Cardiovascular Disease in 1160 Older Men and 2464 Older Women in a Long-term Health Care Facility. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2002, 57, M45-M46.	1.7	79
988	Medicaid Prescriber Compliance with Joint National Committee VI Hypertension Treatment Guidelines. Annals of Pharmacotherapy, 2002, 36, 1505-1511.	0.9	23
989	Evaluation and Treatment of Patients With Systemic Hypertension. Circulation, 2002, 105, 2458-2461.	1.6	19
991	Cardiovascular Disease Among Women Residing in Rural America: Epidemiology, Explanations, and Challenges. American Journal of Public Health, 2002, 92, 548-551.	1.5	45

#	ARTICLE	IF	CITATIONS
992	Twenty-Four-Hour Blood Pressure Variability after Acute Ischemic Stroke. Critical Care Nursing Quarterly, 2002, 25, 1-12.	0.4	2
993	Standards of Medical Care for Patients With Diabetes Mellitus. Diabetes Care, 2002, 25, 213-229.	4.3	201
994	Control of Hypertension and Risk of Stroke Recurrence. Stroke, 2002, 33, 2652-2657.	1.0	68
995	Effects of a Contemporary, Exercise-Based Rehabilitation and Cardiovascular Risk-Reduction Program on Coronary Patients With Abnormal Baseline Risk Factors. Chest, 2002, 122, 338-343.	0.4	34
996	Renal Ischemia-reperfusion injury in the rat is prevented by a novel immune modulation therapy. Transplantation, 2002, 74, 1425-1433.	0.5	12
997	Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial. Journal of Hypertension, 2002, 20, 729-737.	0.3	44
998	Chronic Hypertension in Pregnancy. Obstetrics and Gynecology, 2002, 100, 369-377.	1.2	138
999	Firefighters??? Blood Pressure and Employment Status on Hazardous Materials Teams in Massachusetts: A Prospective Study. Journal of Occupational and Environmental Medicine, 2002, 44, 669-676.	0.9	24
1000	Critical Pathways. Critical Pathways in Cardiology, 2002, 1, 184-193.	0.2	1
1002	Angiotensin converting enzyme DD genotype is associated with hypertensive crisis*. Critical Care Medicine, 2002, 30, 2236-2241.	0.4	29
1003	Comparison of a Fixed-Dose Combination of 40 mg Telmisartan Plus 12.5 mg Hydrochlorothiazide With 40 mg Telmisartan in the Control of Mild to Moderate Hypertension. American Journal of Therapeutics, 2002, 9, 111-117.	0.5	41
1004	Recent Dietary Guidelines to Prevent and Treat Cardiovascular Disease, Diabetes, and Obesity. Heart Disease (Hagerstown, Md), 2002, 4, 220-230.	1.3	14
1005	Diabetes and Cardiovascular Diseases. American Journal of Therapeutics, 2002, 9, 510-515.	0.5	48
1006	Reduction of Coronary Events With Aspirin in Older Patients With Prior Myocardial Infarction Treated With and Without Statins. Heart Disease (Hagerstown, Md), 2002, 4, 159-161.	1.3	33
1007	Natural History of Fabry Renal Disease. Medicine (United States), 2002, 81, 122-138.	0.4	400
1008	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 275-280.	1.5	3
1011	Comparative Effects on Dynamic Renal Potassium Excretion of ACE Inhibition versus Angiotensin Receptor Blockade in Hypertensive Patients with Type II Diabetes Mellitus. Journal of Clinical Pharmacology, 2002, 42, 754-761.	1.0	20
1012	Physical exercise and blood pressure with reference to the angiotensinogen M235T polymorphism. Physiological Genomics, 2002, 10, 71-77.	1.0	37

#	Article	IF	CITATIONS
1013	Improving Care for Patients With Chronic Heart Failure in the Community. Chest, 2002, 122, 906-912.	0.4	64
1014	Barriers to blood pressure control in African Americans. Postgraduate Medicine, 2002, 112, 51-70.	0.9	31
1015	Blood pressure lowering efficacy of calcium channel blockers for primary hypertension. The Cochrane Library, 2002, , .	1.5	2
1016	Glucose Tolerance and Cardiovascular Risk in Young Adult African Americans. American Journal of the Medical Sciences, 2002, 323, 231-237.	0.4	7
1017	Osteoporosis Screening by Community Pharmacists: Use of National Osteoporosis Foundation Resources. Journal of the American Pharmacists Association, 2002, 42, 101-111.	0.6	37
1018	Supplementation of Plant Sterols and Minerals Benefits Obese Zucker Rats Fed an Atherogenic Diet. Journal of Nutrition, 2002, 132, 231-237.	1.3	28
1019	Optimal treatment of hypertension in African Americans. Postgraduate Medicine, 2002, 112, 73-84.	0.9	6
1020	Managing big issues on lean evidence: treating obesity hypertension. Nephrology Dialysis Transplantation, 2002, 17, 353-355.	0.4	15
1021	NHBPEP: Working to Reduce Death and Disability From High Blood Pressure. Journal of the American Pharmacists Association, 2002, 42, 886-888.	0.6	0
1022	Hypertension in an Adolescent Boy. American Journal of the Medical Sciences, 2002, 323, 227-230.	0.4	2
1023	Identification of Cardiovascular Risk Factors in Homeless Adults. American Journal of the Medical Sciences, 2002, 324, 243-246.	0.4	65
1024	Arterial intima-media thickness: site-specific associations with HRT and habitual exercise. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H1409-H1417.	1.5	55
1025	The Epidemiology of End-Stage Renal Disease among African Americans. American Journal of the Medical Sciences, 2002, 323, 65-71.	0.4	78
1026	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 147-152.	1.5	11
1027	Clinical Management of the Obese Hypertensive Patient. Cardiology in Review, 2002, 10, 127-138.	0.6	47
1028	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 123-129.	1.5	81
1029	Autonomic dysfunction associates with prolongation of QT intervals and blunted night BP in obese women with visceral obesity. Journal of Endocrinological Investigation, 2002, 25, RC32-RC35.	1.8	24
1030	Evidence-Based Nutrition Principles and Recommendations for the Treatment and Prevention of Diabetes and Related Complications. Diabetes Care, 2002, 25, 148-198.	4.3	745

#	Article	IF	CITATIONS
1031	Blood Pressure Response to Heart Rate During Exercise Test and Risk of Future Hypertension. Hypertension, 2002, 39, 761-766.	1.3	205
1032	The Treatment of Hypertension in Adult Patients With Diabetes. Diabetes Care, 2002, 25, 134-147.	4.3	280
1033	Factors Affecting Medication Adherence in Hypertensive Patients. Annals of Pharmacotherapy, 2002, 36, 40-45.	0.9	90
1034	Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease. American Journal of Medicine, 2002, 112, 126-134.	0.6	49
1035	Current medical therapies for patients with peripheral arterial disease: a critical review. American Journal of Medicine, 2002, 112, 49-57.	0.6	131
1036	Lay beliefs about high blood pressure in a low- to middle-income urban African-American community: an opportunity for improving hypertension control. American Journal of Medicine, 2002, 112, 26-30.	0.6	70
1037	Hypertension in the Elderly: A Review of the Importance of Systolic Blood Pressure Elevation. Journal of Clinical Hypertension, 2002, 4, 108-119.	1.0	25
1038	Physician Practice Patterns in the Treatment of Isolated Systolic Hypertension in a Primary Care Setting. Journal of Clinical Hypertension, 2002, 4, 93-100.	1.0	10
1039	The Effect of a Losartan-Based Treatment Regimen on Isolated Systolic Hypertension. Journal of Clinical Hypertension, 2002, 4, 101-107.	1.0	72
1040	Factors Influencing the Systolic Blood Pressure Response to Drug Therapy. Journal of Clinical Hypertension, 2002, 4, 35-40.	1.0	20
1041	Therapeutic Considerations in the Treatment of Obesity Hypertension. Journal of Clinical Hypertension, 2002, 4, 189-196.	1.0	7
1042	Refractory or Resistant Hypertension. Journal of Clinical Hypertension, 2002, 4, 61-61.	1.0	0
1043	The Diagnosis of Hypertension. Journal of Clinical Hypertension, 2002, 4, 166-180.	1.0	1
1044	Reproducibility of Blood Pressure Response to Hydrochlorothiazide. Journal of Clinical Hypertension, 2002, 4, 408-412.	1.0	7
1045	How Relevant and Frequent Is the Presence of Mild Renal Insufficiency in Essential Hypertension?. Journal of Clinical Hypertension, 2002, 4, 332-336.	1.0	39
1046	Antihypertensive Efficacy of Olmesartan Medoxomil, a New Angiotensin II Receptor Antagonist, as Assessed by Ambulatory Blood Pressure Measurements. Journal of Clinical Hypertension, 2002, 4, 325-331.	1.0	42
1047	Premature Termination of Clinical Trials-Lessons Learned. Journal of Clinical Hypertension, 2002, 4, 219-225.	1.0	4
1048	A "Touch―of High Blood Pressure. Journal of Clinical Hypertension, 2002, 4, 10-12.	1.0	0

#	Article	IF	CITATIONS
1049	Effectiveness of the Electronic Medical Record in Improving the Management of Hypertension. Journal of Clinical Hypertension, 2002, 4, 415-419.	1.0	23
1050	Clinical Impact of Renin-Angiotensin System Blockade: Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Antagonists. Journal of Clinical Hypertension, 2002, 4, 11-31.	1.0	5
1051	Will We Ever Wipe Out Stroke?. Journal of Clinical Hypertension, 2002, 4, 337-344.	1.0	0
1052	Alcohol's (other) Dark Side. Journal of Clinical Hypertension, 2002, 4, 362-362.	1.0	0
1053	Sleep Apnea and Hypertension. Journal of Clinical Hypertension, 2002, 4, 437-440.	1.0	3
1054	Update on the Management of Hypertension: Do Recent Clinical Trial Results Indicate a Change in National Recommendations for Therapy?. Journal of Clinical Hypertension, 2002, 4, 20-31.	1.0	8
1055	Original Papers. Success and Predictors of Blood Pressure Control in Diverse North American Settings: The Antihypertensive and Lipidâ€Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of Clinical Hypertension, 2002, 4, 393-404.	1.0	835
1056	Quality of Clinical Reports on Behavioral Interventions for Hypertension. Preventive Medicine, 2002, 34, 463-475.	1.6	3
1057	Evidence-based evaluation of calcium channel blockers for hypertension. Journal of the American College of Cardiology, 2002, 39, 315-322.	1.2	67
1058	Postexercise blood pressure reduction in elderly hypertensive patients. Journal of the American College of Cardiology, 2002, 39, 676-682.	1.2	161
1059	Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects. Journal of the American College of Cardiology, 2002, 39, 878-885.	1.2	133
1060	Sympathetic neural mechanisms in white-coat hypertension. Journal of the American College of Cardiology, 2002, 40, 126-132.	1.2	127
1061	Optimizing the diabetic formulary: beyond aspirin and insulin. Journal of the American College of Cardiology, 2002, 40, 652-661.	1.2	26
1062	Evaluation of the extent and duration of the "ABPM effect―in hypertensive patients. Journal of the American College of Cardiology, 2002, 40, 710-717.	1.2	93
1063	Coronary atherosclerosis in diabetes mellitus. Journal of the American College of Cardiology, 2002, 40, 946-953.	1.2	324
1064	Task Force #4—adherence issues and behavior changes: achieving a long-term solution. Journal of the American College of Cardiology, 2002, 40, 630-640.	1.2	86
1065	Task Force #3â€"getting results: who, where, and how?. Journal of the American College of Cardiology, 2002, 40, 615-630.	1.2	15
1066	If only cardiologists did properly measure blood pressure. Journal of the American College of Cardiology, 2002, 40, 2201-2203.	1.2	33

#	ARTICLE	IF	Citations
1067	Self-selected women with polycystic ovary syndrome are reproductively and metabolically abnormal and undertreated. Fertility and Sterility, 2002, 78, 51-57.	0.5	26
1068	Systolic blood pressure is a better predictor of cardio-vascular disease risk than diastolic blood pressure in hypertensive men. Evidence-based Cardiovascular Medicine, 2002, 6, 162-163.	0.0	O
1069	Prevention of heart failure. Journal of Cardiac Failure, 2002, 8, 333-346.	0.7	84
1070	Diastolic heart failure in the community: Clinical profile, natural history, therapy, and impact of proposed diagnostic criteria. Journal of Cardiac Failure, 2002, 8, 279-287.	0.7	134
1071	Insulin Resistance as an Independent Predictor of Cardiovascular Mortality in Patients with End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2002, 13, 1894-1900.	3.0	339
1072	Prevention of Post-transplant Cardiovascular Disease - Report and Recommendations of an Ad Hoc Group1. American Journal of Transplantation, 2002, 2, 491-500.	2.6	71
1073	Clinical Pharmacokinetics and Selective Pharmacodynamics of New Angiotensin Converting Enzyme Inhibitors. Clinical Pharmacokinetics, 2002, 41, 207-224.	1.6	97
1074	??-Adrenergic Blockers in Systemic Hypertension. Clinical Pharmacokinetics, 2002, 41, 505-516.	1.6	63
1075	Rationale for Fixed-Dose Combinations in the Treatment of Hypertension. Drugs, 2002, 62, 443-462.	4.9	263
1076	Candesartan Cilexetil plus Hydrochlorothiazide Combination. Drugs, 2002, 62, 787-816.	4.9	42
1077	Candesartan Cilexetil. Drugs, 2002, 62, 1253-1287.	4.9	62
1079	Valsartan/Hydrochlorothiazide. Drugs, 2002, 62, 1983-2005.	4.9	64
1080	The Role of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists in the Management of Diabetic Complications. Drugs, 2002, 62, 2007-2012.	4.9	13
1081	Fixed Combination Trandolapril/Verapamil Sustained-Release. Drugs, 2002, 62, 2541-2569.	4.9	11
1082	Risk Factors for Cardiovascular and Ischaemic Heart Disease in a Mediterranean Country. Clinical Drug Investigation, 2002, 22, 241-251.	1.1	7
1083	Low-Dose Combination Therapy with Perindopril and Indapamide Compared with Irbesartan. Clinical Drug Investigation, 2002, 22, 553-560.	1.1	15
1084	Impact of a Low-Dose Combination of Isradipine SRO and Spirapril on Left Ventricular Mass and Left Ventricular Performance in Patients with Hypertension and Left Ventricular Hypertrophy. Clinical Drug Investigation, 2002, 22, 667-675.	1,1	1
1085	Metoprolol Succinate SR plus Hydrochlorothiazide (Beloc-Zok?? Comp) in Patients with Essential Hypertension in General Practice. Clinical Drug Investigation, 2002, 22, 719-729.	1.1	3

#	ARTICLE	IF	CITATIONS
1086	Guest Editorial: What Is the Appropriate Treatment of Hypertension in Elders?. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2002, 57, M483-M486.	1.7	35
1087	Modeling the circadian variability of ambulatorily monitored blood pressure by multiple-component analysis. Chronobiology International, 2002, 19, 461-481.	0.9	106
1088	Treatment of Microalbuminuria in Patients with Type 2 Diabetes Mellitus. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2002, 1, 163-173.	1.8	33
1089	Smooth Blood Pressure Control Obtained with Extended-Release Felodipine in Elderly Patients with Hypertension. Drugs and Aging, 2002, 19, 541-551.	1.3	8
1090	Issues in the Perioperative Management of the Elderly Patient with Cardiovascular Disease. Drugs and Aging, 2002, 19, 429-451.	1.3	44
1091	Antagonistas de los receptores de la angiotensina II. Una revisión farmacoterapéutica. Hipertension Y Riesgo Vascular, 2002, 19, 129-138.	0.3	1
1092	Documento de consenso 2002 sobre pautas e detección, prevención y tratamiento e la nefropatÃa diabética en España. Semergen, 2002, 28, 631-638.	0.2	8
1096	Pautas de detección, prevención y tratamiento de la nefropatÃa diabética en españa. Hipertension Y Riesgo Vascular, 2002, 19, 412-420.	0.3	1
1098	Prevalencia de la hipertensi \tilde{A}^3 n arterial sist \tilde{A}^3 lica aislada en una poblaci \tilde{A}^3 n mayor de 60 a $\tilde{A}\pm$ os. Hipertension Y Riesgo Vascular, 2002, 19, 384-389.	0.3	2
1099	Antihipertensivos cl \tilde{A}_i sicos o modernos en el tratamiento de la hipertensi \tilde{A}^3 n arterial: \hat{A}_i debe seguir existiendo controversia en su elecci \tilde{A}^3 n?. Semergen, 2002, 28, 560-572.	0.2	1
1100	Olmesartan Medoxomil: profile report. Drugs and Therapy Perspectives, 2002, 18, 5-7.	0.3	0
1101	Antihypertensive Drugs. American Journal of Cardiovascular Drugs, 2002, 2, 77-89.	1.0	36
1102	Calcium Channel Antagonists in the Treatment of Hypertension. American Journal of Cardiovascular Drugs, 2002, 2, 415-431.	1.0	18
1103	Effects of Policosanol on Older Patients with Hypertension and Type II Hypercholesterolaemia. Drugs in R and D, 2002, 3, 159-172.	1.1	28
1104	Angiotensin blockade for hypertension: a promise fulfilled. Lancet, The, 2002, 359, 990-992.	6.3	44
1105	Diagnosis and management of preeclampsia and eclampsia. International Journal of Gynecology and Obstetrics, 2002, 77, 67-75.	1.0	442
1106	Single LDL apheresis improves serum remnant-like particle-cholesterol, C-reactive protein, and malondialdehyde-modified-low-density lipoprotein concentrations in Japanese hypercholesterolemic subjects. Clinica Chimica Acta, 2002, 321, 107-112.	0.5	28
1107	Irbesartan monotherapy in systemic hypertension: An open-label, uncontrolled trial. Current Therapeutic Research, 2002, 63, 176-185.	0.5	1

#	Article	IF	CITATIONS
1108	Evaluation of long-term efficacy and tolerability of irbesartan in elderly hypertensive patients with renal impairment in an open-label study. Current Therapeutic Research, 2002, 63, 201-215.	0.5	2
1109	Genetics of leukoaraiosis. Journal of Stroke and Cerebrovascular Diseases, 2002, 11, 241-251.	0.7	3
1110	Cardiovascular risk factors associated with immunosuppression in renal transplantation. Transplantation Reviews, 2002, 16, 1-21.	1.2	18
1111	Amlodipine and chlorthalidone are equally effective for stage I isolated systolic hypertension. Evidence-based Cardiovascular Medicine, 2002, 6, 114-115.	0.0	0
1112	Abdominal aortic calcific deposits are associated with increased risk for congestive heart failure: The Framingham Heart Study. American Heart Journal, 2002, 144, 733-739.	1.2	62
1113	Simple, shared guidelines raise the quality of antihypertensive treatment in routine care. American Heart Journal, 2002, 144, 726-732.	1.2	11
1114	Design of the omapatrilat in persons with enhanced risk of atherosclerotic events (OPERA) trial. American Journal of Hypertension, 2002, 15, 193-198.	1.0	24
1115	Nighttime blood pressure dipping: the role of the sympathetic nervous system. American Journal of Hypertension, 2002, 15, 111-118.	1.0	260
1116	Effects of alcohol restriction on ambulatory blood pressure, heart rate, and heart rate variability in Japanese men. American Journal of Hypertension, 2002, 15, 125-129.	1.0	27
1117	A low-calorie diet improves endothelium-dependent vasodilation in obese patients with essential hypertension. American Journal of Hypertension, 2002, 15, 302-309.	1.0	137
1118	The role of spironolactone in the treatment of patients with refractory hypertension. American Journal of Hypertension, 2002, 15, 333-339.	1.0	196
1119	Ace inhibition and cardiovascular mortality and morbidity in essential hypertension: The end of the search or a need for further investigations?. American Journal of Hypertension, 2002, 15, 367-371.	1.0	20
1120	The relationship between body mass index and pulse pressure in older adults with isolated systolic hypertension. American Journal of Hypertension, 2002, 15, 538-543.	1.0	21
1121	Ambulatory blood pressure and coronary artery calcification in middle-aged and younger adults. American Journal of Hypertension, 2002, 15, 518-524.	1.0	29
1122	Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. American Journal of Hypertension, 2002, 15, 550-556.	1.0	46
1123	The PROGRESS trial: questions about the effectiveness of angiotensin converting enzyme inhibitors. American Journal of Hypertension, 2002, 15, 472-474.	1.0	8
1124	The ASH specialists program: a progress report. American Journal of Hypertension, 2002, 15, 577-579.	1.0	8
1125	Hypertension management in 2002: where have we been? where might we be going?. American Journal of Hypertension, 2002, 15, 101S-107S.	1.0	16

#	Article	IF	CITATIONS
1126	Strategies to meet lower blood pressure goals with a new standard in angiotensin II receptor blockade. American Journal of Hypertension, 2002, 15, 108S-114S.	1.0	16
1127	The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. American Journal of Hypertension, 2002, 15, 123S-128S.	1.0	44
1128	Elevated blood pressure among U.S. adults with diabetes, 1988–19941 1The full text of this article is available via AJPM Online at http://www.elsevier.com/locate/ajpmonline American Journal of Preventive Medicine, 2002, 22, 42-48.	1.6	112
1129	Evaluation of captopril for the management of hypertension in autonomic dysreflexia: A pilot study. Archives of Physical Medicine and Rehabilitation, 2002, 83, 604-608.	0.5	46
1130	Diabetes mellitus and cardiovascular disease. European Journal of Internal Medicine, 2002, 13, 15-30.	1.0	12
1131	Hypertension is frequently present in patients with reflux esophagitis or Barrett's esophagus but not in those with non-ulcer dyspepsia. European Journal of Internal Medicine, 2002, 13, 369-375.	1.0	30
1132	Insulin sensitivity correlates with glycogen synthesis rate, but not with von Willebrand factor in type 2 diabetes. European Journal of Internal Medicine, 2002, 13, 439-444.	1.0	5
1133	A retrospective electronic chart review of blood pressure changes in elderly patients treated with amlodipine or an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker. Clinical Therapeutics, 2002, 24, 930-941.	1.1	3
1134	A postmarketing, open-label study to evaluate the tolerability and effectiveness of replacing standard-formulation doxazosin with doxazosin in the gastrointestinal therapeutic system formulation in adult patients with hypertension. Clinical Therapeutics, 2002, 24, 786-797.	1.1	8
1135	Myocardial ischemia and autonomic activity in dippers and non-dippers with coronary artery disease: assessment of normotensive and hypertensive patients. International Journal of Cardiology, 2002, 83, 133-142.	0.8	42
1136	Role of Ambulatory Blood Pressure Measurement in Diagnosis and Control of Hypertension. Medical Journal Armed Forces India, 2002, 58, 307-309.	0.3	0
1137	Hypertension in the elderly: evidence-based management. International Congress Series, 2002, 1237, 75-85.	0.2	1
1138	The role of emotional regulation in the development of hypertension. International Congress Series, 2002, 1241, 91-97.	0.2	5
1139	Increased levels of monocyte-related cytokines in patients with unstable angina. Atherosclerosis, 2002, 161, 403-408.	0.4	64
1140	Cardioselective beta-blockers for reversible airway disease. The Cochrane Library, 2002, , CD002992.	1.5	57
1142	Hiperlipoproteinemias secundarias. ClÃnica E Investigación En Arteriosclerosis, 2002, 14, 142-149.	0.4	2
1144	Estudio de actitud, comportamiento y satisfacci \tilde{A}^3 n de los m \tilde{A} ©dicos de APS con el tratamiento antihipertensivo actual. Hipertension Y Riesgo Vascular, 2002, 19, 338-344.	0.3	1
1145	Bloqueadores betaadrenérgicos: análisis comparativo. FMC Formacion Medica Continuada En Atencion Primaria, 2002, 9, 605-612.	0.0	0

#	ARTICLE	IF	CITATIONS
1146	Respuesta a un "análisis―crÃŧico sobre la atención farmacéutica. Semergen, 2002, 28, 51-54.	0.2	3
1148	Tratamiento de las crisis hipertensivas. FMC Formacion Medica Continuada En Atencion Primaria, 2002, 9, 355-365.	0.0	2
1155	Hipertensi?n arterial. EMC - Tratado De Medicina, 2002, 6, 1-9.	0.0	2
1157	Atherosclerotic renal artery disease. Cardiology Clinics, 2002, 20, 547-562.	0.9	39
1159	Nondrug interventions in hypertension prevention and control. Cardiology Clinics, 2002, 20, 249-263.	0.9	33
1161	The global burden of hypertension: good news and bad news. Cardiology Clinics, 2002, 20, 181-185.	0.9	38
1162	Guidelines for the Reporting of Renal Artery Revascularization in Clinical Trials. Journal of Vascular and Interventional Radiology, 2002, 13, 959-974.	0.2	50
1164	Pathogenesis and clinical physiology of hypertension. Cardiology Clinics, 2002, 20, 195-206.	0.9	7
1169	Resistant hypertension, secondary hypertension, and hypertensive crises. Cardiology Clinics, 2002, 20, 281-289.	0.9	27
1170	Cambios en la presión arterial y la frecuencia cardÃaca inducidos por la práctica y cese de ejercicio fÃsico moderado en jóvenes normotensos. ClÃnica E Investigación En Arteriosclerosis, 2002, 14, 9-16.	0.4	0
1171	Prevention of cardiovascular diseases. Clinics in Geriatric Medicine, 2002, 18, 463-483.	1.0	13
1173	Evaluaci \tilde{A}^3 n econ \tilde{A}^3 mica retrospectiva con costes espa $\tilde{A}\pm$ oles de un estudio comparativo de amlodipino y enalapril en el tratamiento de la hipertensi \tilde{A}^3 n ligera a moderada. Hipertension Y Riesgo Vascular, 2002, 19, 271-278.	0.3	1
1174	Clinical pharmacology of antihypertensive drugs. Cardiology Clinics, 2002, 20, 265-280.	0.9	9
1175	Thrombotic microangiopathies. Critical Care Clinics, 2002, 18, 309-320.	1.0	30
1176	Hipertensi \tilde{A}^3 n arterial y enfermedad vascular perif \tilde{A} ©rica de origen ateroscler \tilde{A}^3 tico. Hipertension Y Riesgo Vascular, 2002, 19, 17-27.	0.3	1
1177	Cardiovascular disease prevention. Primary Care - Clinics in Office Practice, 2002, 29, 667-696.	0.7	6
1178	The heart, kidney, and brain as target organs in hypertension. Cardiology Clinics, 2002, 20, 225-247.	0.9	50
1179	Chronic Renal Ischemia: Implications for Cardiovascular Disease Risk. Journal of Vascular and Interventional Radiology, 2002, 13, 1187-1198.	0.2	15

#	Article	IF	CITATIONS
1181	Effective strategies for blood pressure control. Cardiology Clinics, 2002, 20, 321-333.	0.9	12
1182	Tratamiento de la hipertensión arterial con antagonistas de los receptores de la angiotensina II. Hipertension Y Riesgo Vascular, 2002, 19, 257-261.	0.3	0
1185	Estatinas en el tratamiento de la hipertensión arterial. Hipertension Y Riesgo Vascular, 2002, 19, 400-405.	0.3	3
1186	Detecci \tilde{A}^3 n precoz de la hipertensi \tilde{A}^3 n arterial: \hat{A}_{ζ} hay un lugar para las oficinas de farmacia?. Hipertension Y Riesgo Vascular, 2002, 19, 297-298.	0.3	0
1187	Evolución del control de la hipertensión arterial en España. Resultados del estudio Controlpres 2001. Hipertension Y Riesgo Vascular, 2002, 19, 390-399.	0.3	89
1188	El problema del control de la hipertensión en España. Hipertension Y Riesgo Vascular, 2002, 19, 377-381.	0.3	5
1189	Hipertensión arterial en el paciente dislipidémico. Hipertension Y Riesgo Vascular, 2002, 19, 222-237.	0.3	3
1193	Quality Improvement Guidelines for Angiography, Angioplasty, and Stent Placement in the Diagnosis and Treatment of Renal Artery Stenosis in Adults. Journal of Vascular and Interventional Radiology, 2002, 13, 1069-1083.	0.2	74
1194	Preventive health care for older patients. Primary Care - Clinics in Office Practice, 2002, 29, 599-614.	0.7	3
1195	A Randomized Trial of an Intervention to Improve Self-Care Behaviors of African-American Women With Type 2 Diabetes: Impact on physical activity. Diabetes Care, 2002, 25, 1576-1583.	4.3	228
1196	Life : une étude qui vaprobablement modifiernotre approchedans le traitement del'hypertension artérielle. Medecine/Sciences, 2002, 18, 563-564.	0.0	0
1197	Autopercepção corporal de variáveis da aptidão fÃsica relacionada à saúde. Revista Brasileira De Medicina Do Esporte, 2002, 8, 37-49.	0.1	7
1199	Systolic blood pressure. BMJ: British Medical Journal, 2002, 325, 917-918.	2.4	39
1200	Blood Pressure Management in Acute Stroke: Comparison of Current Guidelines with Prescribing Patterns. Canadian Journal of Neurological Sciences, 2002, 29, 125-131.	0.3	20
1201	Increase in Pulse Pressure Relates to Diabetes Mellitus and Low HDL Cholesterol, but Not to Hyperlipidemia in Hypertensive Patients Aged 50 Years or Older Hypertension Research, 2002, 25, 335-341.	1.5	21
1202	The Lucent-Takes-Heart Cardiovascular Health Management Program. AAOHN Journal, 2002, 50, 365-372.	0.5	10
1203	Recruitment and Coaching of Healthy Elderly Subjects for Invasive Cardiovascular Research with Right-Sided Catheterisation. European Journal of Cardiovascular Nursing, 2002, 1, 289-298.	0.4	1
1204	How Important Is Pulse Pressure as a Predictor of Cardiovascular Risk?. Hypertension, 2002, 39, .	1.3	11

#	ARTICLE	IF	CITATIONS
1205	Effective diabetes care: a need for realistic targets. BMJ: British Medical Journal, 2002, 324, 1577-1580.	2.4	84
1206	Green Coffee Bean Extract and Its Metabolites Have a Hypotensive Effect in Spontaneously Hypertensive Rats. Hypertension Research, 2002, 25, 99-107.	1.5	138
1207	Improving the Managed Care of Hypertension with Angiotensin II Antagonists. American Journal of the Medical Sciences, 2002, 323, 25-33.	0.4	4
1208	Commentary: Salt intake, hypertension and risk of cardiovascular disease: an important public health challenge. International Journal of Epidemiology, 2002, 31, 327-331.	0.9	21
1209	Diabetic Renal Disease in African Americans. American Journal of the Medical Sciences, 2002, 323, 78-84.	0.4	31
1210	Hypertensive emergencies: Diagnosis and management. Progress in Cardiovascular Diseases, 2002, 45, 33-48.	1.6	20
1211	Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol \hat{a} % ± 125 mg/dl treated with statins versus no lipid-lowering drug. American Journal of Cardiology, 2002, 89, 67-69.	0.7	108
1212	Blood glucose concentrations â‰\$25 mg/dl and coronary heart disease risk. American Journal of Cardiology, 2002, 89, 596-599.	0.7	21
1213	Incidence of new coronary events in older persons with prior myocardial infarction and systemic hypertension treated with beta blockers, angiotensin-converting enzyme inhibitors, diuretics, calcium antagonists, and alpha blockers. American Journal of Cardiology, 2002, 89, 1207-1209.	0.7	35
1214	Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol â%¥125 mg/dl treated with statins versus no lipid-lowering drug. American Journal of Cardiology, 2002, 90, 147-149.	0.7	78
1215	Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade. American Journal of Cardiology, 2002, 90, 662-663.	0.7	25
1216	Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol â%¥125 mg/dl treated with statins versus no lipid-lowering drug. American Journal of Cardiology, 2002, 90, 789-791.	0.7	73
1217	Comparison of usefulness of systolic, diastolic, and mean blood pressure and pulse pressure as predictors of cardiovascular death in patients ≥60 years of age (The Dubbo Study). American Journal of Cardiology, 2002, 90, 1398-1401.	0.7	19
1218	Combination therapy for dyslipidemia: safety and regulatory considerations. American Journal of Cardiology, 2002, 90, 50-60.	0.7	97
1219	Cost-Benefit Analysis Indicates the Positive Economic Benefits of the Expanded Food and Nutrition Education Program Related to Chronic Disease Prevention. Journal of Nutrition Education and Behavior, 2002, 34, 26-37.	0.3	51
1220	Apolipoprotein C-III and E Polymorphisms and Cardiovascular Syndrome, Hyperlipidemia, and Insulin Resistance in Renal Transplantation. American Journal of Transplantation, 2002, 2, 343-348.	2.6	15
1222	A population-based, cross-sectional survey of the zuni pueblo: a collaborative approach to an epidemic of kidney disease. American Journal of Kidney Diseases, 2002, 39, 358-368.	2.1	33
1223	Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. American Journal of Kidney Diseases, 2002, 39, 503-512.	2.1	116

#	Article	IF	CITATIONS
1224	Treatment of hypertension from volume to vasoconstriction: The ACE up your sleeve. Seminars in Vascular Surgery, 2002, 15, 225-236.	1.1	0
1225	Factor analysis of ethnic variation in the multiple metabolic (insulin resistance) syndrome in three Canadian populations. American Journal of Human Biology, 2002, 14, 649-658.	0.8	41
1226	Can we alter physician behavior by educational methods? Lessons learned from studies of the management and follow-up of hypertension. Journal of Continuing Education in the Health Professions, 2002, 22, 11-22.	0.4	77
1227	Improving blood pressure control in diabetes: Limitations of a clinical reminder in influencing physician behavior. Journal of Continuing Education in the Health Professions, 2002, 22, 23-32.	0.4	20
1228	Previous stroke but not vascular risk factors are associated with depression in a cognitively impaired older Korean population. International Journal of Geriatric Psychiatry, 2002, 17, 453-458.	1.3	16
1229	Mean arterial pressure (MAP): An alternative and preferable measurement to systolic blood pressure (SBP) in patients for hypotension detection during hemapheresis. Journal of Clinical Apheresis, 2002, 17, 55-64.	0.7	26
1230	Interrelations among smoking habits, casual blood pressure and intraocular pressure in middle and old-aged Japanese residents. Environmental Health and Preventive Medicine, 2002, 7, 162-168.	1.4	3
1231	Isolated systolic hypertension in the elderly. Current Treatment Options in Cardiovascular Medicine, 2002, 4, 87-93.	0.4	5
1232	Proteinuria: An underappreciated risk factor in cardiovascular disease. Current Cardiology Reports, 2002, 4, 458-462.	1.3	23
1233	Systolic versus diastolic blood pressure versus pulse pressure. Current Cardiology Reports, 2002, 4, 463-467.	1.3	20
1234	Why \hat{l}^2 -blockers are not cardioprotective in elderly patients with hypertension. Current Cardiology Reports, 2002, 4, 468-473.	1.3	22
1235	Vasodilatory edema: A common side effect of antihypertensive therapy. Current Cardiology Reports, 2002, 4, 479-482.	1.3	116
1236	Microalbuminuria in diabetes: Focus on cardiovascular and renal risk reduction. Current Diabetes Reports, 2002, 2, 258-262.	1.7	9
1237	The choice of antihypertensive drugs in patients with diabetes: Angiotensin II and beyond. Current Diabetes Reports, 2002, 2, 423-430.	1.7	0
1238	Blood pressure controlâ€"Effects on diabetic nephropathy progression: How low does blood pressure have to be?. Current Diabetes Reports, 2002, 2, 530-538.	1.7	5
1239	Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes. Current Hypertension Reports, 2002, 4, 185-190.	1.5	17
1240	Resistant hypertension. Current Hypertension Reports, 2002, 4, 221-228.	1.5	49
1241	Cost of treating hypertension in the elderly. Current Hypertension Reports, 2002, 4, 420-423.	1.5	5

#	Article	IF	CITATIONS
1242	Compliance and persistence with newer antihypertensive agents. Current Hypertension Reports, 2002, 4, 424-433.	1.5	41
1243	Obesity-related hypertension: Role of the sympathetic nervous system, insulin, and leptin. Current Hypertension Reports, 2002, 4, 112-118.	1.5	38
1244	Genetic targeting of the renin-angiotensin system for long-term control of hypertension. Current Hypertension Reports, 2002, 4, 25-31.	1.5	7
1245	Optimizing blood pressure control in the obese patient. Current Hypertension Reports, 2002, 4, 358-362.	1.5	5
1246	Putting LIFE into hypertension. Current Hypertension Reports, 2002, 4, 275-277.	1.5	1
1247	Is fixed combination therapy appropriate for initial hypertension treatment?. Current Hypertension Reports, 2002, 4, 278-285.	1.5	47
1248	Are angiotensin converting enzyme inhibitors and angiotensin receptor blockers becoming the treatment of choice in African-Americans?. Current Hypertension Reports, 2002, 4, 286-289.	1.5	12
1249	Fixed low-dose combination therapy for hypertension. Current Hypertension Reports, 2002, 4, 298-306.	1.5	7
1250	Contemporary treatment of heart failure: Is there adequate evidence to support a unique strategy for African-Americans? con position. Current Hypertension Reports, 2002, 4, 311-318.	1.5	9
1251	Renal protection by antihypertensive therapy. Current Hypertension Reports, 2002, 4, 324-328.	1.5	5
1252	Low sodium diet after DASH: Has the situation changed?. Current Hypertension Reports, 2002, 4, 329-332.	1.5	8
1253	Family physicians' and general practitioners' approaches to drug management of diabetic hypertension in primary care. Journal of Evaluation in Clinical Practice, 2002, 8, 19-30.	0.9	22
1254	Prescribing pattern of antihypertensive drugs by family physicians and general practitioners in the primary care setting in Bahrain. Journal of Evaluation in Clinical Practice, 2002, 8, 407-414.	0.9	12
1255	Ischemic heart disease after renal transplantation. Kidney International, 2002, 61, 356-369.	2.6	32
1256	Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney International, 2002, 61, 1047-1055.	2.6	108
1257	Moderate renal insufficiency and the risk of cardiovascular mortality: Results from the NHANES I. Kidney International, 2002, 61, 1486-1494.	2.6	274
1258	Albuminuria and renal insufficiency prevalence guides population screening: Results from the NHANES III. Kidney International, 2002, 61, 2165-2175.	2.6	287
1259	An increase in the cell component of the cortical interstitium antedates interstitial fibrosis in type 1 diabetic patients 11 See Editorial by Fogo, p. 2274 Kidney International, 2002, 61, 2058-2065.	2.6	82

#	Article	IF	CITATIONS
1260	Cardiovascular disease risk status in elderly persons with renal insufficiency. Kidney International, 2002, 62, 997-1004.	2.6	146
1261	Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney International, 2002, 62, 1718-1723.	2.6	74
1262	Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease. Kidney International, 2002, 62, 2230-2237.	2.6	48
1263	Kidney and hypertension. Kidney International, 2002, 61, S62-S67.	2.6	52
1264	Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Kidney International, 2002, 62, S47-S52.	2.6	65
1265	Angiotensin blockade in type 2 diabetic renal disease. Kidney International, 2002, 62, S61-S63.	2.6	2
1266	Angiotensin II type 1 receptor blockade to control blood pressure in postmenopausal women: Influence of hormone replacement therapy. Kidney International, 2002, 62, S36-S41.	2.6	29
1267	Noncompliance with antihypertensive medications. Journal of General Internal Medicine, 2002, 17, 504-511.	1.3	314
1268	Management of patients with hypertensive urgencies and emergencies. Journal of General Internal Medicine, 2002, 17, 937-945.	1.3	135
1269	Prevalence of and Association Between Silent Myocardial Ischemia and New Coronary Events in Older Men and Women with and without Cardiovascular Disease. Journal of the American Geriatrics Society, 2002, 50, 1075-1078.	1.3	23
1270	Isolated systolic hypertension. Anaesthesia, 2002, 57, 606-625.	1.8	0
1271	Vasopeptidase inhibitors and their potential role in diabetes. Diabetes, Obesity and Metabolism, 2002, 4, 89-95.	2.2	1
1272	Blood pressure control in patients with type 2 diabetes and hypertension. Diabetes, Obesity and Metabolism, 2002, 4, 81-88.	2.2	4
1273	Teaching patients to monitor their risk factors retards the progression of vascular complications in high-risk patients with Type 2 diabetes mellitus-a randomized prospective study. Diabetic Medicine, 2002, 19, 385-392.	1.2	102
1274	Predictors of insulin sensitivity in Type 2 diabetes mellitus. Diabetic Medicine, 2002, 19, 535-542.	1.2	49
1275	Obesity and cardiovascular risk factors in Hong Kong Chinese. Obesity Reviews, 2002, 3, 173-182.	3.1	47
1276	Blood Pressure Behaviour in Chronic Daily Headache. Cephalalgia, 2002, 22, 190-194.	1.8	16
1277	The prevalence of various arrhythmias in normotensive and hypertensive elderly patients. Archives of Gerontology and Geriatrics, 2002, 35, 227-235.	1.4	3

#	Article	IF	CITATIONS
1278	The COMpliance PraxiS Survey (COMPASS): a multidimensional instrument to monitor compliance for patients on antihypertensive medication. Journal of Human Hypertension, 2002, 16, 779-787.	1.0	19
1279	Association between the blood pressure response to a change in posture and the 6-year incidence of hypertension: prospective findings from the ARIC study. Journal of Human Hypertension, 2002, 16, 771-777.	1.0	48
1280	Adiposity and Fat Distribution Outcome Measures: Assessment and Clinical Implications. Obesity, 2002, 10, 14S-21S.	4.0	59
1281	Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney International, 2002, 62, 1402-1407.	2.6	475
1282	Reducing global risk for cardiovascular disease: Using lifestyle changes and pharmacotherapy. Clinical Cardiology, 2002, 25, 205-212.	0.7	23
1283	Trends in hypertension management in Type I diabetes across Europe, 1989/1990 ? 1997/1999. Diabetologia, 2002, 45, 1362-1371.	2.9	33
1284	Severely increased blood pressure in the emergency department. Annals of Emergency Medicine, 2003, 41, 513-529.	0.3	80
1285	Reproducibility of increased blood pressure during an emergency department or urgent care visit. Annals of Emergency Medicine, 2003, 41, 507-512.	0.3	79
1286	Renal insufficiency as a predictor of adverse events and mortality after renal artery stent placement. American Journal of Kidney Diseases, 2003, 42, 926-935.	2.1	97
1287	Systolic, diastolic, and pulse pressures as coronary risk factors in a population with low cholesterol levels: A prospective 10-year evaluation. Clinical Cardiology, 2003, 26, 91-97.	0.7	15
1288	Angiotensin II blockade: A therapeutic strategy with wide applications. Clinical Cardiology, 2003, 26, 500-502.	0.7	4
1289	Getting to goal in complex patients. Clinical Cardiology, 2003, 26, 3-6.	0.7	1
1290	Evolution of calcium antagonists: Past, present, and future. Clinical Cardiology, 2003, 26, 12-16.	0.7	24
1291	Emerging data on calcium-channel blockers: The COHORT study. Clinical Cardiology, 2003, 26, 17-20.	0.7	22
1292	Target blood pressure for patients with type 2 diabetes is difficult to achieve in the setting of a busy diabetes clinic. Irish Journal of Medical Science, 2003, 172, 168-170.	0.8	4
1293	Management of diabetes with coronary artery disease. Current Treatment Options in Cardiovascular Medicine, 2003, 5, 75-88.	0.4	2
1294	The importance of systolic blood pressure control and cardiovascular disease prevention. Current Treatment Options in Cardiovascular Medicine, 2003, 5, 271-277.	0.4	5
1295	Prevention of cardiovascular disease in women. Current Treatment Options in Cardiovascular Medicine, 2003, 5, 287-298.	0.4	0

#	Article	IF	CITATIONS
1296	Clinical trials report. Current Atherosclerosis Reports, 2003, 5, 339-340.	2.0	1
1297	Uncontrolled hypertension as a risk for coronary artery disease: Patient characteristics and the role of physician intervention. Current Atherosclerosis Reports, 2003, 5, 131-138.	2.0	13
1298	Trials in isolated systolic hypertension: An update. Current Cardiology Reports, 2003, 5, 427-434.	1.3	1
1299	Epidemiology of the insulin resistance syndrome. Current Diabetes Reports, 2003, 3, 73-79.	1.7	64
1300	Combination lipid-lowering therapy in diabetes. Current Diabetes Reports, 2003, 3, 263-268.	1.7	4
1301	Are low target blood pressure goals justified in persons with diabetes mellitus?. Current Hypertension Reports, 2003, 5, 231-238.	1.5	3
1302	Management of diabetic and hypertensive cardiovascular disease. Current Hypertension Reports, 2003, 5, 309-315.	1.5	3
1303	Trials in isolated systolic hypertension: An update. Current Hypertension Reports, 2003, 5, 329-336.	1.5	8
1304	Use of calcium antagonists in renal patients: Therapeutic benefit or medical malpractice?. Current Hypertension Reports, 2003, 5, 430-436.	1.5	1
1305	Anaesthesia and hypertension. Current Anaesthesia and Critical Care, 2003, 14, 100-107.	0.3	1
1306	Metabolic syndrome: what is it and how should I treat it?. ACC Current Journal Review, 2003, 12, 37-40.	0.1	3
1307	Cardiovascular Disease Reduction in the Outpatient Kidney Transplant Clinic. American Journal of Transplantation, 2003, 3, 1393-1399.	2.6	20
1308	High-normal blood pressure and microalbuminuria. American Journal of Kidney Diseases, 2003, 41, 588-595.	2.1	94
1309	Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. American Journal of Kidney Diseases, 2003, 42, 1260-1269.	2.1	56
1310	Cocoa and chocolate flavonoids: Implications for cardiovascular health. Journal of the American Dietetic Association, 2003, 103, 215-223.	1.3	276
1311	Chronic kidney disease: issues and establishing programs and clinics for improved patient outcomes. American Journal of Kidney Diseases, 2003, 41, 903-924.	2.1	69
1312	Prevalence of hematuria among zuni indians with and without diabetes: the zuni kidney project. American Journal of Kidney Diseases, 2003, 41, 1195-1204.	2.1	6
1313	Coronary Heart Disease Risk in People 65 Years of Age and Older. Progress in Cardiovascular Nursing, 2003, 18, 135-140.	0.5	17

#	Article	IF	CITATIONS
1314	Treating patients with peripheral arterial disease and claudication. Journal of Vascular Nursing, 2003, 21, 5-16.	0.2	14
1315	Comparison of Changes in Blood Pressure Measurements and Antihypertensive Therapy in Older, Hypertensive, Ambulatory Care Patients Prescribed Celecoxib or Rofecoxib. Pharmacotherapy, 2003, 23, 1416-1423.	1.2	16
1316	Calcium Channel Blockers as the Treatment of Choice for Hypertension in Renal Transplant Recipients: Fact or Fiction. Pharmacotherapy, 2003, 23, 788-801.	1.2	30
1317	Position of the American Dietetic Association: Integration of medical nutrition therapy and pharmacotherapy. Journal of the American Dietetic Association, 2003, 103, 1363-1370.	1.3	29
1318	Comparative prognostic value of systolic, diastolic, and pulse pressure. American Journal of Cardiology, 2003, 91, 433-435.	0.7	10
1319	Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. American Journal of Cardiology, 2003, 91, 1421-1426.	0.7	139
1320	Antiatherosclerotic effects of β-blockers. American Journal of Cardiology, 2003, 91, 25-29.	0.7	52
1321	Prevalence of left main coronary artery disease, of three- or four-vessel coronary artery disease, and of obstructive coronary artery disease in patients with and without peripheral arterial disease undergoing coronary angiography for suspected coronary artery disease. American Journal of Cardiology, 2003, 92, 304-305.	0.7	61
1322	Edward David Frohlich, MD: a conversation with the editor**This series of interviews is underwritten by an unrestricted grant from Bristol-Myers Squibb American Journal of Cardiology, 2003, 92, 565-581.	0.7	0
1323	Synthesis, \hat{l}^2 -adrenergic blocking activity and \hat{l}^2 -receptor binding affinities of 1-substituted-3-(2-isopropyl-5-methyl-phenoxy)-propan-2-ol oxalates. Il Farmaco, 2003, 58, 557-562.	0.9	8
1324	1,4-dihydropyridine calcium channel ligands: Selectivity of action. The roles of pharmacokinetics, state-dependent interactions, channel isoforms, and other factors. Drug Development Research, 2003, 58, 5-17.	1.4	41
1325	Medicines in the 21st century Or pills, politics, potions, and profits: Where is public policy?. Drug Development Research, 2003, 59, 269-291.	1.4	19
1326	Treatment of diabetic nephropathy in its early stages. Diabetes/Metabolism Research and Reviews, 2003, 19, 101-114.	1.7	19
1327	The role of lipid profile in determining the risk of ischemic stroke in the elderly: a case–control study. Archives of Gerontology and Geriatrics, 2003, 37, 51-62.	1.4	21
1328	Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Archives of Gerontology and Geriatrics, 2003, 37, 203-212.	1.4	39
1329	The apo A-I gene promoter region polymorphism determines the severity of hyperlipidemia after heart transplantation. Clinical Transplantation, 2003, 17, 56-62.	0.8	6
1330	Blood pressure - lower targets, greater challenges. Journal of Clinical Pharmacy and Therapeutics, 2003, 28, 441-443.	0.7	0
1331	Dietary minerals and modification of cardiovascular risk factors. Journal of Nutritional Biochemistry, 2003, 14, 492-506.	1.9	177

#	Article	IF	CITATIONS
1332	Association of interleukin-6 -174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney International, 2003, 64, 616-622.	2.6	75
1333	Maps of end-stage renal disease and amounts of angiotensin-converting enzyme inhibitors prescribed in Japan. Kidney International, 2003, 64, 1445-1449.	2.6	33
1334	Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney International, 2003, 63, 678-685.	2.6	116
1335	Identification of persons at high risk for kidney disease via targeted screening: The NKF Kidney Early Evaluation Program. Kidney International, 2003, 63, S50-S55.	2.6	49
1336	Reduction in natural death and renal failure from a systematic screening and treatment program in an Australian Aboriginal community. Kidney International, 2003, 63, S66-S73.	2.6	56
1337	How Well Have Practices Followed Guidelines in Prescribing Antihypertensive Drugs: The Role of Health Insurance. Value in Health, 2003, 6, 18-28.	0.1	23
1338	Vascular disease risk factor management 4â€∫years after carotid endarterectomy: are opportunities missed?. ANZ Journal of Surgery, 2003, 73, 225-231.	0.3	3
1339	Chronic renal insufficiency and renoprotective strategies. Internal Medicine Journal, 2003, 33, 237-241.	0.5	0
1340	Evidence-based treatment of hypertension in patients with diabetes mellitus. Diabetes, Obesity and Metabolism, 2003, 5, 13-26.	2.2	15
1341	Hypertension in people with Type 2 diabetes: knowledge-based diabetes-specific guidelines. Diabetic Medicine, 2003, 20, 972-987.	1.2	44
1342	Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy. Diabetic Medicine, 2003, 20, 708-712.	1.2	17
1343	Characterizing blood pressure control in individuals with Type 2 diabetes: the relationship between clinic and selfâ€monitored blood pressure. Diabetic Medicine, 2003, 20, 752-757.	1.2	5
1344	Relationship Between Migraine, Blood Pressure and Carotid Thickness. A Population-Based Study in the Elderly. Cephalalgia, 2003, 23, 914-920.	1.8	64
1345	The activity of single vasoconstrictor nerve units in hypertension. Acta Physiologica Scandinavica, 2003, 177, 367-376.	2.3	29
1346	Blood pressure response to conventional and low-dose enalapril in chronic renal failure. British Journal of Clinical Pharmacology, 2003, 55, 139-146.	1.1	14
1347	Primary aldosteronism, diagnosed by the aldosterone to renin ratio, is a common cause of hypertension. Clinical Endocrinology, 2003, 59, 427-430.	1.2	24
1348	Body mass index is the main risk factor for arterial hypertension in young subjects without major comorbidity. European Journal of Clinical Investigation, 2003, 33, 223-230.	1.7	9
1349	Aortic stiffness and carotid intima-media thickness: two independent markers of subclinical vascular damage in young adults?. European Journal of Clinical Investigation, 2003, 33, 949-954.	1.7	66

#	Article	IF	CITATIONS
1350	Hypertension in Older Urban Native-American Primary Care Patients. Journal of the American Geriatrics Society, 2003, 51, 774-781.	1.3	11
1353	Hypertension in diabetes: what's new, what's true, what's next?. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2003, 20, 247-254.	0.2	3
1354	Blood pressure control in diabetes: are we achieving the guideline targets?. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2003, 20, 276-282.	0.2	7
1355	Antihypertensive drug-associated sexual dysfunction: a prescription analysis-based study. Pharmacoepidemiology and Drug Safety, 2003, 12, 203-212.	0.9	12
1356	Misperceptions about \hat{l}^2 -blockers and diuretics. Journal of General Internal Medicine, 2003, 18, 977-983.	1.3	48
1357	Framingham-based tools to calculate the global risk of coronary heart disease. Journal of General Internal Medicine, 2003, 18, 1039-1052.	1.3	149
1358	Abnormal Neurovascular Control during Sympathoexcitation in Obesity. Obesity, 2003, 11, 1411-1419.	4.0	58
1359	Sympathovagal Balance, Nighttime Blood Pressure, and QT Intervals in Normotensive Obese Women. Obesity, 2003, 11, 653-659.	4.0	40
1360	Individual saturated fatty acids and nonfatal acute myocardial infarction in Costa Rica. European Journal of Clinical Nutrition, 2003, 57, 1447-1457.	1.3	65
1361	Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. International Journal of Obesity, 2003, 27, 260-268.	1.6	569
1362	Detection of cardiovascular risk factors by indices of obesity obtained from anthropometry and dual-energy X-ray absorptiometry in Japanese individuals. International Journal of Obesity, 2003, 27, 232-237.	1.6	135
1363	Change in cardiovascular risk profile by echocardiography in medium-risk elderly hypertensives. Journal of Human Hypertension, 2003, 17, 101-106.	1.0	9
1364	Sagittal abdominal diameter is associated with insulin sensitivity in Chinese hypertensive patients and their siblings. Journal of Human Hypertension, 2003, 17, 193-198.	1.0	21
1365	Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. Journal of Human Hypertension, 2003, 17, 207-212.	1.0	41
1366	Renin-angiotensin-aldosterone system and G-protein beta-3 subunit gene polymorphisms in salt-sensitive essential hypertension. Journal of Human Hypertension, 2003, 17, 187-191.	1.0	42
1367	Night-time blood pressure load is associated with higher left ventricular mass index in renal transplant recipients. Journal of Human Hypertension, 2003, 17, 239-244.	1.0	41
1368	Abdominal adiposity, age, education level and therapy associated with uncontrolled hypertension. Journal of Human Hypertension, 2003, 17, 365-366.	1.0	2
1369	The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALL predictable, and no big surprise out of a HAT?. Journal of Human Hypertension, 2003, 17, 367-372.	1.0	5

#	Article	IF	CITATIONS
1370	ALLHAT: a saga of missed opportunities. Journal of Human Hypertension, 2003, 17, 373-377.	1.0	8
1371	Adherence to an intensive antihypertensive follow-up programme. Journal of Human Hypertension, 2003, 17, 437-439.	1.0	2
1372	Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. Journal of Human Hypertension, 2003, 17, 425-432.	1.0	78
1373	Awareness of hypertension guidelines in primary care: results of a regionwide survey in Italy. Journal of Human Hypertension, 2003, 17, 541-547.	1.0	30
1374	Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertensionâ€"a randomised ABPM study. Journal of Human Hypertension, 2003, 17, 569-575.	1.0	23
1375	Associations of blood pressure with carotid intima-media thickness in elderly Finns with diabetes mellitus or impaired glucose tolerance. Journal of Human Hypertension, 2003, 17, 705-711.	1.0	15
1376	Hospital and 1-year outcome after acute myocardial infarction in patients with diabetes mellitus and hypertension. Journal of Human Hypertension, 2003, 17, 665-670.	1.0	23
1377	Treatment and blood pressure control in isolated systolic hypertension vs diastolic hypertension in primary care. Journal of Human Hypertension, 2003, 17, 681-687.	1.0	24
1378	Relation between the angiotensin-converting enzyme insertion/deletion polymorphism and blood pressure in Japanese male subjects. Journal of Human Hypertension, 2003, 17, 713-718.	1.0	20
1379	Headache is not more frequent among patients with moderate to severe hypertension. Journal of Human Hypertension, 2003, 17, 787-790.	1.0	28
1381	Renal Ischemia as a Predictor of Cardiovascular Morbidity. Journal of Vascular and Interventional Radiology, 2003, 14, P159-P164.	0.2	0
1384	Comprehensive Evaluation of the Older Woman. Mayo Clinic Proceedings, 2003, 78, 1157-1185.	1.4	25
1386	Preventing cardiovascular disease in diabetes and glucose intolerance: evidence and implications for care. Primary Care - Clinics in Office Practice, 2003, 30, 569-592.	0.7	17
1387	Factores de riesgo e ictus en pacientes de diferentes edades. Revista Clinica Espanola, 2003, 203, 189-192.	0.2	8
1389	Protección del riesgo vascular del paciente diabético hipertenso. Hipertension Y Riesgo Vascular, 2003, 20, 127-135.	0.3	0
1390	Effects of dietary modification to reduce vascular risks and treatment of obesity. Cardiology Clinics, 2003, 21, 415-433.	0.9	4
1395	HipertensiÃ ³ n arterial de bata blanca o clÃnica aislada. Hipertension Y Riesgo Vascular, 2003, 20, 305-314.	0.3	1
1398	DÃa de análisis en Granada de la hipertensión arterial. Estudio DAGA. Hipertension Y Riesgo Vascular, 2003, 20, 195-199.	0.3	O

#	Article	IF	CITATIONS
1402	The New Hypertension Guidelines From JNC 7: Is the Devil in the Details? Mayo Clinic Proceedings, 2003, 78, 1078-1081.	1.4	5
1403	Estudio comparativo de efectividad y tolerabilidad de quinapril 40 mg frente a la combinación de quinapril 20 mg e hidroclorotiazida 12,5 mg en el tratamiento de la hipertensión arterial ligera-moderada. Hipertension Y Riesgo Vascular, 2003, 20, 246-251.	0.3	1
1404	Malignant Hypertension as a Presenting Symptom of Takayasu Arteritis. Mayo Clinic Proceedings, 2003, 78, 231-236.	1.4	10
1405	Documento de consenso: obesidad y riesgo cardiovascular. ClÃnica E Investigación En Arteriosclerosis, 2003, 15, 196-232.	0.4	22
1407	Manejo clÃnico de la hipertensión en el anciano. Revista Clinica Espanola, 2003, 203, 80-82.	0.2	0
1411	Criterios de derivaci \tilde{A}^3 n de pacientes hipertensos a una Unidad de Hipertensi \tilde{A}^3 n Arterial. Hipertension Y Riesgo Vascular, 2003, 20, 354-360.	0.3	2
1413	Diabetes mellitus en el anciano. Medicine, 2003, 8, 5834-5840.	0.0	0
1414	Resultados de la primera encuesta sobre patrones de uso e interés por las nuevas tecnologÃas de los pacientes atendidos en Unidades de Hipertensión Arterial en España. Hipertension Y Riesgo Vascular, 2003, 20, 50-55.	0.3	4
1415	Efecto del tratamiento antihipertensivo con irbesart \tilde{A}_i n sobre el riesgo cardiovascular absoluto. Revista Clinica Espanola, 2003, 203, 183-188.	0.2	2
1417	Hipertensi \tilde{A}^3 n arterial en pacientes infectados por el virus de la inmunodeficiencia humana. Hipertension Y Riesgo Vascular, 2003, 20, 63-73.	0.3	1
1419	Evaluación económica del cambio de tratamiento de doxazosina estándar a doxazosina de liberación modificada en pacientes con hipertensión leve a moderada en condiciones habituales de cuidado médico. Hipertension Y Riesgo Vascular, 2003, 20, 200-211.	0.3	0
1421	Guidelines for the Reporting of Renal Artery Revascularization in Clinical Trials. Journal of Vascular and Interventional Radiology, 2003, 14, S477-S492.	0.2	66
1423	A Practical Approach to Hypertension in the 21st Century. Journal of Vascular and Interventional Radiology, 2003, 14, 961-975.	0.2	5
1424	Diuréticos: clasificación y farmacologÃa clÃnica. Efectos secundarios. Indicaciones prácticas para su empleo clÃnico. Medicine, 2003, 8, 5998-6008.	0.0	0
1425	Actualización (2003) de las GuÃas de Práctica ClÃnica de la Sociedad Española de CardiologÃa en hipertensión arterial. Revista Espanola De Cardiologia, 2003, 56, 487-497.	0.6	37
1429	Nifedipino oral o sublingual: utilidad y efectividad a largo plazo de la educación médica para disminuir su uso en la hipertensión. Revista Clinica Espanola, 2003, 203, 10-14.	0.2	2
1431	Utilización de antihipertensivos en Atención Primaria. Hipertension Y Riesgo Vascular, 2003, 20, 96-104.	0.3	5
1434	Exercise considerations in hypertension, obesity, and dyslipidemia. Clinics in Sports Medicine, 2003, 22, 101-121.	0.9	8

#	Article	IF	CITATIONS
1435	Association of newer diastolic function parameters with age in healthy subjects: a population-based study. Journal of the American Society of Echocardiography, 2003, 16, 1049-1056.	1.2	156
1436	Pharmacist Intervention Program for Control of Hypertension. Annals of Pharmacotherapy, 2003, 37, 1186-1193.	0.9	116
1437	The prevalence and severity of coronaryartery calcification on coronary arterycomputed tomography in black and white subjects. Journal of the American College of Cardiology, 2003, 41, 39-44.	1.2	153
1438	Left atrial volume as an index ofleft atrial size: a population-based study. Journal of the American College of Cardiology, 2003, 41, 1036-1043.	1.2	524
1439	Hypertension, angiotensin II, aldosterone, and race**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology. Journal of the American College of Cardiology, 2003, 41, 1156-1158.	1.2	8
1440	Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. Journal of the American College of Cardiology, 2003, 41, 1148-1155.	1.2	214
1441	Task force #1—identification of coronary heart disease risk: is there a detection gap?. Journal of the American College of Cardiology, 2003, 41, 1863-1874.	1.2	184
1442	Pharmacological Treatment of Patients with Peripheral Arterial Disease. Drugs, 2003, 63, 637-647.	4.9	10
1443	Current Treatment of Patients with Hypertension. Drugs, 2003, 63, 1435-1444.	4.9	7
1444			
	Lacidipine. Drugs, 2003, 63, 2327-2356.	4.9	51
1445	Lacidipine. Drugs, 2003, 63, 2327-2356. Managing Hypertension with Combination Diuretics and Methyldopa in Nigerian Blacks at???the???Primary Care Level. Clinical Drug Investigation, 2003, 23, 583-590.	1.1	3
	Managing Hypertension with Combination Diuretics and Methyldopa in Nigerian Blacks		
1445	Managing Hypertension with Combination Diuretics and Methyldopa in Nigerian Blacks at???the???Primary Care Level. Clinical Drug Investigation, 2003, 23, 583-590. Survival and hospitalization in heart failure patients with or without diabetes treated with β-blockers.	1.1	3
1445 1446	Managing Hypertension with Combination Diuretics and Methyldopa in Nigerian Blacks at???the???Primary Care Level. Clinical Drug Investigation, 2003, 23, 583-590. Survival and hospitalization in heart failure patients with or without diabetes treated with β-blockers. Journal of Cardiac Failure, 2003, 9, 192-202. Effects of Severe Hypertension on Endothelial and Platelet Microparticles. Hypertension, 2003, 41,	0.7	3 51
1445 1446 1447	Managing Hypertension with Combination Diuretics and Methyldopa in Nigerian Blacks at???the???Primary Care Level. Clinical Drug Investigation, 2003, 23, 583-590. Survival and hospitalization in heart failure patients with or without diabetes treated with β-blockers. Journal of Cardiac Failure, 2003, 9, 192-202. Effects of Severe Hypertension on Endothelial and Platelet Microparticles. Hypertension, 2003, 41, 211-217. Insulin resistance is independently related to age in Mexican women. Journal of Endocrinological	1.1 0.7 1.3	3 51 444
1445 1446 1447	Managing Hypertension with Combination Diuretics and Methyldopa in Nigerian Blacks at???the???Primary Care Level. Clinical Drug Investigation, 2003, 23, 583-590. Survival and hospitalization in heart failure patients with or without diabetes treated with β-blockers. Journal of Cardiac Failure, 2003, 9, 192-202. Effects of Severe Hypertension on Endothelial and Platelet Microparticles. Hypertension, 2003, 41, 211-217. Insulin resistance is independently related to age in Mexican women. Journal of Endocrinological Investigation, 2003, 26, 42-48. Glyburide/metformin tablets: a new therapeutic option for the management of Type 2 diabetes. Expert	1.1 0.7 1.3	3 51 444 13
1445 1446 1447 1448 1449	Managing Hypertension with Combination Diuretics and Methyldopa in Nigerian Blacks at????the???Primary Care Level. Clinical Drug Investigation, 2003, 23, 583-590. Survival and hospitalization in heart failure patients with or without diabetes treated with β-blockers. Journal of Cardiac Failure, 2003, 9, 192-202. Effects of Severe Hypertension on Endothelial and Platelet Microparticles. Hypertension, 2003, 41, 211-217. Insulin resistance is independently related to age in Mexican women. Journal of Endocrinological Investigation, 2003, 26, 42-48. Glyburide/metformin tablets: a new therapeutic option for the management of Type 2 diabetes. Expert Opinion on Pharmacotherapy, 2003, 4, 1417-1430. Progression of Coronary Artery Calcification in Type 1 Diabetes: The importance of glycemic control.	1.1 0.7 1.3 1.8	3 51 444 13 22

#	Article	IF	CITATIONS
1453	Prevention and Rehabilitation. American Heart Journal, 2003, 145, 888-895.	1.2	76
1454	Session. American Heart Journal, 2003, 146, 20.	1.2	4
1455	Screening for left ventricular systolic dysfunction among patients with risk factors for heart failure. American Heart Journal, 2003, 146, 736-740.	1.2	34
1456	Evaluating the benefits of treating dyslipidemia: the importance of diabetes as a risk factor. American Journal of Medicine, 2003, 115, 122-128.	0.6	7
1457	Improving Patient Compliance: A Major Goal in the Management of Hypertension. Journal of Clinical Hypertension, 2003, 5, 127-132.	1.0	73
1458	The Differences Between ACE Inhibitor-Treated and Calcium Channel Blocker-Treated Hypertensive Patients. Journal of Clinical Hypertension, 2003, 5, 337-344.	1.0	2
1459	Drugs That Interrupt the Renin-Angiotensin System Should Be Among the Preferred Initial Drugs to Treat Hypertension. Journal of Clinical Hypertension, 2003, 5, 137-144.	1.0	8
1460	Benefits of Antihypertensive Pharmacologic Therapy and Blood Pressure Reduction in Outcome Trials. Journal of Clinical Hypertension, 2003, 5, 66-75.	1.0	26
1461	How Pharmacists Can Assist Physicians With Controlling Blood Pressure. Journal of Clinical Hypertension, 2003, 5, 31-37.	1.0	55
1462	Treatment of Hypertension in African Americans and Latinos: The Effect of JNC VI on Urban Prescribing Practices. Journal of Clinical Hypertension, 2003, 5, 107-112.	1.0	13
1463	Meta-Analysis, Meta-Regression, and Meta-Physics. Journal of Clinical Hypertension, 2003, 5, 64-75.	1.0	0
1464	Evaluation of Angiotensin II Receptor Blockers for 24-Hour Blood Pressure Control: Meta-Analysis of a Clinical Database. Journal of Clinical Hypertension, 2003, 5, 58-63.	1.0	63
1465	Physician-Nurse Team Approaches to Improve Blood Pressure Control. Journal of Clinical Hypertension, 2003, 5, 386-392.	1.0	5
1466	Drug-Induced Hypertension. Journal of Clinical Hypertension, 2003, 5, 83-85.	1.0	4
1467	Prospective Surveillance of Hypertension in Firefighters. Journal of Clinical Hypertension, 2003, 5, 315-320.	1.0	30
1468	Results of the ALLHAT Trial: Is the Debate About Initial Antihypertensive Drug Therapy Over?. Journal of Clinical Hypertension, 2003, 5, 5-8.	1.0	31
1469	Cardiovascular Disease: a Continuing Threat to Homeland Defense. Journal of Clinical Hypertension, 2003, 5, 350-351.	1.0	7
1470	Rationale for Combination Therapy in the Management of Hypertension. Journal of Clinical Hypertension, 2003, 5, 17-25.	1.0	12

#	Article	IF	CITATIONS
1471	Effects of low-dose combination therapy with an angiotensin-converting enzyme inhibitor and a diuretic on flow-mediated vasodilation in hypertensive patients: a 6-month, single-center study. Current Therapeutic Research, 2003, 64, 715-724.	0.5	4
1472	The Effects of Amlodipine Compared to Losartan in Patients With Mild to Moderately Severe Hypertension. Journal of Clinical Hypertension, 2003, 5, 17-30.	1.0	32
1473	Awareness of hypertension and dyslipidemia in a semirural population of young adults: the bogalusa heart study. Preventive Medicine, 2003, 36, 398-402.	1.6	19
1474	The potential impact of nonpharmacologic population-wide blood pressure reduction on coronary heart disease events: pronounced benefits in African-Americans and hypertensives. Preventive Medicine, 2003, 37, 327-333.	1.6	43
1475	Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochemical and Biophysical Research Communications, 2003, 308, 698-705.	1.0	470
1476	Effects of Verapamil Slow Release Plus Trandolapril Combination Therapy on Essential Hypertension. Current Therapeutic Research, 2003, 64, 10-20.	0.5	1
1477	Efficacy and Tolerability of Nilvadipine in Combination with an Angiotensin II Receptor Antagonist in Patients with Essential Hypertension: A Multicenter, Open-Label, Uncontrolled Study. Current Therapeutic Research, 2003, 64, 151-166.	0.5	1
1478	Effects of the fixed combination of manidipine plus delapril in the treatment of hypertension inadequately controlled by monotherapy with either component: a phase III, multicenter, open-label, clinical trial. Current Therapeutic Research, 2003, 64, 422-433.	0.5	5
1479	Effects of fenofibrate on albuminuria in patients with hypertriglyceridemia and/or hyperuricemia: a multicenter, randomized, double-blind, placebo-controlled, crossover study. Current Therapeutic Research, 2003, 64, 434-446.	0.5	11
1480	Comparison of candesartan and felodipine alone and combined in the treatment of hypertension: a single-center, double-blind, randomized, crossover trial. Current Therapeutic Research, 2003, 64, 380-388.	0.5	1
1481	Insulin therapy in type 2 diabetes. Disease-a-Month, 2003, 49, 377-420.	0.4	12
1482	Estimation of sodium intake by urinary excretion and dietary records in children and adolescents from Porto Alegre, Brazil: a comparision of two methods. Nutrition Research, 2003, 23, 1477-1487.	1.3	19
1483	Impaired fasting glucose and risk of diabetes in Taiwan: follow-up over 3 years. Diabetes Research and Clinical Practice, 2003, 60, 177-182.	1.1	42
1484	Relationship between development of diabetes and family history by gender in Japanese-Americans. Diabetes Research and Clinical Practice, 2003, 61, 109-115.	1.1	17
1485	A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a medicare choice population. Clinical Therapeutics, 2003, 25, 647-662.	1.1	7
1486	Restoration of nocturnal dip in blood pressure is associated with improvement in left ventricular ejection fraction International Journal of Cardiology, 2003, 89, 159-166.	0.8	14
1487	Risk factors for cardiovascular disease in a Brazilian population-based cohort study. International Journal of Cardiology, 2003, 90, 205-211.	0.8	25
1488	High-amplitude QRS complex in the electrocardiograms of normotensive people and risk of subsequent hypertension. International Journal of Cardiology, 2003, 91, 37-42.	0.8	0

#	Article	IF	CITATIONS
1489	Clinical Implications of Therapeutic Exercise in HIV/AIDS. Journal of the Association of Nurses in AIDS Care, 2003, 14, 73-78.	0.4	40
1490	Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respiratory Medicine, 2003, 97, 1094-1101.	1.3	132
1491	Family history assessment. American Journal of Preventive Medicine, 2003, 24, 136-142.	1.6	91
1492	Screening for high blood pressure. American Journal of Preventive Medicine, 2003, 25, 151-158.	1.6	85
1493	Screening for high blood pressure. American Journal of Preventive Medicine, 2003, 25, 159-164.	1.6	22
1494	An overview of hypertensive disorders in women. Primary Care Update for Ob/Gyns, 2003, 10, 14-18.	0.1	1
1495	National health and nutrition examination survey 1999-2000: effect of observer training and protocol standardization on reducing blood pressure measurement error. Journal of Clinical Epidemiology, 2003, 56, 768-774.	2.4	93
1497	Clinical evaluation of the obese patient. Primary Care - Clinics in Office Practice, 2003, 30, 341-356.	0.7	5
1498	Tratamiento de la hipertensión arterial. Medicina ClÃnica, 2003, 120, 108-116.	0.3	1
1501	Olmesartan Medoxomil: The Seventh Angiotensin Receptor Antagonist. Annals of Pharmacotherapy, 2003, 37, 99-105.	0.9	34
1509	Cardiovascular Drug Therapy in the Elderly: Theoretical and Practical Considerations. Drugs and Aging, 2003, 20, 445-463.	1.3	23
1510	Systolic Blood Pressure Elevation. Drugs and Aging, 2003, 20, 287-288.	1.3	0
1511	Prevalence and Implications of Uncontrolled Systolic Hypertension. Drugs and Aging, 2003, 20, 277-286.	1.3	49
1512	Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Review of Cardiovascular Therapy, 2003, 1, 43-50.	0.6	67
1513	Prevalence and Characteristics of the Metabolic Syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes, 2003, 52, 2160-2167.	0.3	394
1514	Treatment of Hypertension in Bahrain. Annals of Pharmacotherapy, 2003, 37, 1511-1517.	0.9	10
1515	Comparison of Acute Cardiovascular Effects of Cadmium and Captopril in Relation to Oxidant and Angiotensin Converting Enzyme Activity in Rats. Drug and Chemical Toxicology, 2003, 26, 213-218.	1.2	19
1516	Blood Pressure Characteristics of Hypertensive Patients in Austria as Determined by Self-monitoring (SCREEN-II). Blood Pressure, 2003, 12, 134-138.	0.7	11

#	Article	IF	Citations
1517	Financial and Health Costs of Uncontrolled Blood Pressure in the United Kingdom. Pharmacoeconomics, 2003, 21, 33-41.	1.7	30
1518	The Cost Effectiveness of ACE Inhibitors as First-Line Antihypertensive Therapy. Pharmacoeconomics, 2003, 21, 573-585.	1.7	15
1519	Preventing Macrovascular Disease in Patients with Type 2 Diabetes Mellitus. American Journal of Cardiovascular Drugs, 2003, 3, 283-297.	1.0	18
1520	Therapeutic Potential of Renin Inhibitors in the Management of Cardiovascular Disorders. American Journal of Cardiovascular Drugs, 2003, 3, 389-394.	1.0	64
1521	Valsartan/Hydrochlorothiazide is Effective in Hypertensive Patients Inadequately Controlled by Valsartan Monotherapy. Blood Pressure, 2003, 12, 36-43.	0.7	55
1522	Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 2003, 42, 1206-1252.	1.3	11,852
1523	Effectiveness of hypertension treatment assessed by blood pressure level achieved in primary care setting in Poland. Blood Pressure, 2003, 12, 232-238.	0.7	11
1524	False Claims of Blood Pressure–Independent Protection by Blockade of the Renin Angiotensin Aldosterone System?. Hypertension, 2003, 41, 193-196.	1.3	43
1525	Blood Pressure Indices and Cardiovascular Disease in the Asia Pacific Region. Hypertension, 2003, 42, 69-75.	1.3	155
1526	Walking Performance and Cardiovascular Response: Associations With Age and Morbidity–The Health, Aging and Body Composition Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2003, 58, M715-M720.	1.7	137
1528	Plasma Homocysteine and Risk for Congestive Heart Failure in Adults Without Prior Myocardial Infarction. JAMA - Journal of the American Medical Association, 2003, 289, 1251.	3.8	177
1530	Mild Renal Dysfunction and Subclinical Cardiovascular Damage in Primary Hypertension. Hypertension, 2003, 42, 14-18.	1.3	69
1531	A Controlled Trial of Web-Based Diabetes Disease Management: The MGH Diabetes Primary Care Improvement Project. Diabetes Care, 2003, 26, 750-757.	4.3	179
1532	The Zuni Kidney Project: A Collaborative Approach to an Epidemic of Kidney Disease. Journal of the American Society of Nephrology: JASN, 2003, 14, S139-S143.	3.0	20
1533	Primary Aldosteronism and Hypertensive Disease. Hypertension, 2003, 42, 161-165.	1.3	433
1534	Prevention of Hypertension and Its Complications: Theoretical Basis and Guidelines for Treatment. Journal of the American Society of Nephrology: JASN, 2003, 14, S92-S98.	3.0	70
1535	Optimization of desflurane administration in morbidly obese patients: a comparison with sevoflurane using an â€~inhalation bolus' technique. British Journal of Anaesthesia, 2003, 91, 638-650.	1.5	67
1536	Morning Blood Pressure Peak, QT Intervals, and Sympathetic Activity in Hypertensive Patients. Hypertension, 2003, 41, 237-243.	1.3	79

#	Article	IF	CITATIONS
1537	Combination ACE Inhibitors and Angiotensin II Receptor Blockers for Hypertension. Annals of Pharmacotherapy, 2003, 37, 886-889.	0.9	13
1538	Genetics of blood pressure, hypertensive complications, and antihypertensive drug responses. Pharmacogenomics, 2003, 4, 53-65.	0.6	44
1539	Outcomes With Nifedipine GITS or Co-Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension, 2003, 41, 431-436.	1.3	154
1540	Control of Hypertension in Diabetes. Diabetes Care, 2003, 26, 534-535.	4.3	4
1541	Burden of Systolic and Diastolic Ventricular Dysfunction in the Community. JAMA - Journal of the American Medical Association, 2003, 289, 194.	3.8	2,611
1542	Echocardiographic Wall Motion Abnormalities in Hypertensive Patients With Electrocardiographic Left Ventricular Hypertrophy. Hypertension, 2003, 41, 75-82.	1.3	36
1543	Effect of Different Intensities of Exercise on Endothelium-Dependent Vasodilation in Humans. Circulation, 2003, 108, 530-535.	1.6	505
1544	Estimated Number of Adults With Prediabetes in the U.S. in 2000: Opportunities for prevention. Diabetes Care, 2003, 26, 645-649.	4.3	172
1545	Atubular Glomeruli and Glomerulotubular Junction Abnormalities in Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2003, 14, 908-917.	3.0	105
1546	Pulse Pressure Responses in Patients Treated with Valsartan and Hydrochlorothiazide Combination Therapy. Journal of International Medical Research, 2003, 31, 370-377.	0.4	6
1547	Administration Time–Dependent Effects of Aspirin on Blood Pressure in Untreated Hypertensive Patients. Hypertension, 2003, 41, 1259-1267.	1.3	69
1548	Trends in Stroke Mortality. Circulation, 2003, 108, e108.	1.6	0
1549	Antioxidant Activities and Oxidative Stress Byproducts in Human Hypertension. Hypertension, 2003, 41, 1096-1101.	1.3	356
1550	Hypertension and Renal Dysfunction: NHANES III. Journal of the American Society of Nephrology: JASN, 2003, 14, S71-S75.	3.0	18
1551	Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy. Hypertension, 2003, 41, 64-68.	1.3	446
1552	Arterial Stiffness Increases With Deteriorating Glucose Tolerance Status. Circulation, 2003, 107, 2089-2095.	1.6	418
1553	Plasma Brain Natriuretic Peptide Levels and Blood Pressure Tracking in the Framingham Heart Study. Hypertension, 2003, 41, 978-983.	1.3	58
1554	Screening for Chronic Kidney Disease: Unresolved Issues. Journal of the American Society of Nephrology: JASN, 2003, 14, S81-S87.	3.0	44

#	Article	IF	CITATIONS
1555	Standards of Medical Care for Patients With Diabetes Mellitus. Diabetes Care, 2003, 26, S33-S50.	4.3	613
1556	Treatment of Uncomplicated Hypertension: Are ACE Inhibitors and Calcium Channel Blockers as Effective as Diuretics and Â-Blockers?. Journal of the American Board of Family Medicine, 2003, 16, 156-a-164.	0.8	6
1557	Review: ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2003, 4, 74-79.	1.0	5
1558	Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2003, 4, 197-203.	1.0	66
1559	Impact of Type 2 Diabetes Mellitus on Sympathetic Neural Mechanisms in Hypertension. Circulation, 2003, 108, 3097-3101.	1.6	258
1560	Maintenance of Goal Blood Pressure following Conversion from Lisinopril to Fosinopril. Journal of Pharmacy Technology, 2003, 19, 266-270.	0.5	0
1561	Epidemic of Diabetic and Nondiabetic Renal Disease among the Zuni Indians: The Zuni Kidney Project. Journal of the American Society of Nephrology: JASN, 2003, 14, 1320-1329.	3.0	35
1562	Design and Statistical Aspects of the African American Study of Kidney Disease and Hypertension (AASK). Journal of the American Society of Nephrology: JASN, 2003, 14, S154-S165.	3.0	86
1563	Impact of Incident Diabetes and Incident Nonfatal Cardiovascular Disease on 18-Year Mortality: The Multiple Risk Factor Intervention Trial experience. Diabetes Care, 2003, 26, 848-854.	4.3	131
1564	\hat{l}^2 2 -Adrenergic Receptor Gene Polymorphism, Age, and Cardiovascular Phenotypes. Hypertension, 2003, 41, 361-367.	1.3	52
1565	Administration Time–Dependent Effects of Valsartan on Ambulatory Blood Pressure in Hypertensive Subjects. Hypertension, 2003, 42, 283-290.	1.3	144
1566	Measuring Blood Pressure Accurately. JAMA - Journal of the American Medical Association, 2003, 289, 1027.	3.8	214
1567	Secondary Prevention of Renal and Cardiovascular Disease: Results of a Renal and Cardiovascular Treatment Program in an Australian Aboriginal Community. Journal of the American Society of Nephrology: JASN, 2003, 14, S178-S185.	3.0	25
1568	Accurate Measurement of Blood PressureAccurate Measurement of Blood Pressure. JAMA - Journal of the American Medical Association, 2003, 289, 2792.	3.8	5
1569	Ambulatory blood pressure monitoring and prognosis in the management of essential hypertension. Expert Review of Cardiovascular Therapy, 2003, 1, 79-89.	0.6	10
1570	Effects of Nifedipine on Carotid and Femoral Arterial Wall Thickness in Previously Untreated Hypertensive Patients. Blood Pressure, 2003, 12, 22-29.	0.7	13
1571	Are Undergraduate Engineering Students at Greater Risk for Heart Disease than Other Undergraduate Students?. Journal of Engineering Education, 2003, 92, 73-77.	1.9	14
1572	B Vitamins and Plasma Homocysteine Concentrations in an Urban and Rural Area of Costa Rica. Journal of the American College of Nutrition, 2003, 22, 224-231.	1.1	23

#	Article	IF	CITATIONS
1573	Renal participation in cardiovascular risk inessential hypertension. Expert Review of Cardiovascular Therapy, 2003, 1, 309-315.	0.6	2
1574	Effects of the Dietary Approaches to Stop Hypertension (DASH) Diet on the Pressure-Natriuresis Relationship. Hypertension, 2003, 42, 8-13.	1.3	107
1575	Lifestyle Modification to Improve Blood Pressure Control in Individuals With Diabetes: Is physician advice effective?. Diabetes Care, 2003, 26, 602-607.	4.3	45
1576	Heart Failure: The frequent, forgotten, and often fatal complication of diabetes. Diabetes Care, 2003, 26, 2433-2441.	4.3	387
1577	Low Glomerular Filtration Rate in Normoalbuminuric Type 1 Diabetic Patients: An Indicator of More Advanced Glomerular Lesions. Diabetes, 2003, 52, 1036-1040.	0.3	273
1578	Renoprotection by ACE Inhibition or Aldosterone Blockade Is Blood Pressure–Dependent. Hypertension, 2003, 41, 201-206.	1.3	111
1579	A Comprehensive Public Health Approach to Address the Burden of Renal Disease in Singapore. Journal of the American Society of Nephrology: JASN, 2003, 14, S122-S126.	3.0	11
1580	Seasonal Variation of Fibrinogen in Dipper and Nondipper Hypertensive Patients. Circulation, 2003, 108, 1101-1106.	1.6	59
1581	The Human Peroxisome Proliferator-Activated Receptor Â2 (PPARÂ2) Pro12Ala Polymorphism Is Associated With Decreased Risk of Diabetic Nephropathy in Patients With Type 2 Diabetes. Diabetes, 2003, 52, 3010-3013.	0.3	76
1582	Noninvasive Assessment of Arterial Stiffness and Risk of Atherosclerotic Events. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 554-566.	1.1	722
1583	Factors Associated with Uncontrolled Hypertension in an Affluent, Elderly Population. Annals of Pharmacotherapy, 2003, 37, 485-489.	0.9	4
1584	High Prevalence of Secondary Hypertension and Insulin Resistance in Patients with Refractory Hypertension. Blood Pressure, 2003, 12, 149-154.	0.7	44
1585	Plasma Homocysteine, Hypertension Incidence, and Blood Pressure Tracking. Hypertension, 2003, 42, 1100-1105.	1.3	104
1586	Health Care in America: Lost Opportunities Amid Plenty. Qualitative Health Research, 2003, 13, 857-870.	1.0	4
1587	The current status of sports medicine training in United States internal medicine residency programmes. British Journal of Sports Medicine, 2003, 37, 219-225.	3.1	10
1589	Effects of the Selective Aldosterone Blocker Eplerenone Versus the Calcium Antagonist Amlodipine in Systolic Hypertension. Hypertension, 2003, 41, 1021-1026.	1.3	273
1590	Physician–nurse practitioner teams in chronic disease management: the impact on costs, clinical effectiveness, and patients' perception of care. Journal of Interprofessional Care, 2003, 17, 223-237.	0.8	206
1591	The Rationale and Design of the AASK Cohort Study. Journal of the American Society of Nephrology: JASN, 2003, 14, S166-S172.	3.0	97

#	Article	IF	Citations
1592	Blood Pressure Predicts Risk of Developing End-Stage Renal Disease in Men and Women. Hypertension, 2003, 41, 1341-1345.	1.3	286
1593	Rhinitis Is Associated with Increased Systolic Blood Pressure in Men. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 538-543.	2.5	44
1595	Commentary: Help! Grandma's Stroking: Balancing Morbidity and Mortality in the Treatment of Hypertension Among the Very Old. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2003, 58, M660-M661.	1.7	0
1596	Risk Factors for Chronic Kidney Disease: A Prospective Study of 23,534 Men and Women in Washington County, Maryland. Journal of the American Society of Nephrology: JASN, 2003, 14, 2934-2941.	3.0	453
1597	Hyperglycaemia in patients with acute ischaemic stroke: how often do we screen for undiagnosed diabetes?. QJM - Monthly Journal of the Association of Physicians, 2003, 96, 491-497.	0.2	27
1598	Weight loss improves neurovascular and muscle metaboreflex control in obesity. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H974-H982.	1.5	113
1599	Size isn't everything - ALLHAT in perspective. Journal of Hypertension, 2003, 21, 459-461.	0.3	17
1600	Validity of a Modified CHAMPS Physical Activity Questionnaire among African-Americans. Medicine and Science in Sports and Exercise, 2003, 35, 1537-1545.	0.2	98
1601	Doxazosin GITS versus hydrochlorothiazide as addâ€on therapy in patients with uncontrolled hypertension. Blood Pressure, 2003, 12, 16-21.	0.7	14
1602	Primary care in the United States: Innovations in primary care in the United States * Commentary: What can primary care in the United States learn from the United Kingdom?. BMJ: British Medical Journal, 2003, 326, 796-799.	2.4	53
1603	Secondary Prevention of Stroke in Italy. Stroke, 2003, 34, 1010-1014.	1.0	68
1604	Relationship Between Blood Pressure and Stroke Risk in Patients With Symptomatic Carotid Occlusive Disease. Stroke, 2003, 34, 2583-2590.	1.0	219
1605	Defining hypertension. Journal of Hypertension, 2003, 21, 473-474.	0.3	4
1606	Medicine partnerships. British Heart Journal, 2003, 89, 19ii-21.	2.2	6
1607	Global risk of cardiovascular disease. British Heart Journal, 2003, 89, 2ii-5.	2.2	50
1608	Trends in the Incidence, Mortality, and Survival Rate of Cardiovascular Disease in a Japanese Community. Stroke, 2003, 34, 2349-2354.	1.0	389
1609	Sleep-Disordered Breathing as a Risk Factor for Cerebrovascular Disease. Stroke, 2003, 34, 2916-2921.	1.0	80
1610	Is blood pressure at 68 an independent predictor of cognitive decline at 81? Results from follow-up study 'Men born in 1914', Malmö, Sweden. Aging and Mental Health, 2003, 7, 61-72.	1.5	13

#	Article	IF	CITATIONS
1611	Is Glycosylated Hemoglobin A1c a Surrogate for Metabolic Syndrome in Nondiabetic, First-Degree Relatives of African-American Patients with Type 2 Diabetes?. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4596-4601.	1.8	74
1612	Peripheral Arterial Disease and Cognitive Function. Psychosomatic Medicine, 2003, 65, 757-763.	1.3	56
1613	How well are we managing and monitoring high blood pressure?. Current Opinion in Nephrology and Hypertension, 2003, 12, 299-304.	1.0	10
1614	Effects of Weight Reduction Interventions by Community Pharmacists. Journal of the American Pharmacists Association: JAPhA, 2003, 43, 583-589.	0.7	56
1615	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2003, 10, 65-73.	1.5	39
1616	Diabetes Mellitus and Hypertension: A Mandate for Intense Treatment According to New Guidelines. American Journal of Therapeutics, 2003, 10, 363-369.	0.5	6
1617	Very-low-dose combination: a first-line choice for the treatment of hypertension?. Journal of Hypertension, 2003, 21, S3-S10.	0.3	12
1618	Blood pressure is insufficiently controlled in European patients with established coronary heart disease. Journal of Hypertension, 2003, 21, 1831-1840.	0.3	69
1619	The Use of Calcium Antagonists in the Therapy of Hypertension in the Elderly. American Journal of Therapeutics, 2003, 10, 383-395.	0.5	6
1620	Management of Refractory Hypertension. American Journal of Therapeutics, 2003, 10, 122-126.	0.5	9
1621	The right drug and the right dose. Journal of Hypertension, 2003, 21, S31-S36.	0.3	1
1622	Prediction of cardiac death in hypertensive patients with suspected or known coronary artery disease by stress technetium-99m tetrofosmin myocardial perfusion imaging. Journal of Hypertension, 2003, 21, 1945-1951.	0.3	16
1623	Cardiovascular Reactivity and Development of Preclinical and Clinical Disease States. Psychosomatic Medicine, 2003, 65, 46-62.	1.3	543
1624	Assessing the prevalence of hypertension in populations. Journal of Hypertension, 2003, 21, 509-517.	0.3	91
1625	Monitoring compliance in resistant hypertension: an important step in patient management. Journal of Hypertension, 2003, 21, S37-S42.	0.3	72
1626	Orlistat in hypertensive overweight/obese patients. Journal of Hypertension, 2003, 21, 2159-2165.	0.3	20
1627	The ???ABPM effect??? gradually decreases but does not disappear in successive sessions of ambulatory monitoring. Journal of Hypertension, 2003, 21, 2265-2273.	0.3	32
1628	Protein intake and blood pressure in cardiovascular disease. Proceedings of the Nutrition Society, 2003, 62, 495-504.	0.4	25

#	Article	IF	CITATIONS
1629	Drug Therapy of Neurovascular Disease. Cardiology in Review, 2003, 11, 122-146.	0.6	0
1630	A Comprehensive Cardiac Rehabilitation Program in Post-CABG Patients. Critical Pathways in Cardiology, 2003, 2, 20-33.	0.2	3
1631	NEW-ONSET DIABETES AFTER TRANSPLANTATION: 2003 INTERNATIONAL CONSENSUS GUIDELINES1. Transplantation, 2003, 75, SS3-SS24.	0.5	547
1632	Ambulatory blood pressure measurement in kidney transplantation: an overview. Transplantation, 2003, 76, 1643-1644.	0.5	11
1633	Treatment of posttransplant hypertension: too little, too late?. Transplantation, 2003, 76, 1645-1646.	0.5	0
1634	Diabetes and Heart Disease. Cardiology in Review, 2003, 11, 262-274.	0.6	28
1635	Undiagnosed Hypertension and Hypercholesterolemia Among Uninsured and Insured Adults in the Third National Health and Nutrition Examination Survey. American Journal of Public Health, 2003, 93, 2051-2054.	1.5	93
1636	Hypertension in Chronic Dialysis Patients: Pathophysiology, Monitoring, and Treatment. American Journal of the Medical Sciences, 2003, 325, 194-201.	0.4	21
1638	The Association of Hypertension and Secondary Cardiovascular Disease With Sleep-Disordered Breathing. Chest, 2003, 123, 244-260.	0.4	80
1639	Identifying At-Risk Patients Through Community Pharmacy-Based Hypertension and Stroke Prevention Screening Projects. Journal of the American Pharmacists Association, 2003, 43, 50-55.	0.6	64
1640	The evolution of treatment guidelines for diabetic nephropathy. Postgraduate Medicine, 2003, 113, 35-50.	0.9	4
1644	The effect of low-dose potassium supplementation on blood pressure in apparently healthy volunteers. British Journal of Nutrition, 2003, 90, 53-60.	1.2	52
1645	Genetics of hypertension. Genetics in Medicine, 2003, 5, 413-429.	1.1	51
1646	<i>CYP3A5</i> genotype predicts renal CYP3A activity and blood pressure in healthy adults. Journal of Applied Physiology, 2003, 95, 1297-1300.	1.2	123
1647	Diagnosis and Therapy of Coronary Artery Disease in Renal Failure, End-Stage Renal Disease, and Renal Transplant Populations. American Journal of the Medical Sciences, 2003, 325, 214-227.	0.4	40
1648	Treatment of Systemic Hypertension in Patients With Pulmonary Disease. Chest, 2003, 123, 222-243.	0.4	54
1650	REAP and WAVE: New Tools to Rapidly Assess/Discuss Nutrition with Patients. Journal of Nutrition, 2003, 133, 556S-562S.	1.3	101
1651	Effect of a Telephone Medication Renewal Service on Blood Pressure Control. Journal of the American Pharmacists Association: JAPhA, 2003, 43, 561-565.	0.7	2

#	Article	IF	Citations
1652	Hypertension is related to the degradation of dietary frying oils. American Journal of Clinical Nutrition, 2003, 78, 1092-1097.	2.2	163
1654	Compliance with Antihypertensive Therapy after Renal Artery Stenting. Biological Research for Nursing, 2003, 5, 37-46.	1.0	4
1655	Anaesthesia and Isolated Systolic Hypertension— Pathophysiology and Anaesthesia Risk. Anaesthesia and Intensive Care, 2003, 31, 619-628.	0.2	7
1656	Lowering blood pressure in 2003. Medical Journal of Australia, 2003, 179, 306-312.	0.8	5
1658	Pharmacologic Therapy in Patients with Chronic Renal Failure. Taehan Uihak Hyophoe Chi the Journal of the Korean Medical Association, 2003, 46, 246.	0.1	1
1659	Influência de programas não-formais de exercÃcios (doméstico e comunitário) sobre a aptidão fÃsica, pressão arterial e variáveis bioquÃmicas em pacientes hipertensos. Revista Brasileira De Medicina Do Esporte, 2003, 9, 267-274.	0.1	10
1660	Avaliação quanto à presença de microalbuminúria e hiperfiltração glomerular no estágio de tolerância à glicose diminuÃda. Arquivos Brasileiros De Endocrinologia E Metabologia, 2003, 47, 158-165.	1.3	1
1661	Prevalência de sobrepeso e obesidade em pacientes com diabetes tipo 1. Arquivos Brasileiros De Endocrinologia E Metabologia, 2003, 47, 677-683.	1.3	14
1662	Diabetic nephropathy in type 2 diabetes mellitus: risk factors and prevention. Arquivos Brasileiros De Endocrinologia E Metabologia, 2003, 47, 207-219.	1.3	17
1663	Detection of renal dysfunction based on serum creatinine levels in a Brazilian community: the BambuÃ-Health and Ageing Study. Brazilian Journal of Medical and Biological Research, 2003, 36, 393-401.	0.7	26
1664	Does whole body autoregulation mediate the hemodynamic responses to increased dietary salt in rats with clamped ANG II?. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H2670-H2678.	1.5	17
1665	Avaliação antropomà ©trica e dietà ©tica de hipertensos atendidos em ambulatório de um hospital universitário. Revista De Nutricao, 2003, 16, 61-71.	0.4	8
1666	Drug Therapy for Hypertension: Does ALLHAT Alter our Approach?. Hospital Pharmacy, 2003, 38, 533-543.	0.4	0
1667	Epidemiology and Stroke Risk Factors. , 2003, , 252-268.		0
1668	White-Coat Hypertension Contributes to the Presence of Carotid Arteriosclerosis. Hypertension Research, 2004, 27, 739-745.	1.5	39
1670	Hypertension in a Dental School Patient Population. Journal of Dental Education, 2004, 68, 956-964.	0.7	15
1671	Prevention of coronary heart disease in women. , 2004, , 209-224.		1
1672	Thermoregulation in hypertensive men exercising in the heat with water ingestion. Brazilian Journal of Medical and Biological Research, 2004, 37, 409-417.	0.7	11

#	Article	IF	CITATIONS
1674	Can Selective Beta-Blockers be Prescribed Safely for Hemodialysis Patients? A Retrospective Review. Hospital Pharmacy, 2004, 39, 144-148.	0.4	2
1676	Highâ€sodium diets in Japanese evacuation centers increase blood pressures of evacuees. Blood Pressure, 2004, 13, 37-40.	0.7	4
1677	Recent progress in the therapeutic management of pre-eclampsia. Expert Opinion on Pharmacotherapy, 2004, 5, 2233-2239.	0.9	8
1678	Hypertension and left ventricular hypertrophy in autosomal dominant polycystic kidney disease. Expert Review of Cardiovascular Therapy, 2004, 2, 369-374.	0.6	17
1679	Blood Pressure Control and Nephroprotection in Diabetes. Journal of Clinical Pharmacology, 2004, 44, 431-438.	1.0	24
1680	Drug Therapy of Common Cardiac Disorders. , 2004, , 225-239.		0
1681	Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril Study. Hypertension, 2004, 44, 637-642.	1.3	114
1682	Guidelines for Antihypertensive Treatment: An Update after the ALLHAT Study. Journal of the American Society of Nephrology: JASN, 2004, 15, 51S-54.	3.0	19
1684	Comparing Warfarin With Aspirin After Biological Aortic Valve Replacement. Circulation, 2004, 110, 496-500.	1.6	98
1685	Meta-Analysis of Interventions for Medication Adherence to Antihypertensives. Annals of Pharmacotherapy, 2004, 38, 1617-1624.	0.9	56
1686	Review: simplifying dosing regimens appears to improve treatment adherence in patients with high blood pressure in ambulatory settings. Evidence-based Nursing, 2004, 7, 110-110.	0.1	2
1687	A Collaborative Initiative to Improve the Care of Elderly Medicare Patients With Hypertension. American Journal of Medical Quality, 2004, 19, 103-111.	0.2	4
1688	Periprocedural Hypertension: Current Concepts in Management for the Vascular Surgeon. Vascular and Endovascular Surgery, 2004, 38, 361-366.	0.3	6
1689	Does a family history of coronary heart disease modify the relationship between physical activity and blood pressure in young adults?. European Journal of Cardiovascular Prevention and Rehabilitation, 2004, 11, 201-206.	3.1	3
1690	Cardiovascular Risk Factor Control Among Veterans With Diabetes: The Ambulatory Care Quality Improvement Project. Diabetes Care, 2004, 27, B33-B38.	4.3	11
1691	Acute and chronic effects of oestradiol on left ventricular diastolic function in hypertensive postmenopausal women with left ventricular diastolic dysfunction. British Heart Journal, 2004, 90, 777-781.	2.2	35
1692	Race, Rural Residence, and Control of Diabetes and Hypertension. Annals of Family Medicine, 2004, 2, 563-568.	0.9	112
1693	Chapter 2 Primary Prevention of Stroke by Modification of Selected Risk Factors. Blue Books of Practical Neurology, 2004, 29, 5-54.	0.1	O

#	Article	IF	CITATIONS
1694	Surrogate Markers for Cardiovascular Disease: Functional Markers. Circulation, 2004, 109, IV-31-IV-46.	1.6	215
1695	Blood Pressure Elevation with Rofecoxib in Older Adults. Journal of Pharmacy Technology, 2004, 20, 80-84.	0.5	0
1696	Race-Specific Differences in Endothelial Function. Circulation, 2004, 109, 2511-2517.	1.6	303
1697	Sympathetic activity is reduced by nCPAP in hypertensive obstructive sleep apnoea patients. European Respiratory Journal, 2004, 23, 255-262.	3.1	81
1698	Clinical Usefulness of Ambulatory Blood Pressure Monitoring. Journal of the American Society of Nephrology: JASN, 2004, 15, 30S-33.	3.0	41
1699	Hypertensive Therapy: Part I. Circulation, 2004, 109, 2953-2958.	1.6	33
1700	The Levels of Soluble Adhesion Molecules in Diabetic and Nondiabetic Patients with Combined Hyperlipoproteinemia and the Effect of Ciprofibrate Therapy. Angiology, 2004, 55, 629-639.	0.8	13
1701	Principles for National and Regional Guidelines on Cardiovascular Disease Prevention. Circulation, 2004, 109, 3112-3121.	1.6	314
1702	Factors Associated With Hypertension Awareness, Treatment, and Control in a Representative Sample of the Chinese Population. Hypertension, 2004, 43, 578-585.	1.3	91
1703	Impaired Cerebral Autoregulation in Patients With Malignant Hypertension. Circulation, 2004, 110, 2241-2245.	1.6	218
1704	Ambient Pollution and Blood Pressure in Cardiac Rehabilitation Patients. Circulation, 2004, 110, 2184-2189.	1.6	237
1705	Heterogeneity of Cardiorenal Characteristics in Normotensive Subjects. Hypertension, 2004, 43, 219-223.	1.3	16
1706	Guidelines for Hypertension: Are Quality-Assurance Measures on Target?. Hypertension, 2004, 43, 198-202.	1.3	30
1707	Use of \hat{I}^2 -Blockers in Patients with COPD. Annals of Pharmacotherapy, 2004, 38, 142-145.	0.9	36
1708	Quantifying Risk of Adverse Clinical Events With One Set of Vital Signs Among Primary Care Patients with Hypertension. Annals of Family Medicine, 2004, 2, 209-217.	0.9	20
1709	Clinical Correlates and Heritability of Flow-Mediated Dilation in the Community. Circulation, 2004, 109, 613-619.	1.6	551
1711	Simultaneous Use of Antidepressant and Antihypertensive Medications Increases Likelihood of Diagnosis of Obstructive Sleep Apnea Syndrome. Chest, 2004, 125, 1279-1285.	0.4	45
1712	Concomitant administration of cyclosporine and ketoconazole in idiopathic nephrotic syndrome. Nephrology Dialysis Transplantation, 2004, 19, 2266-2271.	0.4	7

#	Article	IF	CITATIONS
1713	Guidelines from the British Hypertension Society. BMJ: British Medical Journal, 2004, 328, 593-594.	2.4	24
1714	Carotid Arterial Remodeling. Stroke, 2004, 35, 671-676.	1.0	66
1715	Determinants of Blood Pressure Response to Quinapril in Black and White Hypertensive Patients. Hypertension, 2004, 43, 1202-1207.	1.3	98
1716	Measuring Adherence to Practice Guidelines for the Management of Hypertension. Hypertension, 2004, 44, 602-608.	1.3	102
1717	Determinants of JNC VI Guideline Adherence, Intensity of Drug Therapy, and Blood Pressure Control by Race and Ethnicity. Hypertension, 2004, 44, 429-434.	1.3	74
1718	Inflammation, Abdominal Obesity, and Smoking as Predictors of Hypertension. Hypertension, 2004, 44, 859-865.	1.3	291
1719	The Deep-Breath Test as a Diagnostic Maneuver for White-Coat Effect in Hypertensive Patients. Journal of the American Board of Family Medicine, 2004, 17, 184-189.	0.8	3
1720	Changing Prescribing Patterns and Increasing Prescription Expenditures in Medicaid. Annals of Family Medicine, 2004, 2, 488-493.	0.9	12
1721	Blood Pressure Control and Physician Management of Hypertension in Hospital Hypertension Units in Spain. Hypertension, 2004, 43, 1338-1344.	1.3	183
1722	Effects of estradiol on myocardial global performance index in hypertensive postmenopausal women. Gynecological Endocrinology, 2004, 19, 282-292.	0.7	15
1723	Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2004, 109, 837-842.	1.6	598
1724	Dietary Sodium Restriction Rapidly Improves Large Elastic Artery Compliance in Older Adults With Systolic Hypertension. Hypertension, 2004, 44, 35-41.	1.3	214
1725	Measures of Global Risk: Old Versus New Methods. Clinical and Experimental Hypertension, 2004, 26, 653-662.	0.5	1
1726	Everyday Life for Black American Adults. Western Journal of Nursing Research, 2004, 26, 499-514.	0.6	34
1727	Use of diuretics in cardiovascular disease: (2) hypertension. Postgraduate Medical Journal, 2004, 80, 271-276.	0.9	25
1728	Translating Research into Practice: Are Physicians Following Evidence-Based Guidelines in the Treatment of Hypertension?. Medical Care Research and Review, 2004, 61, 453-473.	1.0	14
1729	Combination Therapy Improves Survival After Acute Myocardial Infarction in the Elderly with Chronic Kidney Disease. Renal Failure, 2004, 26, 715-725.	0.8	19
1730	Cardiovascular and Renal Risk Assessment as a Guide for Treatment in Primary Hypertension. Journal of the American Society of Nephrology: JASN, 2004, 15, 34S-36.	3.0	5

#	Article	IF	Citations
1731	Progress Report on the HOMEDâ€BP Study: Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure Study. Clinical and Experimental Hypertension, 2004, 26, 119-127.	0.5	11
1732	Relationship between Blood Glucose Control, Pathogenesis and Progression of Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2004, 15, 1S-5.	3.0	27
1733	Blood Pressure Response to Caffeine Shows Incomplete Tolerance After Short-Term Regular Consumption. Hypertension, 2004, 43, 760-765.	1.3	94
1734	New European, American and International guidelines for hypertension management: agreement and disagreement. Expert Review of Cardiovascular Therapy, 2004, 2, 359-368.	0.6	37
1735	Drug treatment of essential hypertension: the case for initial combination therapy. International Journal of Clinical Practice, 2004, 58, 956-963.	0.8	15
1736	The effect of polymorphism in the intestinal fatty acid-binding protein 2 gene on fat metabolism is associated with gender and obesity amongst non-diabetic Japanese-Americans. Diabetes, Obesity and Metabolism, 2004, 6, 45-49.	2.2	34
1737	Diabetic renal disease: from recent studies to improved clinical practice. Diabetic Medicine, 2004, 21, 4-17.	1.2	45
1738	Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria. Diabetic Medicine, 2004, 21, 1192-1199.	1.2	30
1739	Evaluating the treatment of hypertension in diabetes mellitus: a need for better control?. Journal of Evaluation in Clinical Practice, 2004, 10, 107-116.	0.9	17
1740	Inadequate management of cerebrovascular risk factors in participants of a public stroke prevention program in Austria. European Journal of Neurology, 2004, 11, 679-685.	1.7	2
1741	Aerobic exercise training and cardiovascular reactivity to psychological stress in sedentary young normotensive men and women. Psychophysiology, 2004, 41, 552-562.	1.2	76
1742	Blood pressure lability and glomerulosclerosis after normotensive 5/6 renal mass reduction in the rat. Kidney International, 2004, 65, 209-218.	2.6	48
1743	Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy. Kidney International, 2004, 66, 1180-1186.	2.6	40
1744	Development of a Parametric Simulation Model for Forecasting Goal-Oriented Treatment Outcomes. Value in Health, 2004, 7, 482-489.	0.1	0
1745	Prevalence of nutrition and exercise counseling for patients with hypertension. Journal of General Internal Medicine, 2004, 19, 917-924.	1.3	61
1747	Frequency of angiotensin-converting enzyme gene polymorphism in Turkish hypertensive patients. International Journal of Clinical Practice, 2004, 58, 838-843.	0.8	25
1748	The case for blood pressure control in risk groups. International Journal of Clinical Practice, 2004, 58, 844-849.	0.8	4
1750	Effect of telmisartan 80â€∫mg once daily on 24-h blood pressure profile in patients with mild-to-moderate hypertension failing to respond to prior antihypertensive therapy. International Journal of Clinical Practice, 2004, 58, 9-15.	0.8	7

#	Article	IF	CITATIONS
1751	The Influence of Ambulatory Blood Pressure Profile on Left Ventricular Geometry. Echocardiography, 2004, 21, 7-10.	0.3	17
1752	Waist-to-hip ratio is a better screening measure for cardiovascular risk factors than other anthropometric indicators in Tehranian adult men. International Journal of Obesity, 2004, 28, 1325-1332.	1.6	125
1753	Impact of the high-risk and mass strategies on hypertension control and stroke mortality in primary health care. Journal of Human Hypertension, 2004, 18, 97-105.	1.0	16
1754	Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients. Journal of Human Hypertension, 2004, 18, 215-222.	1.0	18
1755	Risk factors for uncontrolled hypertension in Italy. Journal of Human Hypertension, 2004, 18, 207-213.	1.0	56
1756	Do variations in blood pressures of South Asian, African and Chinese descent children reflect those of the adult populations in the UK? A review of cross-sectional data. Journal of Human Hypertension, 2004, 18, 229-237.	1.0	38
1757	Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IV. Journal of Human Hypertension, 2004, 18, 139-185.	1.0	1,072
1758	Creatinine clearance and signs of end-organ damage in primary hypertension. Journal of Human Hypertension, 2004, 18, 511-516.	1.0	19
1759	Prevalence, awareness, treatment and control of hypertension in North America, North Africa and Asia. Journal of Human Hypertension, 2004, 18, 545-551.	1.0	133
1760	Prevalence, awareness, treatment and control of hypertension in employees of factories of Northern Greece: the Naoussa study. Journal of Human Hypertension, 2004, 18, 623-629.	1.0	32
1761	Arterial hypertension in Poland in 2002. Journal of Human Hypertension, 2004, 18, 557-562.	1.0	56
1762	Association of ACE gene haplotype with essential hypertension. Journal of Human Hypertension, 2004, 18, 913-914.	1.0	4
1763	Impact of Obesity and Body Fat Distribution on Cardiovascular Risk Factors in Hong Kong Chinese. Obesity, 2004, 12, 1805-1813.	4.0	90
1764	Normal Insulin Sensitivity in Lean Offspring of Obese Parents. Obesity, 2004, 12, 621-626.	4.0	5
1765	Isolate diffuse thickening of glomerular capillary basement membrane: a renal lesion in prediabetes?. Modern Pathology, 2004, 17, 1506-1512.	2.9	50
1766	Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. American Journal of Transplantation, 2004, 4, 13-53.	2.6	320
1767	Pathogenesis of Hypertension in African Americans. Congestive Heart Failure, 2004, 10, 24-29.	2.0	39
1768	Residual dissection of the brachiocephalic arteries: Significance, management, and long-term outcome. Journal of Thoracic and Cardiovascular Surgery, 2004, 128, 303-312.	0.4	25

#	Article	IF	CITATIONS
1769	Epidemiology of coronary heart disease in women. Progress in Cardiovascular Diseases, 2004, 46, 287-295.	1.6	157
1770	The Burden of Chronic Kidney Disease in Renal Transplant Recipients. American Journal of Transplantation, 2004, 4, 262-269.	2.6	133
1771	Achievement of target blood pressure levels in chronic kidney disease: a salty question?. American Journal of Kidney Diseases, 2004, 43, 782-795.	2.1	91
1772	Optimizing hypertension andvascular health: Focus on ethnicity. Clinical Cornerstone, 2004, 6, 28-36.	1.0	8
1773	Development and Preliminary Testing of a Patient Decision Aid to Assist Pharmaceutical Care in the Prevention of Cardiovascular Disease. Pharmacotherapy, 2004, 24, 909-922.	1.2	41
1774	A systematic critique of diabetes on the world wide web for patients and their physicians. International Journal of Medical Informatics, 2004, 73, 687-694.	1.6	51
1775	Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. American Journal of Cardiology, 2004, 93, 870-875.	0.7	424
1776	A likely explanation for the J-curve of blood pressure cardiovascular risk. American Journal of Cardiology, 2004, 94, 380-384.	0.7	132
1777	Analysis of late risk of systemic blood pressures < 120/80 mm Hg. American Journal of Cardiology, 2004, 94, 1575-1576.	0.7	0
1778	Anger response styles and blood pressure: At least Don't Ruminate about it!. Annals of Behavioral Medicine, 2004, 27, 38-49.	1.7	70
1779	Patients with uncontrolled hypertension or concomitant hypertension and benign prostatic hyperplasia. Clinical Cardiology, 2004, 27, 63-69.	0.7	5
1780	Evolving targets for risk reduction in diabetes. Clinical Cardiology, 2004, 27, 125-128.	0.7	1
1781	Characteristics of contemporary patients with hypertension and coronary artery disease. Clinical Cardiology, 2004, 27, 571-576.	0.7	16
1782	Effects of valsartan/ hydrochlorothiazide and amlodipine on ambulatory blood pressure and plasma norepinephrine levels in high-risk hypertensive patients. Advances in Therapy, 2004, 21, 149-161.	1.3	14
1783	Health Conditions Among Aging Narcotics Addicts: Medical Examination Results. Journal of Behavioral Medicine, 2004, 27, 607-622.	1.1	75
1784	Treatment of hypertension and prevention of ischemic stroke. Current Cardiology Reports, 2004, 6, 124-129.	1.3	31
1785	Hypertension in black patients: Special issues and considerations. Current Cardiology Reports, 2004, 6, 416-420.	1.3	12
1786	Combination drug treatment of hypertension: Have we come full circle?. Current Cardiology Reports, 2004, 6, 421-426.	1.3	21

#	Article	IF	Citations
1787	Remission and regression of diabetic nephropathy. Current Hypertension Reports, 2004, 6, 377-382.	1.5	23
1788	Diastolic heart failure: The forgotten manifestation of hypertensive heart disease. Current Hypertension Reports, 2004, 6, 164-170.	1.5	8
1789	Evaluation of drug prescription at the Geneva prison's outpatient service in comparison to an urban outpatient medical service. Pharmacoepidemiology and Drug Safety, 2004, 13, 633-644.	0.9	16
1790	Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Statistics in Medicine, 2004, 23, 1631-1660.	0.8	1,302
1791	Analysis of data with multiple sources of correlation in the framework of generalized estimating equations. Statistics in Medicine, 2004, 23, 3209-3226.	0.8	21
1792	Differentiating thrombotic microangiopathies induced by severe hypertension from anemia and thrombocytopenia seen in thrombotic thrombocytopenia purpura. Journal of Clinical Apheresis, 2004, 19, 125-129.	0.7	28
1793	Artériopathie diabétique des membres inférieurs. EMC - Endocrinologie, 2004, 1, 117-132.	0.0	3
1794	Coenzyme Q10 and Adverse Effects of Statins. Journal of Nutritional and Environmental Medicine, 2004, 14, 17-28.	0.1	4
1795	Pharmacotherapy and blood pressure control in elderly hypertensives in a primary care setting in Bahrain. Aging Clinical and Experimental Research, 2004, 16, 319-325.	1.4	5
1796	Ultrasound Monitoring of Carotid Lesions in Hypertension. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 35-41.	1.0	0
1797	Pharmacoeconomic Burden of Undertreating Hypertension. Pharmacoeconomics, 2004, 22, 907-928.	1.7	30
1798	The new American Guidelines. American Journal of Cardiovascular Drugs, 2004, 4, 7-11.	1.0	1
1799	New strategies for hypertension control. American Journal of Cardiovascular Drugs, 2004, 4, 37-42.	1.0	0
1800	Relations of Plasma Matrix Metalloproteinase-9 to Clinical Cardiovascular Risk Factors and Echocardiographic Left Ventricular Measures. Circulation, 2004, 109, 2850-2856.	1.6	173
1804	Efectividad de una intervenci \tilde{A}^3 n de mejora de calidad en la reducci \tilde{A}^3 n del riesgo cardiovascular en pacientes hipertensos. Revista Espanola De Cardiologia, 2004, 57, 644-651.	0.6	7
1806	\hat{A}_{ξ} La hora del d \tilde{A}_{a} en la toma de la presi \tilde{A}^{3} n arterial determina el grado de control de los pacientes hipertensos?. Hipertension Y Riesgo Vascular, 2004, 21, 228-232.	0.3	4
1813	Insuficiencia renal crónica. EMC - Tratado De Medicina, 2004, 8, 1-8.	0.0	0
1814	GuÃas para el tratamiento de las dislipemias en el adulto: Adult Treatment Panel III (ATP-III). Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2004, 51, 254-265.	0.8	10

#	Article	IF	Citations
1819	Chronobiology of rupture and dissection of aortic aneurysms. Journal of Vascular Surgery, 2004, 40, 382-388.	0.6	91
1820	Community screening for left ventricular hypertrophy in patients with hypertension using hand-held echocardiography. Journal of the American Society of Echocardiography, 2004, 17, 56-61.	1.2	37
1823	Use of Antihypertensive Drugs in Spain (1995-2001). Revista Espanola De Cardiologia (English Ed), 2004, 57, 241-249.	0.4	7
1824	Ambulatory Blood Pressure Monitoring to Study White Coat Effect in Patients With Hypertension Followed in Primary Care. Revista Espanola De Cardiologia (English Ed), 2004, 57, 652-660.	0.4	1
1825	Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/Indapamide in hypertensive subjects: comparison with atenolol. Journal of the American College of Cardiology, 2004, 43, 92-99.	1.2	308
1826	Relationship of neurovascular compression to central sympathetic discharge and essential hypertension. Journal of the American College of Cardiology, 2004, 43, 1453-1458.	1.2	43
1827	Cardiology management improves secondary prevention measures among patients with coronary artery disease. Journal of the American College of Cardiology, 2004, 43, 1517-1523.	1.2	25
1828	Therapeutic Update: Non-Selective Beta- and Alpha-Adrenergic Blockade in Patients With Coexistent Chronic Obstructive Pulmonary Disease and Chronic Heart Failure. Journal of the American College of Cardiology, 2004, 44, 497-502.	1.2	56
1829	Age and Gender Affect Ventricular-Vascular Coupling During Aerobic Exercise. Journal of the American College of Cardiology, 2004, 44, 611-617.	1.2	163
1830	Pharmacist Involvement in Primary Care Improves Hypertensive Patient Clinical Outcomes. Annals of Pharmacotherapy, 2004, 38, 2023-2028.	0.9	98
1831	Relationship of ethnicity, gender, and ambulatory blood pressure to pain sensitivity: effects of individualized pain rating scales. Journal of Pain, 2004, 5, 183-191.	0.7	58
1832	Advanced Glycation Endproduct Crosslinking in the Cardiovascular System. Drugs, 2004, 64, 459-470.	4.9	120
1833	Fixed-Dose Combination Enalapril/Nitrendipine. Drugs, 2004, 64, 1135-1148.	4.9	18
1834	Efficacy and Safety of Valsartan 160mg/Hydrochlorothiazide 25mg Combination in Patients with Hypertension not Adequately Controlled by Valsartan 160mg/Hydrochlorothiazide 12.5mg. Clinical Drug Investigation, 2004, 24, 593-602.	1.1	5
1835	What is the Relationship Between Exercise and Metabolic Abnormalities?. Sports Medicine, 2004, 34, 371-418.	3.1	249
1836	National Performance Measures for Diabetes Mellitus Care. Disease Management and Health Outcomes, 2004, 12, 285-298.	0.3	4
1837	New-Onset Diabetes After Transplantation 2003 International Consensus Guidelines: An endocrinologist's view. Diabetes Care, 2004, 27, 805-812.	4.3	150
1838	Should the Insulin Resistance Syndrome be Treated in the Elderly?. Drugs and Aging, 2004, 21, 141-151.	1.3	14

#	Article	IF	CITATIONS
1839	Do We Need Drug Therapy to Manage Mild Hypertension in the Elderly?. Drugs and Aging, 2004, 21, 1-6.	1.3	3
1841	Indicadores de calidad mÃnimos para la mejora de la gestión de la hipertensión arterial en Atención Primaria. Hipertension Y Riesgo Vascular, 2004, 21, 100-107.	0.3	1
1843	Antihypertensive Therapy and Incidence of Type 2 Diabetes: A systematic review. Diabetes Care, 2004, 27, 247-255.	4.3	185
1844	Hypertension: a review for clinicians. Nursing Clinics of North America, 2004, 39, 793-814.	0.7	8
1845	Primary Prevention and Risk Reduction for Cardiovascular/Pulmonary Disordersâ€"Preferred Practice Pattern 6A., 2004, , 253-269.		2
1846	Pacientes hipertensos mal controlados: variables relacionadas con el tiempo hasta modificar el tratamiento (estudio HIMOT: hipertensi \tilde{A}^3 n y modificaci \tilde{A}^3 n del tratamiento). Hipertension Y Riesgo Vascular, 2004, 21, 442-447.	0.3	0
1847	Obstructive Sleep Apnea and Cardiovascular Disease. Mayo Clinic Proceedings, 2004, 79, 1036-1046.	1.4	439
1849	Frequency of cardiovascular events in patients treated with anti hypertensive agents: A cohort study based on claims data generated by primary care practice. Current Therapeutic Research, 2004, 65, 398-412.	0.5	0
1850	Variability in the presence of the metabolic syndrome in Type 2 diabetic patients attending a diabetes clinic. Diabetes Research and Clinical Practice, 2004, 65, 135-142.	1.1	18
1851	Commentary. Evidence-based Cardiovascular Medicine, 2004, 8, 123.	0.0	0
1852	Incidence, associations, and evaluation of sixth nerve palsy using a population-based method. Ophthalmology, 2004, 111, 369-375.	2.5	178
1853	Blood pressure profile and treatment quality in liver allograft recipients—benefit of tacrolimus versus cyclosporine. Transplantation Proceedings, 2004, 36, 1512-1515.	0.3	14
1854	Ischemic heart disease in women and the role of hormone therapy. International Journal of Cardiology, 2004, 96, 7-19.	0.8	17
1855	Ventricular hypertrophy increases NT-proBNP in subjects with and without hypertension. International Journal of Cardiology, 2004, 96, 265-271.	0.8	19
1856	Effects of a weight reduction program with and without aerobic exercise in the metabolic syndrome. International Journal of Cardiology, 2004, 97, 115-122.	0.8	48
1857	Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data. American Heart Journal, 2004, 147, 564-572.	1.2	23
1858	Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. American Heart Journal, 2004, 148, 285-292.	1.2	102
1859	Slowing the progression of diabetic nephropathy and its cardiovascular consequences. American Heart Journal, 2004, 148, 243-251.	1.2	32

#	ARTICLE	IF	CITATIONS
1860	Oxidized low-density lipoprotein levels circulating in plasma and deposited in the tissues: Comparison between Helicobacter pylori-associated gastritis and acute myocardial infarction. American Heart Journal, 2004, 148, 818-825.	1.2	37
1861	The end of the disease era. American Journal of Medicine, 2004, 116, 179-185.	0.6	394
1862	Identifying gaps between guidelines and clinical practice in the evaluation and treatment of patients with hypertension. American Journal of Medicine, 2004, 117, 14-18.	0.6	87
1863	Clinician awareness of adherence to hypertension guidelines. American Journal of Medicine, 2004, 117, 747-754.	0.6	88
1864	Serum adiponectin in young adultsâ€"interactions with central adiposity, circulating levels of glucose, and insulin resistance: the CARDIA study. Annals of Epidemiology, 2004, 14, 492-498.	0.9	95
1865	Postmarketing surveillance study of benazepril in chinese patients with hypertension: An open-label, experimental, epidemiologic study. Current Therapeutic Research, 2004, 65, 300-319.	0.5	4
1866	Blood pressure control and weight loss in overweight or obese patients with previously treated or untreated mild to moderate hypertension given valsartan: An open-label study comparing pretreatment and posttreatment values. Current Therapeutic Research, 2004, 65, 172-184.	0.5	3
1867	Hypertension, hypertensive heart disease and perioperative cardiac risk $\hat{a}\in$. British Journal of Anaesthesia, 2004, 92, 570-583.	1.5	356
1868	Prevalence of asymptomatic arteriosclerosis obliterans and its relationship with risk factors in inhabitants of rural communities in Japan: Tanno-Sobetsu study. Atherosclerosis, 2004, 177, 83-88.	0.4	55
1869	Patterns of insulin resistance in the general population of southeast Spain. Diabetes Research and Clinical Practice, 2004, 65, 247-256.	1.1	26
1870	Reducing the Public Health Burden From Elevated Blood Pressure Levels in the United States by Lowering Intake of Dietary Sodium. American Journal of Public Health, 2004, 94, 19-22.	1.5	77
1871	Optimizing postoperative outcomes with efficient preoperative assessment and management. Critical Care Medicine, 2004, 32, S76-S86.	0.4	153
1872	Simultaneous Measurements of Blood Pressures in Right and Left Brachial Arteries. Cardiology in Review, 2004, 12, 276-278.	0.6	17
1873	Exercise and Hypertension. Medicine and Science in Sports and Exercise, 2004, 36, 533-553.	0.2	1,421
1874	Cross-Sectional versus Longitudinal Performance Assessments in the Management of Diabetes. Medical Care, 2004, 42, II-34.	1.1	11
1875	VALUE. Journal of Hypertension, 2004, 22, 1431-1434.	0.3	9
1876	A Review of Studies of the Hamilton Depression Rating Scale in Healthy Controls. Journal of Nervous and Mental Disease, 2004, 192, 595-601.	0.5	118
1877	Drug therapy for autonomic dysreflexia. Cmaj, 2004, 170, 1210-1210.	0.9	8

#	Article	IF	CITATIONS
1878	C-reactive protein for the prediction of cardiovascular risk: Ready for prime-time?. Cmaj, 2004, 170, 1563-1565.	0.9	8
1879	Exercise intensity alters postexercise hypotension. Journal of Hypertension, 2004, 22, 1881-1888.	0.3	149
1880	The S447X polymorphism of the lipoprotein lipase gene is associated with lipoprotein lipid and blood pressure levels in Chinese patients with essential hypertension. Journal of Hypertension, 2004, 22, 1503-1509.	0.3	15
1881	Biofeedback Applications in the Treatment of Cardiovascular Diseases. Cardiology in Review, 2004, 12, 177-181.	0.6	21
1882	Prediction of Stroke by Self-Measurement of Blood Pressure at Home Versus Casual Screening Blood Pressure Measurement in Relation to the Joint National Committee 7 Classification. Stroke, 2004, 35, 2356-2361.	1.0	120
1883	Trends in blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2000/01. Journal of Hypertension, 2004, 22, 1479-1485.	0.3	51
1885	A review of studies of the Montgomery???Asberg Depression Rating Scale in controls: implications for the definition of remission in treatment studies of depression. International Clinical Psychopharmacology, 2004, 19, 1-7.	0.9	80
1886	Intensified treatment of patients with type 2 diabetes mellitus and overt nephropathy. QJM - Monthly Journal of the Association of Physicians, 2004, 97, 219-227.	0.2	36
1887	Does comorbidity explain trends in prescribing of newer antihypertensive agents?. Journal of Hypertension, 2004, 22, 2209-2215.	0.3	13
1888	Progress in Clinical Neurosciences: Pharmacotherapies for the Secondar Prevention of Stroke. Canadian Journal of Neurological Sciences, 2004, 31, 295-303.	0.3	1
1889	Cardiovascular risk profile and blood pressure control in Italian hypertensive patients under specialist care. Journal of Hypertension, 2004, 22, 51-57.	0.3	65
1890	Reasons for not intensifying antihypertensive treatment (RIAT). Journal of Hypertension, 2004, 22, 1221-1229.	0.3	61
1891	Facts and fiction of poor compliance as a cause of inadequate blood pressure control. Journal of Hypertension, 2004, 22, 1849-1855.	0.3	152
1892	Effect of dietary fiber intake on blood pressure. Journal of Hypertension, 2004, 22, 73-80.	0.3	108
1893	Improvement of insulin resistance by troglitazone ameliorates cardiac sympathetic nervous dysfunction in patients with essential hypertension. Journal of Hypertension, 2004, 22, 1761-1768.	0.3	11
1894	New High Blood Pressure Guidelines Create New At-Risk Classification. Journal of Cardiovascular Nursing, 2004, 19, 367-371.	0.6	6
1895	"The Mirror―and "The Village― A New Method for Teaching Practice-Based Learning and Improvement and Systems-Based Practice. Academic Medicine, 2004, 79, 83-88.	0.8	98
1896	Low-renin status in therapy-resistant hypertension. Journal of Hypertension, 2004, 22, 2217-2226.	0.3	229

#	Article	IF	CITATIONS
1897	Doctors??? estimation of cardiovascular risk and willingness to give drug treatment in hypertension. Journal of Hypertension, 2004, 22, 65-71.	0.3	29
1898	If Suicide Is a Public Health Problem, What Are We Doing to Prevent It?. American Journal of Public Health, 2004, 94, 37-45.	1.5	238
1899	Insulin Resistance and Fasting Hyperinsulinemia Are Risk Factors for New Cardiovascular Events in Patients With Prior Coronary Artery Disease and Normal Glucose Tolerance. Circulation Journal, 2004, 68, 47-52.	0.7	40
1900	Clinical Practice Guidelines and Performance Indicators as Related—But Often Misunderstood—Tools. Joint Commission Journal on Quality and Safety, 2004, 30, 48-56.	1.3	0
1901	Clinical Practice Guidelines and Performance Indicators as Relatedâ€"But Often Misunderstoodâ€"Tools. Joint Commission Journal on Quality and Safety, 2004, 30, 163-171.	1.3	21
1902	Oral Enalapril-Hydrochlorothiazide-Methyldopa as First Line Treatment for Severe Hypertension in Nigerians. Tropical Doctor, 2004, 34, 32-33.	0.2	5
1903	Men's Health Initiative Risk Assessment Study: Effect of Community Pharmacy–Based Screening. Journal of the American Pharmacists Association: JAPhA, 2004, 44, 569-577.	0.7	13
1905	Race/Ethnicity, Income, Major Risk Factors, and Cardiovascular Disease Mortality. American Journal of Public Health, 2005, 95, 1417-1423.	1.5	110
1906	A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in Patients Treated With a Calcium Antagonist Versus an Atenolol Hypertension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST). Psychosomatic Medicine, 2005, 67, 398-406.	1.3	47
1907	Bell or diaphragm in the measurement of blood pressure?. Journal of Hypertension, 2005, 23, 499-503.	0.3	22
1908	Regression of Left Ventricular Hypertrophy With Moexipril, an Angiotensin-Converting Enzyme Inhibitor, in Hypertensive Patients. American Journal of Therapeutics, 2005, 12, 3-8.	0.5	20
1909	Associations of plant food, dairy product, and meat intakes with 15-y incidence of elevated blood pressure in young black and white adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. American Journal of Clinical Nutrition, 2005, 82, 1169-1177.	2.2	280
1911	Recent advances in hypertension, stroke, and cardiorenal disease. Current Opinion in Cardiology, 2005, 20, 258-263.	0.8	8
1912	Sodium directly impairs target organ function in hypertension. Current Opinion in Cardiology, 2005, 20, 424-429.	0.8	39
1913	Lowering blood pressure for cardiovascular risk reduction. Journal of Hypertension, 2005, 23, S3-S8.	0.3	68
1914	Does nocturnal blood pressure fall in people of African and South Asian descent differ from that in European white populations? A systematic review and meta-analysis. Journal of Hypertension, 2005, 23, 913-920.	0.3	39
1915	Severe cardiac disease in pregnancy, part II: impact of congenital and acquired cardiac diseases during pregnancy. Current Opinion in Critical Care, 2005, 11, 435-448.	1.6	35
1916	Cultural Diversity in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2005, 19, 250-255.	0.6	30

#	Article	IF	CITATIONS
1917	Pharmacogenomics of blood pressure response to antihypertensive treatment. Journal of Hypertension, 2005, 23, 1311-1325.	0.3	56
1918	Value of Doppler Sonography for Predicting Clinical Outcome After Renal Artery Revascularization in Atherosclerotic Renal Artery Stenosis. Journal of Ultrasound in Medicine, 2005, 24, 1641-1647.	0.8	49
1919	Posting Guidelines: A Practical and Effective Way to Promote Appropriate Hypertension Treatment. Joint Commission Journal on Quality and Patient Safety, 2005, 31, 227-232.	0.4	6
1920	Improved Endothelium Dependent Vasodilation in Endurance Athletes and Its Relation With ACE I/D Polymorphism. Circulation Journal, 2005, 69, 1105-1110.	0.7	37
1921	The Effects of Yoga on Hypertensive Persons in Thailand. Holistic Nursing Practice, 2005, 19, 173-180.	0.3	100
1922	Improving control of hypertension by an integrated approach ??? results of the ???Manage it well!??? programme. Journal of Hypertension, 2005, 23, 203-211.	0.3	13
1923	The Impact of a Stroke Prevention Clinic in Diagnosing Modifiable Risk Factors for Stroke. Canadian Journal of Neurological Sciences, 2005, 32, 496-500.	0.3	14
1924	Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril Study (INVEST). Clinical Cardiology, 2005, 28, 321-328.	0.7	8
1925	Medical management of peripheral arterial disease. Journal of Thrombosis and Haemostasis, 2005, 3, 1628-1637.	1.9	50
1926	Patterns of antihypertensive therapy among patients with diabetes. Journal of General Internal Medicine, 2005, 20, 842-846.	1.3	32
1927	Hypertension outcomes through blood pressure monitoring and evaluation by pharmacists (HOME) Tj ETQq0 0 0) rgBT /Ove	erlock 10 Tf 5
1928	Hypertension knowledge, awareness, and attitudes in a hypertensive population. Journal of General Internal Medicine, 2005, 20, 219-225.	1.3	152
1929	Clinical implications of an accurate problem list on heart failure treatment. Journal of General Internal Medicine, 2005, 20, 143-147.	1.3	62
1930	Blood Pressure Response to Strength Training May Be Influenced by Angiotensinogen A–20C and Angiotensin II Type I Receptor A1166C Genotypes in Older Men and Women. Journal of the American Geriatrics Society, 2005, 53, 204-210.	1.3	31
1931	Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. Kidney International, 2005, 67, S20-S24.	2.6	22
1932	Prevalence of chronic kidney disease in an urban Mexican population. Kidney International, 2005, 68, S11-S17.	2.6	96
1933	Sustainable and tenable renal health model: A Latin American proposal of classification, programming, and evaluation. Kidney International, 2005, 68, S23-S30.	2.6	11
1934	Microalbuminuria as a predictor of myocardial infarction in a Mexican population: The Mexico City Diabetes Study. Kidney International, 2005, 68, S34-S39.	2.6	13

#	Article	IF	CITATIONS
1935	Prevalance of proteinuria in Mexico: A conjunctive consolidation approach with other cardiovascular risk factors: The Mexican Health Survey 2000. Kidney International, 2005, 68, S112-S119.	2.6	6
1936	Usefulness of total cholesterol/HDL-cholesterol ratio in the management of diabetic dyslipidaemia. Diabetic Medicine, 2005, 22, 26-31.	1.2	34
1937	Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients. International Journal of Clinical Practice, 2005, 59, 478-484.	0.8	9
1938	Provision of Foods Differing in Energy Density Affects Longâ€√Ferm Weight Loss. Obesity, 2005, 13, 1052-1060.	4.0	139
1939	Incidence of extragenital vascular disease in patients with erectile dysfunction of arterial origin. International Journal of Impotence Research, 2005, 17, 277-282.	1.0	15
1940	Effect of lifestyle modifications on blood pressure by race, sex, hypertension status, and age. Journal of Human Hypertension, 2005, 19, 21-31.	1.0	195
1941	Effects of weight status on the recommendations of and adherence to lifestyle modifications among hypertensive adults. Journal of Human Hypertension, 2005, 19, 365-371.	1.0	17
1942	High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension. Journal of Human Hypertension, 2005, 19, 491-496.	1.0	39
1943	Left ventricular filling abnormalities and obesity-associated hypertension: relationship with overproduction of circulating transforming growth factor \hat{l}^21 . Journal of Human Hypertension, 2005, 19, 543-550.	1.0	21
1944	Knowledge of blood pressure levels and targets in patients with coronary artery disease in the USA. Journal of Human Hypertension, 2005, 19, 769-774.	1.0	19
1945	Hypertension prevention: from nutrients to (fortified) foods to dietary patterns. Focus on fatty acids. Journal of Human Hypertension, 2005, 19, S25-S33.	1.0	46
1946	Renin–angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics Journal, 2005, 5, 14-20.	0.9	44
1947	Analysis of factors affecting pain in intravenous catheter placement: a survey of 925 patients. International Journal of Clinical Practice, 2005, 59, 675-679.	0.8	7
1948	Factors influencing the switch in the use of antihypertensive medications. International Journal of Clinical Practice, 2005, 59, 85-91.	0.8	8
1949	Factors affecting pain in intravenous catheter placement: role of depression illness. International Journal of Clinical Practice, 2005, 59, 276-280.	0.8	2
1950	Modified TEI Index: A Promising Parameter in Essential Hypertension?. Echocardiography, 2005, 22, 296-304.	0.3	29
1951	Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. American Journal of Cardiology, 2005, 95, 29-35.	0.7	320
1952	Prognostic Value of a Multiparametric Risk Score in Patients Undergoing Dipyridamole Stress Echocardiography. American Journal of Cardiology, 2005, 96, 529-532.	0.7	5

#	Article	IF	CITATIONS
1953	Characterization of Systemic Hypertension in the San Francisco Chinese Community. American Journal of Cardiology, 2005, 96, 570-573.	0.7	15
1955	The Impact of Co-Morbid Conditions on the SF-36: A Primary-Care-Based Study Among Hypertensives. Archives of Medical Research, 2005, 36, 136-141.	1.5	44
1956	Genetic Polymorphisms of Estrogen Receptors in Patients with Premature Coronary Artery Disease. Archives of Medical Research, 2005, 36, 511-517.	1.5	68
1957	Determinants of racial/ethnic differences in blood pressure management among hypertensive patients. BMC Cardiovascular Disorders, 2005, 5, 16.	0.7	26
1958	Mean arterial pressure and systolic blood pressure for detection of hypotension during hemapheresis: Implications for patients with baseline hypertension. Journal of Clinical Apheresis, 2005, 20, 154-165.	0.7	3
1959	Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study. Arthritis and Rheumatism, 2005, 52, 402-411.	6.7	815
1960	The risk of congestive heart failure in rheumatoid arthritis: A population-based study over 46 years. Arthritis and Rheumatism, 2005, 52, 412-420.	6.7	398
1961	Cardiovascular death in rheumatoid arthritis: A population-based study. Arthritis and Rheumatism, 2005, 52, 722-732.	6.7	818
1962	Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial. European Journal of Clinical Pharmacology, 2005, 61, 87-96.	0.8	20
1963	Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy. European Journal of Clinical Pharmacology, 2005, 61, 225-230.	0.8	24
1964	Long-term Follow-up after Adrenalectomy for Primary Aldosteronism. World Journal of Surgery, 2005, 29, 155-159.	0.8	94
1965	An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia, 2005, 48, 17-26.	2.9	192
1966	Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia, 2005, 48, 1300-1306.	2.9	188
1967	Atherosclerosis in childhood and adolescent type 1 diabetes: early disease, early treatment?. Diabetologia, 2005, 48, 1445-1453.	2.9	115
1969	Vascular risk factors in the Swiss population. Journal of Neurology, 2005, 252, 1210-1216.	1.8	13
1970	Efficacy and safety of combination therapy using high- or low-dose hydrochlorothiazide with valsartan or other angiotensin-receptor blockers. Advances in Therapy, 2005, 22, 263-277.	1.3	8
1971	Effect of low-dose omega-3 fatty acids substitution on blood pressure, hyperinsulinemia and dyslipidemia in Indians with essential hypertension: A pilot study. Indian Journal of Clinical Biochemistry, 2005, 20, 4-9.	0.9	4
1972	Treatment of leukoaraiosis. Current Treatment Options in Cardiovascular Medicine, 2005, 7, 173-177.	0.4	10

#	Article	IF	CITATIONS
1973	Hypertension in black patients: Special issues and considerations. Current Hypertension Reports, 2005, 7, 244-248.	1.5	24
1974	Management of hypertension and diabetes: Treatment goals, drug choices, current practice, and strategies for improving care. Current Hypertension Reports, 2005, 7, 439-449.	1.5	8
1975	Hypertension and head injury. Current Hypertension Reports, 2005, 7, 450-453.	1.5	15
1976	Does ALLHAT change the management of hypertension in chronic kidney disease?. Current Hypertension Reports, 2005, 7, 474-483.	1.5	5
1977	Physical Activity, Cardiorespiratory Fitness, and their Relationship to Cardiovascular Risk Factors in African Americans and Non-African Americans With Above-Optimal Blood Pressure. Journal of Community Health, 2005, 30, 107-124.	1.9	12
1978	Garlic supplementation prevents oxidative DNA damage in essential hypertension. Molecular and Cellular Biochemistry, 2005, 275, 85-94.	1.4	74
1979	Different antioxidants status, total antioxidant power and free radicals in essential hypertension. Molecular and Cellular Biochemistry, 2005, 277, 89-99.	1.4	80
1980	Secondary Prevention in Coronary Heart Disease: Goal Achievement and Drug Prescribing. International Journal of Clinical Pharmacy, 2005, 27, 472-474.	1.4	2
1981	Renal impairment and hypertension in brain tumor patients treated in childhood are mainly associated with cisplatin treatment. Pediatric Blood and Cancer, 2005, 44, 363-369.	0.8	24
1982	Management of Hypertensive Emergencies and Urgencies. , 2005, , 826-837.		1
1983	Job Strain and Risk of Cardiovascular Events in Treated Hypertensive Japanese Workers: Hypertension Followâ€Up Group Study. Journal of Occupational Health, 2005, 47, 102-111.	1.0	69
1984	Impact of an interdisciplinary team on drug therapy outcomes in a geriatric clinic. American Journal of Health-System Pharmacy, 2005, 62, 626-629.	0.5	13
1985	Assessment of the cardiovascular effects of electroconvulsive therapy in individuals older than 50 years. Brazilian Journal of Medical and Biological Research, 2005, 38, 1349-1357.	0.7	17
1987	Medication Adherence for Antihypertensive Therapy. , 2005, , 430-446.		6
1988	Long-Term Results of Adrenalectomy in Patients with Aldosterone-Producing Adenomas: Multivariate Analysis of Factors Affecting Unresolved Hypertension and Review of the Literature. American Surgeon, 2005, 71, 864-869.	0.4	121
1990	Management of Hypertension in Solid-Organ Transplantation. Progress in Transplantation, 2005, 15, 17-22.	0.4	5
1991	Prevalence of and Risk Factors for Atrial Fibrillation in Korean Adults Older than 40 Years. Journal of Korean Medical Science, 2005, 20, 26.	1.1	94
1992	Prevalence of retinopathy in Caucasian type 2 diabetic patients from the South of Brazil and relationship with clinical and metabolic factors. Brazilian Journal of Medical and Biological Research, 2005, 38, 221-225.	0.7	14

#	Article	IF	CITATIONS
1993	A community-based epidemiological study of elevated serum alanine aminotransferase levels in Kinmen, Taiwan. World Journal of Gastroenterology, 2005, 11, 1616.	1.4	24
1994	Efeitos da suplementação de potássio via sal de cozinha sobre a pressão arterial e a resistência à insulina em pacientes obesos hipertensos em uso de diuréticos. Revista De Nutricao, 2005, 18, 5-17.	0.4	7
1995	Diagnosis and Prevention of Atherosclerotic Cerebral Infarction. CNS Spectrums, 2005, 10, 553-566.	0.7	12
1996	Identifying patients with chronic kidney disease from general practice computer records. Family Practice, 2005, 22, 234-241.	0.8	128
1997	First-Line First? Trends in Thiazide Prescribing for Hypertensive Seniors. PLoS Medicine, 2005, 2, e80.	3.9	11
1998	Prehypertension and Cardiovascular Morbidity. Annals of Family Medicine, 2005, 3, 294-299.	0.9	194
1999	Interaction of Body Mass Index and Framingham Risk Score in Predicting Incident Coronary Disease in Families. Circulation, 2005, 111, 1871-1876.	1.6	77
2000	Cost-Effectiveness Analysis of Hypertension Guidelines in South Africa. Circulation, 2005, 112, 3569-3576.	1.6	123
2001	Diabetic Retinopathy Is Associated With Mortality and Cardiovascular Disease Incidence: The EURODIAB Prospective Complications Study. Diabetes Care, 2005, 28, 1383-1389.	4.3	157
2002	An Emergency Department Approach to Drug Treatment of Hypertensive Urgency and Emergency. Journal of Pharmacy Practice, 2005, 18, 363-376.	0.5	2
2003	Atheromatous embolization. Vascular Medicine, 2005, 10, 309-326.	0.8	37
2004	General Practitioners' Approach to Hypertension in Urban Pakistan. Circulation, 2005, 111, 1278-1283.	1.6	66
2005	Persistence with Antihypertensives Related to Formulation: The Case of Nifedipine. Annals of Pharmacotherapy, 2005, 39, 237-242.	0.9	13
2006	Low-Grade Albuminuria and the Risks of Hypertension and Blood Pressure Progression. Circulation, 2005, 111, 1370-1376.	1.6	202
2007	Age- and Gender-Related Ventricular-Vascular Stiffening. Circulation, 2005, 112, 2254-2262.	1.6	736
2008	Daily usage and efficiency of remote home monitoring in hypertensive patients over a one-year period. Journal of Telemedicine and Telecare, 2005, 11, 34-36.	1.4	43
2009	Patterns and Predictors of Prehypertension Among "Healthy―Urban Adults in India. Angiology, 2005, 56, 557-563.	0.8	23
2010	Low Plasma Adiponectin Levels Predict Progression of Coronary Artery Calcification. Circulation, 2005, 111, 747-753.	1.6	268

#	Article	IF	CITATIONS
2011	Impact of a Community-Based Multiple Risk Factor Intervention on Cardiovascular Risk in Black Families With a History of Premature Coronary Disease. Circulation, 2005, 111, 1298-1304.	1.6	103
2012	Impact of Achieved Blood Pressure on Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial. Journal of the American Society of Nephrology: JASN, 2005, 16, 2170-2179.	3.0	297
2013	Explaining socioeconomic inequality in mortality among South Koreans: an examination of multiple pathways in a nationally representative longitudinal study. International Journal of Epidemiology, 2005, 34, 630-637.	0.9	68
2014	Review: Cardiovascular risk and diabetes in old people. British Journal of Diabetes and Vascular Disease, 2005, 5, 7-11.	0.6	2
2015	Management of Prehypertension. Hypertension, 2005, 45, 1056-1061.	1.3	69
2016	Elevated Brain Natriuretic Peptide Predicts Blood Pressure Response After Stent Revascularization in Patients With Renal Artery Stenosis. Circulation, 2005, 111, 328-333.	1.6	106
2017	Assessment for Chronic Kidney Disease Service in High-Risk Patients at Community Health Clinics. Annals of Pharmacotherapy, 2005, 39, 22-27.	0.9	54
2018	Predictors of New-Onset Diastolic and Systolic Hypertension. Circulation, 2005, 111, 1121-1127.	1.6	258
2019	Blood Pressure Control and Risk of Stroke. Stroke, 2005, 36, 725-730.	1.0	137
2020	Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM - Monthly Journal of the Association of Physicians, 2005, 98, 493-497.	0.2	114
2021	Combination of antihypertensive drugs from a historical perspective. Blood Pressure, 2005, 14, 72-79.	0.7	5
2022	Influence of regression of left ventricular hypertrophy on left atrial size and function in patients with moderate hypertension. Blood Pressure, 2005, 14, 273-278.	0.7	42
2023	Epidemiology of Uncontrolled Hypertension in the United States. Circulation, 2005, 112, 1651-1662.	1.6	291
2024	Masterclass series in peripheral arterial disease. Vascular Medicine, 2005, 10, 241-246.	0.8	31
2025	Relations of Insulin Sensitivity to Longitudinal Blood Pressure Tracking. Circulation, 2005, 112, 1719-1727.	1.6	48
2026	Mechanisms of Late Cardiovascular Toxicity From Cancer Chemotherapy. Journal of Clinical Oncology, 2005, 23, 9051-9052.	0.8	17
2027	Angiotensin-Converting Enzyme Inhibition and Renal Protection in Nondiabetic Patients: The Data of the Meta-Analyses. Journal of the American Society of Nephrology: JASN, 2005, 16, S58-S63.	3.0	74
2028	WNK1 Kinase Polymorphism and Blood Pressure Response to a Thiazide Diuretic. Hypertension, 2005, 46, 758-765.	1.3	75

#	Article	IF	CITATIONS
2029	Suboptimal intensity of risk factor modification in PAD. Vascular Medicine, 2005, 10, 91-96.	0.8	29
2030	Intentional and Unintentional Nonadherence to Antihypertensive Medication. Annals of Pharmacotherapy, 2005, 39, 1198-1203.	0.9	155
2031	Blood Pressure as a Risk Factor for Stroke and the Impact of Antihypertensive Treatment. Cerebrovascular Diseases, 2005, 20, 40-52.	0.8	23
2032	North American Ginseng Exerts a Neutral Effect on Blood Pressure in Individuals With Hypertension. Hypertension, 2005, 46, 406-411.	1.3	70
2033	Autonomic Effects of Expressive Writing in Individuals with Elevated Blood Pressure. Journal of Health Psychology, 2005, 10, 197-209.	1.3	68
2034	Increased Stroke Volume and Aortic Stiffness Contribute to Isolated Systolic Hypertension in Young Adults. Hypertension, 2005, 46, 221-226.	1.3	238
2035	Prevalence of Cardiovascular Disease Risk Factor Clustering Among the Adult Population of China. Circulation, 2005, 112, 658-665.	1.6	206
2036	Acculturation and Socioeconomic Position as Predictors of Coronary Calcification in a Multiethnic Sample. Circulation, 2005, 112, 1557-1565.	1.6	114
2037	Circulating Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor Binding Protein-3 Are Associated With Early Carotid Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 617-621.	1.1	95
2038	Hypertension Prevalence, Awareness, Treatment, and Control in an Adult Type 1 Diabetes Population and a Comparable General Population. Diabetes Care, 2005, 28, 301-306.	4.3	125
2039	Pulse Pressure and Coronary Atherosclerosis Progression in Postmenopausal Women. Hypertension, 2005, 45, 53-57.	1.3	33
2040	Pulse Pressure and Cardiovascular Events in Postmenopausal Women With Coronary Heart Disease. Chest, 2005, 127, 1498-1506.	0.4	39
2041	Improved Blood Pressure Control With a Physician-Nurse Team and Home Blood Pressure Measurement. Mayo Clinic Proceedings, 2005, 80, 31-36.	1.4	33
2042	Sesame Oil Exhibits Additive Effect on Nifedipine and Modulates Oxidative Stress and Electrolytes in Hypertensive Patients. Journal of Nutraceuticals, Functional and Medical Foods, 2005, 4, 133-145.	0.5	7
2043	Detection of hypertension in the emergency department. Emergency Medicine Journal, 2005, 22, 636-640.	0.4	45
2044	Ethnic Variation in Hypertension Among Premenopausal and Perimenopausal Women. Hypertension, 2005, 46, 689-695.	1.3	34
2045	Improved Quality of Stroke Care for Hospitalized Medicare Beneficiaries in Michigan. Stroke, 2005, 36, 1227-1231.	1.0	19
2046	Is Prehypertension a Risk Factor for Cardiovascular Diseases?. Stroke, 2005, 36, 1859-1863.	1.0	249

#	ARTICLE	IF	CITATIONS
2047	In-Hospital Medical Complications and Long-Term Mortality After Ischemic Stroke. Stroke, 2005, 36, 2441-2445.	1.0	72
2048	Prevalence of chronic renal failure in adults in Delhi, India. Nephrology Dialysis Transplantation, 2005, 20, 1638-1642.	0.4	121
2049	$11\hat{l}^2$ -Hydroxysteroid dehydrogenase type 2 activity is associated with left ventricular mass in essential hypertension. European Heart Journal, 2005, 26, 498-504.	1.0	21
2052	Control de la hipertensi \tilde{A}^3 n arterial y de otros factores de riesgo cardiovascular en poblaci \tilde{A}^3 n de alto riesgo asistida en Atenci \tilde{A}^3 n Primaria. Estudio EVENTO. Semergen, 2005, 31, 53-60.	0.2	9
2053	Improved Blood Pressure Control With a Physician-Nurse Team and Home Blood Pressure Measurement. Mayo Clinic Proceedings, 2005, 80, 31-36.	1.4	36
2054	EpidemiologÃa de la hipertensión arterial en España. Situación actual y perspectivas. Hipertension Y Riesgo Vascular, 2005, 22, 353-362.	0.3	46
2055	Management of Cardiovascular Disease in the Renal Transplant Recipient. Cardiology Clinics, 2005, 23, 331-342.	0.9	11
2056	Diabetes and hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy. Cardiology Clinics, 2005, 23, 139-152.	0.9	33
2057	Potassium, Magnesium, and Electrolyte Imbalance and Complications in Disease Management. Clinical and Experimental Hypertension, 2005, 27, 95-112.	0.5	32
2058	A Model for Coronary Heart Disease and Stroke with Applications to Critical Illness Insurance Underwriting I: The Model. North American Actuarial Journal, 2005, 9, 13-40.	0.8	16
2059	Effects of exercise and diet on chronic disease. Journal of Applied Physiology, 2005, 98, 3-30.	1.2	446
2060	Who's really hypertensive? $\hat{a} \in \mathbb{C}$ Quality control issues in the assessment of blood pressure for randomized trials. Blood Pressure, 2005, 14, 133-138.	0.7	11
2061	Effect of irbesartan monotherapy compared with ACE inhibitors and calciumâ€channel blockers on patient compliance in essential hypertension patients: A multicenter, openâ€labeled, threeâ€armed study. Blood Pressure, 2005, 14, 23-31.	0.7	10
2062	Place of Drug Therapy in the Treatment of Carotid Stenosis. CNS Drugs, 2005, 19, 597-622.	2.7	5
2063	Hypertension guideline adherence of private practitioners and primary health care physicians in Pretoria. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2005, 47, 51-54.	0.2	5
2064	Drug-induced diabetes mellitus. Expert Opinion on Drug Safety, 2005, 4, 1097-1109.	1.0	34
2065	Relations of Serum Uric Acid to Longitudinal Blood Pressure Tracking and Hypertension Incidence. Hypertension, 2005, 45, 28-33.	1.3	419
2066	Is there an independent association between waist-to-hip ratio and cardiovascular risk factors in overweight and obese women?. International Journal of Cardiology, 2005, 101, 39-46.	0.8	27

#	Article	IF	CITATIONS
2067	Platelet–monocyte aggregates predict troponin rise after percutaneous coronary intervention and are inhibited by Abciximab. International Journal of Cardiology, 2005, 101, 249-255.	0.8	29
2068	Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan. International Journal of Cardiology, 2005, 104, 213-223.	0.8	12
2069	Modest Improvement in Risk Factor Control After Admission for a Stroke or Transient Ischemic Attack. Journal of Stroke and Cerebrovascular Diseases, 2005, 14, 174-178.	0.7	8
2070	Acute administration of $17\hat{l}^2$ -estradiol improves endothelium-dependent vasodilation in postmenopausal women. Maturitas, 2005, 50, 266-274.	1.0	38
2071	Baseline characteristics of menopausal women with coronary heart disease in cardiovascular outcomes clinical trials of menopausal hormone therapy or raloxifene. Contemporary Clinical Trials, 2005, 26, 612-615.	0.8	3
2072	Role of transforming growth factor- \hat{l}^2 2 in, and apossible transforming growth factor- \hat{l}^2 2 gene polymorphism as a marker of, renal dysfunction in essential hypertension: A study in Turkish patients. Current Therapeutic Research, 2005, 66, 266-278.	0.5	1
2073	Effects of oral fixed-dose combinations of telmisartan plus ramipril and losartan plus ramipril in hypertension: A multicenter, prospective, randomized, double-blind, phase iii trial in adult indian patients. Current Therapeutic Research, 2005, 66, 630-642.	0.5	2
2074	Heterogeneity of early-onset and ketosis-resistant diabetes in Korean subjectsâ€"is it possible to determine cut-off age of early-onset type 2 diabetes?. Diabetes Research and Clinical Practice, 2005, 70, 38-45.	1.1	6
2075	Role of endothelial dysfunction in the development of cardiorenal syndrome in patients with type 1 diabetes mellitus. Diabetes Research and Clinical Practice, 2005, 68, S65-S72.	1.1	26
2076	Hypertension: A Review and Rationale of Treatment. Disease-a-Month, 2005, 51, 548-614.	0.4	9
2077	High prevalence of subclinical peripheral artery disease in Greek hospitalized patients. European Journal of Internal Medicine, 2005, 16, 187-191.	1.0	17
2078	The â^374A allele of the receptor for advanced glycation end products gene is associated with a decreased risk of ischemic heart disease in African-Brazilians with type 2 diabetes. Molecular Genetics and Metabolism, 2005, 85, 149-156.	0.5	57
2079	Effects of hormone replacement therapy on blood coagulation and fibrinolysis in hypertensive and normotensive postmenopausal women. Thrombosis Research, 2005, 115, 359-366.	0.8	22
2080	Blood Pressure and Graft Outcome in Renal Transplantation. Transplantation Proceedings, 2005, 37, 997-998.	0.3	14
2081	Wide pulse pressure is an independent predictor of cardiovascular mortality in Puerto Rican men. Nutrition, Metabolism and Cardiovascular Diseases, 2005, 15, 71-78.	1.1	13
2082	Positive benefits of a pharmacist-managed hypertension clinic in Nigeria. Public Health, 2005, 119, 792-798.	1.4	34
2083	Systolic hypertension: An overview. American Heart Journal, 2005, 149, 769-775.	1.2	9
2084	Barriers to hypertension control. American Heart Journal, 2005, 149, 785-794.	1.2	100

#	Article	IF	CITATIONS
2085	Indinavir impairs endothelial function in healthy HIV-negative men. American Heart Journal, 2005, 150, 933.e1-933.e7.	1.2	86
2086	Lack of relationship between hypertension-associated symptoms and blood pressure in hypertensive ED patients. American Journal of Emergency Medicine, 2005, 23, 106-110.	0.7	36
2087	Community Health Workers as Interventionists in the Prevention and Control of Heart Disease and Stroke. American Journal of Preventive Medicine, 2005, 29, 128-133.	1.6	192
2088	Group versus individual academic detailing to improve the use of antihypertensive medications in primary care: a cluster-randomized controlled trial. American Journal of Medicine, 2005, 118, 521-528.	0.6	81
2089	Update on the drug treatment of hypertension in patients with cardiovascular disease. American Journal of Medicine, 2005, 118, 695-705.	0.6	25
2090	Cardiovascular risk factors in minorities. American Journal of Medicine, 2005, 118, 1314-1322.	0.6	43
2095	Antihypertensive Medication Adherence and Blood Pressure Control in Patients With Psychotic Disorders Compared to Persons Without Psychiatric Illness. Psychosomatics, 2005, 46, 135-141.	2.5	36
2096	Trandolapril/Verapamil Sustained Release. Drugs, 2005, 65, 1893-1914.	4.9	11
2098	Control of Hypertension in Elderly Patients Receiving Primary Care in Spain. Revista Espanola De Cardiologia (English Ed), 2005, 58, 359-366.	0.4	6
2099	Prevalence of Cardiovascular Risk Factors in the Balearic Islands (CORSAIB Study). Revista Espanola De Cardiologia (English Ed), 2005, 58, 1411-1419.	0.4	5
2100	Diastolic dysfunction and left atrial volume. Journal of the American College of Cardiology, 2005, 45, 87-92.	1.2	552
2101	Increased Ambulatory Pulse Pressure Is a Strong Risk Factor for Coronary Endothelial Vasomotor Dysfunction. Journal of the American College of Cardiology, 2005, 45, 1461-1466.	1.2	28
2102	Coronary Calcium Independently Predicts Incident Premature Coronary Heart Disease Over Measured Cardiovascular Risk Factors. Journal of the American College of Cardiology, 2005, 46, 807-814.	1.2	580
2103	Place du sport dans le traitement de l'hypertension artérielle. EMC - Cardiologie-Angeiologie, 2005, 2, 431-435.	0.9	3
2104	Risk Factors for Atherosclerotic Vascular Disease. Handbook of Experimental Pharmacology, 2005, , 71-105.	0.9	21
2105	Independent and Additive Impact of Blood Pressure Control and Angiotensin II Receptor Blockade on Renal Outcomes in the Irbesartan Diabetic Nephropathy Trial: Clinical Implications and Limitations. Journal of the American Society of Nephrology: JASN, 2005, 16, 3027-3037.	3.0	341
2106	How Does Renal Intervention Compare to Medical Management Alone?. Journal of Vascular and Interventional Radiology, 2005, 16, P100-P103.	0.2	0
2107	Severe Hypertension in the Emergency Department Patient. Emergency Medicine Clinics of North America, 2005, 23, 1141-1158.	0.5	19

#	Article	IF	CITATIONS
2108	Hypertension in the Elderly. Drugs and Aging, 2005, 22, 297-314.	1.3	11
2109	Cardiovascular Disease Morbidity and Mortality in Patients with Type 1 Diabetes Mellitus. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2005, 4, 75-86.	1.8	9
2110	Cardioselective beta-blockers for chronic obstructive pulmonary disease. The Cochrane Library, 2005, , CD003566.	1.5	212
2111	Hypertensive Urgencies and Emergencies. Primary Care - Clinics in Office Practice, 2006, 33, 613-623.	0.7	12
2112	Prehypertension and risk of cardiovascular disease. Expert Review of Cardiovascular Therapy, 2006, 4, 111-117.	0.6	18
2113	Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection. Expert Review of Cardiovascular Therapy, 2006, 4, 319-333.	0.6	6
2114	Optimal Medical Management of Peripheral Arterial Disease. Vascular and Endovascular Surgery, 2006, 40, 312-327.	0.3	62
2115	A Review of Calcium Channel Antagonists in the Treatment of Pediatric Hypertension. Paediatric Drugs, 2006, 8, 357-373.	1.3	39
2116	Controversies on the Diagnosis of Primary Aldosteronism. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 173-178.	1.0	0
2117	Costâ€effectiveness of ambulatory blood pressure monitoring in the followâ€up of hypertension. Blood Pressure, 2006, 15, 27-36.	0.7	23
2119	Applications of 24-hour Noninvasive Ambulatory Blood Pressure Monitoring. Journal of the Formosan Medical Association, 2006, 105, 955-963.	0.8	10
2120	Management of Global Risk Across the Continuum of Hypertensive Heart Disease. Journal of Clinical Hypertension, 2006, 8, 21-30.	1.0	2
2121	Multiple metabolic risk factors and total and cardiovascular mortality in men with low prevalence of obesity. Atherosclerosis, 2006, 187, 123-130.	0.4	9
2122	Efficacy and tolerability of the perindopril/indapamide combination therapy for hypertension: the PRIMUS study. Current Medical Research and Opinion, 2006, 22, 1849-1858.	0.9	5
2123	Limitations of Estimating Glomerular Filtration Rate From Serum Creatinine in the General Population. Mayo Clinic Proceedings, 2006, 81, 1427-1434.	1.4	75
2124	Use of Ejection Fraction Tests and Coronary Angiography in Patients With Heart Failure. Mayo Clinic Proceedings, 2006, 81, 906-913.	1.4	16
2126	Initiation of Acetylcholinesterase Inhibitors and Complications of Chronic Airways Disorders in Elderly Patients. Drug Safety, 2006, 29, 1077-1085.	1.4	12
2127	Indapamide Sustained Release. Drugs, 2006, 66, 257-271.	4.9	34

#	Article	IF	Citations
2130	Diabetic Cardiomyopathy. Heart Failure Clinics, 2006, 2, 71-80.	1.0	2
2131	Hypertension, Menopause, and Coronary Artery Disease Risk in the Women's Ischemia Syndrome Evaluation (WISE) Study. Journal of the American College of Cardiology, 2006, 47, S50-S58.	1.2	88
2132	Predictors of Adverse Outcome Among Patients With Hypertension and Coronary Artery Disease. Journal of the American College of Cardiology, 2006, 47, 547-551.	1.2	51
2133	Prognostic Value of Pharmacological Stress Echocardiography in Diabetic and Nondiabetic Patients With Known or Suspected Coronary Artery Disease. Journal of the American College of Cardiology, AOOJATA, 2005600 delines for the Management of Patients With Peripheral Arterial Disease (Lower) Tj ETQq0 0 0 0	1.2 gBT /Ove	72 rlock 10 Tf 50
2134	Association for Vascular Surgery/Society for Vascular Surgery,âŽSociety for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional		

#	Article	IF	CITATIONS
2148	Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial. American Heart Journal, 2006, 151, 1173-1179.	1.2	82
2149	Sex and classic risk factors after myocardial infarction: a community study. American Heart Journal, 2006, 152, 461-468.	1.2	29
2150	Metabolic characteristics and insulin resistance of impaired fasting glucose among the middle-aged and elderly Taiwanese. Diabetes Research and Clinical Practice, 2006, 71, 170-176.	1.1	28
2151	Pharmacist-Led Cardiac Risk Reduction Model. Preventive Cardiology, 2006, 9, 202-208.	1.1	32
2152	Are Racial Differences in Antihypertensive Responsiveness Reflected in Usage After Stroke?. Journal of Stroke and Cerebrovascular Diseases, 2006, 15, 260-265.	0.7	1
2153	Conjugated estrogen plus medroxyprogesterone does not impair blood rheological properties in hypertensive postmenopausal women. Maturitas, 2006, 53, 306-314.	1.0	9
2154	Risk of stroke and hormone replacement therapy. Maturitas, 2006, 54, 11-18.	1.0	22
2155	Larger hip circumference independently contributed to reduced metabolic risks in Tehranian adult women. International Journal of Cardiology, 2006, 108, 338-345.	0.8	25
2156	Assessing risk factors of coronary heart disease and its risk prediction among Korean adults: The 2001 Korea National Health and Nutrition Examination Survey. International Journal of Cardiology, 2006, 110, 184-190.	0.8	37
2157	Influence of family history and lifestyle on blood pressure and heart rate in young adults in Jordan. Public Health, 2006, 120, 1027-1032.	1.4	10
2158	The â^'106CC genotype of the aldose reductase gene is associated with an increased risk of proliferative diabetic retinopathy in Caucasian-Brazilians with type 2 diabetes. Molecular Genetics and Metabolism, 2006, 88, 280-284.	0.5	26
2159	Vasodilatory factors in treatment of older men with symptomatic benign prostatic hyperplasia. Urology, 2006, 67, 225-231.	0.5	8
2160	Incidence of erectile dysfunction in 800 hypertensive patients: A multicenter Egyptian national study. Urology, 2006, 67, 575-578.	0.5	48
2161	Management of chronic prostatitis/chronic pelvic pain syndrome: An evidence-based approach. Urology, 2006, 67, 881-888.	0.5	36
2162	Clustering of metabolic abnormalities in adolescents with the hypertriglyceridemic waist phenotype. American Journal of Clinical Nutrition, 2006, 83, 36-46.	2.2	119
2163	Isolated systolic hypertension: primary care practice patterns in a Nigerian high-risk subpopulation. Sao Paulo Medical Journal, 2006, 124, 105-109.	0.4	5
2164	Reducing Hypertensive Cardiovascular Disease Risk of African Americans with Diet: Focus on the Facts. Journal of Nutrition, 2006, 136, 1099-1102.	1.3	20
2165	Leptin is not associated independently with hypertension in Japanese-Brazilian women. Brazilian Journal of Medical and Biological Research, 2006, 39, 99-105.	0.7	9

#	Article	IF	CITATIONS
2166	Measurement of Adherence to Anti-Hypertensive Medication as Perceived by Doctors and Patients. Qatar Medical Journal, 2006, 2006, 16.	0.2	4
2167	Perioperative management of hypertension. , 0, , 107-124.		0
2168	Inflammatory Aspects of Sleep Apnea and Their Cardiovascular Consequences. Southern Medical Journal, 2006, 99, 58-67.	0.3	92
2169	Systemic Oxidative Alterations Are Associated with Visceral Adiposity and Liver Steatosis in Patients with Metabolic Syndrome. Journal of Nutrition, 2006, 136, 3022-3026.	1.3	162
2173	The Need for Quality Management in Primary Health Care in Cyprus. Quality Management in Health Care, 2006, 15, 58-65.	0.4	6
2174	Blood pressure and the global burden of disease 2000. Part 1: Estimates of blood pressure levels. Journal of Hypertension, 2006, 24, 413-422.	0.3	126
2175	Lifestyle, family history and progression of hypertension. Journal of Hypertension, 2006, 24, 1479-1487.	0.3	37
2176	Progression to hypertension in the non-hypertensive participants in the Flemish Study on Environment, Genes and Health Outcomes. Journal of Hypertension, 2006, 24, 1719-1727.	0.3	50
2177	Cardiovascular Disease Risk Reduction in Older Adults. Journal of Cardiovascular Nursing, 2006, 21, S27-S39.	0.6	14
2178	Hypertension artérielle. EMC - Traité De Médecine AKOS, 2006, 1, 1-9.	0.0	0
2179	Adherence to Treatment Factors in Hypertensive African American Women. Journal of Cardiovascular Nursing, 2006, 21, 201-207.	0.6	11
2180	Comparative evaluation of anthropometric measures to predict cardiovascular risk factors in Tehranian adult women. Public Health Nutrition, 2006, 9, 61-69.	1.1	58
2181	Dietary diversity score and cardiovascular risk factors in Tehranian adults. Public Health Nutrition, 2006, 9, 728-736.	1.1	120
2182	New Insights in Hypertension. Refresher Courses in Anesthesiology, 2006, 34, 43-53.	0.1	0
2184	Pression artérielle. Régulation et épidémiologie. Mesures et valeurs normales. EMC - Cardiologie, 2006, 1, 1-15.	0.0	0
2185	ADVANCE: breaking new ground in type 2 diabetes. Journal of Hypertension, 2006, 24, S22-S28.	0.3	18
2186	Trends in Prescription Drug Expenditures by Medicaid Enrollees. Medical Care, 2006, 44, 27-35.	1.1	30
2187	Should sports activity be encouraged or contraindicated in hypertensive subjects?. Journal of Cardiovascular Medicine, 2006, 7, 288-295.	0.6	2

#	Article	IF	CITATIONS
2188	Blood pressure rise with swimming versus walking in older women: the Sedentary Women Exercise Adherence Trial 2 (SWEAT 2). Journal of Hypertension, 2006, 24, 307-314.	0.3	47
2189	Women and Hypertension. Cardiology in Review, 2006, 14, 267-275.	0.6	44
2190	How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. Journal of Hypertension, 2006, 24, 2131-2141.	0.3	138
2191	Hypertension: a new look at an old problem. Current Opinion in Anaesthesiology, 2006, 19, 59-64.	0.9	23
2192	Mental Disorders and Hypertension: Factors Associated With Awareness and Treatment of Hypertension in the General Population of Germany. Psychosomatic Medicine, 2006, 68, 246-252.	1.3	12
2193	Preventing end-stage renal disease: flexible strategies to overcome obstacles. Current Opinion in Nephrology and Hypertension, 2006, 15, 473-480.	1.0	11
2194	Oxidative stress explains differences in large elastic artery compliance between sedentary and habitually exercising postmenopausal women. Menopause, 2006, 13, 951-958.	0.8	45
2195	Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: the SMOOTH study. Journal of Hypertension, 2006, 24, 837-843.	0.3	74
2196	Sex-specific cardiovascular morbidity and mortality in a cohort treated for hypertension. Journal of Hypertension, 2006, 24, 1523-1529.	0.3	22
2197	Blood pressure categories, hypertensive subtypes, and the metabolic syndrome. Journal of Hypertension, 2006, 24, 2009-2016.	0.3	53
2198	Short-term incidence rate of hypertension in Korea middle-aged adults. Journal of Hypertension, 2006, 24, 2177-2182.	0.3	22
2199	Impact of Therapy Initiation with Amlodipine or Losartan on Hemodynamic Endpoints and JNC-VI Blood Pressure Stage. American Journal of Therapeutics, 2006, 13, 94-100.	0.5	1
2200	Therapeutic Goal Attainment in Patients With Hypertension and Dyslipidemia. Medical Care, 2006, 44, 39-46.	1.1	90
2201	Dyslipidemia in Menopause: Mechanisms and Management. Obstetrical and Gynecological Survey, 2006, 61, 608-613.	0.2	22
2202	Pharmacy- and Community-Based Screenings for Diabetes and Cardiovascular Conditions in High-Risk Individuals. Journal of the American Pharmacists Association: JAPhA, 2006, 46, 370-377.	0.7	66
2203	Responsiveness of Two Methods for Measuring Foot and Ankle Volume. Foot and Ankle International, 2006, 27, 826-832.	1.1	23
2204	General medical practitioners in Pakistan fail to educate patients adequately about complications of diabetes. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2006, 23, 57-61.	0.2	4
2205	Multifactorial approach and adherence to prescribed oral medications in patients with type 2 diabetes*. International Journal of Clinical Practice, 2006, 60, 422-428.	0.8	54

#	Article	IF	CITATIONS
2206	Initiation of hypertension treatment with a fixed-dose combination or its monocomponents - does it really matter?. International Journal of Clinical Practice, 2006, 60, 265-274.	0.8	17
2207	Antihypertensive therapy in diabetic nephropathy. Nephrology, 2006, 11, S73-S78.	0.7	O
2208	CRITICAL CARE ISSUES FOR THE NEPHROLOGIST: Current Diagnosis and Management of Hypertensive Emergency. Seminars in Dialysis, 2006, 19, 502-512.	0.7	41
2209	Indications for and utilization of ACE inhibitors in older individuals with diabetes. Journal of General Internal Medicine, 2006, 21, 315-319.	1.3	30
2210	Duloxetine for Patients with Diabetic Peripheral Neuropathic Pain: A 6-Month Open-Label Safety Study. Pain Medicine, 2006, 7, 373-385.	0.9	78
2211	A Review of the Clinical Experience with the Angiotensin II Receptor Antagonist Irbesartan. Cardiovascular Drug Reviews, 2000, 18, 103-126.	4.4	7
2212	Protection of the Cardiovascular System by Imidapril, a Versatile Angiotensinâ€Converting Enzyme Inhibitor. Cardiovascular Drug Reviews, 2002, 20, 93-110.	4.4	18
2213	Calcium Antagonists in Patients with Type 2 Diabetes and Hypertension. Cardiovascular Drug Reviews, 2003, 21, 105-118.	4.4	16
2214	Eplerenone: A Selective Aldosterone Blocker. Cardiovascular Drug Reviews, 2003, 21, 169-184.	4.4	24
2215	Adiponectin, Visceral Fat, Oxidative Stress, and Early Macrovascular Disease: The Coronary Artery Risk Development in Young Adults Study*. Obesity, 2006, 14, 319-326.	1.5	63
2216	Waist circumference cutoff points and action levels for Asian Indians for identification of abdominal obesity. International Journal of Obesity, 2006, 30, 106-111.	1.6	231
2217	Influence of childhood socioeconomic circumstances, height, and obesity on pulse pressure and systolic and diastolic blood pressure in older people. Journal of Human Hypertension, 2006, 20, 73-82.	1.0	24
2218	Aim, design and methods of the †reasons for not intensifying antihypertensive treatment†(RIAT): an international registry in essential hypertension. Journal of Human Hypertension, 2006, 20, 31-36.	1.0	6
2219	Evaluation of cerebral blood flow by single-photon emission computed tomography in young Asian Indians with hypertension. Journal of Human Hypertension, 2006, 20, 143-148.	1.0	5
2220	The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy. Journal of Human Hypertension, 2006, 20, 169-175.	1.0	36
2221	Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. Journal of Human Hypertension, 2006, 20, 255-262.	1.0	31
2222	Antihypertensive pharmacotherapy in a developing economy: pattern, acquisition costs and conformity to international guidelines in a tertiary-care setting. Journal of Human Hypertension, 2006, 20, 894-897.	1.0	14
2223	â€~Hypertension' and â€~microalbuminuria': The bell tolls for thee. Kidney International, 2006, 69, 22-28.	2.6	64

#	Article	IF	CITATIONS
2224	Global approach to cardiovascular risk in chronic kidney disease: Reality and opportunities for intervention. Kidney International, 2006, 69, 538-545.	2.6	112
2225	Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria. Kidney International, 2006, 70, 151-156.	2.6	38
2226	Clinical Policy: Critical Issues in the Evaluation and Management of Adult Patients With Asymptomatic Hypertension in the Emergency Department. Annals of Emergency Medicine, 2006, 47, 237-249.	0.3	84
2227	Evaluation and Treatment of Patients With Severely Elevated Blood Pressure in Academic Emergency Departments: A Multicenter Study. Annals of Emergency Medicine, 2006, 47, 230-236.	0.3	59
2228	Liquid chromatography–tandem mass spectrometry validated method for the estimation of indapamide in human whole blood. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 834, 149-154.	1.2	20
2229	Determinants of poor adherence in hypertensive patients: Development and validation of the "Maastricht Utrecht Adherence in Hypertension (MUAH)-questionnaire― Patient Education and Counseling, 2006, 64, 151-158.	1.0	46
2230	Using Regular Expressions to Abstract Blood Pressure and Treatment Intensification Information from the Text of Physician Notes. Journal of the American Medical Informatics Association: JAMIA, 2006, 13, 691-695.	2.2	78
2231	Analysis of Yearly Variations in Drug Expenditure for One Patient Using Data Warehouse in a Hospital. Journal of Medical Systems, 2006, 31, 17-24.	2.2	5
2232	Failure to decrease blood pressure during sleep: non-dippers are among us. International Journal of Cardiovascular Imaging, 2006, 22, 167-169.	0.7	1
2233	The Role of Pulse Pressure in the Hemodynamic Control of Hypertension: Exploring the Link to Cardiovascular Remodeling. Cardiovascular Engineering (Dordrecht, Netherlands), 2006, 6, 71-82.	1.0	O
2234	Statins and Peripheral Arterial Disease: Potential Mechanisms and Clinical Benefits. Annals of Vascular Surgery, 2006, 20, 696-705.	0.4	49
2235	Ankylosing spondylitis and heart abnormalities: do cardiac conduction disorders, valve regurgitation and diastolic dysfunction occur more often in male patients with diagnosed ankylosing spondylitis for over 15Âyears than in the normal population?. Clinical Rheumatology, 2006, 25, 24-29.	1.0	86
2236	Proposal for mapping renal failure in Japan and its application for strategy to arrest endstage renal disease. Clinical and Experimental Nephrology, 2006, 10, 8-12.	0.7	10
2237	Is \hat{l}^2 -thalassemia trait a protective factor against hypertension in young adults?. Annals of Hematology, 2006, 85, 29-31.	0.8	17
2238	Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the united states?. Current Hypertension Reports, 2006, 8, 219-225.	1.5	6
2239	Predictors of Development of Diabetes Mellitus in Patients With Coronary Artery Disease Taking Antihypertensive Medications (Findings from the INternational VErapamil SR-Trandolapril STudy) Tj ETQq1 1 0.78-	430 1. ≉ rgBT	/ <mark>6</mark> 8erlock 1
2240	Does personality predict blood pressure over a 10-year period?. Personality and Individual Differences, 2006, 40, 1313-1321.	1.6	10
2241	From JNC I to JNC 7—What Have We Learned?. Progress in Cardiovascular Diseases, 2006, 48, 303-315.	1.6	26

#	Article	IF	CITATIONS
2242	Systolic Hypertension in Older Persons: How Aggressive Should Treatment Be?. Progress in Cardiovascular Diseases, 2006, 48, 397-406.	1.6	5
2243	Long-term safety of antihypertensive therapy. Progress in Cardiovascular Diseases, 2006, 49, 16-25.	1.6	25
2244	Hypomagnesemia, oxidative stress, inflammation, and metabolic syndrome. Diabetes/Metabolism Research and Reviews, 2006, 22, 471-476.	1.7	122
2245	The Nutrition, Aging, and Memory in Elders (NAME) study: design and methods for a study of micronutrients and cognitive function in a homebound elderly population. International Journal of Geriatric Psychiatry, 2006, 21, 519-528.	1.3	66
2246	Lipoprotein-Associated Phospholipase A2and Prognosis After Myocardial Infarction in the Community. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2517-2522.	1.1	85
2247	Medium-Term Variability of Blood Pressure and Potential Underdiagnosis of Hypertension in Patients With Previous Transient Ischemic Attack or Minor Stroke. Stroke, 2006, 37, 2776-2783.	1.0	33
2248	Metabolic Syndrome and the Risk of Stroke in Middle-Aged Men. Stroke, 2006, 37, 806-811.	1.0	192
2249	Therapy Insight: management of cardiovascular disease in the renal transplant recipient. Nature Clinical Practice Nephrology, 2006, 2, 514-526.	2.0	14
2250	Polycystic ovary syndrome and metabolic syndrome. Expert Review of Obstetrics and Gynecology, 2006, 1, 183-194.	0.4	0
2251	Insulin sensitivity is preserved despite disrupted endothelial function. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E691-E696.	1.8	17
2252	$\hat{l}\pm 2B$ -Adrenergic receptor deletion polymorphism and cardiac autonomic nervous system responses to exercise in obese women. International Journal of Obesity, 2006, 30, 214-220.	1.6	18
2253	Early changes in serum markers of cardiac extra-cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes. European Journal of Heart Failure, 2006, 8, 147-153.	2.9	62
2254	Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women: a randomized controlled trial. International Journal of Obesity, 2006, 30, 1545-1556.	1.6	75
2255	Comparative Study of Barnidipine and Felodipine in Chinese Patients with Essential Hypertension. Journal of International Medical Research, 2006, 34, 406-412.	0.4	5
2256	Estimation of 10-Year Risk of Fatal and Nonfatal Ischemic Cardiovascular Diseases in Chinese Adults. Circulation, 2006, 114, 2217-2225.	1.6	200
2257	Long-Term and Short-Term Changes in Antihypertensive Prescribing by Office-Based Physicians in the United States. Hypertension, 2006, 48, 213-218.	1.3	82
2258	Changes in Antihypertensive Prescribing During US Outpatient Visits for Uncomplicated Hypertension Between 1993 and 2004. Hypertension, 2006, 48, 846-852.	1.3	80
2259	Risk Factors for Arterial Hypertension in Adults With Initial Optimal Blood Pressure. Hypertension, 2006, 47, 162-167.	1.3	119

#	ARTICLE	IF	CITATIONS
2260	Rapid High-Volume Population Screening for Three Major Risk Factors of Future Stroke: Phase I Results. Vascular and Endovascular Surgery, 2006, 40, 177-187.	0.3	13
2261	Genetic Variation of the Renin-Angiotensin System and Chronic Kidney Disease Progression in Black Individuals in the Atherosclerosis Risk in Communities Study. Journal of the American Society of Nephrology: JASN, 2006, 17, 504-512.	3.0	73
2262	Plasma Sphingomyelin and Subclinical Atherosclerosis: Findings from the Multi-Ethnic Study of Atherosclerosis. American Journal of Epidemiology, 2006, 163, 903-912.	1.6	122
2263	Atherosclerotic vascular disease in systemic lupus erythematosus and related disorders. Lupus, 2006, 15, 35-38.	0.8	1
2264	Blood Pressure and Hematocrit in Diabetes and the Role of Endothelial Responses in the Variability of Blood Viscosity. Diabetes Care, 2006, 29, 1523-1528.	4.3	37
2265	Habitual aerobic exercise is associated with smaller femoral artery intima–media thickness with age in healthy men and women. European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 805-811.	3.1	30
2266	Metabolic Syndrome May Not Associate With Carotid Plaque in Subjects With Optimal, Normal, or High-Normal Blood Pressure. Hypertension, 2006, 48, 411-417.	1.3	16
2267	An Open-label, Randomized, Controlled, 4-week Comparative Clinical Trial of Barnidipine Hydrochloride, a Calcium-channel Blocker, and Benazepril, an Angiotensin-converting Enzyme Inhibitor, in Chinese Patients with Renal Parenchymal Hypertension. Journal of International Medical Research, 2006, 34, 121-128.	0.4	2
2268	Development of the Purposeful Action Medication-Taking Questionnaire. Western Journal of Nursing Research, 2006, 28, 335-351.	0.6	16
2269	Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology, 2006, 45, 283-286.	0.9	155
2271	Effects of estradiol alone and combined with norethisterone acetate on pulse-wave velocity in hypertensive postmenopausal women. Gynecological Endocrinology, 2006, 22, 557-563.	0.7	10
2272	Review of epidemiological studies on drinking water hardness and cardiovascular diseases. European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 495-506.	3.1	70
2273	Development and clinical outcomes of pharmacist-managed diabetes care clinics. American Journal of Health-System Pharmacy, 2006, 63, 1325-1331.	0.5	58
2274	The value of self-measured home blood pressure in predicting stroke. Expert Review of Neurotherapeutics, 2006, 6, 163-173.	1.4	21
2275	Prediction of Stroke by Home "Morning―Versus "Evening―Blood Pressure Values. Hypertension, 2006, 48, 737-743.	1.3	143
2276	Diagnostic Thresholds for Ambulatory Blood Pressure Monitoring Based on 10-Year Cardiovascular Risk. Circulation, 2007, 115, 2145-2152.	1.6	277
2277	Association of Antihypertensive Therapy and Diastolic Hypotension in Chronic Kidney Disease. Hypertension, 2007, 50, 474-480.	1.3	31
2278	Relationship Between Blood Pressure and Stroke Recurrence in Patients With Intracranial Arterial Stenosis. Circulation, 2007, 115, 2969-2975.	1.6	149

#	Article	IF	CITATIONS
2279	Prevalence and Prognostic Significance of Heart Failure Stages. Circulation, 2007, 115, 1563-1570.	1.6	416
2280	Metabolic risks in individuals with normal body mass index and normal waist circumference. European Journal of Cardiovascular Prevention and Rehabilitation, 2007, 14, 200-207.	3.1	5
2281	Response to Target Blood Pressure Level Before Antihypertensive Class to Improve Outcomes More Quickly in Uncomplicated Hypertension. Hypertension, 2007, 49, .	1.3	0
2282	Incidence and prevalence of the metabolic syndrome in a cohort of naive HIV-infected patients: Prospective analysis at 48 weeks of highly active antiretroviral therapy. International Journal of STD and AIDS, 2007, 18, 184-187.	0.5	42
2283	Multidisciplinary Group Behavioral and Pharmacologic Intervention for Cardiac Risk Reduction in Diabetes. The Diabetes Educator, 2007, 33, 118-127.	2.6	24
2284	Sleep apnea: epidemiology, pathophysiology, and relation to cardiovascular risk. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 293, R1671-R1683.	0.9	168
2285	Effects of normal blood pressure, prehypertension and hypertension on left ventricular diastolic function and aortic elastic properties. Blood Pressure, 2007, 16, 114-121.	0.7	30
2286	Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study. Journal of Human Hypertension, 2007, 21, 479-485.	1.0	70
2287	Dobutamine stress echocardiography and the effect of revascularization on outcome in diabetic and nonâ€diabetic patients with chronic ischaemic left ventricular dysfunction. European Journal of Heart Failure, 2007, 9, 1038-1043.	2.9	18
2288	Suboptimal Control of Atherosclerotic Disease Risk Factors After Cardiac and Cerebrovascular Procedures. Stroke, 2007, 38, 929-934.	1.0	14
2289	Risk Factors for Intracerebral Hemorrhage in a Pooled Prospective Study. Stroke, 2007, 38, 2718-2725.	1.0	301
2290	A Friendly Dog as Potential Moderator of Cardiovascular Response to Speech in Older Hypertensives. Anthrozoos, 2007, 20, 51-63.	0.7	59
2291	Review: Lisinopril in paediatric medicine: a retrospective chart review of long-term treatment in children. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2007, 8, 3-12.	1.0	13
2292	Metabolic Risk Factors for Vascular Disease in Obstructive Sleep Apnea. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 190-195.	2.5	212
2293	Body Mass Index of 23 or More is a Risk Factor for Hypertension and Hyperlipidemia in Japanese Workers. Perceptual and Motor Skills, 2007, 104, 733-738.	0.6	10
2294	Awareness, treatment and control of hypertension in Denmark. The Inter99 study. Blood Pressure, 2007, 16, 312-319.	0.7	22
2295	Hope in progress-A tale of two trials: Blood pressure reduction or drug mechanism?. The American Journal of Geriatric Cardiology, 2007, 11, 332-333.	0.7	0
2296	Impact of the components of metabolic syndrome on oxidative stress and enzymatic antioxidant activity in essential hypertension. Journal of Human Hypertension, 2007, 21, 68-75.	1.0	62

#	Article	IF	CITATIONS
2297	The Effect of Music on Hypertensive Patients. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2007, 2007, 4649-51.	0.5	21
2298	Distribution of Abdominal Adiposity and Cardiovascular Risk Factors in Yaquis Indians from Sonora, México. Metabolic Syndrome and Related Disorders, 2007, 5, 353-358.	0.5	3
2299	Treatment of hypertension and diabetes mellitus in patients with chronic kidney disease: a review. Expert Opinion on Pharmacotherapy, 2007, 8, 2543-2551.	0.9	7
2300	Relationship between obesity, hypertension and diabetes, and health-related quality of life among the elderly. European Journal of Cardiovascular Prevention and Rehabilitation, 2007, 14, 456-462.	3.1	83
2301	Prehypertension and Cardiovascular Disease Risk in the Women's Health Initiative. Circulation, 2007, 115, 855-860.	1.6	256
2302	Multiple Biomarkers and the Risk of Incident Hypertension. Hypertension, 2007, 49, 432-438.	1.3	161
2303	IgACE: A Placebo-Controlled, Randomized Trial of Angiotensin-Converting Enzyme Inhibitors in Children and Young People with IgA Nephropathy and Moderate Proteinuria. Journal of the American Society of Nephrology: JASN, 2007, 18, 1880-1888.	3.0	218
2304	Serum Cystatin C Predicts Progression of Subclinical Coronary Atherosclerosis in Individuals With Type 1 Diabetes. Diabetes, 2007, 56, 2774-2779.	0.3	69
2305	Plasma Thrombomodulin, Fibrinogen, and Activity of Tissue Factor as Risk Factors for Acute Cerebral Infarction. American Journal of Clinical Pathology, 2007, 128, 287-292.	0.4	15
2306	Effects of Normal Blood Pressure, Prehypertension, and Hypertension on Coronary Microvascular Function. Circulation, 2007, 115, 593-599.	1.6	125
2307	Antihypertensive properties of a highâ€dose combination of trandolapril and verapamilâ€SR. Blood Pressure, 2007, 16, 6-9.	0.7	4
2308	Association of diarrhoea in childhood with blood pressure and coronary heart disease in older age: analyses of two UK cohort studies. International Journal of Epidemiology, 2007, 36, 1349-1355.	0.9	9
2309	Blood Pressure Control and Improved Cardiovascular Outcomes in the International Verapamil SR-Trandolapril Study. Hypertension, 2007, 50, 299-305.	1.3	174
2311	The Influence of \hat{I}^2 -Blockers on Delayed Memory Function in People With Cognitive Impairment. American Journal of Alzheimer's Disease and Other Dementias, 2007, 22, 57-61.	0.9	53
2312	Risk Factors of Intracranial Cerebral Atherosclerosis among Asymptomatics. Cerebrovascular Diseases, 2007, 24, 355-360.	0.8	114
2313	Clinical and Genetic Correlates of Aldosterone-to-Renin Ratio and Relations to Blood Pressure in a Community Sample. Hypertension, 2007, 49, 846-856.	1.3	187
2314	Relationship of Physician Volume With Process Measures and Outcomes in Diabetes. Diabetes Care, 2007, 30, 1442-1447.	4.3	23
2315	The New "Normal" Blood Pressure: What Are the Implications for Family Medicine?. Journal of the American Board of Family Medicine, 2007, 20, 45-51.	0.8	7

#	Article	IF	CITATIONS
2317	Interrelationship Between Insulin Resistance and Menopause on the Metabolic Syndrome and Its Individual Component Among Nondiabetic Women in the Kinmen Study. American Journal of the Medical Sciences, 2007, 333, 208-214.	0.4	16
2318	Higher Heart Rate Predicts the Risk of Developing Hypertension in a Normotensive Screened Cohort. Circulation Journal, 2007, 71, 1755-1760.	0.7	50
2319	Increased Phospholipid Transfer Protein Activity Associated with the Impaired Cellular Cholesterol Efflux in Type 2 Diabetic Subjects with Coronary Artery Disease. Tohoku Journal of Experimental Medicine, 2007, 213, 129-137.	0.5	28
2320	Dietary energy density in the treatment of obesity: a year-long trial comparing 2 weight-loss diets. American Journal of Clinical Nutrition, 2007, 85, 1465-1477.	2.2	313
2321	KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenetics and Genomics, 2007, 17, 719-729.	0.7	65
2322	Metabolic Syndrome: Treatment of Hypertensive Patients. American Journal of Therapeutics, 2007, 14, 386-402.	0.5	40
2323	Clinical Utility of the Stanford Brief Activity Survey in Men and Women With Early-Onset Coronary Artery Disease. Journal of Cardiopulmonary Rehabilitation and Prevention, 2007, 27, 227-232.	1.2	30
2324	Strategies for Conducting Complex Clinical Trials in Diverse Community Practices. Medical Care, 2007, 45, 1221-1226.	1.1	7
2325	Cardiorespiratory Fitness, BMI, and Risk of Hypertension. Medicine and Science in Sports and Exercise, 2007, 39, 1687-1692.	0.2	67
2326	Hypertension and Cognitive Function in the Elderly. American Journal of Therapeutics, 2007, 14, 533-554.	0.5	34
2327	New insights from ADVANCE. Journal of Hypertension, 2007, 25, S23-S30.	0.3	5
2328	Factors That Impact Decision Making Among Rheumatologists in the Initiation of Treatment for Hypertension in Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2007, 13, 307-312.	0.5	6
2329	Dual Therapy in Hypertensive Patients with Coronary Artery Disease: The Role of Calcium Channel Blockers and ??-Blockers. American Journal of Cardiovascular Drugs, 2007, 7, 25???29.	1.0	3
2331	Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most. Current Opinion in Cardiology, 2007, 22, 267-272.	0.8	13
2332	Physical Activity in Young Adults and Incident Hypertension Over 15 Years of Follow-Up: The CARDIA Study. American Journal of Public Health, 2007, 97, 703-709.	1.5	109
2333	Establishing Sound Goals for Hypertension Management. JAAPA: Official Journal of the American Academy of Physician Assistants, 2007, 20, 9-13.	0.1	0
2334	Partnering With Your Patient in HYPERTENSION CONTROL. JAAPA: Official Journal of the American Academy of Physician Assistants, 2007, 20, 3-8.	0.1	0
2335	Blood Pressure Responses to Lifestyle Physical Activity Among Young, Hypertension-Prone African-American Women. Journal of Cardiovascular Nursing, 2007, 22, 107-117.	0.6	32

#	Article	IF	CITATIONS
2336	Effects of the Angiotensin II Type 1 Receptor Antagonist Valsartan on the Expression of Superoxide Dismutase in Hypertensive Patients. Journal of Clinical Pharmacology, 2007, 47, 397-403.	1.0	12
2337	Obesity and Benign Prostatic Enlargement: A Large Observational Study in China. Urology, 2007, 69, 680-684.	0.5	40
2338	Les facteurs non hémodynamiques deÂvariation deÂlaÂpression artérielle chezÂd'anciens sportifs demeurés actifs. Science and Sports, 2007, 22, 28-34.	0.2	0
2339	The impact of seizures and adverse effects on global health ratings. Epilepsy and Behavior, 2007, 11, 179-184.	0.9	29
2340	Hypertension Treatment Guidelines: Is It Time for an Update?. Journal of Clinical Hypertension, 2007, 9, 9-14.	1.0	9
2341	Obesity Paradox in Patients with Hypertension and Coronary Artery Disease. American Journal of Medicine, 2007, 120, 863-870.	0.6	477
2342	Predictors of Significant Short-Term Increases in Blood Pressure in a Community-Based Population. American Journal of Medicine, 2007, 120, 960-967.	0.6	23
2343	Observational Study on the Beneficial Effect of Preoperative Statins in Reducing Atrial Fibrillation After Coronary Surgery. Annals of Thoracic Surgery, 2007, 84, 1158-1164.	0.7	89
2344	The medication Adherence and Blood Pressure Control (ABC) trial: A multi-site randomized controlled trial in a hypertensive, multi-cultural, economically disadvantaged population. Contemporary Clinical Trials, 2007, 28, 459-471.	0.8	23
2345	Hypertension treatment in a medicare population: Adherence and systolic blood pressure control. Clinical Therapeutics, 2007, 29, 972-984.	1.1	118
2346	Hypertension in people with diabetes in sub-Saharan Africa: Revealing the hidden face of the iceberg. Diabetes Research and Clinical Practice, 2007, 77, 293-299.	1.1	52
2348	Automedida de la presión arterial. Documento de Consenso Español 2007. Revista Espanola De Geriatria Y Gerontologia, 2007, 42, 115-128.	0.2	1
2349	Automedida de la presión arterial. Documento de Consenso Español 2007. Hipertension, 2007, 24, 70-83.	0.0	16
2351	Automedida de la presión arterial. Documento de Consenso Español 2007. Semergen, 2007, 33, 176-187.	0.2	0
2352	Functional Vascular Endothelial Growth Factor -634G>C SNP Is Associated With Proliferative Diabetic Retinopathy: A case-control study in a Brazilian population of European ancestry. Diabetes Care, 2007, 30, 275-279.	4.3	38
2353	Is estimated cardiovascular risk higher in HIV-infected patients than in the general population?. Scandinavian Journal of Infectious Diseases, 2007, 39, 805-812.	1.5	39
2354	Effects of Nighttime Alcohol Intake on Evening and Next Morning Home Blood Pressure in Japanese Normotensives. Clinical and Experimental Hypertension, 2007, 29, 43-49.	0.5	19
2355	Candesartan cilexetil – a review of effects on cardiovascular complications in hypertension and chronic heart failure. Current Medical Research and Opinion, 2007, 23, 1693-1705.	0.9	20

#	Article	IF	CITATIONS
2356	Study on the Responses of Hypertensive Patients to Music. , 2007, , .		5
2357	A Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacodynamic Interaction of Coadministered Amlodipine and Atorvastatin in 1660 Patients With Concomitant Hypertension and Dyslipidemia: The Respond Trial. Journal of Clinical Pharmacology, 2007, 47, 1555-1569.	1.0	53
2358	Prevalence, Awareness, Treatment, and Control of Hypertension Among United States Adults 1999–2004. Hypertension, 2007, 49, 69-75.	1.3	1,225
2359	Supplementation of Conventional Therapy With the Novel Grain Salba (<i>Salvia hispanica L</i>). Improves Major and Emerging Cardiovascular Risk Factors in Type 2 Diabetes. Diabetes Care, 2007, 30, 2804-2810.	4.3	156
2361	Automedida de la presi \tilde{A}^3 n arterial. Documento de Consenso Espa $\tilde{A}\pm$ ol 2007. Hipertension Y Riesgo Vascular, 2007, 24, 70-83.	0.3	7
2362	Prevalence of and risk factors for peripheral arterial disease in the patients with hypertension among Han Chinese. Journal of Vascular Surgery, 2007, 46, 296-302.	0.6	34
2363	Applying Hypertension Guidelines to Reduce the Burden of Heart Failure. Cardiology Clinics, 2007, 25, 507-522.	0.9	6
2365	Quinapril for Treatment of Hypertension in Turkey. Clinical Drug Investigation, 2007, 27, 613-622.	1.1	0
2366	BP Goal Achievement in Patients withÂUncontrolled Hypertension. Clinical Drug Investigation, 2007, 27, 783-796.	1,1	6
2367	Additional Prognostic Value of Coronary Flow Reserve in Diabetic and Nondiabetic Patients With Negative Dipyridamole Stress Echocardiography by Wall Motion Criteria. Journal of the American College of Cardiology, 2007, 50, 1354-1361.	1.2	164
2369	Blood Pressure in Westernized and Isolated Populations. , 2007, , 21-30.		2
2370	Treatment Guidelines: The United States JNC7., 2007, , 1173-1175.		0
2373	Prevalence of metabolic syndrome in a rural area of Brazil. Sao Paulo Medical Journal, 2007, 125, 155-162.	0.4	49
2374	Which body mass index is best associated with risk of diabetes mellitus and hypertension in a Japanese-Brazilian population?. Cadernos De Saude Publica, 2007, 23, 297-304.	0.4	2
2375	Perioperative Hypertension: Preparing the Hypertensive Patient for Anesthesia for Surgery., 2007,, 737-746.		0
2376	Community-Based Weight Management in Long-Term Heart Transplant Recipients: A Pilot Study. Progress in Transplantation, 2007, 17, 315-323.	0.4	6
2377	Establishing Sound Goals for Hypertension Management. JAAPA: Official Journal of the American Academy of Physician Assistants, 2007, 20, 9-13.	0.1	0
2378	Partnering With Your Patient in HYPERTENSION CONTROL. JAAPA: Official Journal of the American Academy of Physician Assistants, 2007, 20, 3-8.	0.1	0

#	Article	IF	CITATIONS
2379	Dynamic NMR study and theoretical calculations on the conformational exchange of valsartan and related compounds. Magnetic Resonance in Chemistry, 2007, 45, 929-936.	1.1	16
2380	Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997–2003. Pharmacoepidemiology and Drug Safety, 2007, 16, 412-421.	0.9	27
2381	Preventing stroke: a narrative review of community interventions for improving hypertension control in black adults. Health and Social Care in the Community, 2008, 16, 165-187.	0.7	23
2382	Improving Quality of Care for Urban Older People with Diabetes Mellitus and Cardiovascular Disease. Journal of the American Geriatrics Society, 2007, 55, 1656-1662.	1.3	19
2383	The Puzzle of Dietary Fat Intake and Risk of Ischemic Stroke: A Brief Review of Epidemiologic Data. Journal of the American Dietetic Association, 2007, 107, 287-295.	1.3	23
2384	The PREMIER Intervention Helps Participants Follow the Dietary Approaches to Stop Hypertension Dietary Pattern and the Current Dietary Reference Intakes Recommendations. Journal of the American Dietetic Association, 2007, 107, 1541-1551.	1.3	89
2385	Prognostic Implications of Dipyridamole or Dobutamine Stress Echocardiography for Evaluation of Patients ≥65 Years of Age With Known or Suspected Coronary Heart Disease. American Journal of Cardiology, 2007, 99, 1491-1495.	0.7	14
2386	Impact of Sex, Metabolic Syndrome, and Diabetes Mellitus on Cardiovascular Events. American Journal of Cardiology, 2007, 100, 227-233.	0.7	28
2387	Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. American Journal of Cardiology, 2007, 99, S4-S20.	0.7	189
2388	Comparison of Clinical Characteristics and Arterial Remodeling by Intravascular Ultrasonic Imaging in Three Age Groups (â‰ \$ 5, 56 to 69 and ≥70 Years) of Japanese Patients With Acute Myocardial Infarction. American Journal of Cardiology, 2007, 100, 1713-1717.	0.7	6
2389	Comparison of Prognostic Value of Pharmacologic Stress Echocardiography in Chest Pain Patients With Versus Without Diabetes Mellitus and Positive Exercise Electrocardiography. American Journal of Cardiology, 2007, 100, 1744-1749.	0.7	18
2390	Prevalence of Dyslipidemia and Associated Factors Among the Hypertensive Rural Chinese Population. Archives of Medical Research, 2007, 38, 432-439.	1.5	30
2391	Hypertension and Coronary Artery Disease: A Summary of the American Heart Association Scientific Statement. Journal of Clinical Hypertension, 2007, 9, 790-795.	1.0	29
2392	Enhancing Dosage Flexibility in Combination Therapy. Journal of Clinical Hypertension, 2007, 9, 796-799.	1.0	4
2393	Missing data on the Center for Epidemiologic Studies Depression Scale: A comparison of 4 imputation techniques. Research in Social and Administrative Pharmacy, 2007, 3, 1-27.	1.5	124
2394	La diabetes mellitus entendida como una enfermedad cardiovascular de origen metab $ ilde{A}^3$ lico. Revista Espanola De Cardiologia Suplementos, 2007, 7, 12H-19H.	0.2	4
2395	Low levels of awareness of suboptimal health conditions in a high-risk working population: The "better health for better Hong Kong―health promotion campaign. International Journal of Behavioral Medicine, 2007, 14, 63-69.	0.8	15
2396	Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. European Journal of Clinical Pharmacology, 2007, 63, 1055-1061.	0.8	61

#	Article	IF	CITATIONS
2397	Antihypertensive drug utilization at health centres in a district of Istanbul. International Journal of Clinical Pharmacy, 2007, 29, 116-121.	1.4	13
2398	Cardiovascular risk under electromagnetic exposure in physiotherapy. The Environmentalist, 2007, 27, 539-543.	0.7	12
2399	The Importance of Managing Hypertension and Dyslipidemia to Decrease Cardiovascular Disease. Cardiovascular Drugs and Therapy, 2007, 21, 297-309.	1.3	49
2400	JNC-7 guidelines: Are they still relevant?. Current Hypertension Reports, 2007, 9, 380-386.	1.5	8
2401	Prehypertension: Progression to hypertension and management considerations. Current Cardiovascular Risk Reports, 2007, 1, 188-197.	0.8	1
2402	Can a Chronic Care Model Collaborative Reduce Heart Disease Risk in Patients with Diabetes?. Journal of General Internal Medicine, 2007, 22, 215-222.	1.3	89
2403	Hypertensive Patients' Race, Health Beliefs, Process of Care, and Medication Adherence. Journal of General Internal Medicine, 2007, 22, 768-774.	1.3	93
2404	Process of Care and Outcomes in Patients with Peripheral Arterial Disease. Journal of General Internal Medicine, 2007, 22, 942-948.	1.3	25
2405	Association Between Antihypertensive Medication Use and Non-cardiovascular Outcomes in Older Men. Journal of General Internal Medicine, 2007, 22, 1661-1667.	1.3	8
2406	Physician counseling for hypertension: What do doctors really do?. Patient Education and Counseling, 2008, 72, 115-121.	1.0	52
2407	Retinal and renal complications in patients with a mutation of mitochondrial DNA at position 3,243 (maternally inherited diabetes and deafness). A case–control study. Diabetologia, 2008, 51, 1664-1670.	2.9	37
2408	Posttransplant diabetes and hypertension: Pathophysiologic insights and therapeutic rationale. Current Diabetes Reports, 2008, 8, 221-227.	1.7	3
2409	Race-based therapeutics. Current Hypertension Reports, 2008, 10, 276-285.	1.5	18
2410	Pharmacologic considerations in the positioning of \hat{l}^2 -blockers in antihypertensive therapy. Current Hypertension Reports, 2008, 10, 330-335.	1.5	8
2411	Does earlier attainment of blood pressure goal translate into fewer cardiovascular events?. Current Hypertension Reports, 2008, 10, 398-404.	1.5	30
2412	Impact of Computerized Decision Support on Blood Pressure Management and Control: A Randomized Controlled Trial. Journal of General Internal Medicine, 2008, 23, 429-441.	1.3	77
2413	Hypertension Management in Minority Communities: A Clinician Survey. Journal of General Internal Medicine, 2008, 23, 81-86.	1.3	10
2414	The Accuracy of Clinician Perceptions of "Usual―Blood Pressure Control. Journal of General Internal Medicine, 2008, 23, 180-183.	1.3	30

#	Article	IF	CITATIONS
2415	Why Don't Diabetes Patients Achieve Recommended Risk Factor Targets? Poor Adherence versus Lack of Treatment Intensification. Journal of General Internal Medicine, 2008, 23, 588-594.	1.3	214
2416	The Impact of Concordant and Discordant Conditions on the Quality of Care for Hyperlipidemia. Journal of General Internal Medicine, 2008, 23, 1208-1213.	1.3	39
2417	Prehypertension: Detection, evaluation, and management. Current Treatment Options in Cardiovascular Medicine, 2008, 10, 273-282.	0.4	2
2418	Severe Impairment of Endothelial Function with the HIV-1 Protease Inhibitor Indinavir is not Mediated by Insulin Resistance in Healthy Subjects. Cardiovascular Toxicology, 2008, 8, 15-22.	1.1	26
2419	The cost of treating high blood pressure in general practice in France. European Journal of Health Economics, 2008, 9, 229-236.	1.4	10
2420	Combining data from primary and ancillary surveys to assess the association between neighborhoodâ€level characteristics and health outcomes: the Multiâ€Ethnic Study of Artherosclerosis. Statistics in Medicine, 2008, 27, 5745-5763.	0.8	5
2421	The patterns of antihypertensive drug prescription by cardiologists in Kerman province of Iran, 2006. Pharmacoepidemiology and Drug Safety, 2008, 17, 180-185.	0.9	9
2422	Optimal risk factor modification and medical management of the patient with peripheral arterial disease. Catheterization and Cardiovascular Interventions, 2008, 71, 475-489.	0.7	50
2423	Utility of Routine Testing for Patients With Asymptomatic Severe Blood Pressure Elevation in the Emergency Department. Annals of Emergency Medicine, 2008, 51, 231-239.	0.3	21
2424	Managing hypertension in cardiology practice according to risk profile. International Journal of Clinical Practice, 2008, 62, 1403-1412.	0.8	14
2425	Cumulative Anticholinergic Exposure Is Associated with Poor Memory and Executive Function in Older Men. Journal of the American Geriatrics Society, 2008, 56, 2203-2210.	1.3	192
2426	Arterial stiffness, metabolic syndrome and inflammation amongst Asian ischaemic stroke patients. European Journal of Neurology, 2008, 15, 872-875.	1.7	13
2427	Arterial stiffness is associated with raised levels of the inflammatory marker erythrocyte sedimentation rate among ischaemic stroke patients. Internal Medicine Journal, 2008, 38, 918-920.	0.5	3
2428	Twentyâ€four hour ambulatory blood pressure in a population of elderly men. Journal of Internal Medicine, 2000, 248, 501-510.	2.7	1
2429	Blood pressure in diabetic nephropathy – current controversies. Journal of Internal Medicine, 2001, 249, 215-223.	2.7	0
2430	Rational pharmacotherapy of hypertension in the elderly: analysis of the choice and dosage of drugs. Journal of Clinical Pharmacy and Therapeutics, 2001, 26, 33-42.	0.7	3
2431	Exercise Blood Pressure and the Risk of Incident Cardiovascular Disease (from the Framingham Heart) Tj ETQq0 0	OrgBT /O	verlock 10 Tf 101
2432	Cardiovascular Risk Factors and Acculturation in Yaquis and Tepehuanos Indians from Mexico. Archives of Medical Research, 2008, 39, 352-357.	1.5	27

#	Article	IF	CITATIONS
2433	Management of Hypertension in Peripheral Arterial Disease: Does the Choice of Drugs Matter?. European Journal of Vascular and Endovascular Surgery, 2008, 35, 701-708.	0.8	55
2434	Patient and Social Environment Factors Associated With Self Blood Pressure Monitoring by Male Veterans With Hypertension. Journal of Clinical Hypertension, 2008, 10, 692-699.	1.0	7
2435	Blood Pressure Control by Drug Group in the Antihypertensive and Lipid‣owering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of Clinical Hypertension, 2008, 10, 751-760.	1.0	80
2436	National Utilization of Antihypertensive Medications From 2000 to 2006 in the Veterans Health Administration: Focus on Thiazide Diuretics. Journal of Clinical Hypertension, 2008, 10, 770-778.	1.0	10
2437	Diagnostic Thresholds for Ambulatory Blood Pressure Moving Lower: A Review Based on a Meta-Analysis—Clinical Implications. Journal of Clinical Hypertension, 2008, 10, 377-381.	1.0	34
2438	Remission in depressed outpatients: More than just symptom resolution?. Journal of Psychiatric Research, 2008, 42, 797-801.	1.5	76
2444	Eplerenona en la disfunción cardiorrenal y bloqueo del sistema renina-angiotensina-aldosterona. Dialisis Y Trasplante, 2008, 29, 21-28.	0.4	0
2445	Biophysical Basis of Glomerular Filtration. , 2008, , 565-587.		3
2446	Cardiovascular Disease: Overview and Trends. , 2008, , 511-538.		0
2447	Antihypertensive drug medication adherence and its affecting factors in South Korea. International Journal of Cardiology, 2008, 128, 392-398.	0.8	48
2448	Blood pressure control in the year following coronary events. International Journal of Cardiology, 2008, 130, 205-210.	0.8	3
2449	Disparities in Antihypertensive Medication Adherence in Persons With Disabilities and Without Disabilities: Results of a Korean Population-Based Study. Archives of Physical Medicine and Rehabilitation, 2008, 89, 1460-1467.	0.5	28
2450	Verapamil-sustained release–based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: An INternational VErapamil SR-Trandolapril (INVEST) substudy. American Heart Journal, 2008, 156, 241-247.	1.2	48
2451	Central obesity: Association with left ventricular dysfunction and mortality in the community. American Heart Journal, 2008, 156, 975-981.	1.2	78
2452	Hypertension in the ED: still an unrecognized problem. American Journal of Emergency Medicine, 2008, 26, 913-917.	0.7	26
2453	A Panel Assessment of Glaucoma Management: Modification of Existing RAND-like Methodology for Consensus in Ophthalmology. Part II: Results and Interpretation. American Journal of Ophthalmology, 2008, 145, 575-581.e6.	1.7	41
2455	Management of Hypertension and Cerebrovascular Disease in the Elderly. American Journal of Medicine, 2008, 121, S23-S31.	0.6	29
2456	Prevalence, awareness, treatment and control of hypertension in Malaysia: A national study of 16,440 subjects. Public Health, 2008, 122, 11-18.	1.4	123

#	Article	IF	CITATIONS
2457	A possible association between aldosterone response to vasopressin and circadian change of aldosterone in the patients with aldosterone-producing adenoma. Peptides, 2008, 29, 2225-2231.	1.2	4
2458	Periventricular white matter hyperintensities as predictors of suicide attempts in bipolar disorders and unipolar depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1501-1507.	2.5	102
2459	Maternally inherited hypertension is associated with the mitochondrial tRNAlle A4295G mutation in a Chinese family. Biochemical and Biophysical Research Communications, 2008, 367, 906-911.	1.0	43
2460	The mitochondrial ND1 T3308C mutation in a Chinese family with the secondary hypertension. Biochemical and Biophysical Research Communications, 2008, 368, 18-22.	1.0	22
2461	The ADVANCE trial. Lancet, The, 2008, 371, 25.	6.3	6
2462	Traitement de l'hypertension artérielle. , 2008, , 41-71.		0
2463	Efficacy of a Very-low-dose Combination of Perindopril and Indapamideâ€"Preterax Compared with Cilazapril Monotherapy in Patients with Inadequate Blood Pressure Controlâ€"A Randomized, Double-blind, Add-on Study. Journal of the Chinese Medical Association, 2008, 71, 247-253.	0.6	1
2464	Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?. Annals of the Rheumatic Diseases, 2008, 67, 64-69.	0.5	277
2465	Abnormal Cardiac Structure and Function in the Metabolic Syndrome: A Population-Based Study. Mayo Clinic Proceedings, 2008, 83, 1350-1357.	1.4	57
2466	Comparison of hypertension and its risk factors between the Guangxi Bai Ku Yao and Han populations. Blood Pressure, 2008, 17, 306-316.	0.7	24
2467	Amlodipine/Atorvastatin Fixed-Dose Combination. American Journal of Cardiovascular Drugs, 2008, 8, 51-67.	1.0	28
2468	Prediabetes and its Relationship with Obesity in Mexican Adults: The Mexican Diabetes Prevention (MexDiab) Study. Metabolic Syndrome and Related Disorders, 2008, 6, 15-23.	0.5	48
2469	The Product of Fasting Glucose and Triglycerides As Surrogate for Identifying Insulin Resistance in Apparently Healthy Subjects. Metabolic Syndrome and Related Disorders, 2008, 6, 299-304.	0.5	934
2470	Aortic Root Diameter and Longitudinal Blood Pressure Tracking. Hypertension, 2008, 52, 473-477.	1.3	16
2471	The Role of Asymmetric Dimethylarginine (ADMA) and Leptin in Hypertensive Patients. Journal of International Medical Research, 2008, 36, 54-62.	0.4	4
2472	Effect of Board Certification on Antihypertensive Treatment Intensification in Patients With Diabetes Mellitus. Circulation, 2008, $117,623-628$.	1.6	66
2473	Serum magnesium and C-reactive protein levels. Archives of Disease in Childhood, 2008, 93, 676-680.	1.0	47
2474	Screening for Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 616-623.	2.2	89

#	Article	IF	Citations
2475	Gender Difference in Blood Pressure Control and Cardiovascular Risk Factors in Americans With Diagnosed Hypertension. Hypertension, 2008, 51, 1142-1148.	1.3	204
2476	Pathophysiology of Primary Hypertension. , 2008, , 794-895.		3
2477	Predicting Stroke Risk in Hypertensive Patients With Coronary Artery Disease. Stroke, 2008, 39, 343-348.	1.0	29
2478	Pulse Pressure and Risk of Adverse Outcome in Coronary Bypass Surgery. Anesthesia and Analgesia, 2008, 107, 1122-1129.	1.1	65
2479	Methodological Overview of an African American Couple-Based HIV/STD Prevention Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, S3-S14.	0.9	18
2480	Survey of blood pressure control status in patients with ischemic stroke or transient ischemic attack in China. Neurological Research, 2008, 30, 348-355.	0.6	10
2481	Peripheral Arterial Disease in HIV Patients Older than 50 Years of Age. AIDS Research and Human Retroviruses, 2008, 24, 1043-1046.	0.5	39
2482	Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ: British Medical Journal, 2008, 336, 1114-1117.	2.4	684
2483	PREMIER—A Trial of Lifestyle Interventions for Blood Pressure Control: Intervention Design and Rationale. Health Promotion Practice, 2008, 9, 271-280.	0.9	63
2484	Screening, Treatment, and Control of Hypertension in US Private Physician Offices, 2003–2004. Hypertension, 2008, 51, 1275-1281.	1.3	43
2485	Hypertension in Mexico and among Mexican Americans: prevalence and treatment patterns. Journal of Human Hypertension, 2008, 22, 617-626.	1.0	33
2486	Characteristics of the patients referred to a Hypertension Unit between 1989 and 2003. Journal of Human Hypertension, 2008, 22, 119-121.	1.0	10
2487	The relationship between dietary protein intake and blood pressure: results from the PREMIER study. Journal of Human Hypertension, 2008, 22, 745-754.	1.0	75
2488	â€Induction of inflammatory gene expression by THP-1 macrophages cultured in normocholesterolaemic hypertensive sera and modulatory effects of green tea polyphenols'. Journal of Human Hypertension, 2008, 22, 141-143.	1.0	19
2489	Culturally Tailored Aerobic Exercise Intervention for Low-Income Latinas. American Journal of Health Promotion, 2008, 22, 155-163.	0.9	76
2490	Chronic heart failure, selected risk factors and coâ€morbidities among adults treated for hypertension in a cardiac referral hospital in Cameroon. European Journal of Heart Failure, 2008, 10, 367-372.	2.9	32
2491	Adherence to the Mediterranean Diet Is Inversely Associated With Circulating Interleukin-6 Among Middle-Aged Men. Circulation, 2008, 117, 169-175.	1.6	122
2492	Prevalence of and Risk Factors for Isolated Systolic Hypertension in the Rural Adult Population of Liaoning Province, China. Journal of International Medical Research, 2008, 36, 353-356.	0.4	8

#	ARTICLE	IF	CITATIONS
2493	Prevalence, Awareness, Treatment, and Control of Hypertension in the Jackson Heart Study. Hypertension, 2008, 51, 650-656.	1.3	127
2494	Prevalence, Awareness, Treatment, and Control of Hypertension in China. Circulation, 2008, 118, 2679-2686.	1.6	467
2495	Impacts of Measurement Protocols on Blood Pressure Tracking From Childhood Into Adulthood. Hypertension, 2008, 51, 642-649.	1.3	30
2496	Thiazide-Type Diuretics and \hat{l}^2 -Adrenergic Blockers as First-Line Drug Treatments for Hypertension. Circulation, 2008, 117, 2691-2705.	1.6	46
2497	Cash Component of Conditional Cash Transfer Program Is Associated with Higher Body Mass Index and Blood Pressure in Adults. Journal of Nutrition, 2008, 138, 2250-2257.	1.3	93
2498	Renal Insufficiency and Mortality in Patients with Known or Suspected Coronary Artery Disease. Journal of the American Society of Nephrology: JASN, 2008, 19, 158-163.	3.0	66
2499	The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney International, 2008, 73, 327-333.	2.6	94
2500	Blood Pressure Control and Pharmacotherapy Patterns in the United States Before and After the Release of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) Guidelines. Journal of the American Board of Family Medicine, 2008, 21, 512-521	0.8	40
2501	Evaluation of a workplace health program to reduce coronary risk factors. Clinical Governance, 2008, 13, 95-105.	0.4	11
2502	Serum N-3 Polyunsaturated Fatty Acid Levels Correlate With the Extent of Coronary Plaques and Calcifications in Patients With Acute Myocardial Infarction. Circulation Journal, 2008, 72, 1836-1843.	0.7	43
2503	Continued Smoking Exacerbates but Cessation Ameliorates Progression of Early Type 2 Diabetic Nephropathy. American Journal of the Medical Sciences, 2008, 335, 284-291.	0.4	67
2504	Assessment of Aortic Atheromatous Plaque and Stiffness by 64-Slice Computed Tomography is Useful for Identifying Patients With Coronary Artery Disease. Circulation Journal, 2008, 72, 2021-2027.	0.7	14
2505	Interindividual variation in serum sodium and longitudinal blood pressure tracking in the Framingham Heart Study. Journal of Hypertension, 2008, 26, 2121-2125.	0.3	23
2506	Risk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study. Yearbook of Medicine, 2008, 2008, 347-349.	0.1	0
2507	Food Intake Patterns May Explain the High Prevalence of Cardiovascular Risk Factors among Iranian Women. Journal of Nutrition, 2008, 138, 1469-1475.	1.3	113
2508	Left ventricular mass and incident hypertension in individuals with initial optimal blood pressure: the Strong Heart Study. Journal of Hypertension, 2008, 26, 1868-1874.	0.3	25
2509	Can Prevention of Hypertension Work?. American Journal of Therapeutics, 2008, 15, 334-339.	0.5	3
2510	The Accuracy and Clinical Feasibility of a New Bayesian-Based Closed-Loop Control System for Propofol Administration Using the Bispectral Index as a Controlled Variable. Anesthesia and Analgesia, 2008, 107, 1200-1210.	1.1	111

#	Article	IF	CITATIONS
2511	Albuminuria, but not estimated glomerular filtration rate, is associated with maladaptive arterial remodeling: the Hoorn Study. Journal of Hypertension, 2008, 26, 791-797.	0.3	45
2512	Association between hypertensive urgencies and subsequent cardiovascular events in patients with hypertension. Journal of Hypertension, 2008, 26, 657-662.	0.3	53
2513	Investigation of Hypertension in Childhood. , 2008, , 645-663.		3
2514	Significance of Pulsatility of Brachial Artery Pressure for Blood Pressure Control . International Heart Journal, 2008, 49, 295-302.	0.5	0
2517	Rates and Related Factors of Progression to Hypertension among Prehypertensive Local Residents Aged 45 or Over in Chuncheon City: Hallym Aging Study from a Community-Based Cross-Sectional Study. Korean Circulation Journal, 2008, 38, 43.	0.7	6
2518	Prehypertension. Korean Circulation Journal, 2008, 38, 1.	0.7	1
2519	Therapeutic Strategies for Diastolic Dysfunction: A Clinical Perspective. Journal of Cardiovascular Imaging, 2009, 17, 86.	0.8	19
2520	Depressão em idosos portadores de insuficiência renal crônica em tratamento hemodialÃŧico. ACTA Paulista De Enfermagem, 2009, 22, 505-508.	0.1	6
2523	Relations of Matrix Remodeling Biomarkers to Blood Pressure Progression and Incidence of Hypertension in the Community. Circulation, 2009, 119, 1101-1107.	1.6	58
2524	Plasma Uric Acid and Hypertension in a Chinese Community: Prospective Study and Metaanalysis. Clinical Chemistry, 2009, 55, 2026-2034.	1.5	97
2525	What do studies of diet patterns tell us?. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 567-568.	8.2	2
2526	Internationally recognized guidelines for 'sensible' alcohol consumption: is exceeding them actually detrimental to health and social circumstances? Evidence from a population-based cohort study. Journal of Public Health, 2009, 31, 360-365.	1.0	20
2527	Coadministered Amlodipine and Atorvastatin Produces Early Improvements in Arterial Wall Compliance in Hypertensive Patients With Dyslipidemia. American Journal of Hypertension, 2009, 22, 137-144.	1.0	34
2528	Single Versus Combined Blood Pressure Components and Risk for Cardiovascular Disease. Circulation, 2009, 119, 243-250.	1.6	287
2529	Shifting the Disease Management Paradigm From Glucose: What are the pros?. Diabetes Care, 2009, 32, S349-S352.	4.3	6
2530	Use of single-pill combination therapy in the evolving paradigm of hypertension management. Expert Opinion on Pharmacotherapy, 2009, 10, 1869-1874.	0.9	10
2531	Lipoprotein-Associated Phospholipase A ₂ and High-Sensitivity C-Reactive Protein Improve the Stratification of Ischemic Stroke Risk in the Atherosclerosis Risk in Communities (ARIC) Study. Stroke, 2009, 40, 376-381.	1.0	79
2532	Racial Differences in Vascular Risk Factors and Outcomes of Patients With Intracranial Atherosclerotic Arterial Stenosis. Stroke, 2009, 40, 719-725.	1.0	51

#	Article	IF	Citations
2533	Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). Journal of Human Hypertension, 2009, 23, 196-210.	1.0	34
2534	Efficacy of exercise, losartan, enalapril, atenolol and rilmenidine in subjects with blood pressure hyperreactivity at treadmill stress test and left ventricular hypertrophy. Journal of Human Hypertension, 2009, 23, 259-266.	1.0	2
2535	Salt excretion in normotensive individuals with metabolic syndrome: a population-based study. Hypertension Research, 2009, 32, 906-910.	1.5	20
2536	Lifestyle Modification Counseling for Hypertensive Patients: Results From the National Health and Nutrition Examination Survey 1999-2004. American Journal of Hypertension, 2009, 22, 325-331.	1.0	38
2537	Endothelium-specific overexpression of human IC53 downregulates endothelial nitric oxide synthase activity and elevates systolic blood pressure in mice. Cardiovascular Research, 2009, 84, 292-299.	1.8	7
2538	Resistance exercise plus to aerobic activities is associated with better lipids' profile among healthy individuals: the ATTICA study. QJM - Monthly Journal of the Association of Physicians, 2009, 102, 609-616.	0.2	33
2539	Reasons for therapeutic inertia when managing hypertension in clinical practice in non-Western countries. Journal of Human Hypertension, 2009, 23, 151-159.	1.0	50
2540	Initial combination therapy for rapid and effective control of moderate and severe hypertension. Journal of Human Hypertension, 2009, 23, 4-11.	1.0	14
2541	Failures in Mitochondrial tRNA ^{Met} and tRNA ^{Gln} Metabolism Caused by the Novel 4401A>G Mutation Are Involved in Essential Hypertension in a Han Chinese Family. Hypertension, 2009, 54, 329-337.	1.3	65
2542	Allostatic Load and Frailty in the Women's Health and Aging Studies. Biological Research for Nursing, 2009, 10, 248-256.	1.0	63
2543	Isolated Systolic Hypertension and Incident Heart Failure in Older Adults. Hypertension, 2009, 53, 458-465.	1.3	65
2544	Lifestyle Interventions Reduce Coronary Heart Disease Risk. Circulation, 2009, 119, 2026-2031.	1.6	216
2545	Physical, Psychological, and Functional Comorbidities of Multisymptom Illness in Australian Male Veterans of the 1991 Gulf War. American Journal of Epidemiology, 2009, 170, 1048-1056.	1.6	35
2546	Clinical Review: Is the Perioperative Use of \hat{l}^2 -Blockers Still Recommended? A Critical Review of Recent Controversies. Journal of Cardiovascular Pharmacology and Therapeutics, 2009, 14, 258-268.	1.0	7
2547	Genetic Effect on Blood Pressure Is Modulated by Age. Hypertension, 2009, 53, 35-41.	1.3	56
2548	Characteristics and Outcomes of Revascularized Patients With Hypertension. Hypertension, 2009, 53, 624-630.	1.3	8
2549	Aging white matter and cognition: Differential effects of regional variations in diffusion properties on memory, executive functions, and speed. Neuropsychologia, 2009, 47, 916-927.	0.7	398
2550	Clinical Foundation for Efficient Treatment of Obstructive Sleep Apnea. Journal of Oral and Maxillofacial Surgery, 2009, 67, 2171-2182.	0.5	9

#	Article	IF	CITATIONS
2551	Electrocardiographic diagnosis of left ventricular hypertrophy: depolarization changes. Journal of Electrocardiology, 2009, 42, 228-232.	0.4	10
2552	Computer Confirmation of Improved Blood Pressure Control in Diabetic Patients. Preventive Cardiology, 2009, 12, 149-154.	1.1	0
2553	JNC 8: Expectations, Challenges, and Wishes-A Primary Care Perspective. Journal of Clinical Hypertension, 2009, 11, 573-576.	1.0	2
2554	Pattern of normal age-related regional differences in white matter microstructure is modified by vascular risk. Brain Research, 2009, 1297, 41-56.	1.1	172
2555	Failure of betaâ€cell function to compensate lack of insulin action in hyperuricemic subjects. Diabetes/Metabolism Research and Reviews, 2009, 25, 535-541.	1.7	12
2556	Recommendations for global hypertension monitoring and prevention. Current Hypertension Reports, 2009, 11, 444-449.	1.5	24
2557	Hypertension Guideline Adherence Among Nursing Home Patients. Journal of General Internal Medicine, 2009, 24, 499-503.	1.3	14
2558	Obesity and metabolic changes are common in young childhood brain tumor survivors. Pediatric Blood and Cancer, 2009, 52, 853-859.	0.8	81
2559	Time trends in the use of antiâ€hypertensive medications: results from the Multiâ€Ethnic Study of Atherosclerosis. Pharmacoepidemiology and Drug Safety, 2009, 18, 826-832.	0.9	5
2560	Hypertension Improvement Project (HIP): study protocol and implementation challenges. Trials, 2009, 10, 13.	0.7	40
2561	Cardioprotection with betaâ€blockers: myths, facts and Pascal's wager. Journal of Internal Medicine, 2009, 266, 232-241.	2.7	30
2562	Aetiology and outcomes of adult superior oblique palsies: a modern series. Eye, 2009, 23, 640-644.	1.1	56
2563	Oxidant Stress in Healthy Normalâ€weight, Overweight, and Obese Individuals. Obesity, 2009, 17, 460-466.	1.5	58
2564	Management of hypertension in patients with diabetes: the place of angiotensinâ€l receptor blockers. Diabetes, Obesity and Metabolism, 2009, 11, 757-769.	2,2	19
2565	Nonpharmacologic Interventions Successfully Treat Hypertension in Older Persons. Nutrition Reviews, 2009, 56, 341-343.	2.6	4
2566	Dietary Patterns and Blood Pressure in African Americans. Nutrition Reviews, 1999, 57, 356-358.	2.6	10
2567	How Prevalent Is Thiamin Deficiency in Heart Failure Patients?. Nutrition Reviews, 2001, 59, 342-344.	2.6	3
2568	Prescribing Trends and Drug Budget Impact of the ARBs in the UK. Value in Health, 2009, 12, 302-308.	0.1	10

#	Article	IF	CITATIONS
2569	Urinary incontinence in community-dwelling older Mexican American and European American women. Archives of Gerontology and Geriatrics, 2009, 48, 232-237.	1.4	8
2570	Systolic Blood Pressure and Subjective Wellâ€Being in Patients with Coronary Artery Disease. Clinical Cardiology, 2009, 32, 627-632.	0.7	15
2571	Introduction: The European INVESTigators meeting. Clinical Cardiology, 2001, 24, A6-A6.	0.7	2
2572	Characteristics of patients with coronary artery disease and hypertension: A report from INVEST. Clinical Cardiology, 2001, 24, V-6-V-8.	0.7	0
2573	INVEST substudies: Design and patient characteristics. Clinical Cardiology, 2001, 24, V-9-V-11.	0.7	3
2574	How will INVEST and other hypertension trials change clinical practice?. Clinical Cardiology, 2009, 24, V-24-V-29.	0.7	5
2575	The patient with cardiovascular disease: Treatment strategies for preventing major events. Clinical Cardiology, 2009, 29, 4-12.	0.7	1
2576	Hypertension, Diabetes, And Elevated Cholesterol Among Insured And Uninsured U.S. Adults. Health Affairs, 2009, 28, w1151-w1159.	2.5	62
2577	High blood pressure response to stress ergometry could predict future hypertension. European Journal of Internal Medicine, 2009, 20, 366-368.	1.0	22
2578	Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 110-114.	1.1	55
2579	The Effect of a Hypertension Self-Management Intervention on Diabetes and Cholesterol Control. American Journal of Medicine, 2009, 122, 639-646.	0.6	19
2580	Introduction. American Journal of Medicine, 2009, 122, S1-S6.	0.6	1
2581	Effect of Treatment and Adherence on Ethnic Differences in Blood Pressure Control Among Adults with Hypertension. Annals of Epidemiology, 2009, 19, 172-179.	0.9	26
2582	A Systematic Review of the Management of Autonomic Dysreflexia After Spinal Cord Injury. Archives of Physical Medicine and Rehabilitation, 2009, 90, 682-695.	0.5	330
2583	Atrial Fibrillation at Baseline and During Follow-Up in ALLHAT (Antihypertensive and Lipid-Lowering) Tj ETQq0 0 0 r 2023-2031.	rgBT /Over 1.2	rlock 10 Tf 50 165
2584	Components of metabolic syndrome and the incidence of type 2 diabetes in an elderly Taiwanese cohort. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2009, 3, 90-95.	1.8	4
2585	Ethnic South Asian ischaemic stroke patients have a higher prevalence of a family history of vascular disease compared to age, gender and diabetes-matched ethnic Chinese subjects. Journal of the Neurological Sciences, 2009, 285, 118-120.	0.3	7
2586	Combined hyperlipidemia in relation to race/ethnicity, obesity, and insulin resistance in the Multi-Ethnic Study of Atherosclerosis. Metabolism: Clinical and Experimental, 2009, 58, 212-219.	1.5	32

#	Article	IF	CITATIONS
2588	Effectiveness and Tolerability of Fixed-Dose Combination Enalapril plus Nitrendipine in Hypertensive Patients. Clinical Drug Investigation, 2009, 29, 459-469.	1.1	5
2589	The effects of sour tea (Hibiscus sabdariffa) on hypertension in patients with type II diabetes. Journal of Human Hypertension, 2009, 23, 48-54.	1.0	84
2590	Mitochondrial Transfer RNA ^{Met} 4435A>G Mutation Is Associated With Maternally Inherited Hypertension in a Chinese Pedigree. Hypertension, 2009, 53, 1083-1090.	1.3	82
2591	Hypertensive Status and Lipoprotein Oxidation in an Elderly Population at High Cardiovascular Risk. American Journal of Hypertension, 2009, 22, 68-73.	1.0	18
2592	INVEST revisited: review of findings from the International Verapamil SR–Trandolapril Study. Expert Review of Cardiovascular Therapy, 2009, 7, 1329-1340.	0.6	36
2593	Comparison of Information Content of Structured and Narrative Text Data Sources on the Example of Medication Intensification. Journal of the American Medical Informatics Association: JAMIA, 2009, 16, 362-370.	2.2	40
2595	The Indian Polycap Study (TIPS). Lancet, The, 2009, 374, 781-782.	6.3	5
2596	Responses of Blood Lipids to Aerobic, Resistance, and Combined Aerobic with Resistance Exercise Training: A Systematic Review of Current Evidence. Angiology, 2009, 60, 614-632.	0.8	160
2597	Age-dependent increase in blood pressure in two different Native American communities in Brazil. Journal of Hypertension, 2009, 27, 1753-1760.	0.3	20
2598	2007 ESH/ESC Guidelines for the management of hypertension, from theory to practice: global cardiovascular risk concept. Journal of Hypertension, 2009, 27, S3-S11.	0.3	31
2599	Treatment Intensification and Risk Factor Control. Medical Care, 2009, 47, 395-402.	1.1	68
2600	Medication Acquisition and Self-Reported Adherence in Veterans With Hypertension. Medical Care, 2009, 47, 474-481.	1.1	47
2601	Hypertensive Emergency Successfully Treated With Metoprolol. Pediatric Emergency Care, 2009, 25, 333-335.	0.5	3
2602	Differential risks of stroke in pharmacotherapy on uncomplicated hypertensive patients?. Journal of Hypertension, 2009, 27, 174-180.	0.3	8
2603	Blood pressure, atherosclerosis, and albuminuria in 10 113 participants in the Atherosclerosis Risk In Communities study. Journal of Hypertension, 2009, 27, 397-409.	0.3	28
2604	Mortality in Diastolic Heart Failure. Cardiology in Review, 2009, 17, 51-55.	0.6	15
2605	Trends for Blood Pressure and Its Contribution to Stroke Incidence in the Middle-Aged Japanese Population. Stroke, 2009, 40, 1571-1577.	1.0	104
2606	Application of hypertension guidelines in clinical practice: implementation of the 2007 ESH/ESC European practice Guidelines in Spain. Journal of Hypertension, 2009, 27, S27-S32.	0.3	25

#	Article	IF	Citations
2607	Arterial stiffness is associated with intracranial large artery disease among ethnic Chinese and South Asian ischemic stroke patients. Journal of Hypertension, 2009, 27, 1453-1458.	0.3	23
2608	Antihypertensive Effect of Pre-germinated Brown Rice in Spontaneously Hypertensive Rats. Food Science and Technology Research, 2009, 15, 625-630.	0.3	20
2609	Long-term Effects of Renin-Angiotensin System–Blocking Therapy and a Low Blood Pressure Goal on Progression of Hypertensive Chronic Kidney Disease in African Americans. Yearbook of Cardiology, 2009, 47-48.	0.0	1
2610	Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial. Yearbook of Cardiology, 2009, 2009, 51-53.	0.0	0
2611	Patients With Peripheral Artery Disease Who Complete 12-Week Supervised Exercise Training Program Show Reduced Cardiovascular Mortality and Morbidity. Circulation Journal, 2009, 73, 167-173.	0.7	82
2612	Embolic Potential of Cardiac Tumors and Outcome After Resection. Stroke, 2009, 40, 156-162.	1.0	102
2613	Association Between Prehypertension and Clustering of Cardiovascular Disease Risk Factors Among Chinese Adults. Journal of Cardiovascular Pharmacology, 2009, 53, 388-400.	0.8	26
2614	Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes. Yearbook of Cardiology, 2009, 2009, 49-51.	0.0	0
2615	Insulin Therapy, Hyperglycemia, and Hypertension in Type 1 Diabetes Mellitus. Yearbook of Cardiology, 2009, 2009, 111-113.	0.0	0
2616	Combination of polymorphisms in the \hat{l}^2 2-adrenergic receptor and nitric oxide synthase 3 genes increases the risk for hypertension. Journal of Hypertension, 2009, 27, 1377-1383.	0.3	19
2618	Treatment blood pressure targets for hypertension. Yearbook of Cardiology, 2010, 2010, 37-39.	0.0	0
2619	Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Yearbook of Cardiology, 2010, 2010, 67-68.	0.0	0
2620	Alterations in capillary morphology are found in mild blood pressure elevation. Journal of Hypertension, 2010, 28, 2258-2266.	0.3	11
2621	Guidelines for Diagnosis and Treatment of Patients With Vasospastic Angina (Coronary Spastic) Tj ETQq $1\ 1\ 0.78$	4314 rgBT 0.7	/Qyerlock 1
2622	Evaluation of selected lipid parameters and blood pressure in ethnically-homogenous population of middle-aged persons, depending on gender, age and body mass. Open Medicine (Poland), 2010, 5, 486-494.	0.6	1
2624	Modulation of Gene Expression by Polyalthia longifolia in Postmenopausal Women with Coronary Artery Disease: An In Vitro Study. Journal of Cardiovascular Translational Research, 2010, 3, 570-579.	1.1	2
2625	Effects of the PREMIER Interventions on Health-Related Quality of Life. Annals of Behavioral Medicine, 2010, 40, 302-312.	1.7	22
2626	The Role of Combination Therapy for Hypertension After ACCOMPLISH. Current Cardiovascular Risk Reports, 2010, 4, 251-255.	0.8	O

#	Article	IF	CITATIONS
2627	Increased occurrence of cardiovascular events and comorbidities in a general rheumatology cohort. Irish Journal of Medical Science, 2010, 179, 273-276.	0.8	2
2628	Body size adjustments for left ventricular mass by cardiovascular magnetic resonance and their impact on left ventricular hypertrophy classification. International Journal of Cardiovascular Imaging, 2010, 26, 459-468.	0.7	68
2629	Alcohol Drinking May Not Be a Major Risk Factor for Fatty Liver in Japanese Undergoing a Health Checkup. Digestive Diseases and Sciences, 2010, 55, 176-182.	1.1	31
2630	A community-based study of hypertension and cardio-metabolic syndrome in semi-urban and rural communities in Nigeria. BMC Health Services Research, 2010, 10, 71.	0.9	116
2631	Construct validity of a continuous metabolic syndrome score in children. Diabetology and Metabolic Syndrome, 2010, 2, 8.	1.2	101
2632	A Systematic Review of Implementation of Established Recommended Secondary Prevention Measures in Patients with PAOD. European Journal of Vascular and Endovascular Surgery, 2010, 39, 70-86.	0.8	56
2633	Relation Between the Framingham Risk Score, Coronary Calcium, and Incident Coronary Heart Disease Among Low-Risk Men. American Journal of Cardiology, 2010, 106, 47-50.	0.7	26
2634	Comparison of Intima-Media Thickness of the Carotid Artery and Cardiovascular Disease Risk Factors in Adults With Versus Without the Down Syndrome. American Journal of Cardiology, 2010, 106, 1512-1516.	0.7	58
2636	Peripheral neuropathy in type-II diabetic patients attending diabetic clinics in Al-Azhar University Hospitals, Egypt. International Journal of Diabetes Mellitus, 2010, 2, 20-23.	0.6	16
2637	Association of Capillary Density and Function Measures With Blood Pressure, Fasting Plasma Glucose, and Insulin Sensitivity. Journal of Clinical Hypertension, 2010, 12, 125-135.	1.0	18
2638	Predicted Coronary Heart Disease Risk Reduction and Dual Blood Pressure/Cholesterol Goal Attainment in Patients With Hypertension Treated in Realâ€World Clinical Practice. Journal of Clinical Hypertension, 2010, 12, 396-406.	1.0	3
2639	Epidemiology of gout in women: Fiftyâ€ŧwo–year followup of a prospective cohort. Arthritis and Rheumatism, 2010, 62, 1069-1076.	6.7	181
2640	Metabolic characteristics of breakfast-vegetarian (BV) elderly people in rural Taiwan. Archives of Gerontology and Geriatrics, 2010, 50, 20-23.	1.4	4
2641	Relationship between diabetes mellitus, hypertension and obesity, and healthâ€related quality of life in Gaziantep, a central southâ€eastern city in Turkey. Journal of Clinical Nursing, 2010, 19, 2511-2519.	1.4	36
2642	Effect of combined angiotensinâ€converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients. Nephrology, 2010, 15, 211-215.	0.7	7
2643	Hypertensive Retinopathy and Associated Target Organ Damage in Korean Hypertensive Patients. Journal of Korean Ophthalmological Society, 2010, 51, 1231.	0.0	2
2644	The Heart Failure Epidemic. International Journal of Environmental Research and Public Health, 2010, 7, 1807-1830.	1.2	130
2645	Intra-Arterial Blood Pressure Response in Hypertensive Subjects during Low- and High-Intensity Resistance Exercise. Clinics, 2010, 65, 271-277.	0.6	76

#	Article	IF	CITATIONS
2646	High-sensitivity C-reactive protein and liver enzymes in individuals with Metabolic Syndrome in Talca, Chile. Experimental and Therapeutic Medicine, 2010, 1, 175-179.	0.8	6
2647	The Incidence of Asymptomatic Hypertension in School Children. Journal of Nippon Medical School, 2010, 77, 160-165.	0.3	14
2648	Pharmaceutic guidance to hypertensive patients at USP University Hospital: effect on adherence to treatment. Brazilian Journal of Pharmaceutical Sciences, 2010, 46, 353-362.	1.2	4
2649	Race, Ethnicity, and Shared Decision Making for Hyperlipidemia and Hypertension Treatment: The DECISIONS Survey. Medical Decision Making, 2010, 30, 65-76.	1.2	33
2650	What Is the Optimal Blood Pressure in Patients After Acute Coronary Syndromes?. Circulation, 2010, 122, 2142-2151.	1.6	207
2651	Continuous positive airway pressure titration for obstructive sleep apnoea: automatic versus manual titration. Thorax, 2010, 65, 606-611.	2.7	38
2652	Relations between cardiovascular risk estimates and subclinical atherosclerosis in na \tilde{A} -ve HIV patients: results from the HERMES study. International Journal of STD and AIDS, 2010, 21, 267-272.	0.5	29
2653	Patients' Knowledge about 9 Common Health Conditions: The DECISIONS Survey. Medical Decision Making, 2010, 30, 35-52.	1.2	146
2654	A Randomized Trial of Cholecalciferol versus Doxercalciferol for Lowering Parathyroid Hormone in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 299-306.	2.2	67
2655	Encounter Frequency and Blood Pressure in Hypertensive Patients With Diabetes Mellitus. Hypertension, 2010, 56, 68-74.	1.3	53
2656	Effects of the Dietary Approaches to Stop Hypertension Diet Alone and in Combination With Exercise and Caloric Restriction on Insulin Sensitivity and Lipids. Hypertension, 2010, 55, 1199-1205.	1.3	128
2657	Central nervous system involvement in Sjogren's syndrome: unusual, but not unremarkableclinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology, 2010, 49, 1540-1549.	0.9	115
2658	Prevalence and Relationship Between Diabetic Retinopathy and Nephropathy, and its Risk Factors in the North-East of Spain, a Population-Based Study. Ophthalmic Epidemiology, 2010, 17, 251-265.	0.8	97
2659	Cutoffs of Abdominal Adipose Tissue Compartments as Measured by Magnetic Resonance Imaging for Detection of Cardiovascular Risk Factors in Apparently Healthy Adult Asian Indians in North India. Metabolic Syndrome and Related Disorders, 2010, 8, 243-247.	0.5	25
2660	The epidemiology and management of severe hypertension. Journal of Human Hypertension, 2010, 24, 9-18.	1.0	12
2661	Hypertension and its correlates in two communities of dissimilar genetic ancestry in Sikkim, India. Annals of Human Biology, 2010, 37, 23-43.	0.4	1
2662	Hypertension, Dietary Salt Restriction, and lodine Deficiency Among Adults. American Journal of Hypertension, 2010, 23, 1095-1102.	1.0	38
2663	Association of Serum Uric Acid With Aortic Stiffness and Pressure in a Chinese Workplace Setting. American Journal of Hypertension, 2010, 23, 387-392.	1.0	41

#	ARTICLE	IF	CITATIONS
2664	Trajectories of Neighborhood Poverty and Associations With Subclinical Atherosclerosis and Associated Risk Factors: The Multi-Ethnic Study of Atherosclerosis. American Journal of Epidemiology, 2010, 171, 1099-1108.	1.6	61
2665	Predicting functional outcomes in patients suffering from ischaemic stroke using initial admission variables and physiological data: a comparison between tree model and multivariate regression analysis. Disability and Rehabilitation, 2010, 32, 2088-2096.	0.9	14
2666	Implementation of portable monitor based on mobile phone for music therapy on hypertension. , 2010, , .		1
2667	Tissue Doppler E/E' ratio is a powerful predictor of primary cardiac events in a hypertensive population: an ASCOT substudy. European Heart Journal, 2010, 31, 747-752.	1.0	176
2668	Evidence that prehypertension is a risk factor for Type 2 diabetes. Expert Review of Cardiovascular Therapy, 2010, 8, 335-337.	0.6	5
2669	Economic analysis of the diabetes and hypertension screening collaboration between community pharmacies and a Thai government primary care unit. Primary Care Diabetes, 2010, 4, 155-164.	0.9	15
2670	Trajectories of brain aging in middle-aged and older adults: Regional and individual differences. NeuroImage, 2010, 51, 501-511.	2.1	504
2671	Amlodipine/Atorvastatin. Drugs, 2010, 70, 191-213.	4.9	28
2672	Clinical Versus Statistical Significance: Interpreting P Values and Confidence Intervals Related to Measures of Association to Guide Decision Making. Journal of Pharmacy Practice, 2010, 23, 344-351.	0.5	18
2673	Is newer always better? Re-evaluating the benefits of newer pharmaceuticals. Journal of Health Economics, 2010, 29, 743-750.	1.3	8
2674	Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation. Biochemical and Biophysical Research Communications, 2010, 403, 258-263.	1.0	27
2675	The Multicenter Uveitis Steroid Treatment Trial: Rationale, Design, and Baseline Characteristics. American Journal of Ophthalmology, 2010, 149, 550-561.e10.	1.7	179
2676	Serum Uric Acid Levels and the Risk of Type 2 Diabetes: A Prospective Study. American Journal of Medicine, 2010, 123, 957-961.	0.6	237
2677	Is it Time to Target Prehypertension. Cardiovascular Therapeutics, 2010, 28, 337-338.	1.1	1
2678	Non-dipping pattern of hypertension and obstructive sleep apnea syndrome. Hypertension Research, 2010, 33, 867-871.	1.5	133
2679	Blood Pressure and Bone Mineral Density in Premenopausal and Postmenopausal Women. Journal of Women's Health, 2010, 19, 1209-1215.	1.5	3
2680	Hypertension in the Pediatric Intensive Care Unit., 2011,, 1043-1057.		0
2681	A Genetic Variant of the Atrial Natriuretic Peptide Gene Is Associated With Cardiometabolic Protection in the General Community. Journal of the American College of Cardiology, 2011, 58, 629-636.	1.2	91

#	Article	IF	CITATIONS
2682	Nondiabetic older adults with untreated hypertension in Taiwan: Treatment implication in elderly hypertension. Journal of Clinical Gerontology and Geriatrics, 2011, 2, 58-61.	0.7	5
2683	Factors associated with prevalence, awareness, treatment and control of hypertension in urban adults from 33 communities in China: the CHPSNE Study. Hypertension Research, 2011, 34, 1087-1092.	1.5	41
2684	Health Care Spending Growth. Handbook of Health Economics, 2011, 2, 1-43.	0.2	54
2685	Effectiveness of motivational interviewing and physical activity on prescription on leisure exercise time in subjects suffering from mild to moderate hypertension. BMC Research Notes, 2011, 4, 352.	0.6	19
2686	Uncertain etiologies of proteinuric-chronic kidney disease in rural Sri Lanka. Kidney International, 2011, 80, 1212-1221.	2.6	173
2687	Effects of normal blood pressure, prehypertension, and hypertension on autonomic nervous system function. International Journal of Cardiology, 2011, 151, 50-53.	0.8	41
2688	Prevalence of Early Stages of Chronic Kidney Disease in Healthy Army Personnel. Medical Journal Armed Forces India, 2011, 67, 9-14.	0.3	10
2689	L'ipertensione arteriosa nel Rene Policistico Autosomico Dominante (ADPKD). Giornale De Techniche Nefrologiche & Dialitiche, 2011, 23, 50-56.	0.1	0
2690	Heart Failure as a Consequence of Hypertension. , 2011, , 435-444.		0
2691	Hypertensive emergency as a complication of brachial plexus block. BMJ Case Reports, 2011, 2011, bcr0120113754-bcr0120113754.	0.2	4
2692	FLUVASTATIN INCREASES BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN. Fukushima Journal of Medical Sciences, 2011, 57, 19-27.	0.1	20
2694	Community-Based Participatory Research Approaches for Hypertension Control and Prevention in Churches. International Journal of Hypertension, 2011, 2011, 1-11.	0.5	10
2695	Analysis of the sustained virological response in patients with chronic hepatitis C and liver steatosis. Arquivos De Gastroenterologia, 2011, 48, 179-185.	0.3	0
2696	Prognosis after Stroke. , 2011, , 219-241.		5
2697	What should be the blood pressure target for diabetic patients?. Current Opinion in Cardiology, 2011, 26, 308-313.	0.8	9
2698	A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. Journal of Hypertension, 2011, 29, 980-990.	0.3	214
2699	Physician attitudes to blood pressure control. Journal of Hypertension, 2011, 29, 1633-1640.	0.3	37
2700	Exposure to the Chinese famine in early life and the risk of hypertension in adulthood. Journal of Hypertension, 2011, 29, 1085-1092.	0.3	74

#	Article	IF	CITATIONS
2702	Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. Yearbook of Cardiology, 2011, 2011, 67-69.	0.0	0
2703	BMI and Metabolic Profile in Patients With Prolactinoma Before and After Treatment With Dopamine Agonists. Obesity, 2011, 19, 800-805.	1.5	136
2704	Obesity Duration Is Associated to Pulmonary Function Impairment in Obese Subjects. Obesity, 2011, 19, 1623-1628.	1.5	61
2705	Long-term stable obesity increases risk of hypertension. International Journal of Obesity, 2011, 35, 1056-1062.	1.6	24
2706	Symptomatic subsyndromal depression in hospitalized hypertensive patients. Journal of Affective Disorders, 2011, 135, 168-176.	2.0	8
2707	Development of new concepts of non-adherence measurements among users of antihypertensives medicines. International Journal of Clinical Pharmacy, 2011, 33, 565-572.	1.0	14
2708	Haptoglobin Polymorphism and Association with Complications in Ghanaian Type 2 Diabetic Patients. Indian Journal of Clinical Biochemistry, 2011, 26, 366-372.	0.9	7
2709	Major inducing factors of hypertensive complications and the interventions required to reduce their prevalence: an epidemiological study of hypertension in a rural population in China. BMC Public Health, 2011, 11, 301.	1.2	25
2710	Implementing a hypertension management programme in a rural area: local approaches and experiences from Ba-Vi district, Vietnam. BMC Public Health, 2011, 11, 325.	1.2	23
2711	Project FIT: Rationale, design and baseline characteristics of a school- and community-based intervention to address physical activity and healthy eating among low-income elementary school children. BMC Public Health, $2011, 11, 607$.	1.2	24
2712	A practice-based trial of blood pressure control in African Americans (TLC-Clinic): study protocol for a randomized controlled trial. Trials, 2011, 12, 265.	0.7	10
2713	Hypertension is a potential risk factor for vascular dementia: systematic review. International Journal of Geriatric Psychiatry, 2011, 26, 661-669.	1.3	184
2714	Single-Pill Triple-Combination Therapy: An Alternative to Multiple-Drug Treatment of Hypertension. Postgraduate Medicine, 2011, 123, 21-31.	0.9	19
2715	Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008. Circulation, 2011, 124, 1046-1058.	1.6	519
2716	Severely Elevated Blood Pressure. Journal of Cardiovascular Nursing, 2011, 26, 519-523.	0.6	0
2717	Preeclampsia Is Associated With Persistent Postpartum Cardiovascular Impairment. Hypertension, 2011, 58, 709-715.	1.3	314
2718	Guidelines, Inertia, and Judgment. Hypertension, 2011, 58, 544-545.	1.3	3
2719	Antithrombotic medicines following intracerebral haemorrhage: where's the evidence?. Therapeutic Advances in Drug Safety, 2011, 2, 205-211.	1.0	5

#	Article	IF	Citations
2720	Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction. Circulation, 2011, 124, 164-174.	1.6	516
2721	Better Glycemic Control Is Associated With Maintenance of Lower-Extremity Function Over Time in Mexican American and European American Older Adults With Diabetes. Diabetes Care, 2011, 34, 268-273.	4.3	41
2722	Translational Success Stories: Angiotensin Receptor 1 Antagonists in Heart Failure. Circulation Research, 2011, 109, 437-452.	2.0	56
2723	Association between adiposity indices and cardiometabolic risk factors among adults living in Puerto Rico. Public Health Nutrition, 2011, 14, 1714-1723.	1.1	32
2724	Different kinds of vegetable oils in relation to individual cardiovascular risk factors among Iranian women. British Journal of Nutrition, 2011, 105, 919-927.	1.2	18
2725	Cardiovascular disease risk factors in relation to suicide mortality in Asia: prospective cohort study of over one million Korean men and women. European Heart Journal, 2011, 32, 2773-2780.	1.0	69
2726	The tRNAMet 4435A>G mutation in the mitochondrial haplogroup G2a1 is responsible for maternally inherited hypertension in a Chinese pedigree. European Journal of Human Genetics, 2011, 19, 1181-1186.	1.4	41
2727	Maternally Inherited Essential Hypertension Is Associated With the Novel 4263A>G Mutation in the Mitochondrial tRNA ^{lle} Gene in a Large Han Chinese Family. Circulation Research, 2011, 108, 862-870.	2.0	114
2728	Urinary nitric oxide metabolites and individual blood pressure progression to overt hypertension. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 656-663.	3.1	9
2729	Physical Inactivity and Mortality Risk. Cardiology Research and Practice, 2011, 2011, 1-10.	0.5	70
2730	Determining the feasibility of objective adherence measurement with blister packaging smart technology. American Journal of Health-System Pharmacy, 2012, 69, 872-879.	0.5	28
2731	Electronic Monitoring of Adherence, Treatment of Hypertension, and Blood Pressure Control. American Journal of Hypertension, 2012, 25, 54-59.	1.0	26
2732	Prospective Study of Particulate Air Pollution Exposures, Subclinical Atherosclerosis, and Clinical Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis and Air Pollution (MESA Air). American Journal of Epidemiology, 2012, 176, 825-837.	1.6	126
2734	Use of Cardioselective ß-Blockers in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized, Placebo-controlled, Blinded Trials. Journal of International Medical Research, 2012, 40, 2051-2065.	0.4	37
2735	Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertension Research, 2012, 35, 1102-1110.	1.5	157
2736	Current Approaches to the Treatment of Hypertension in Older Persons. Postgraduate Medicine, 2012, 124, 50-59.	0.9	3
2737	Adherence to Available Clinical Practice Guidelines for Initiation of Antihypertensive Medication in Patients With or Without Diabetes Mellitus and Other Comorbidities in Taiwan. Journal of Clinical Pharmacology, 2012, 52, 576-585.	1.0	3
2738	Impact of age and gender on blood pressure and low-density lipoprotein cholesterol reduction: results of a pooled analysis. Current Medical Research and Opinion, 2012, 28, 1421-1433.	0.9	6

#	Article	IF	CITATIONS
2739	Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus. Kidney International Supplements, 2012, 2, 363-369.	4.6	24
2740	Responses of the second derivative of the finger photoplethysmogram indices and hemodynamic parameters to anesthesia induction. Hypertension Research, 2012, 35, 166-172.	1.5	4
2742	Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology, 2012, 51, 157-168.	0.9	89
2743	The Influence of Subclinical Hyperthyroidism on Blood Pressure, Heart Rate Variability, and Prevalence of Arrhythmias. Thyroid, 2012, 22, 454-460.	2.4	47
2744	Severe Hypoglycemia and Cardiovascular Disease Incidence in Type 1 Diabetes. Diabetes Care, 2012, 35, 1598-1604.	4.3	72
2745	Lifestyle Counseling in Routine Care and Long-Term Glucose, Blood Pressure, and Cholesterol Control in Patients With Diabetes. Diabetes Care, 2012, 35, 334-341.	4.3	48
2746	The Japanese Society of Hypertension Guidelines for Self-monitoring of Blood Pressure at Home (Second Edition). Hypertension Research, 2012, 35, 777-795.	1.5	164
2747	Etiology, Risk Factors and Sex Differences in Ischemic Stroke in the Ludwigshafen Stroke Study, a Population-Based Stroke Registry. Cerebrovascular Diseases, 2012, 33, 69-75.	0.8	99
2748	Cardiovascular Disease Risk Factor Patterns and Their Implications for Intervention Strategies in Vietnam. International Journal of Hypertension, 2012, 2012, 1-11.	0.5	30
2749	Current therapeutic agents and anesthetic considerations for diabetes mellitus. Korean Journal of Anesthesiology, 2012, 63, 195.	0.9	3
2750	Consumption of energy-dense diets in relation to cardiometabolic abnormalities among Iranian women. Public Health Nutrition, 2012, 15, 868-875.	1.1	18
2751	Tungstate activates BK channels in a \hat{I}^2 subunit- and Mg2+-dependent manner: relevance for arterial vasodilatation. Cardiovascular Research, 2012, 95, 29-38.	1.8	12
2752	Presence of baseline prehypertension and risk of incident stroke: A meta-analysis. Yearbook of Cardiology, 2012, 2012, 31-33.	0.0	0
2753	Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Yearbook of Cardiology, 2012, 2012, 53-55.	0.0	0
2754	The quantitative relationship between road traffic noise and hypertension. Journal of Hypertension, 2012, 30, 1075-1086.	0.3	306
2755	Echocardiographic predictors of progression from prehypertension to hypertension. Journal of Hypertension, 2012, 30, 1639-1645.	0.3	7
2756	SF-6D utility index as measure of minimally important difference in health status change. Journal of the American Pharmacists Association: JAPhA, 2012, 52, 34-42.	0.7	12
2757	Survival analysis of pediatric dialysis patients in Taiwan. Nephrology, 2012, 17, 621-627.	0.7	17

#	Article	IF	Citations
2758	Atorvastatin calcium plus amlodipine for the treatment of hypertension. Expert Opinion on Pharmacotherapy, 2012, 13, 2673-2685.	0.9	11
2759	Aspirin for Primary Prevention of Cardiovascular Disease Events. Pharmacotherapy, 2012, 32, 1020-1035.	1.2	34
2760	Difference of antihypertensive prescribing between office- and hospital-based clinics in Taiwan. International Journal of Clinical Pharmacy, 2012, 34, 710-718.	1.0	0
2761	Disparities in adherence to and persistence with antihypertensive regimens: an exploratory analysis from a community-based provider network. Journal of the American Society of Hypertension, 2012, 6, 201-209.	2.3	45
2762	Prognostic Value of Cardiac Troponin T After Myocardial Infarction: A Contemporary Community Experience. Mayo Clinic Proceedings, 2012, 87, 247-254.	1.4	28
2763	Antidepressant Use and Cognitive Deficits in Older Men: Addressing Confounding by Indications with Different Methods. Annals of Epidemiology, 2012, 22, 9-16.	0.9	6
2764	Quality issues of self-report of hypertension: Analysis of a population representative sample of older adults in Taiwan. Archives of Gerontology and Geriatrics, 2012, 55, 338-342.	1.4	10
2765	The relationship between subclinical atherosclerosis, non–high-density lipoprotein cholesterol, exercise, andÂdiet among male participants of the PACC Project. Journal of Clinical Lipidology, 2012, 6, 174-179.	0.6	11
2766	Chemometric resolution of coeluting peaks of eleven antihypertensives from multiple classes in high performance liquid chromatography: A comprehensive research in human serum, health product and Chinese patent medicine samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 902, 96-107.	1.2	23
2768	First-attack pediatric hypertensive crisis presenting to the pediatric emergency department. BMC Pediatrics, 2012, 12, 200.	0.7	30
2769	Effect of branched-chain amino acid-enriched nutritional supplementation on interferon therapy in Japanese patients with chronic hepatitis C virus infection: a retrospective study. Virology Journal, 2012, 9, 282.	1.4	9
2770	Early Left Atrial Mechanics and Volume Abnormalities in Subjects with Prehypertension: A Real Time Threeâ€Dimensional Echocardiography Study. Echocardiography, 2012, 29, 1211-1217.	0.3	13
2771	Antihypertensive Efficacy of the Losartan/Hydrochlorothiazide Combination and its Effect on Plasma B-Type Natriuretic Peptide in Hypertensive Patients Uncontrolled by Angiotensin II Type 1 Receptor Antagonist-Based Therapy. Clinical Drug Investigation, 2012, 32, 171-178.	1.1	2
2772	Presence of mutation m.14484T>C in a Chinese family with maternally inherited essential hypertension but no expression of LHON. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 1535-1543.	1.8	21
2773	Evaluation of existing and candidate measures of obesity for detection of insulin resistance and cardiometabolic risk among Asian Indians: Development of two clinically useful models. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2012, 6, 181-186.	1.8	1
2774	Population Aging: Implications for Nurse Practitioners. Journal for Nurse Practitioners, 2012, 8, 554-559.	0.4	7
2775	Exercise-Training Reduced Blood Pressure and Improve Placental Vascularization in Pregnant Spontaneously Hypertensive Rats –Pilot Study. Fetal and Pediatric Pathology, 2012, 31, 423-431.	0.4	10
2776	Blood pressure reducing effects of <i>Phalaris canariensis </i> in normotensive and spontaneously hypertensive rats. Canadian Journal of Physiology and Pharmacology, 2012, 90, 201-208.	0.7	15

#	Article	IF	CITATIONS
2777	Uric acid concentration as a risk marker for blood pressure progression and incident hypertension: A Chinese cohort study. Metabolism: Clinical and Experimental, 2012, 61, 1747-1755.	1.5	52
2778	Prevalence, awareness, treatment and control of hypertension in Vietnamâ€"results from a national survey. Journal of Human Hypertension, 2012, 26, 268-280.	1.0	116
2779	Prognostic value of myocardial perfusion scintigraphy in elderly patients with hypertension: a 10-year follow-up analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1570-1580.	3.3	3
2780	Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy. BMC Medical Research Methodology, 2012, 12, 119.	1.4	19
2782	Ivabradine Prevents Heart Rate Acceleration in Patients with Chronic Obstructive Pulmonary Disease and Coronary Heart Disease after Salbutamol Inhalation. Pharmaceuticals, 2012, 5, 398-404.	1.7	7
2783	Trends in antihypertensives use among Moroccan patients. Pharmacoepidemiology and Drug Safety, 2012, 21, 1067-1073.	0.9	4
2784	The 12S rRNA A1555G mutation in the mitochondrial haplogroup D5a is responsible for maternally inherited hypertension and hearing loss in two Chinese pedigrees. European Journal of Human Genetics, 2012, 20, 607-612.	1.4	16
2785	Doctor pharmaceutical utilization behaviour changed by the global budget programme strategies on hypertensive outpatient prescription. Journal of Evaluation in Clinical Practice, 2012, 18, 262-268.	0.9	4
2786	Frailty Transitions in the San Antonio Longitudinal Study of Aging. Journal of the American Geriatrics Society, 2012, 60, 652-660.	1.3	159
2787	Uric Acid, Hypertension, and Chronic Kidney Disease Among Alaska Eskimos: The Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) Study. Journal of Clinical Hypertension, 2012, 14, 71-77.	1.0	23
2788	Severity and outcome of acute stroke in women: relation to adrenal sex steroid levels. Metabolism: Clinical and Experimental, 2012, 61, 84-91.	1.5	11
2789	Stroke due to atrial fibrillation in a populationa€based stroke registry (<scp>L</scp> udwigshafen) Ij ETQq1 1 0.7 <scp>CHA</scp> ₂ <scp>DS</scp> ₂ â€ <scp>VAS</scp> c score, underuse of oral anticoagulation, and implications for preventive measures. European Journal of Neurology, 2013, 20,	/84314 rg 1.7	34
2790	Impaired Renal Function Further Increases Odds of 6-Year Coronary Artery Calcification Progression in Adults With Type 1 Diabetes. Diabetes Care, 2013, 36, 2607-2614.	4.3	41
2791	Intracerebral haemorrhage in a population-based stroke registry (LuSSt): incidence, aetiology, functional outcome and mortality. Journal of Neurology, 2013, 260, 2541-2550.	1.8	44
2792	Bringing prevention in geriatrics: Evidences from cardiovascular medicine supporting the new challenge. Experimental Gerontology, 2013, 48, 64-68.	1.2	25
2793	Serum total bilirubin is inversely associated with brachial-ankle pulse wave velocity in men with hypertension. Heart and Vessels, 2013, 28, 453-460.	0.5	12
2794	Ramipril and hydrochlorothiazide treatment of hypertensive urgency in the ED. American Journal of Emergency Medicine, 2013, 31, 1533-1534.	0.7	0
2795	Consequences of Gastrointestinal Surgery on Drug Absorption. Nutrition in Clinical Practice, 2013, 28, 429-436.	1.1	30

#	ARTICLE	IF	CITATIONS
2796	Serum electrolyte levels in relation to macrovascular complications in Chinese patients with diabetes mellitus. Cardiovascular Diabetology, 2013, 12, 146.	2.7	32
2797	Quantifying the contributions of behavioral and biological risk factors to socioeconomic disparities in coronary heart disease incidence: the MORGEN study. European Journal of Epidemiology, 2013, 28, 807-814.	2.5	63
2798	Treatment of Hypertension in Obese Patients. American Journal of Cardiovascular Drugs, 2013, 13, 163-175.	1.0	14
2799	Association Between Pre-hypertension and Cardiovascular Outcomes: A Systematic Review and Meta-analysis of Prospective Studies. Current Hypertension Reports, 2013, 15, 703-716.	1.5	107
2800	Autonomic Dysreflexia: Evaluation and Management. Current Bladder Dysfunction Reports, 2013, 8, 319-325.	0.2	0
2801	Positive association between plasma levels of oxidized lowâ€density lipoprotein and myeloperoxidase after hemodialysis in patients with diabetic endâ€stage renal disease. Hemodialysis International, 2013, 17, 557-567.	0.4	11
2802	Antihypertensive Medication Nonadherence in Black Men: Direct and Mediating Effects of Depressive Symptoms, Psychosocial Stressors, and Substance Use. Journal of Clinical Hypertension, 2013, 15, 201-209.	1.0	17
2803	U.S. and Canadian Hypertension Guidelines. , 2013, , 425-432.		0
2804	Spectroscopic study to characterize in vitro interaction of losartan with gliquidone and pioglitazone. Medicinal Chemistry Research, 2013, 22, 351-359.	1.1	9
2805	Molecular properties prediction, synthesis, and diuretic activity of phenoxy acetic acid bearing pyrazolines. Medicinal Chemistry Research, 2013, 22, 916-926.	1.1	3
2806	Blood pressure and TNF- \hat{l} ± act synergistically to increase leucocyte CD11b adhesion molecule expression in the BELFAST study: implications for better blood pressure control in ageing. Age, 2013, 35, 197-205.	3.0	7
2807	Suspected coronary artery disease and myocardial infarction with normal coronary angiography: A heterogeneous but benign condition?. Revista Portuguesa De Cardiologia (English Edition), 2013, 32, 205-210.	0.2	2
2808	Adrenal Venous Sampling for Primary Hyperaldosteronism in Patients with Concurrent Chronic Kidney Disease. Journal of Vascular and Interventional Radiology, 2013, 24, 726-733.	0.2	8
2809	Relation of estimated glomerular filtration rate and body mass index to mortality in non-dialysis patients with coronary artery disease: A report from the ET-CHD registry, 1997–2003. Journal of Cardiology, 2013, 62, 144-150.	0.8	5
2810	Alcohol is a Risk Factor not for Thalamic but for Putaminal Hemorrhage: The Akita Stroke Registry. Journal of Stroke and Cerebrovascular Diseases, 2013, 22, 1064-1069.	0.7	5
2811	The Cooperative Lifestyle Intervention Program-II (CLIP-II): Design and methods. Contemporary Clinical Trials, 2013, 36, 382-393.	0.8	26
2812	Suspected coronary artery disease and myocardial infarction with normal coronary angiography: A heterogeneous but benign condition?. Revista Portuguesa De Cardiologia, 2013, 32, 205-210.	0.2	3
2813	Are there consequences of labeling patients with prehypertension? An experimental study of effects on blood pressure and quality of life. Journal of Psychosomatic Research, 2013, 74, 433-438.	1.2	14

#	Article	IF	CITATIONS
2814	Risk of type 2 diabetes and cumulative excess weight exposure in the Framingham Offspring Study. Journal of Diabetes and Its Complications, 2013, 27, 214-218.	1.2	14
2815	Biophysical Basis of Glomerular Filtration. , 2013, , 693-719.		2
2816	Evaluating the impact of depression, anxiety & autonomic function on health related quality of life, vocational functioning and health care utilisation in acute coronary syndrome patients: the ADVENT study protocol. BMC Cardiovascular Disorders, 2013, 13, 103.	0.7	12
2817	Epidemiology of Heart Failure. Circulation Research, 2013, 113, 646-659.	2.0	1,352
2818	Factors Related to the Initial Stroke Severity of Posterior Circulation Ischemic Stroke. Cerebrovascular Diseases, 2013, 36, 62-68.	0.8	27
2819	Hypertension Increases With Aging and Obesity in Chimpanzees (<scp>P</scp> an troglodytes). Zoo Biology, 2013, 32, 79-87.	0.5	34
2820	Influence of explanatory and confounding variables on HRQoL after controlling for measurement bias and response shift in measurement. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 841-851.	0.7	7
2821	Metabolic syndrome in the rural population of Wardha, Central India: An exploratory factor analysis. Indian Journal of Community Medicine, 2013, 38, 33.	0.2	13
2822	Nutrition and Blood Pressure. , 2013, , 415-443.		0
2823	Risk Factors for Mortality in Hemodialysis Patients: Two-Year Follow-Up Study. Disease Markers, 2013, 35, 791-798.	0.6	45
2824	Fixed Combination of Amlodipine/Atorvastatin. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 544-549.	1.0	7
2825	Renal Artery Stenosis-An Update. Postgraduate Medicine, 2013, 125, 43-50.	0.9	3
2826	Prevalence, Awareness, Treatment, and Control of Hypertension Among Residents in Guangdong Province, China, 2004 to 2007. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 217-222.	0.9	19
2827	Tâ∈Helper Type 1 Bias in Healthy People Is Associated With Cytomegalovirus Serology and Atherosclerosis: The Multiâ∈Ethnic Study of Atherosclerosis. Journal of the American Heart Association, 2013, 2, e000117.	1.6	56
2828	Antihypertensive Prescriptions Over a 10-Year Period in a Large Chinese Population. American Journal of Hypertension, 2013, 26, 931-938.	1.0	17
2829	The Atrial Natriuretic Peptide Genetic Variant rs5068 Is Associated With a Favorable Cardiometabolic Phenotype in a Mediterranean Population. Diabetes Care, 2013, 36, 2850-2856.	4.3	51
2830	Effect of Meditation on Endothelial Function in Black Americans With Metabolic Syndrome. Psychosomatic Medicine, 2013, 75, 591-599.	1.3	12
2831	Hypertension. Current Opinion in Neurology, 2013, 26, 8-12.	1.8	16

#	Article	IF	CITATIONS
2832	Impact of Diabetes on Cardiovascular Disease: An Update. International Journal of Hypertension, 2013, 2013, 1-15.	0.5	321
2833	Blood Pressure and Cholesterol Control in Hypertensive Hypercholesterolemic Patients. Circulation, 2013, 128, 29-41.	1.6	123
2834	Prevalence, Awareness, Treatment, and Control of Hypertension in Elderly Adults with Chronic Kidney Disease: Results from the Survey of Prevalence, Awareness, and Treatment Rates in Chronic Kidney Disease Patients with Hypertension in China. Journal of the American Geriatrics Society, 2013, 61, 2160-2167.	1.3	32
2835	The <scp>H</scp> ispanic <scp>P</scp> aradox and Predictors of Mortality in an Aging <scp>B</scp> iethnic <scp>C</scp> ohort of <scp>M</scp> exican <scp>A</scp> mericans and <scp>E</scp> uropean <scp>A</scp> mericans: The <scp>S</scp> an <scp>A</scp> ntonio Longitudinal Study of Aging, Journal of the American Geriatrics Society, 2013, 61, 1522-1529.	1.3	24
2836	Different Definitions of Prevalent Hypertension Impact: The Clinical Epidemiology of Hypertension and Attainment of Healthy People Goals. Journal of Clinical Hypertension, 2013, 15, 154-161.	1.0	29
2837	How will the growing threat of resistant hypertension impact the future treatment of high blood pressure?. Expert Review of Cardiovascular Therapy, 2013, 11, 1541-1546.	0.6	0
2838	Simple Integer Risk Score to Determine Prognosis of Patients With Hypertension and Chronic Stable Coronary Artery Disease. Journal of the American Heart Association, 2013, 2, e000205.	1.6	11
2839	Prevalence, awareness, treatment and control of hypertension in the Palestinian population. Journal of Human Hypertension, 2013, 27, 623-628.	1.0	31
2840	Impact of visit-to-visit variability of blood pressure on deterioration of renal function in patients with non-diabetic chronic kidney disease. Hypertension Research, 2013, 36, 151-157.	1.5	65
2841	Prevalence and Factors Associated with a Prolonged QTc Interval in a Cohort of Asymptomatic HIV-Infected Patients. AIDS Research and Human Retroviruses, 2013, 29, 1195-1198.	0.5	10
2842	Cardiovascular Risk Impact in the Oil Industry. , 2013, , .		0
2843	Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. Journal of Hypertension, 2013, 31, 698-704.	0.3	63
2844	Reversed Dipper Blood-Pressure Pattern Is Closely Related to Severe Renal and Cardiovascular Damage in Patients with Chronic Kidney Disease. PLoS ONE, 2013, 8, e55419.	1.1	75
2845	Lycopene Supplement and Blood Pressure: An Updated Meta-Analysis of Intervention Trials. Nutrients, 2013, 5, 3696-3712.	1.7	46
2846	The Mean Platelet Volume in Patients with Retinal Vein Occlusion. Journal of Ophthalmology, 2013, 2013, 1-4.	0.6	27
2847	Beta-Blockers Reduced the Risk of Mortality and Exacerbation in Patients with COPD: A Meta-Analysis of Observational Studies. PLoS ONE, 2014, 9, e113048.	1.1	143
2848	Correlation of fibroblast growth factor 21 serum levels with metabolic parameters in Japanese subjects. Journal of Medical Investigation, 2014, 61, 28-34.	0.2	29
2849	Largeâ€Scale Geneâ€Centric Analysis Identifies Polymorphisms for Resistant Hypertension. Journal of the American Heart Association, 2014, 3, e001398.	1.6	32

#	Article	IF	CITATIONS
2850	Circulating purine compounds, uric acid, and xanthine oxidase/dehydrogenase relationship in essential hypertension and end stage renal disease. Renal Failure, 2014, 36, 613-618.	0.8	51
2851	Factors Influencing the Decline in Stroke Mortality. Stroke, 2014, 45, 315-353.	1.0	655
2852	Update on Clinical Guidelines for Treatment of Hypertension. Current Cardiovascular Risk Reports, 2014, 8, 1.	0.8	0
2853	Differences in Vascular Nitric Oxide and Endothelium-Derived Hyperpolarizing Factor Bioavailability in Blacks and Whites. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1320-1327.	1.1	50
2854	Chapter 3. Principles of treatment. Hypertension Research, 2014, 37, 279-285.	1.5	1
2855	Effects of dietary sodium and the DASH diet on the occurrence of headaches: results from randomised multicentre DASH-Sodium clinical trial. BMJ Open, 2014, 4, e006671.	0.8	48
2856	Bilateral adrenal incidentalomas differ from unilateral adrenal incidentalomas in subclinical cortisol hypersecretion but not in potential clinical implications. European Journal of Endocrinology, 2014, 171, 37-45.	1.9	45
2857	Variations in Aging, Gender, Menopause, and Obesity and Their Effects on Hypertension in Taiwan. International Journal of Hypertension, 2014, 2014, 1-7.	0.5	27
2858	The diagnostic yield of neuroimaging in sixth nerve palsy - Sankara Nethralaya Abducens Palsy Study (SNAPS): Report 1. Indian Journal of Ophthalmology, 2014, 62, 1008.	0.5	25
2859	Visitâ€toâ€Visit Variability of Blood Pressure and Renal Function Decline in Patients With Diabetic Chronic Kidney Disease. Journal of Clinical Hypertension, 2014, 16, 362-366.	1.0	20
2860	Chapter 2. Measurement and clinical evaluation of blood pressure. Hypertension Research, 2014, 37, 266-278.	1.5	15
2861	Cardiovascular and Mortality Risk of Apparent Resistant Hypertension in Women With Suspected Myocardial Ischemia: A Report From the NHLBIâ€Sponsored WISE Study. Journal of the American Heart Association, 2014, 3, e000660.	1.6	57
2862	Molecular characterization of a Chinese family carrying a novel C4329A mutation in mitochondrial tRNAIle and tRNAGIngenes. BMC Medical Genetics, 2014, 15, 84.	2.1	11
2863	Burden and predictors of hypertension in India: results of SEEK (Screening and Early Evaluation of) Tj ETQq $1\ 1\ 0$.	784314 rg	BT_/Overlock
2864	Systematic analysis of the clinical and biochemical characteristics of maternally inherited hypertension in Chinese Han families associated with mitochondrial. BMC Medical Genomics, 2014, 7, 73.	0.7	7
2865	Risk of progression to hypertension in nonhypertensive Japanese workers aged 20–64 years. Journal of Hypertension, 2014, 32, 236-244.	0.3	18
2866	Sex Differences in Mental Stress–Induced Myocardial Ischemia in Young Survivors of an Acute Myocardial Infarction. Psychosomatic Medicine, 2014, 76, 171-180.	1.3	97
2867	The role of body weight, fat distribution and weight change in ethnic differences in the 9-year incidence of hypertension. Journal of Hypertension, 2014, 32, 990-997.	0.3	16

#	Article	IF	CITATIONS
2868	Systolic Blood Pressure Goals to Reduce Cardiovascular Disease Among Older Adults. American Journal of the Medical Sciences, 2014, 348, 129-134.	0.4	11
2869	Anatomy of Success. Hypertension, 2014, 63, 641-647.	1.3	30
2870	The Growing Gap in Hypertension Control Between Insured and Uninsured Adults. Hypertension, 2014, 64, 997-1004.	1.3	55
2872	Difference by sex but not by race/ethnicity in the visceral adipose tissue-depressive symptoms association: The Multi-Ethnic Study of Atherosclerosis. Psychoneuroendocrinology, 2014, 47, 78-87.	1.3	17
2873	Clinical significance of home blood pressure and its possible practical application. Clinical and Experimental Nephrology, 2014, 18, 24-40.	0.7	11
2874	A 12-Week Weight Reduction Intervention for Overweight Individuals Taking Antipsychotic Medications. Community Mental Health Journal, 2014, 50, 974-980.	1.1	18
2875	Changes in blood pressure classification, blood pressure goals and pharmacological treatment of essential hypertension in medical guidelines from 2003 to 2013. IJC Metabolic & Endocrine, 2014, 2, 1-10.	0.5	3
2876	Cardiovascular Disease Prevention and Implications for Worksite Health Promotion Programs in Brazil. Progress in Cardiovascular Diseases, 2014, 56, 493-500.	1.6	15
2877	Multidisciplinary Consensus on Assessment of Unruptured Intracranial Aneurysms. Stroke, 2014, 45, 1523-1530.	1.0	83
2878	Closing the Gap in Hypertension Control Between Younger and Older Adults. Circulation, 2014, 129, 2052-2061.	1.6	34
2879	Atenolol use is associated with longâ€term mortality in communityâ€dwelling older adults with hypertension. Geriatrics and Gerontology International, 2014, 14, 153-158.	0.7	5
2880	Psychosocial Risk Factors for Hypertension: an Update of the Literature. Current Hypertension Reports, 2014, 16, 483.	1.5	131
2881	Preventing Dementia in Older Cardiovascular Patients. Current Cardiovascular Risk Reports, 2014, 8, 1.	0.8	3
2882	Pathophysiology, Diagnosis, and Treatment of Mineralocorticoid Disorders. , 2014, 4, 1083-1119.		12
2883	Healthy, Wealthy, and Wise. Psychological Science, 2014, 25, 1822-1830.	1.8	27
2884	Hypertension in the United States, 1999 to 2012. Circulation, 2014, 130, 1692-1699.	1.6	176
2885	Blood pressure control rate and associated risk factors in hospitals of different grades in Chongqing, China. International Journal of Cardiology, 2014, 176, 800-804.	0.8	5
2886	2014 Hypertension Recommendations From the Eighth Joint National Committee Panel Members Raise Concerns for Elderly Black and Female Populations. Journal of the American College of Cardiology, 2014, 64, 394-402.	1.2	79

#	Article	IF	CITATIONS
2887	2014 Eighth Joint National Committee Panel Recommendation for BloodÂPressureÂTargets Revisited. Journal of the American College of Cardiology, 2014, 64, 784-793.	1.2	67
2888	Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet, The, 2014, 384, 591-598.	6.3	510
2889	Effects of one month treatment with propranolol and metoprolol on the relaxant and contractile function of isolated trachea from rats exposed to cigarette smoke for four months. Inhalation Toxicology, 2014, 26, 271-277.	0.8	8
2890	Is there a relationship between endometrial polyps and obesity, diabetes mellitus, hypertension?. Archives of Gynecology and Obstetrics, 2014, 290, 937-941.	0.8	26
2891	Antihypertensive effect of few-flower wild rice (Zizania latifolia Turcz.) in spontaneously hypertensive rats. Food Science and Biotechnology, 2014, 23, 439-444.	1.2	7
2892	The goal of blood pressure in the hypertensive patient with diabetes is defined: now the challenge is go from recommendations to practice. Diabetology and Metabolic Syndrome, 2014, 6, 31.	1.2	28
2893	Developing Hypertension Guidelines: An Evolving Process. American Journal of Hypertension, 2014, 27, 765-772.	1.0	27
2894	Diagnosis and Treatment of Glomerular Diseases in Elderly Patients. Advances in Chronic Kidney Disease, 2014, 21, 228-246.	0.6	13
2895	Renin-angiotensin system inhibitors and troponin elevation in spinal surgery. Journal of Clinical Neuroscience, 2014, 21, 1133-1140.	0.8	4
2896	Physical Environment May Modify the Association Between Depressive Symptoms and Change in Waist Circumference: The Multi-Ethnic Study of Atherosclerosis. Psychosomatics, 2014, 55, 144-154.	2.5	11
2897	Atherogenic lipids and vascular complications in a selected diabetic population with normal urinary albumin/creatinine ratios. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2014, 8, 124-127.	1.8	3
2898	Five-Year Prognosis After Endovascular Therapy in Claudicant Patients With Iliofemoral Artery Disease. Journal of Endovascular Therapy, 2014, 21, 381-388.	0.8	15
2899	Diabetes and age-related demographic differences in risk factor control. Journal of the American Society of Hypertension, 2014, 8, 394-404.	2.3	11
2900	Guidelines for Diagnosis and Treatment of Patients With Vasospastic Angina (Coronary Spastic) Tj ETQq $1\ 1\ 0.7$	843] 4 rgB	T /gygrlock 1
2901	Weight gain and reduced energy expenditure in low-income Brazilian women living in slums: a 4-year follow-up study. British Journal of Nutrition, 2015, 114, 462-471.	1.2	8
2902	Oscillometric blood pressure in Indian school children: Simplified percentile tables and charts. Indian Pediatrics, 2015, 52, 939-945.	0.2	6
2903	Sasang constitution may act as a risk factor for prehypertension. BMC Complementary and Alternative Medicine, 2015, 15, 231.	3.7	6
2904	Sex and race/ethnic disparities in the cross-sectional association between depressive symptoms and muscle mass: the Multi-ethnic Study of Atherosclerosis. BMC Psychiatry, 2015, 15, 221.	1.1	8

#	Article	IF	Citations
2905	Evaluation of Global Health in Master Swimmers Involved in French National Championships. Sports Medicine - Open, 2015, 1 , 12 .	1.3	5
2906	Beta-blockers in patients with chronic obstructive disease and coexistent cardiac illnesses. COPD Research and Practice, 2015, 1, .	0.7	8
2907	Impact of the Serum Uric Acid Level on Subclinical Atherosclerosis in Middle-aged and Elderly Chinese. Journal of Atherosclerosis and Thrombosis, 2015, 22, 823-832.	0.9	23
2908	Use of Renally Inappropriate Medications in Older Veterans: A National Study. Journal of the American Geriatrics Society, 2015, 63, 2290-2297.	1.3	55
2909	Effect of sour tea (Hibiscus sabdariffa L.) on arterial hypertension. Journal of Hypertension, 2015, 33, 1119-1127.	0.3	102
2910	Concordance with DASH diet and blood pressure change. Journal of Hypertension, 2015, 33, 2223-2230.	0.3	79
2911	The Association between the Polymorphisms in a Sodium Channel Gene <i>SCN7A</i> and Essential Hypertension: A Case-Control Study in the Northern Han Chinese. Annals of Human Genetics, 2015, 79, 28-36.	0.3	13
2912	The Highs and Lows of Blood Pressure Targets in Elderly Adults and Other Highâ€Risk Populations. Journal of the American Geriatrics Society, 2015, 63, 2139-2141.	1.3	1
2913	Risk Factors of Coronary Artery Disease in Secondary Prevention—Results from the AtheroGene—Study. PLoS ONE, 2015, 10, e0131434.	1.1	26
2914	Coronary Atherosclerotic Plaque Detected by Computed Tomographic Angiography in Subjects with Diabetes Compared to Those without Diabetes. PLoS ONE, 2015, 10, e0143187.	1.1	16
2915	Coronary Artery Calcium Improves Risk Assessment in Adults With a Family History of Premature Coronary Heart Disease. Circulation: Cardiovascular Imaging, 2015, 8, e003186.	1.3	49
2916	Trends in Hypertension Control Among the Older Population of Spain From 2000 to 2001 to 2008 to 2010. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 67-76.	0.9	29
2917	A survey of risk factors associated with hypertension in the adult population of Kang, Kgalagadi North, Botswana. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2015, 57, 177-182.	0.2	4
2918	Hypertension in African Americans Aged 60 to 79ÂYears: Statement From the International Society of Hypertension in Blacks. Journal of Clinical Hypertension, 2015, 17, 252-259.	1.0	12
2919	Replacing the hypertension control paradigm with a strategy of cardiovascular risk reduction. European Heart Journal Quality of Care & Dutcomes, 2015, 1, 17-22.	1.8	7
2920	Change in the association of body mass index and systolic blood pressure in Germany – national cross-sectional surveys 1998 and 2008–2011. BMC Public Health, 2015, 15, 705.	1.2	14
2921	Chronic kidney disease as a risk factor for incident gout among men and women: retrospective cohort study using data from the Framingham Heart Study. BMJ Open, 2015, 5, e006843-e006843.	0.8	35
2922	Modeling of the pharmacokinetic/pharmacodynamic interaction between irbesartan and hydrochlorothiazide in normotensive subjects. Biopharmaceutics and Drug Disposition, 2015, 36, 216-231.	1.1	11

#	Article	IF	CITATIONS
2923	Treatment of hypertension in chronic kidney disease patients under specialized care: One-center cross-sectional analyses. Blood Pressure, 2015, 24, 79-85.	0.7	7
2924	Twenty-year brain magnetic resonance imaging follow-up study in Systemic Lupus Erythematosus: Factors associated with accrual of damage and central nervous system involvement. Autoimmunity Reviews, 2015, 14, 510-516.	2.5	34
2925	Antihypertensive Therapy and the J-curve: Fact or Fiction?. Current Hypertension Reports, 2015, 17, 6.	1.5	11
2926	Factors Contributing to 50-ft Walking Speed and Observed Ethnic Differences in Older Community-Dwelling Mexican Americans and European Americans. Physical Therapy, 2015, 95, 871-883.	1.1	18
2927	Risk factors for acute myocardial infarction in Central India: A case-control study. Indian Journal of Community Medicine, 2015, 40, 19.	0.2	13
2928	Tea, but not coffee consumption, is associated with components of arterial pressure. The Observation of Cardiovascular Risk Factors study in Luxembourg. Nutrition Research, 2015, 35, 557-565.	1.3	13
2929	Risk Factors Associated with Recurrent Strokes in Young and Elderly Patients: A Hospital-based Study. International Journal of Gerontology, 2015, 9, 63-66.	0.7	9
2930	Incidence of early-onset dementia in Mar del Plata. NeurologÃa (English Edition), 2015, 30, 77-82.	0.2	0
2931	Understanding multifactorial influences on the continuum of maternal weight trajectories in pregnancy and early postpartum: study protocol, and participant baseline characteristics. BMC Pregnancy and Childbirth, 2015, 15, 71.	0.9	3
2932	Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions. American Journal of Hypertension, 2015, 28, 995-1009.	1.0	18
2933	Severity of Childhood Obstructive Sleep Apnea and Hypertension Improved after Adenotonsillectomy. Otolaryngology - Head and Neck Surgery, 2015, 152, 553-560.	1,1	32
2934	Serum ferritin in HIV-positive patients is related to immune deficiency and inflammatory activity. International Journal of STD and AIDS, 2015, 26, 393-397.	0.5	11
2935	Early Clinical Detection of Pharmacologic Response in Insulin Action in a Nondiabetic Insulin-Resistant Population. Current Therapeutic Research, 2015, 77, 83-89.	0.5	5
2936	Characteristics, Treatments, and Outcomes of Hospitalized Heart Failure Patients Stratified by Etiologies of Cardiomyopathy. JACC: Heart Failure, 2015, 3, 906-916.	1.9	54
2937	The unruptured intracranial aneurysm treatment score. Neurology, 2015, 85, 881-889.	1.5	301
2938	Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients. Journal of Diabetes and Its Complications, 2015, 29, 1165-1170.	1.2	27
2939	Tratamiento anticoagulante en pacientes con fibrilación auricular no valvular en un centro de salud. Grado de control del INR e incidencia de episodios cardioembólicos. Medicina General Y De Familia, 2015, 4, 37-42.	0.1	0
2940	Increased prevalence of polycystic ovary syndrome in premenopausal women with nonalcoholic fatty liver disease. European Journal of Endocrinology, 2015, 173, 739-747.	1.9	29

#	Article	IF	CITATIONS
2941	Cigarette smoking is associated with a reduction in the risk of incident gout: results from the Framingham Heart Study original cohort. Rheumatology, 2015, 54, 91-95.	0.9	36
2942	Provider Perspectives on Essential Functions for Care Management in the Collaborative Treatment of Hypertension: The P.A.R.T.N.E.R. Framework. Journal of General Internal Medicine, 2015, 30, 454-461.	1.3	11
2944	Neighborhood-Level Racial/Ethnic Residential Segregation and Incident Cardiovascular Disease. Circulation, 2015, 131, 141-148.	1.6	216
2945	Incidencia de demencia de inicio precoz en Mar de Plata. NeurologÃa, 2015, 30, 77-82.	0.3	10
2946	Impact of Aspirin According to Type of Stable Coronary Artery Disease: Insights from a Large International Cohort. American Journal of Medicine, 2015, 128, 137-143.	0.6	7
2947	Abdominal Obesity Associated with Elevated Serum Butyrylcholinesterase Activity, Insulin Resistance and Reduced High Density Lipoprotein-Cholesterol Levels. Indian Journal of Clinical Biochemistry, 2015, 30, 275-280.	0.9	12
2949	Perfectionism Affects Blood Pressure in Response to Repeated Exposure to Stress. Stress and Health, 2016, 32, 157-166.	1.4	9
2950	Association of triglycerides and new lipid markers with the incidence of hypertension in a Spanish cohort. Journal of Hypertension, 2016, 34, 1257-1265.	0.3	83
2951	Association of endogenous testosterone with subclinical atherosclerosis in men: the multiâ€ethnic study of atherosclerosis. Clinical Endocrinology, 2016, 84, 700-707.	1.2	25
2952	Associations Between Blood Pressure and Outcomes Among Blacks in the Jackson Heart Study. Journal of the American Heart Association, 2016, 5, .	1.6	5
2953	Pulsatile Load Components, Resistive Load and Incident Heart Failure: The Multi-Ethnic Study of Atherosclerosis (MESA). Journal of Cardiac Failure, 2016, 22, 988-995.	0.7	33
2954	A Hypertension-Associated tRNA ^{Ala} Mutation Alters tRNA Metabolism and Mitochondrial Function. Molecular and Cellular Biology, 2016, 36, 1920-1930.	1.1	48
2955	The Natural History of Patients With Isolated Metabolic Syndrome. Mayo Clinic Proceedings, 2016, 91, 623-633.	1.4	12
2956	Association of Elevated Serum Lipoprotein(a), Inflammation, Oxidative Stress and Chronic Kidney Disease with Hypertension in Non-diabetes Hypertensive Patients. Indian Journal of Clinical Biochemistry, 2016, 31, 446-451.	0.9	4
2957	Diuretics in primary hypertension – Reloaded. Indian Heart Journal, 2016, 68, 720-723.	0.2	17
2958	Fibromyalgia is associated to receiving chronic medications beyond appropriateness: a cross-sectional study. Rheumatology International, 2016, 36, 1691-1699.	1.5	8
2959	Mitochondrial DNA mutation m.5512AÂ>ÂG in the acceptor-stem of mitochondrial tRNATrp causing maternally inherited essential hypertension. Biochemical and Biophysical Research Communications, 2016, 479, 800-807.	1.0	8
2960	Hypertension Treatment in Blacks: Discussion of the U.S. Clinical Practice Guidelines. Progress in Cardiovascular Diseases, 2016, 59, 282-288.	1.6	33

#	Article	IF	CITATIONS
2961	Mitochondrial tRNA mutations in 2070 Chinese Han subjects with hypertension. Mitochondrion, 2016, 30, 208-221.	1.6	30
2962	Relationships between blood pressure and health and fitness-related variables in obese women. Journal of Physical Therapy Science, 2016, 28, 2933-2937.	0.2	6
2963	Isolated Systolic Hypertension: An Update After SPRINT. American Journal of Medicine, 2016, 129, 1251-1258.	0.6	85
2964	Relationship of Albuminuria and Renal Artery Stent Outcomes. Hypertension, 2016, 68, 1145-1152.	1.3	50
2965	Relationship between retinopathy and renal abnormalities in black hypertensive patients. Clinical Hypertension, 2016, 22, 19.	0.7	6
2966	An Update on Nutrients and Blood Pressure. Journal of Atherosclerosis and Thrombosis, 2016, 23, 276-289.	0.9	63
2968	Booker T. Washington and the Secret of Hypertension in African Americans. American Journal of the Medical Sciences, 2016, 352, 416-419.	0.4	0
2969	Managing hypertension in type 2 diabetes mellitus. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 445-454.	2.2	36
2970	Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease. Journal of Women's Health, 2016, 25, 996-1003.	1.5	14
2971	The advantages of combination therapy on hypertension: development of immediate release perindopril–indapamide tablet and assessment of bioequivalence studies. Pharmaceutical Development and Technology, 2016, 21, 239-249.	1.1	3
2972	Modifiable Risk Factors and Determinants of Stroke. , 2016, , 217-233.		2
2973	Tumor Necrosis Factor-Î', Interleukin-6, C-Reactive Protein Levels and Insulin Resistance Associated with Type 2 Diabetes in Abdominal Obesity Women. Indian Journal of Clinical Biochemistry, 2016, 31, 68-74.	0.9	56
2974	The impacts of premorbid hypertension treatment on functional outcomes of ischemic stroke. Journal of the Neurological Sciences, 2016, 363, 1-4.	0.3	6
2975	Ambulatory Blood Pressure Monitoring in Coronary Artery Disease and Heart Failure. , 2016, , 299-321.		0
2976	Patterns and Predictors of Blood Pressure Treatment, Control, and Outcomes among Stroke Survivors in the United States. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 857-865.	0.7	19
2977	Mitochondrial tRNA mutations in Chinese hypertensive individuals. Mitochondrion, 2016, 28, 1-7.	1.6	16
2978	Hypertension unawareness among Chinese patients with first-ever stroke. BMC Public Health, 2016, 16, 170.	1.2	11
2979	The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1889-1916.	1.8	1,921

#	Article	IF	CITATIONS
2980	Glycated apolipoprotein Bâ€"A surrogate marker of subclinical atherosclerosis. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2016, 10, 78-81.	1.8	12
2981	Metabolic syndrome and the risk of sudden cardiac death in middle-aged men. International Journal of Cardiology, 2016, 203, 792-797.	0.8	38
2982	Antihypertensive Drugs and Male Sexual Dysfunction. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 233-244.	1.0	32
2983	Trends in Antihypertensive Medication Use and Blood Pressure Control Among Adults With Hypertension in Germany. American Journal of Hypertension, 2016, 29, 104-113.	1.0	55
2984	Lung function, percent emphysema, and QT duration: The Multi-Ethnic Study of Atherosclerosis (MESA) lung study. Respiratory Medicine, 2017, 123, 1-7.	1.3	12
2985	Racial discrimination associated with higher diastolic blood pressure in a sample of <scp>A</scp> merican <scp>I</scp> ndian adults. American Journal of Physical Anthropology, 2017, 163, 122-128.	2.1	23
2986	Using Predicted Cardiovascular DiseaseÂRisk in Conjunction WithÂBloodÂPressure toÂGuide Antihypertensive Medication Treatment. Journal of the American College of Cardiology, 2017, 69, 2446-2456.	1.2	58
2987	Comparative efficacy of \hat{l}^2 -blockers on mortality and cardiovascular outcomes in patients with hypertension: a systematic review and network meta-analysis. Journal of the American Society of Hypertension, 2017, 11, 394-401.	2.3	19
2988	Declining blood pressure and intensification of blood pressure management among people over 80 years. Journal of Hypertension, 2017, 35, 1276-1282.	0.3	10
2989	Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg. Circulation, 2017, 136, 798-812.	1.6	60
2990	Engagement in Pleasant Leisure Activities and Blood Pressure: A 5-Year Longitudinal Study in Alzheimer Caregivers. Psychosomatic Medicine, 2017, 79, 735-741.	1.3	19
2991	Choline and its metabolites are differently associated with cardiometabolic risk factors, history of cardiovascular disease, and MRI-documented cerebrovascular disease in older adults,. American Journal of Clinical Nutrition, 2017, 105, 1283-1290.	2.2	48
2992	Effect of gender and adiposity on inÂvivo vascular function in young African Americans. Journal of the American Society of Hypertension, 2017, 11, 246-257.	2.3	7
2993	Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China. Clinical Rheumatology, 2017, 36, 1023-1029.	1.0	18
2994	Hypertension: An Evidence Informed, Case Based Approach. Physician Assistant Clinics, 2017, 2, 557-570.	0.1	0
2995	Impact of Clinical Factors on the Achievement of Target Blood Pressure in Hypertensive Patients from Ivanovo Region of Russia: Data of 2015. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 425-435.	1.0	5
2996	Usefulness of Coronary Artery Calcium to Predict Heart Failure With Preserved Ejection Fraction in Men Versus Women (from the Multi-Ethnic Study of Atherosclerosis). American Journal of Cardiology, 2017, 120, 1847-1853.	0.7	21
2997	Reply. Journal of Hypertension, 2017, 35, 2327-2328.	0.3	0

#	ARTICLE	IF	CITATIONS
2998	A hypertension-associated mitochondrial DNA mutation alters the tertiary interaction and function of tRNALeu(UUR). Journal of Biological Chemistry, 2017, 292, 13934-13946.	1.6	29
2999	Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD). Respiratory Research, 2017, 18, 124.	1.4	30
3000	Association between Hypertension and Epistaxis: Systematic Review and Metaâ€analysis. Otolaryngology - Head and Neck Surgery, 2017, 157, 921-927.	1.1	39
3001	Association Between <i>APOL1</i> Genotypes and Risk of Cardiovascular Disease in MESA (Multiâ€Ethnic) Tj ETC	Qq1,1 0.78	34314 rgBT 17
3002	Cardiovascular Risk Factors in White Collar Workers Under Shift Work. Acta Medica Bulgarica, 2017, 44, 5-9.	0.0	3
3004	The Mitochondrial tRNA ^{Ala} T5655C Mutation May Modulate the Phenotypic Expression of tRNA ^{Met} and tRNA ^{Gln} A4401G Mutation in a Han Chinese Family With Essential Hypertension. International Heart Journal, 2017, 58, 95-99.	0.5	8
3005	Global Trends in Cardiovascular Disease. , 2017, , 301-329.		7
3006	Cuadro clÃnico del sÃndrome de apnea-hipopnea obstructiva del sueño (SAHOS). Revista Facultad De Medicina, 2017, 65, 29-37.	0.0	2
3007	Ambient Coarse Particulate Matter and the Right Ventricle: The Multi-Ethnic Study of Atherosclerosis. Environmental Health Perspectives, 2017, 125, 077019.	2.8	6
3008	Implications of Recent Clinical Trials and Hypertension Guidelines on Stroke and Future Cerebrovascular Research. Stroke, 2018, 49, 772-779.	1.0	30
3009	Elevations in neutrophils with obstructive sleep apnea: The Multi-Ethnic Study of Atherosclerosis (MESA). International Journal of Cardiology, 2018, 257, 318-323.	0.8	24
3010	Importance of the lipidâ€related pathways in the association between statins, mortality, and cardiovascular disease risk: The Multiâ€Ethnic Study of Atherosclerosis. Pharmacoepidemiology and Drug Safety, 2018, 27, 365-372.	0.9	7
3011	Global Implications of Blood Pressure Thresholds and Targets. Hypertension, 2018, 71, 985-987.	1.3	11
3012	Evaluation of non-HDL cholesterol as a predictor of non-fatal cardiovascular events in a prospective population cohort. ClÃnica E Investigación En Arteriosclerosis (English Edition), 2018, 30, 64-71.	0.1	5
3013	Hypertension Across a Woman'sÂLifeÂCycle. Journal of the American College of Cardiology, 2018, 71, 1797-1813.	1.2	159
3014	Hypertension in patients with type 2 diabetes mellitus: Targets and management. Maturitas, 2018, 112, 71-77.	1.0	55
3015	\hat{I}^2 -Blockers in myocardial infarction and coronary artery disease with a preserved ejection fraction. Coronary Artery Disease, 2018, 29, 262-270.	0.3	12
3016	Implications of New High Blood Pressure Guidelines for Stroke Primary and Secondary Prevention. Stroke, 2018, 49, 511-512.	1.0	0

#	Article	IF	CITATIONS
3017	Systemic Hypertension., 2018,, 217-229.		1
3018	Valoración del colesterol no HDL como predictor de episodios cardiovasculares no mortales en una cohorte prospectiva de origen poblacional. ClÃnica E Investigación En Arteriosclerosis, 2018, 30, 64-71.	0.4	8
3019	Interactions Between PPARG and AGTR1 Gene Polymorphisms on the Risk of Hypertension in Chinese Han Population. Genetic Testing and Molecular Biomarkers, 2018, 22, 90-97.	0.3	11
3020	Relationship between systolic blood pressure and all-cause mortality: a prospective study in a cohort of Chinese adults. BMC Public Health, 2018, 18, 107.	1.2	10
3021	Basic vs More Complex Definitions of Family History in the Prediction of Coronary Heart Disease: The Multi-Ethnic Study of Atherosclerosis. Mayo Clinic Proceedings, 2018, 93, 1213-1223.	1.4	33
3022	Intensive Blood Pressure Targets for Diabetic and Other High-Risk Populations. Hypertension, 2018, 71, 833-839.	1.3	17
3023	Prevalence of hypertension determined by ambulatory blood pressure monitoring (ABPM) and body composition in long-term survivors of childhood cancer. Pediatric Hematology and Oncology, 2018, 35, 1-10.	0.3	10
3024	Changes in thickness of central macula and retinal nerve fibre layer in severe hypertensive retinopathy: a 1â€year longitudinal study. Acta Ophthalmologica, 2018, 96, e386-e392.	0.6	22
3025	Mortality implications of lower DBP with lower achieved systolic pressures in coronary artery disease. Journal of Hypertension, 2018, 36, 419-427.	0.3	5
3026	Screening of primary aldosteronism by clinical features and daily laboratory tests. Journal of Hypertension, 2018, 36, 326-334.	0.3	8
3027	Asymmetries in reciprocal baroreflex mechanisms and chronic pain severity: Focusing on irritable bowel syndrome. Neurogastroenterology and Motility, 2018, 30, e13186.	1.6	17
3028	Incidencia de enfermedad cerebrovascular en adultos: estudio epidemiol \tilde{A}^3 gico prospectivo basado en poblaci \tilde{A}^3 n cautiva en Argentina. Neurologia Argentina, 2018, 10, 8-15.	0.1	O
3029	Pharmacological heart rate lowering in patients with a preserved ejection fractionâ€"review of a failing concept. Heart Failure Reviews, 2018, 23, 499-506.	1.7	17
3030	Accuracy of self-reported hypertension. Journal of Hypertension, 2018, 36, 970-978.	0.3	55
3031	Mitochondrial tRNA ^{Ala} C5601T mutation may modulate the clinical expression of tRNA ^{Met} A4435G mutation in a Han Chinese family with hypertension. Clinical and Experimental Hypertension, 2018, 40, 595-600.	0.5	9
3032	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology, 2018, 71, e127-e248.	1.2	4,042
3033	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension, 2018, 71, e13-e115.	1.3	3,332
3034	Mitochondrial tRNAThr 15909A>G mutation associated with hypertension in a Chinese Han pedigree. Biochemical and Biophysical Research Communications, 2018, 495, 574-581.	1.0	11

#	Article	IF	CITATIONS
3035	Use of Combination Therapies. , 2018, , 261-267.		0
3036	The association between preinduction arterial blood pressure and postoperative cardiovascular, renal, and neurologic morbidity, and in-hospital mortality in elective noncardiac surgery. Journal of Hypertension, 2018, 36, 2251-2259.	0.3	2
3037	Evaluation of a one-dose package medication support system for community-based elderly patients and eldercare facilities. American Journal of Health-System Pharmacy, 2018, 75, e202-e212.	0.5	8
3038	Cross-sectional study of the association between day-to-day home blood pressure variability and visceral fat area measured using the dual impedance method. PLoS ONE, 2018, 13, e0206945.	1.1	2
3039	High Blood Pressure in Young Adulthood and Risk of Premature Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2018, 320, 1760.	3.8	18
3040	Association of Blood Pressure Classification in Korean Young Adults According to the 2017 American College of Cardiology/American Heart Association Guidelines With Subsequent Cardiovascular Disease Events. JAMA - Journal of the American Medical Association, 2018, 320, 1783.	3.8	170
3041	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2018, 138, e484-e594.	1.6	330
3042	Putting All Guidelines Into Perspective. , 2018, , 469-474.		O
3043	Mechanisms of isolevuglandin-protein adduct formation in inflammation and hypertension. Prostaglandins and Other Lipid Mediators, 2018, 139, 48-53.	1.0	15
3044	Updated American Heart Association/American College of Cardiology; European Society of Hypertension/European Society of Cardiology Guidelines. , 2018, , 459-468.		1
3045	Long-Term Cardiovascular Risk Associated With Stage 1 Hypertension Defined by the 2017 ACC/AHA Hypertension Guideline. Journal of the American College of Cardiology, 2018, 72, 1201-1210.	1.2	100
3047	Diuretics in Hypertension. , 2018, , 211-221.		2
3048	Association between Obstructive Sleep Apnea and Cardiovascular Risk Factors: Variation by Age, Sex, and Race. The Multi-Ethnic Study of Atherosclerosis. Annals of the American Thoracic Society, 2018, 15, 970-977.	1.5	59
3049	Complexity Changes in Brain Activity in Healthy Ageing: A Permutation Lempel-Ziv Complexity Study of Magnetoencephalograms. Entropy, 2018, 20, 506.	1.1	12
3050	Increased levels of substance P in patients taking betaâ€blockers are linked with a protective effect on oropharyngeal dysphagia. Neurogastroenterology and Motility, 2018, 30, e13397.	1.6	12
3051	Prevalence and determinants of hypertension among adult population in Nepal: Data from Nepal Demographic and Health Survey 2016. PLoS ONE, 2018, 13, e0198028.	1.1	58
3052	Prevalence of severe hypertension in a Sub-Saharan African community. International Journal of Cardiology: Hypertension, 2019, 2, 100016.	2.2	5
3053	Angiotensin Receptor Blockers and Subclinical Interstitial Lung Disease: The MESA Study. Annals of the American Thoracic Society, 2019, 16, 1451-1453.	1.5	8

#	Article	IF	CITATIONS
3054	Role of Nutrition and Exercise Programs in Reducing Blood Pressure: A Systematic Review. Journal of Clinical Medicine, 2019, 8, 1393.	1.0	18
3055	Hypertension Awareness, Treatment, and Control in US Adults: Trends in the Hypertension Control Cascade by Population Subgroup (National Health and Nutrition Examination Survey, 1999–2016). American Journal of Epidemiology, 2019, 188, 2165-2174.	1.6	48
3056	Tapered vs. Uniform Tube-Load Modeling of Blood Pressure Wave Propagation in Human Aorta. Frontiers in Physiology, 2019, 10, 974.	1.3	6
3057	Impact of Department of Veterans Affairs Cooperative Studies Program clinical trials on practice guidelines for high blood pressure management. Contemporary Clinical Trials Communications, 2019, 13, 100313.	0.5	3
3058	A unified mapping framework of multifaceted pharmacodynamic responses to hypertension interventions. Drug Discovery Today, 2019, 24, 883-889.	3.2	2
3059	Differences in left ventricular geometry in hypertensive African-Europeans and Caucasian patients. European Journal of Internal Medicine, 2019, 62, 43-47.	1.0	4
3060	Is Prevalence of Atherosclerotic Risk Factors Increasing Among Young Adults? It Depends on How You Ask. Journal of the American Heart Association, 2019, 8, e010883.	1.6	9
3061	Evolution of Blood Pressure Clinical Practice Guidelines: A Personal Perspective. Canadian Journal of Cardiology, 2019, 35, 570-581.	0.8	13
3062	Cholesterol Mass Efflux Capacity, Incident Cardiovascular Disease, and Progression of Carotid Plaque. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 89-96.	1.1	91
3063	Asymptomatic Coronary Artery Disease in Japanese Patients With the Acute Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 612-618.	0.7	6
3064	Blood Pressure Goals in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 161-169.	2.2	42
3065	Potential Cardiovascular Disease Events Prevented with Adoption of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline. Circulation, 2019, 139, 24-36.	1.6	42
3066	Association of High Levels of Spot Urine Protein with High Blood Pressure, Mean Arterial Pressure and Pulse Pressure with the Development of Diabetic Chronic Kidney Dysfunction or Failure among Diabetic Patients. Statistical Regression Modeling to Predict Diabetic Proteinuria. Current Diabetes Reviews, 2019, 15, 486-496.	0.6	6
3067	Hypertension and Coronary Artery Disease in Women: Is Aggressive Blood Pressure Control Appropriate?. Journal of Women's Health, 2020, 29, 135-136.	1.5	0
3068	Diabetes Mellitus Is an Independent Predictor for the Development of Heart Failure. Mayo Clinic Proceedings, 2020, 95, 124-133.	1.4	26
3069	Clusters of Cardiovascular Risk Factors and Their Impact on the 20-Year Cardiovascular Risk in a General Population. Journal of Cardiovascular Nursing, 2020, 35, 210-216.	0.6	5
3070	Systolic blood pressure, heart rate, and outcomes in patients with coronary disease and heart failure. ESC Heart Failure, 2020, 7, 124-130.	1.4	5
3071	The pharmacological management of malignant hypertension. Journal of Hypertension, 2020, 38, 2325-2330.	0.3	11

#	Article	IF	CITATIONS
3072	A Review of Hypertension Management in Black Male Patients. Mayo Clinic Proceedings, 2020, 95, 1955-1963.	1.4	14
3073	The Story of the Silent Killer. Current Hypertension Reports, 2020, 22, 72.	1.5	31
3074	Association of <i>APOL1</i> Genotypes With Measures of Microvascular and Endothelial Function, and Blood Pressure in MESA. Journal of the American Heart Association, 2020, 9, e017039.	1.6	7
3075	The use of single-pill combinations as first-line treatment for hypertension: translating guidelines into clinical practice. Journal of Hypertension, 2020, 38, 2369-2377.	0.3	12
3076	Joint trajectories of cognition and gait speed in Mexican American and European American older adults: The San Antonio longitudinal study of aging. International Journal of Geriatric Psychiatry, 2020, 35, 897-906.	1.3	13
3077	Primary Aldosteronism in Patients in China With Recently Detected Hypertension. Journal of the American College of Cardiology, 2020, 75, 1913-1922.	1.2	112
3078	Association between Serum Mg2+ Concentrations and Cardiovascular Organ Damage in a Cohort of Adult Subjects. Nutrients, 2020, 12, 1264.	1.7	3
3079	Trends in ambulatory blood pressure monitoring use for confirmation or monitoring of hypertension and resistant hypertension among the commercially insured in the U.S., 2008–2017. International Journal of Cardiology: Hypertension, 2020, 6, 100033.	2.2	9
3080	Identifying hotspots of cardiometabolic outcomes based on a Bayesian approach: The example of Chile. PLoS ONE, 2020, 15, e0235009.	1.1	6
3081	Chronic Diseases Multimorbidity among Adult People Living with HIV at Hawassa University Comprehensive Specialized Hospital, Southern Ethiopia. International Journal of Chronic Diseases, 2020, 2020, 1-9.	1.9	9
3082	Reimbursement of ambulatory blood pressure monitoring in the US commercial insurance marketplace. Journal of Clinical Hypertension, 2020, 22, 6-15.	1.0	10
3083	An evaluation of empagliflozin and it $\hat{a} \in \mathbb{N}$ s applicability to hypertension as a therapeutic option. Expert Opinion on Pharmacotherapy, 2020, 21, 1157-1166.	0.9	4
3084	Effects of chronic consumption of specific fruit (berries, citrus and cherries) on CVD risk factors: a systematic review and meta-analysis of randomised controlled trials. European Journal of Nutrition, 2021, 60, 615-639.	1.8	42
3085	The Population-Attributable Fraction for Premature Mortality Due to Cardiovascular Disease Associated With Stage 1 and 2 Hypertension Among Japanese. American Journal of Hypertension, 2021, 34, 56-63.	1.0	6
3086	National guidelines on nutrient reference values for the healthy adult population and for pregnant or lactating women are based on heterogeneous sources of evidence: review of guidelines. Nutrition Reviews, 2021, 79, 462-478.	2.6	0
3087	Spatially Weighted Coronary Artery Calcium Score and Coronary Heart Disease Events in the Multi-Ethnic Study of Atherosclerosis. Circulation: Cardiovascular Imaging, 2021, 14, e011981.	1.3	16
3088	Cardiovascular Risk Assessment in Hypertensive Patients. American Journal of Hypertension, 2021, 34, 569-577.	1.0	17
3089	Laboratory evaluation of endocrine hypertension. , 2021, , 391-447.		1

#	Article	IF	CITATIONS
3090	The frontal plane QRS-T angle may affect our perspective on prehypertension: A prospective study. Clinical and Experimental Hypertension, 2021, 43, 1-6.	0.5	5
3091	Differences between beta-blockers in the treatment of arterial hypertension. Journal of Hypertension, 2021, 39, 384-385.	0.3	1
3092	Resistance training to reduce resting blood pressure and increase muscle strength in users and non-users of anti-hypertensive medication: A meta-analysis. Clinical and Experimental Hypertension, 2021, 43, 1-12.	0.5	9
3093	Office Blood Pressure Range and Cardiovascular Events in Patients With Hypertension: A Nationwide Cohort Study in South Korea. Journal of the American Heart Association, 2021, 10, e017890.	1.6	7
3094	Molecular characterization of two Chinese pedigrees with maternally inherited hypertension. Journal of Gene Medicine, 2021, 23, e3328.	1.4	7
3095	Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage. Nephrology Dialysis Transplantation, 2021, 36, 1326-1346.	0.4	18
3096	Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease. JAMA Network Open, 2021, 4, e218418.	2.8	19
3097	Clinical and molecular features of two diabetes families carrying mitochondrial ND1 T3394C mutation. Irish Journal of Medical Science, 2022, 191, 749-758.	0.8	6
3098	Progression of Preclinical Heart Failure: A Description of Stage A and B Heart Failure in a Community Population. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007216.	0.9	7
3099	Potassium Metabolism and Management in Patients with CKD. Nutrients, 2021, 13, 1751.	1.7	36
3100	High plasma renin activity associates with obesity-related diabetes and arterial hypertension, and predicts persistent hypertension after bariatric surgery. Cardiovascular Diabetology, 2021, 20, 118.	2.7	8
3101	Relation between Retinopathy and Progression of Coronary Artery Calcium in Individuals with Versus Without Diabetes Mellitus (From the Multi–Ethnic Study of Atherosclerosis). American Journal of Cardiology, 2021, 149, 1-8.	0.7	3
3102	Cumulative exposure to psychosocial stressors at work and global cognitive function: the PROspective Quebec Study on Work and Health. Occupational and Environmental Medicine, 2021, 78, 884-892.	1.3	4
3103	Erectile dysfunction and diabetes: A melting pot of circumstances and treatments. Diabetes/Metabolism Research and Reviews, 2022, 38, e3494.	1.7	74
3104	Assessment of hypertension in kidney transplantation by ambulatory blood pressure monitoring: a systematic review and meta-analysis. CKJ: Clinical Kidney Journal, 2022, 15, 31-42.	1.4	14
3105	Risk of Atrial Fibrillation in Young Adults With Isolated Diastolic, Isolated Systolic, and Systolic-Diastolic Hypertension. Hypertension, 2021, 78, 1248-1258.	1.3	7
3106	Sleep apnea, coronary artery calcium density, and cardiovascular events: results from the Multi-Ethnic Study of Atherosclerosis. Journal of Clinical Sleep Medicine, 2021, 17, 2075-2083.	1.4	5
3107	Effects of Caloric Restriction Diet on Arterial Hypertension and Endothelial Dysfunction. Nutrients, 2021, 13, 274.	1.7	35

#	Article	IF	Citations
3108	Lifestyle Modifications to Prevent Hypertension. JAMA - Journal of the American Medical Association, 2003, 289, 843-a-843.	3.8	5
3110	Blood Pressure and Cardiovascular Disease. , 0, , 146-160.		1
3111	Length of Dialysis Session Is More Important Than Large Kt/V in Hemodialysis. Home Hemodialysis International International Symposium on Daily Home Hemodialysis, 1999, 3, 16-22.	0.8	3
3113	Sexual Dimorphism in Cardiovascular Disease. , 1999, , 187-217.		3
3114	Pharmacology of Cav1 (L-Type) Channels. , 2004, , 21-72.		6
3115	Definition of Diabetic Renal Disease in Insulin Dependent Diabetes Mellitus Based on Renal Function Tests., 2000,, 13-28.		9
3116	Microalbuminuria, Blood Pressure and Diabetic Renal Disease: Origin and Development of Ideas. , 2000, , 655-706.		9
3117	Definition of Diabetic Renal Disease in Insulin-Dependent Diabetes Mellitus Based on Renal Function Tests., 1998,, 17-29.		2
3118	Ambulatory Monitoring of Blood Pressure. , 2001, , 57-75.		12
3119	Cardiovascular Reactivity in Youth. , 2004, , 251-263.		2
3120	Ambulatory Blood Pressure Methodology and Norms in Children. , 2004, , 107-120.		1
3121	Vascular Aging. , 2005, , 517-547.		1
3122	The Importance of Hypertension in the Geriatric Population. , 2005, , 3-9.		1
3123	α-Adrenoceptor Blockers for Management of Hypertension in the Elderly. , 2005, , 381-397.		1
3124	Development of Blood Pressure Norms in Children. , 2011, , 135-146.		2
3125	Beta-Blockers. Contemporary Cardiology, 2015, , 1-68.	0.0	1
3126	Blood Pressure Norms and Definition of Hypertension in Children. , 2013, , 141-152.		3
3127	Severe Cardiac Disease in Pregnancy. , 2008, , 269-290.		1

#	Article	IF	CITATIONS
3128	Integration of Primary Care and Behavioral Health., 2020,, 273-300.		1
3129	Predicting Mortality from Profiles of Biological Risk and Performance Measures of Functioning. Mortality in an International Perspective, 2014, , 119-135.	0.6	2
3130	The Analysis of Variability of Short Data Sets Based on Mahalanobis Distance Calculation and Surrogate Time Series Testing. Contributions To Statistics, 2018, , 275-287.	0.2	1
3131	PIESYS: A Patient Model-Based Intelligent System for Continuing Hypertension Management. , 2007, , 137-148.		1
3132	Systemic Hypertension., 2002,, 1015-1064.		2
3133	Investigation of Hypertension in Childhood. , 2016, , 1339-1360.		2
3134	Preoperative Assessment. , 2002, , 61-76.		1
3135	The National High Blood Pressure Education Programâ€fâ€fThe National High Blood Pressure Education Program by Edward J. Roccella, Ph.D., is in the Public Domain , 2005, , 7-15.		3
3136	Carotid Occlusive Disease., 2011,, 3615-3620.		1
3137	Epidemiology of Stroke. , 2011, , 198-218.		2
3138	Kidney Disease. , 2012, , 1523-1607.		5
3139	Systemic Hypertension., 2012,, 955-974.		2
3140	Medical Management of Patients with Renal Artery Stenosis., 2008,, 647-659.		1
3141	Relationship of Resting Baroreflex Activity to 24-Hour Blood Pressure and Mood in Healthy People. Journal of Psychophysiology, 2010, 24, 149-160.	0.3	15
3142	Rational pharmacotherapy of hypertension in the elderly: analysis of the choice and dosage of drugs. Journal of Clinical Pharmacy and Therapeutics, 2001, 26, 33-42.	0.7	13
3143	Twenty-four hour ambulatory blood pressure in a population of elderly men. Journal of Internal Medicine, 2000, 248, 501-510.	2.7	24
3144	Blood pressure in diabetic nephropathy - current controversies. Journal of Internal Medicine, 2001, 249, 215-223.	2.7	6
3145	The role of lifestyle management in the overall treatment plan for prevention and management of hypertension. Seminars in Nephrology, 2002, 22, 35-43.	0.6	13

#	Article	IF	CITATIONS
3146	Pathophysiology of hypertension in the elderly. Seminars in Nephrology, 2002, 22, 65-70.	0.6	20
3147	What Is the Role of Dietary Sodium and Potassium in Hypertension and Target Organ Injury?. American Journal of the Medical Sciences, 1999, 317, 152-159.	0.4	27
3148	Abnormalities of Kidney Function as a Cause and a Consequence of Cardiovascular Disease. American Journal of the Medical Sciences, 1999, 317, 176-182.	0.4	42
3149	Consortium for Southeastern Hypertension Control. American Journal of the Medical Sciences, 1999, 318, 357.	0.4	27
3150	Diuretic Complications. American Journal of the Medical Sciences, 2000, 319, 10.	0.4	216
3151	Rising Levels of Cardiovascular Mortality in Mississippi, 1979???1995. American Journal of the Medical Sciences, 2000, 319, 131-137.	0.4	23
3152	The Association of Left Ventricular Mass with Cardiovascular Risk Factors in African American Women. American Journal of the Medical Sciences, 2000, 320, 13-17.	0.4	6
3153	Beta-blocker therapy for hypertension. Dimensions of Critical Care Nursing, 2001, 20, 2-9.	0.4	1
3154	Coronary Risk Factors: Influences on the Lipid Profile. Journal of Cardiovascular Nursing, 2000, 14, 16-28.	0.6	8
3155	Factors Influencing Blood Pressure: Development of a Risk Model. Journal of Cardiovascular Nursing, 2000, 15, 62-79.	0.6	13
3156	Evidence-Based Medicine and ACE Inhibition. Journal of Cardiovascular Pharmacology, 1998, 32, S24-S35.	0.8	18
3157	Cerebral Perfusion in Hypertensive Patients: Effects of Lacidipine and Hydrochlorothiazide. Journal of Cardiovascular Pharmacology, 2000, 35, S13-S18.	0.8	3
3158	Ethnic differences in intake and excretion of sodium, potassium, calcium and magnesium in South Africans. European Journal of Cardiovascular Prevention and Rehabilitation, 2005, 12, 355-362.	3.1	30
3159	Volume Control in Hemodialysis Patients. Hemodialysis International, 2000, 4, 68-74.	0.4	4
3160	ACE inhibitors and insulin sensitivity. Postgraduate Medical Journal, 1999, 75, 445-445.	0.9	1
3161	Patient adherence to antihypertensive medications in upper Egypt: a cross-sectional study. Egyptian Heart Journal, 2020, 72, 29.	0.4	13
3162	Heart Rate Variability and Blood Pressure Variability in Obstetrics and Gynecology., 2012,, 157-184.		2
3163	Prevalence of Major Chronic Conditions among Older Chinese Adults: The Study on Global AGEing and Adult Health (SAGE) Wave 1. PLoS ONE, 2013, 8, e74176.	1.1	88

#	Article	IF	CITATIONS
3164	Total and Abdominal Adiposity and Hypertension in Indigenous Women in Midwest Brazil. PLoS ONE, 2016, 11, e0155528.	1.1	11
3165	Socioeconomic Status and Poor Health Outcome at 10 Years of Follow-Up in the Multi-Ethnic Study of Atherosclerosis. PLoS ONE, 2016, 11, e0165651.	1.1	26
3166	Cardiovascular Disease Risk Factors in Post-Menopausal Women in West Anatolia . International Heart Journal, 2004, 45, 119-131.	0.6	8
3167	Development of a Health Risk Index Associated with Degree of Overweight in School Children. The Showa University Journal of Medical Sciences, 2001, 13, 235-241.	0.1	1
3168	Blood pressure and lipid profile in young women: the role of anthropometric measurement. Revista Brasileira De Educação FÃsica E Esporte: RBEFE, 2014, 28, 553-560.	0.1	3
3169	Condições sociodemográficas e de saúde de idosos residentes em domicÃłio no municÃpio de Jequié-BA. Revista Brasileira De Geriatria E Gerontologia, 2009, 12, 267-274.	0.1	5
3172	Relação entre hipertensão arterial sistêmica e sÃndrome da apnéia obstrutiva do sono. Revista Brasileira De Otorrinolaringologia, 2002, 68, 619-622.	0.2	3
3173	Hipertensão arterial entre trabalhadores de petróleo expostos a ruÃdo. Cadernos De Saude Publica, 2001, 17, 1481-1488.	0.4	8
3174	Incidence of high blood pressure in a group of tannery workers in Brazil. Cadernos De Saude Publica, 2004, 20, 1121-1124.	0.4	3
3175	Differences in self-rated health among older adults according to socioeconomic circumstances: the BambuÃ-Health and Aging Study. Cadernos De Saude Publica, 2005, 21, 830-839.	0.4	32
3176	NÃveis séricos de creatinina: hipercreatininemia em segmento da população adulta de Salvador, Brasil. Revista Brasileira De Epidemiologia, 2004, 7, 176-186.	0.3	9
3177	Renal Failure in the Recipients of Nonrenal Solid Organ Transplants. Journal of the American Society of Nephrology: JASN, 1999, 10, 1136-1144.	3.0	104
3178	Pronatriodilatin Gene Polymorphisms, Microvascular Permeability, and Diabetic Nephropathy in Type 1 Diabetes Mellitus. Journal of the American Society of Nephrology: JASN, 1999, 10, 1530-1541.	3.0	12
3179	Hepatitis C Virus-Associated Glomerular Disease in Patients with Human Immunodeficiency Virus Coinfection. Journal of the American Society of Nephrology: JASN, 1999, 10, 1566-1574.	3.0	84
3180	Explained and Unexplained Ischemic Heart Disease Risk after Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2000, 11, 1735-1743.	3.0	440
3181	Recommendations for the Outpatient Surveillance of Renal Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2000, 11, S1-S86.	3.0	514
3182	Hypertension in Autosomal-Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2001, 12, 194-200.	3.0	150
3183	Renal Function and Intensive Lowering of Blood Pressure in Hypertensive Participants of the Hypertension Optimal Treatment (HOT) Study. Journal of the American Society of Nephrology: JASN, 2001, 12, 218-225.	3.0	415

#	Article	IF	CITATIONS
3184	The Thiazide-Sensitive Na-Cl Cotransporter and Human Disease. Journal of the American Society of Nephrology: JASN, 2003, 14, 538-540.	3.0	28
3185	Food Patterns, Lifestyle, and Hypertension. Zahedan Journal of Researches in Medical Sciences, 2016, 18,	0.1	3
3186	Dyslipidemia in Industrial Workers in Hot Environments. Central European Journal of Public Health, 2006, 14, 15-17.	0.4	20
3187	Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH). Therapeutics and Clinical Risk Management, 2007, 3, 181-196.	0.9	9
3188	Assessment of cognitive function in patients with essential hypertension treated with lercanidipine. Vascular Health and Risk Management, 2006, 2, 491-498.	1.0	10
3189	The Impact of Treatment Adherence for Patients With Diabetes and Hypertension on Cardiovascular Disease Risk: Protocol for a Retrospective Cohort Study, 2008-2018. JMIR Research Protocols, 2019, 8, e13571.	0.5	2
3190	Prediction of Incident Hypertension Within the Next Year: Prospective Study Using Statewide Electronic Health Records and Machine Learning. Journal of Medical Internet Research, 2018, 20, e22.	2.1	151
3191	Validation of a new score for outcome prediction in patients with heart failure with reduced ejection fraction. Minerva Cardioangiologica, 2019, 67, 191-199.	1.2	4
3192	Dietary Intake Ratios of Calcium-to-Phosphorus and Sodium-to-Potassium Are Associated with Serum Lipid Levels in Healthy Korean Adults. Preventive Nutrition and Food Science, 2012, 17, 93-100.	0.7	19
3195	Morbidity pattern and its sociodemographic determinants among elderly population of Raichur district, Karnataka, India. Journal of Family Medicine and Primary Care, 2017, 6, 340.	0.3	12
3196	The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the Aace System of Intensive Diabetes Self-Management—2002 Update. Endocrine Practice, 2002, 8, 40-82.	1.1	201
3197	The Need for Evidence in Hypertension Management: Historical Perspective. Annals of Saudi Medicine, 2005, 25, 368-374.	0.5	1
3198	An Association between Plasma Homocysteine Concentrations and Ischemic Stroke in Elderly Japanese. Journal of Atherosclerosis and Thrombosis, 2002, 9, 121-125.	0.9	17
3199	Association Between Posttraumatic Stress Disorder and Epigenetic Age Acceleration in a Sample of Twins. Psychosomatic Medicine, 2022, 84, 151-158.	1.3	9
3200	Is any association between alternate healthy eating index (AHEI) with lipid profile and liver enzymes? A cross-sectional Study. Journal of Diabetes and Metabolic Disorders, 2021, 20, 1537-1544.	0.8	1
3201	Impact of the level of adherence to the Mediterranean Diet on blood pressure: A systematic review and meta-analysis of observational studies. Clinical Nutrition, 2021, 40, 5771-5780.	2.3	9
3202	Randomized controlled trial of stress reduction with meditation and health education in black men and women with high normal and normal blood pressure. American Journal of Preventive Cardiology, 2021, 8, 100279.	1.3	5
3204	Scientific Basis for New Guidelines for the Treatment of Hypertension in Type 2 Diabetes. , 2000, , 611-621.		0

#	Article	IF	CITATIONS
3205	Blood Pressure Elevation in Diabetes: The Results from 24-h Ambulatory Blood Pressure Recordings. , 2000, , 339-362.		2
3206	Cerebrovascular Disease in Women. , 2000, , 797-810.		1
3207	Antihypertensive Treatment in NIDDM, with Special Reference to Abnormal Albuminuria., 2000,, 441-459.		5
3208	Comparison between captopril and nicardipine for the treatment of postsurgical hypertension. European Journal of Anaesthesiology, 2000, 17, 131.	0.7	0
3209	Should Antihypertensive Treatment be Guided by Casual Measurement or Trough ABPM?. Developments in Cardiovascular Medicine, 2000, , 351-358.	0.1	0
3210	Combination Therapy for Hypertension and Renal Disease in Diabetes. , 2000, , 559-573.		1
3211	Evaluation of an Antihypertensive Therapy Utilising Meta-analysis of a Clinical Trial Database. Journal of Cardiovascular Pharmacology, 2000, 35, S1-S6.	0.8	2
3212	Update of the Latest Intervention Trials in Hypertension and Type 2 Diabetes., 2000,, 601-610.		0
3213	Herz-Kreislauf-Krankheiten., 2000,, 25-67.		2
3214	Metabolic and Cardiovascular Factors Contributing to Hypertension in the Elderly. , 2000, , 249-261.		1
3215	Langzeitblutdruckmessung. , 2000, , 49-60.		0
3217	Correlation of fibroblast growth factor 21 serum levels with metabolic parameters in Japanese subjects . Journal of Medical Investigation, 2000, 40, 28-34.	0.2	0
3218	至é©è;€åœ§ã•ã,‰ã•ã¥é™åœ§ç™,法(<特集II>第63回 日本徳環噓å¦ä¼šå¦è;"集会). Journal	ofol.0.S Car	diologists, 20
3219	Elevated Ambulatory and Normal Office Blood Pressure. Annals of Internal Medicine, 2000, 132, 842.	2.0	0
3220	When to refer to a hypertensive specialist. , 2000, , 74-78.		0
3221	Antihypertensive drug therapy. , 2000, , 43-54.		0
3222	Evaluation of the new hypertensive patient. , 2000, , 26-33.		0
3223	Allgemeine therapeutische Aspekte der arteriellen Hypertonie. , 2001, , 221-233.		0

#	Article	IF	CITATIONS
3224	Epidemiologie zerebrovaskulÃ r er Erkrankungen. , 2001, , 123-149.		0
3225	ACE and diabetes. , 2001, , 177-184.		0
3226	Antihypertensive Therapie bei Diabetes mellitus. , 2001, , 191-206.		1
3227	Sodium and Other Dietary Factors in Hypertension. , 2001, , 51-57.		O
3228	The Diabetic Hypertensive (or Hypertensive Diabetic) - A Compelling Need to Optimize Blood Pressure. Advances in Experimental Medicine and Biology, 2001, 498, 119-125.	0.8	0
3229	Antihypertensive Therapie in speziellen Populationen. , 2001, , 406-431.		0
3230	Kontraindikationen, AnwendungseinschrÄ r kungen und Arzneimittelinteraktionen spezifischer Antihypertensiva., 2001,, 347-351.		0
3231	Medikamentöse Therapie der arteriellen Hypertonie. , 2001, , 250-269.		0
3232	Medical Complications of Immunosuppression. , 2001, , 427-443.		0
3233	Special Situations in the Management of Hypertension. , 2001, , 252-274.		1
3234	Antihypertensive Agents: Mechanisms of Drug Action. , 2001, , 144-161.		0
3235	Drug Usage in Elderly Persons. , 2001, , 174-184.		0
3236	Risk Factors for Atherosclerosis in the Elderly. , 2001, , 448-459.		0
3237	Evaluation of Journals, Diaries, and Indexes of Worksite and Environmental Stress., 2001,, 29-44.		1
3238	Evaluation and Management of the Patient with Hypertension. , 2001, , 133-142.		0
3239	Risk Factors for and Prevention of Atherosclerotic Cardiovascular Disease. , 2001, , 97-106.		0
3240	Antihypertensive Therapie in besonderen Situationen. , 2001, , 392-405.		0
3241	Nichtmedikamentöse Therapie der arteriellen Hypertonie. , 2001, , 234-249.		0

#	Article	IF	CITATIONS
3242	Rise in Albuminuria and Blood Pressure in Patients Who Progressed to Diabetic Nephropathy in the Diabetes Control and Complications Trial. Journal of the American Society of Nephrology: JASN, 2001, 12, 333-340.	3.0	24
3243	Matching the right drug to the right patient in essential hypertension. Heart, 2001, 86, 113-120.	1.2	1
3244	æœ¬æ‹æ€§é«~血圧, èŽå®Ÿè³ªæ€§é«~血圧ã«ãŠã'ā,‹èŽéšœå®³äº^é~²ã₽ãŸã,ã₽血圧ã,³ãƒ³ãƒ^ãƒãƒ¥	ãfo ∖(t<ç%	‰¹éd†>第65å
3245	Risikofaktoren der KHK und Möglichkeiten ihrer Reduzierung. , 2002, , 67-92.		O
3246	Cerebrovascular Diseases., 2002,, 1075-1112.		0
3247	Hypertensive Crisis., 2002,, 797-807.		O
3248	Hypertensive Crises., 2002,, 863-876.		0
3250	Hypertensive Crises., 2002,, 863-876.		0
3251	Anxiety and Depression. Developments in Cardiovascular Medicine, 2002, , 351-394.	0.1	0
3252	Hypertension, Diabetes and the Heart., 2002, , 65-84.		O
3253	Prevenção Primária e Detecção Precoce da Hipertensão Arterial em Escolas do Ensino Médio. Projeto Comunitário Envolvendo Estudantes de Medicina. Revista Brasileira De Educacao Medica, 2002, 26, 88-93.	0.0	1
3255	Hemodynamic responses to stress among black women: fitness and parental hypertension. Medicine and Science in Sports and Exercise, 2002, 34, 1105.	0.2	O
3258	Arterielle Hypertonie., 2003,, 224-240.		0
3260	Hypertension, microvascular function and diabetes mellitus. , 2003, , 127-134.		O
3261	Antihypertensive therapy: Progression of Renal Injury. , 2003, , 209-240.		0
3262	Primary and Secondary Prevention of Coronary Heart Disease., 2003,, 145-174.		O
3264	Hypertension in Type 2 Diabetes Mellitus. , 2003, , 63-84.		1
3265	Antihypertensive Agents: Mechanisms of Drug Action. , 2003, , 155-174.		O

#	Article	IF	CITATIONS
3266	Special Situations in the Management of Hypertension. , 2003, , 257-281.		0
3267	Ernärung bei Herz-Kreislauf-Krankheiten. , 2003, , 564-581.		O
3268	Renal Artery Disease., 2003,, 81-109.		2
3270	Evaluation of the efficiency of combined therapy with telmisartan and lacidipine in patients with isolated systolic arterial hypertension. Arterial Hypertension (Russian Federation), 2003, 9, 26-29.	0.1	0
3271	Disproportionality of daily blood pressure variations in patients with arterial hypertension and type 2 diabetes mellitus. Arterial Hypertension (Russian Federation), 2003, 9, 59-63.	0.1	2
3272	Blood Pressure and Risk of Vascular Disease., 2003, , .		0
3274	Strategies for Treatment of Hypertension. , 2003, , .		0
3276	Alcohol and Cardiovascular Disease. , 2003, , 89-104.		0
3277	Vascular Function, Aging, and the Impact of Diet., 2004,, 379-398.		0
3278	Blood pressure control in chronic hemodialysis patients. , 2004, , 741-764.		0
3279	Hypertensive Disorders in Pregnancy. , 2004, , 43-67.		0
3280	Prevention of Microvascular Complications of Diabetes. , 2004, , 619-638.		0
3282	Primary Prevention of Cardiovascular Events in Older Individuals. Developments in Cardiovascular Medicine, 2004, , 83-113.	0.1	0
3283	Hh., 2004,, 125-146.		0
3284	Herz, GefÃße, Lunge. , 2004, , 81-196.		0
3285	Refractory Hypertension. , 2004, , 3-20.		0
3286	Hypertension in Chronic Kidney Disease. , 2004, , 39-62.		0
3287	Hypertensive Krise., 2004,, 573-578.		0

#	Article	IF	CITATIONS
3288	An Expert System on Detection, Evaluation and Treatment of Hypertension. Lecture Notes in Computer Science, 2004, , 251-264.	1.0	2
3289	Hypertension and diabetes care among primary care doctors in Germany: results from an epidemiological cross-sectional study., 2004,, 203-217.		3
3290	Trichlormethiazide., 2004,, 612-614.		1
3291	Sleep Apnea and Hypertension. , 2004, , 307-332.		0
3293	Hypertonie bei Diabetes mellitus. , 2004, , 353-365.		0
3294	24-hour blood pressure monitoring in clinical practice: do we overestimate its value?. Arterial Hypertension (Russian Federation), 2004, 10, 5-12.	0.1	3
3295	The Concept of Total Risk., 2005,, 219-229.		0
3296	Dietary Approaches to Hypertension Management: The DASH Studies. , 2005, , 453-463.		0
3297	Anesthesia and Hypertension. , 2005, , 813-825.		0
3298	Initial Evaluation and Follow-Up Assessment. , 2005, , 295-304.		0
3299	Prognostic and Diagnostic Value of Ambulatory Blood Pressure Monitoring., 2005,, 305-317.		2
3300	The VALUE Trial., 2005, , 366-375.		1
3301	Triage. , 2006, , 283-290.		0
3302	Epidemiology of Cerebrovascular Disease * *This work was supported in part by the National Institute of Neurological Disorders and Stroke Grant No. 5R01 NS17950 and the National Heart, Lung, and Blood Institute's Framingham Heart Study Contract No. N01-HC-25195, 2006, , 411-432.		0
3303	Blood Pressure Response to Exercise Test and Serum Lipids in Normotensive Men with Positive Family History of Hypertension. Central European Journal of Public Health, 2006, 14, 186-188.	0.4	1
3305	Peripheral Vascular Surgery. , 2007, , 394-398.		O
3306	U.S. and Canadian Guidelines for Hypertension. , 2007, , 551-570.		0
3307	Hypertension Disease Management Services. , 2007, , 527-534.		1

#	Article	IF	Citations
3308	Postoperative Hypertension (HTN)., 2007,, 588-589.		0
3309	Atherosclerotic Vulnerable Plaques: Pathophysiology, Detection, and Treatment., 2007,, 621-639.		0
3310	Arterial Hypertension., 2007,, 19-61.		1
3311	Organoprotective properties of fixed-drug combination verapamil-SR and trandolapril. Arterial Hypertension (Russian Federation), 2007, 13, 266-274.	0.1	0
3313	Management of Renal Artery Stenosis - an Update. Libyan Journal of Medicine, 2008, 3, 91-100.	0.8	0
3314	Risk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study. Yearbook of Cardiology, 2008, 2008, 70-72.	0.0	0
3315	Relationship between Low Evaluation by Recipients under 40 years old of Health Interviews by Occupational Health Nurses and Deterioration in Health Checkup Results over One year. Keio Journal of Medicine, 2008, 57, 90-98.	0.5	2
3316	Der hypertensive Notfall. , 2008, , 453-459.		0
3317	Biochemical Aspects, Laboratory Diagnosis and Follow-Up of High Blood Cholesterol: NCEP ATP III Guidelines. Journal of Medical Biochemistry, 2008, 27, 64-85.	0.7	0
3320	The Occurence and Distribution of Cardiovascular System Diseases Risk Factors Among Youth with Different Levels of Physical Activity. Medicina Sportiva, 2008, 12, 86-91.	0.3	3
3321	Obesity and the Cardiometabolic Syndrome: Impact on Chronic Kidney Disease and CVD., 2009, , 193-213.		0
3323	Hypertensive Emergencies., 2009,, 957-967.		0
3325	Systemic Diseases and Glaucoma. , 2010, , 689-709.		1
3327	Drug Therapy and Follow-Up., 2011,, 563-631.		0
3329	Traitement non mÃ@dicamenteux., 2011,, 33-40.		0
3331	Hypertensive crises. , 2011, , 583-588.		0
3333	Microparticles Novel Mechanisms of Intracellular Communication: Implication in Health and Disease. Indonesian Biomedical Journal, 2011, 3, 18.	0.2	0
3334	Secondary Prevention Strategies. , 2012, , 169-182.		0

#	Article	IF	CITATIONS
3335	Chapitre 10. Les modà les de risque en mà © decine. Quelles consà © quences pour la dà © finition des normes et pour le jugement cliniqueÂ? exemple du calcul du risque cardiovasculaire global. , 2012, , 199.	_	1
3337	Provocative dietary factors in geriatric hypertension: A surveillance study. AYU: an International Quarterly Journal of Research in Ayurveda, 2012, 33, 530.	0.3	0
3338	Krankheiten des Kreislaufsystems. , 2012, , 395-419.		0
3339	The influence of subclinical hyperthyroidism on blood pressure, heart rate variability and incidence of arrhythmia. Thyroid, 0, , 120120123521003.	2.4	2
3340	Periodontal Treatment of Medically Compromised Patients. , 2012, , 396-411.		2
3341	SCOPE AND NEED OF COMBINATION OF ANTIHYPERTENSIVE DRUGS. Indian Drugs, 2012, 49, 5-19.	0.1	0
3342	Discussion: Lipid Profile. , 2014, , 123-140.		0
3343	Literature Review: Cardiovascular Disorders and Lipid Profile. , 2014, , 45-66.		0
3344	Hipertensão Arterial Sistêmica: Representações Sociais de idosos sobre a doença e seu tratamento. Cadernos Saude Coletiva, 2013, 21, 121-128.	0.2	3
3345	Systemic Diseases and Glaucoma., 2014,, 479-507.		0
3347	The Effect of Nutrition and Exercise or Exercise Program alone on Macronutrients, Sodium Intake and Physical Strength in Middle Aged Obese Women. The Korean Journal of Obesity, 2014, 23, 187.	0.2	0
3348	The Value of Exercise Stress Testing for Renal-Cardiac Risk Assessment in Military Personnel: Exploring the Hidden Half!. Journal of Archives in Military Medicine, 2014, 2, .	0.0	O
3349	Hypertensive Patients and Diabetes. Journal of Cardiovascular Pharmacology, 1998, 32, S1-S8.	0.8	8
3350	Combination Therapy for Hypertension and Renal Disease in Diabetes. , 1998, , 559-568.		0
3351	Blood Pressure Elevation in Diabetes: The Results From 24-H Ambulatory Blood Pressure Recordings. , 1998, , 335-355.		2
3353	é«~血圧ç"ç©¶ã®é€²æ©(å¾³ç'°å™¨å¦ 1997å¹´ã®é€²æ©). Journal of JCS Cardiologists, 1998, 6, 75-80.	0.1	0
3354	é«~è;€åœ§ã®æ²»ç™,ãëä°å¾Œ(å¾°ç°°å™°ç−¾æ,£ã®æ²»ç™,ãëä°å¾Œ)(<特é>†>å¾°ç°°å™°å¦ã®é€²æ©). Jou	unomant of JCs	3 G ardiologis
3355	Behandlung der Hypertonie mit AT1-Rezeptorantagonisten. , 1999, , 77-102.		O

#	Article	IF	Citations
3356	Hypertrophy and Hypertension. Developments in Cardiovascular Medicine, 1999, , 55-64.	0.1	O
3357	Nephroprotektion durch Antihypertensiva. , 1999, , 185-201.		0
3358	Human Aging at the Millennium. , 1999, , 11-18.		0
3359	Exercise and Hypertension in Older Adults. , 1999, , 45-50.		4
3360	ã,∰f³ã,¹ãfªãf³æŠµæŠ—性ã•å‹•è"^硬åŒ−∶2.å‹•è"^硬åŒ−ã®ç™ºç−‡ãf¡ã,«ãf∢ã,ºãfã•åţ種é™åœ§è¬¬(<特é	ś> †₫⋊ 第6	2්බාž æ—¥æœ
3361	ACE inhibition in Chronic Renal Failure and in the Treatment of Diabetic Nephropathy: Focus on Spirapril. Journal of Cardiovascular Pharmacology, 1999, 34, S31-S34.	0.8	O
3362	Clinical Experience with Spirapril in Human Hypertension. Journal of Cardiovascular Pharmacology, 1999, 34, S25-S30.	0.8	5
3363	Prognostic Role of Pulse Pressure in the Acute Phase of Myocardial Infarction. World Journal of Cardiovascular Diseases, 2015, 05, 254-260.	0.0	O
3364	Improving Medicine Adherence among Elderly Hypertensive Patients by Using a One-dose Package Medication Support System. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and) Tj ETQq0 0 0 rg	şΒ Ѣ/O verlo	oc k 10 Tf 50 4
3365	Diagnostic Value of Noninvasive Cardiac Function Measurement for Hypertensive Disorders in Pregnancy. Open Journal of Obstetrics and Gynecology, 2015, 05, 181-184.	0.1	0
3366	Occurrence of metabolic syndrome with relation to job profile among mine employees. Journal of Obesity and Metabolic Research, 2016, 3, 32.	0.1	O
3367	AN EPIDEMIOLOGICAL STUDY OF HYPERTENSION AMONG THE ADULT POPULATION IN THE URBAN SLUMS OF GUWAHATI CITY, ASSAM. Journal of Evolution of Medical and Dental Sciences, 2016, 2, 5261-5264.	0.1	0
3369	An Observation on a Small Group of Hypertensive and Diabetic Patients in Bangladesh. MOJ Biology and Medicine, $2017, 2, .$	0.2	0
3370	PrimÃrprÃræntion und SekundÃrprÃræntion des Hirninfarkts. Springer Reference Medizin, 2018, , 1-31.	0.0	0
3371	Role of home Blood Pressure Monitoring in overcoming Therapeutic Inertia and improving Hypertension Control in Mexico. Annals of Clinical Hypertension, 0, , 017-023.	0.7	1
3372	A STUDY OF CLINICAL, AETIOLOGICAL PROFILE AND OUTCOME IN ISCHAEMIC POSTERIOR CIRCULATORY STROKE. Journal of Evolution of Medical and Dental Sciences, 2018, 7, 3124-3129.	0.1	0
3373	The Role of theÂBrain in Neurogenic Prehypertension. Updates in Hypertension and Cardiovascular Protection, 2019, , 349-360.	0.1	0
3374	Clinical Practice Guidelines, Evidence-Based Medicine, and Diabetes., 2019, , 333-355.		O

#	Article	IF	CITATIONS
3375	Primà prà vention und Sekundà prà vention des Hirninfarkts. Springer Reference Medizin, 2019, , 1-31.	0.0	0
3376	The Association among Blood Pressure, Blood Pressure Medications, and Glaucoma in a Nationwide Electronic Health Records Database. Ophthalmology, 2022, 129, 276-284.	2.5	13
3377	Poor guideline adherence in a real-world evaluation of hypertensive emergency management. American Journal of Emergency Medicine, 2022, 51, 46-52.	0.7	2
3378	Nutrition and blood pressure. , 2022, , 699-739.		0
3379	The DASH Dietary Pattern. , 2020, , 3-16.		1
3380	PrimĀrprĀvention und SekundĀrprĀvention des Hirninfarkts. Springer Reference Medizin, 2020, , 883-913.	0.0	O
3382	Does Blood Pressure Control by Gentle Ultrafiltration Improve Survival in Hemodialysis Patients?. Hemodialysis International, 2000, 4, 62-67.	0.4	0
3383	Volume Control in Hemodialysis Patients. Hemodialysis International, 2000, 4, 68-74.	0.4	1
3384	Risk of Diabetes and Diabetic Nephropathy. , 2004, , 99-128.		0
3385	Hypertonie., 2005,, 67-74.		1
3386	Arterielle Hypertonie bei Diabetes mellitus. , 2005, , 26-39.		0
3387	Beta-Blockers., 2007,, 1-35.		0
3389	Late onset of type 2 diabetes is associated with mitochondrial tRNA ^{Trp} A5514G and tRNA ^{Ser(AGY)} C12237T mutations. Journal of Clinical Laboratory Analysis, 2022, 36, e24102.	0.9	5
3391	Maternally transmitted diabetes mellitus may be associated with mitochondrial ND5 T12338C and tRNAAla T5587C variants. Irish Journal of Medical Science, 2022, , 1.	0.8	1
3392	Towards detecting morning surge from sleep self-evaluations. , 2020, , .		0
3393	Association of Pericardial Fat with Cardiac Structure, Function, and Mechanics: The Multi-Ethnic Study of Atherosclerosis. Journal of the American Society of Echocardiography, 2022, 35, 579-587.e5.	1.2	2
3394	Immunomodulatory Potential of Diuretics. Biology, 2021, 10, 1315.	1.3	4
3395	Blood pressure interactions with the DASH dietary pattern, sodium, and potassium: The International Study of Macro-/Micronutrients and Blood Pressure (INTERMAP). American Journal of Clinical Nutrition, 2022, 116, 216-229.	2.2	13

#	Article	IF	Citations
3396	Relationship of indoor solid fuel use for cooking with blood pressure and hypertension among the elderly in China. Environmental Science and Pollution Research, 2022, 29, 53444-53455.	2.7	6
3397	Hypertension alters the function and expression profile of the peptide cotransporters PEPT1 and PEPT2 in the rodent renal proximal tubule. Amino Acids, 2022, 54, 1001-1011.	1.2	3
3398	Development of a multivariate model with desirabilityâ€based optimization for determination of atenolol and hydrochlorothiazide by ecoâ€friendly HPLC method with fluorescence detection. Journal of Separation Science, 2022, 45, 824-831.	1.3	7
3400	Association of serum MicroRNA-145-5p levels with microvascular complications of type 1 Diabetes: The EURODIAB prospective complications study. Diabetes Research and Clinical Practice, 2022, 190, 109987.	1.1	2
3401	Isolated Diastolic Hypertension and Risk of Cardiovascular Disease: Controversies in Hypertension - Pro Side of the Argument. Hypertension, 2022, 79, 1563-1570.	1.3	9
3402	Incidence of Preclinical Heart Failure in a Community Population. Journal of the American Heart Association, 0, , .	1.6	3
3403	The Prevalence of Uncontrolled Hypertension among Patients Taking Antihypertensive Medications and the Associated Risk Factors in North Palestine: A Cross-Sectional Study. Advances in Medicine, 2022, 2022, 1-7.	0.3	4
3404	Pulmonary Blood Volume Among Older Adults in the Community: The MESA Lung Study. Circulation: Cardiovascular Imaging, 2022, 15, .	1.3	4
3405	Optimal office blood pressure levels in younger (<50 years old) Korean hypertensive patients: a nationwide cohort study in South Korea. Journal of Hypertension, 0, Publish Ahead of Print, .	0.3	1
3406	A comparative evaluation of fixed dose and separately administered combinations of lisinopril and hydrochlorothiazide in treatment-naìve adult hypertensive patients in a rural Nigerian community. International Journal of Cardiology Cardiovascular Risk and Prevention, 2022, 14, 200144.	0.4	1
3408	Sustained Hemodynamic Effects of the Selective Dopamineâ€1 Agonist, Fenoldopam, during 48â€Hour Infusions in Hypertensive Patients: A Doseâ€Tolerability Study. Journal of Clinical Pharmacology, 1999, 39, 471-479.	1.0	9
3409	COMPREHENSIVE HYPERTENSION CARE IN YOUNG URBAN BLACK MEN. Nursing Clinics of North America, 2000, 35, 773-793.	0.7	10
3410	WOMEN AND CARDIOVASCULAR DISEASE. Nursing Clinics of North America, 2000, 35, 833-839.	0.7	1
3411	Endothelial Function and Physical Exercise: A Key to Cardiovascular Protection?. Updates in Hypertension and Cardiovascular Protection, 2022, , 43-54.	0.1	0
3412	Kidney Disease after Heart and Lung Transplantation. Methodist DeBakey Cardiovascular Journal, 2022, 18, 34-40.	0.5	1
3413	Who should be screened for primary aldosteronism? A comprehensive review of current evidence. Journal of Clinical Hypertension, 2022, 24, 1194-1203.	1.0	6
3414	Role of α1â€blockers in the current management of hypertension. Journal of Clinical Hypertension, 2022, 24, 1180-1186.	1.0	9
3415	Even high normal blood pressure affects live birth rate in women undergoing fresh embryo transfer. Human Reproduction, 2022, 37, 2578-2588.	0.4	1

#	Article	IF	CITATIONS
3417	Role of ambulatory blood pressure monitoring in hypertensive patients having controlled office blood pressure. Indian Heart Journal, 2022, 74, 474-477.	0.2	1
3419	SUBCAPITAL- CLINICAL CORRELATION OF 2ND (INDEX) TO 4TH (RING) DIGIT RATIO WITH HIGH BLOOD PRESSURE AND ITS IMPLICATION FOR CORONARY HEART DISEASE IN WEST U.P. MALES., 2022, , 63-65.		0
3420	Pathophysiological Links Between Diabetes and Cardiovascular Diseases: at the Biochemical and Molecular Levels. Frontiers in Cardiovascular Drug Discovery, 2022, , 191-229.	0.0	0
3421	Changing trends of the disease burden of non-rheumatic valvular heart disease in China from 1990 to 2019 and its predictions: Findings from global burden of disease study. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
3422	MANAGEMENT OF HYPERTENSION AND ITS SEQUELAE WITH ACE INHIBITORS: BIOCHEMICAL, PHARMACOLOGICAL AND CLINICAL ASPECTS. International Journal of Clinical Practice, 1998, 52, 492-500.	0.8	4
3423	The Clinical Predictors of Hypertension and Sleepiness in an Asian Population with Sleep-disordered Breathing. Annals of the Academy of Medicine, Singapore, 2006, 35, 6-10.	0.2	5
3424	Prevalence of Hypertension in Indian Tribal Population: a Systematic Review and Meta-analysis. Journal of Racial and Ethnic Health Disparities, 2024, 11, 451-467.	1.8	3
3425	AddREssing Social Determinants TO pRevent hypErtension (The RESTORE Network): Overview of the Health Equity Research Network to Prevent Hypertension. American Journal of Hypertension, 2023, 36, 232-239.	1.0	0
3426	Concomitant Coronary Artery Disease Among Asian Ischaemic Stroke Patients. Annals of the Academy of Medicine, Singapore, 2008, 37, 573-575.	0.2	4
3427	Association of Preterm Birth With Prevalent and Incident Hypertension, Early-Onset Hypertension, and Cardiovascular Disease in the Women's Health Initiative. American Journal of Cardiology, 2023, 192, 132-138.	0.7	2
3429	Management of the Hypertensive Dental Patient. Journal of the California Dental Association, 2007, 35, 51-59.	0.0	9
3445	Triage. , 2024, , 364-370.		0
3451	Initial Combination Therapies., 2024,, 304-309.		0
3460	13.ÂHypertension., 2023,,.		0
3461	A Cuffless Blood Pressure Monitoring Epidermal Patch Enabled By Deep Learning. , 2024, , .		0